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The	  Human	  Epidermal	  Growth	  Factor	  Receptor	  2	  (HER2)	   is	  an	  oncogene	  expressed	  in	  
25-­‐30%	  of	  invasive	  breast	  cancers.	  The	  HER2	  gene	  encodes	  an	  185kDa	  transmembrane	  
protein	  with	  tyrosine	  kinase	  activity.	  Gene	  amplification	  or	  protein	  expression	  of	  HER2	  
is	   a	   predictor	   of	   poor	   prognosis	   in	   women	  with	   breast	   cancer,	   and	   also	   indicates	   a	  
favourable	  response	  to	  Trastuzumab	  (Herceptin)	  therapy,	  or	  a	  combinational	  therapy	  
comprising	   Herceptin	   plus	   chemotherapy.	   However,	   resistance	   to	   Trastuzumab	  
remains	   the	   case	   in	   approximately	   50%	   of	  HER2	   amplified/overexpressing	   tumours.	  
Understanding	  the	  molecular	  mechanisms	  of	  Trastuzumab	   resistance	   is	  critical	   in	   the	  
treatment	  of	  patients	  whose	  breast	  cancers	  express	  this	  aggressive	  disease	  phenotype.	  
In	   this	   study,	   it	   is	   postulated	   that	   the	   abnormal	   generation	   of	  mRNA	   splice	   variants	  
may	  be	  responsible	  for	  the	  continued	  tumour	  growth	  and	  progression.	  
The	  aim	  of	   this	   study	   is	   to	   investigate	   the	  expression	  of	  alternative	   splice	  variants	   in	  
invasive	  breast	   cancer,	   and	   to	   increase	  our	  understanding	  of	   the	   regulation	  of	  HER2	  
and	  HER2	  splice	  variants	  in	  invasive	  breast	  cancer.	  	  
The	  coding	  region	  of	  HER2	  cDNA	  was	  PCR	  amplified	  in	  HER2	  positive	  cell	  lines	  (SKOV-­‐3,	  
SKBR-­‐3,	   and	  MDA-­‐MB-­‐453).	   The	   regulation	   of	  HER2	   expression	   was	   investigated	   by	  
siRNA	  silencing	  of	  the	  splice	  factor	  SRSF1	  and	  its	  phosphorylating	  gene	  SRPK1.	  The	  role	  
of	   hypoxia	   and	   the	   inhibition	   of	   SRPK1	   via	   SRPIN340	   were	   also	   investigated	   for	   its	  
effects	  of	  HER2	  expression	  in	  cell	  lines.	  Human	  cancer	  tissues	  known	  to	  be	  positive	  for	  
HER2	  were	  tested	  for	  the	  expression	  of	  alternative	  splice	  variants	  of	  HER2.	  
RT-­‐PCR	   results	   reveal	   new	   alternative	   splice	   variants	   in	   invasive	   breast	   cancer	   cells.	  
These	   new	   alternative	   splice	   variants	   of	   HER2	   have	   also	   been	   detected	   in	   HER2-­‐
positive	  breast	  cancer	  samples.	  Furthermore,	  the	  splice	  factor	  SRPK1	  and	  SRSF1	  have	  
shown	   regulatory	   effects	   on	   the	   expression	   of	  HER2	   in	  HER2-­‐positive	   cell	   line	  MDA-­‐
MB-­‐453.	  	  	  
This	   study	   identifies	   for	   the	   first	   time	   two	  novel	   splice	  variants	  with	  deletions	   in	   the	  
transmembrane	   and	   kinase	   domains	   of	   the	   HER2	   gene,	   both	   with	   very	   distinct	  
functional	  and	  structural	  differences.	  These	  findings	  conclude	  that	  alternative	  splicing	  
plays	  a	  crucial	  role	  in	  the	  regulation	  of	  HER2	  expression,	  and	  possibly	  in	  the	  response	  
of	   breast	   cancer	   patients	   to	   current	   targeted	   HER2	   therapies.
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CHAPTER	  1. GENERAL	  INTRODUCTION	  
1.1 Breast	  Cancer	  
Breast	  cancer	  is	  the	  most	  common	  form	  of	  cancer	  in	  women	  worldwide,	  accounting	  for	  
approximately	   16%	   of	   all	   cancers	   in	  women	   (World	   Health	  Organisation,	   2010).	   The	  
WHO	   statistics	   for	   breast	   cancer	   estimate	   that	   nearly	   1.7	   million	   women	   were	  
diagnosed	  of	  breast	  cancer	  in	  2012	  and	  over	  400,000	  women	  died	  from	  breast	  cancer	  
worldwide.	  In	  the	  UK,	  over	  49,936	  new	  cases	  of	  breast	  cancer	  were	  diagnosed	  in	  2010,	  
with	   approximately	   11,600	   patients	   dying	   from	   the	   disease	   (Cancer	   Research	   UK,	  
2010).	   A	   study	   of	   breast	   cancer	   cases	   reported	   between	   2002	   and	   2006	   by	   Cancer	  
Research,	  UK	  showed	  that	  based	  on	  ethnicity,	  the	  incidence	  of	  breast	  cancer	  in	  women	  
in	  the	  UK	  is	  significantly	  higher	  in	  white	  women	  (71%	  incidence	  rate).	  This	  rate	  is	  much	  
lower	   in	   Asian,	   Black,	   and	   mixed	   ethnicities	   (1.4%,	   0.14%,	   and	   0.2%,	   respectively).	  
Studies	  also	  show	  that	  breast	  cancer	  in	  black	  and	  Asian	  women	  tend	  to	  be	  have	  more	  
aggressive	   phenotypes,	   and	   are	   mostly	   triple	   negative	   (ER-­‐,	   PR-­‐	   and	   HER2-­‐),	   while	  
white	  women	  tend	  to	  present	  a	  less	  aggressive	  phenotype.	  These	  differences	  may	  be	  
due	  to	  differences	   in	  genetic	  predispositions	  or	  variations	   in	   lifestyle	  patterns	   (Anon,	  
2013).	  	  
Breast	  cancer	   is	  caused	  by	  malignant	  tumours	  arising	  within	  the	  breast	  epithelia.	  The	  
progression	   of	   breast	   cancer	   is	   believed	   to	   be	   a	   result	   of	   various	   aberrant	  
transformations	  which	  abnormally	  lead	  to	  changes	  in	  the	  breast	  epithelial	  cells	  (Sasso	  
et	  al.,	  2011).	  A	  number	  of	  risk	  factors	  have	  been	  implicated	  in	  the	  incidence	  of	  breast	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cancer.	   Research	   has	   shown	   that	   the	   risk	   of	   developing	   breast	   cancer	   increases	  
significantly	  with	  increase	  in	  age	  (Key	  et	  al.,	  2011;	  Parkin,	  Boyd	  &	  Walker,	  2011).	  Other	  
risk	   factors	   include	   the	   use	   of	   oestrogen-­‐progesterone	   contraceptives,	   excessive	  
alcohol	   intake,	   tobacco	   smoking,	   diet,	   and	   mutations	   in	   the	   BRCA1/BRCA2	   genes	  
(Eliassen	   et	   al.,	   2006;	   Key	   et	   al.,	   2011).	   Breast	   cancer	   is	   not	   a	   single	   disease,	   but	  
comprises	  various	  subtypes	  which	  vary	   in	  morphology,	  prognostic	  profiles,	  molecular	  
entities	   and	   clinical	   outcomes	   (Jackson	   et	   al.,	   2013;	   Eroles	   et	   al.,	   2012).	   Prognostic	  
factors	   for	  breast	  cancer	   include	  tumour	  grade,	  histological	   type,	   tumour	  size,	   lymph	  
node	   involvement,	   distant	   metastasis,	   expression	   of	   steroid	   and	   growth	   factor	  
receptors,	   oestrogen-­‐inducible	   genes	   e.g	   Cathepsin-­‐D,	   proto-­‐oncogenes	   e.g.	   HER2,	  
mutations	  in	  certain	  genes,	  e.g.	  TP53	  (Sørlie	  et	  al.,	  2001).	  Atypical	  hyperplasia	  in	  breast	  
epithelia	   may	   lead	   to	   ductal	   or	   lobular	   carcinomas	   in	   situ;	   where	   malignant	   cells	  
remain	   in	   the	  ducts	  or	   lobules	   respectively,	  or	  may	   lead	  to	   invasive	  ductal	  or	   lobular	  
carcinomas;	   where	   they	   become	   invasive	   and	   the	   carcinoma	   cells	   penetrate	   the	  
basement	  membrane	  of	  the	  breast	  epithelia,	  and	  spread	  into	  surrounding	  stroma,	  skin	  
or	  muscles,	  or	  metastasize	  to	  surrounding	  lymph	  nodes	  or	  distant	  tissues	  such	  as	  the	  
brain,	   liver	   or	   bone	   (Jackson	   et	   al.,	   2013).	   In	   addition,	   the	   overexpression	   or	  
amplification	   of	   certain	   biomarkers	   such	   as	   the	   Oestrogen	   Receptor	   (ER),	   the	  
Progesterone	   Receptor	   (PR),	   and	   the	   Human	   Epidermal	   Growth	   Factor	   Receptor	   2	  
(HER2/neu/c-­‐erbB-­‐2)	   is	  also	  important	  in	  determining	  the	  prognosis	  and	  treatment	  of	  
breast	  cancer	  (Ciocca	  et	  al.,	  2006).	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1.2 Classification	  of	  breast	  cancers	  
In	  the	  past	  few	  decades,	  research	  into	  the	  biology	  of	  breast	  cancer	  has	  revolutionised	  
with	   the	   focus	   on	   new	   methods	   of	   understanding	   the	   expression,	   regulation	   and	  
function	   of	   critical	   signalling	   pathways	   active	   in	   the	   incidence	   and	   progression	   of	  
breast	   cancers	   (Eroles	   et	   al.,	   2012;	   Alvarez	   &	   Hortobagyi,	   2013).	   The	   cellular	   and	  
molecular	   heterogeneity	   of	   breast	   cancer	   contributes	   to	   it	   being	   a	   highly	   complex	  
disease;	  certain	  prognostic	  values	  are	  limited	  in	  the	  information	  that	  can	  be	  obtained	  
about	  the	  biology	  of	  the	  disease.	  Therefore	  the	  parameters	  used	  to	  provide	  prognostic	  
profiles	  are	  not	  self-­‐sufficient	  in	  adequately	  predicting	  patient	  outcome	  in	  many	  cases	  
of	   breast	   cancer.	   	   The	   model	   of	   individualised	   treatment	   (based	   on	   individual	  
molecular	   profiles	   of	   different	   patients)	   has	   gained	   much	   support	   from	   the	   cancer	  
research	   community,	   and	   has	   led	   to	   the	   identification	   of	   different	   subgroups	   of	  
patients	  and	  the	  development	  of	  various	  targeted	  therapies	  for	  breast	  cancer	  patients	  
(Zagozdzon,	  Gallagher	  &	  Crown,	  2011).	  Examples	  of	   these	   targeted	   therapies	   include	  
the	   successful	   use	   of	   hormonal	   therapy	   for	   women	  with	   hormone-­‐sensitive	   tumour	  
subtypes,	  and	  the	  use	  of	  anti-­‐human	  epidermal	  growth	  factor	  receptor	  2	  therapies	  for	  
women	   with	   Human	   Epidermal	   Growth	   Factor	   2	   (HER2)-­‐	   overexpressing	   tumours	  
(Alvarez	  &	  Hortobagyi,	  2013).	  
New	   classifications	   of	   breast	   cancers	   have	   been	   proposed	   with	   the	   aim	   of	   giving	  
potentially	  more	  significant	  prognostic	  information	  and	  providing	  guides	  for	  treatment	  
options	   for	   individual	   subtypes	   (Boyle,	   2012).	   Studies	   have	   focused	   on	   classifying	  
breast	  cancers	  based	  on	  a	  combination	  of	  changes	  in	  gene	  expression	  microarrays	  and	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immunohistochemical	   subtypes,	   resulting	   in	   breast	   cancers	   being	   classified	   into	   six	  
distinct	  phenotypical	  subtypes	  (Table	  1.1)	  
1.2.1 Luminal	  A	  
The	  luminal	  A	  subtype	  represents	  50-­‐60%	  of	  breast	  cancer	  subtypes,	  and	  based	  on	  its	  
histological	  profile,	  tumours	  in	  this	  subtype	  are	  mostly	  lobular	  carcinomas	  in-­‐situ	  and	  
infiltrating	   lobular	   carcinomas	   (Eroles	   et	   al.,	   2012).	   	   The	   luminal	   A	   subtype	   is	  
immunohistochemically	   ER	   positive	   and/or	   PR	   positive,	   and	   HER2	   negative,	   and	   is	  
known	  to	  have	  a	  good	  prognostic	  outcome	  (Eroles	  et	  al.,	  2012;	  Boyle,	  2012;	  Li	  et	  al.,	  
2013).	  Treatment	  is	  mainly	  based	  on	  hormonal	  receptor	  modulators	  such	  as	  Tamoxifen	  
(Eroles	  et	  al.,	  2012).	  	  
1.2.2 Luminal	  B	  
The	  luminal	  B	  subtype	  represents	  10-­‐20%	  of	  all	  breast	  cancers	  and	  is	  a	  more	  aggressive	  
phenotype	  compared	  to	  the	  luminal	  A	  subtype	  (Eroles	  et	  al.,	  2012).	  Like	  the	  Luminal	  A	  
subgroup,	  Luminal	  B	  breast	  cancers	  are	  ER	  positive	  and/or	  PR	  positive.	  However,	  this	  
subtype	  is	  identified	  as	  a	  tumour	  subgroup	  with	  poorer	  patient	  outcome	  compared	  to	  
the	  luminal	  A	  subtype,	  due	  to	  the	  increased	  expression	  of	  proliferation	  genes	  such	  as	  
MKI67,	  Cyclin	  B1	  and	  oncogenes	  such	  as	  HER2	   (Boyle,	  2012;	  Eroles	  et	  al.,	  2012).	  The	  
luminal	   B	   subtype	   is	   also	   characterised	   by	   higher	   histological	   grade.	   In	   combination	  
with	   tamoxifen	   treatment,	   patients	   in	   this	   subgroup	   respond	   well	   to	   neoadjuvant	  
chemotherapy	  (Eroles	  et	  al.,	  2012).	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1.2.3 HER2	  overexpressing	  
	  This	  molecular	  subtype	  accounts	  for	  10-­‐25%	  of	  all	  breast	  cancers	  (Eroles	  et	  al.,	  2012).	  
HER2	   overexpressing	   cancers	   are	   characterised	   by	   the	   absence	   of	   ER	   and	   PR,	   and	   a	  
high	   expression	   of	   the	   HER2	   gene	   and	   also	   exhibit	   an	   overexpression	   of	   genes	  
associated	  with	  cellular	  proliferation	  (Boyle,	  2012;	  Eroles	  et	  al.,	  2012;	  Li	  et	  al.,	  2013).	  
HER2	   overexpressing	   tumours	   are	   histologically	   high	   grade	   tumours	   and	   have	  
unfavourable	   prognostic	   implications.	   Treatment	   is	   mainly	   with	   anti-­‐HER2	   therapies	  
and	  neoadjuvant	  chemotherapy	  (Eroles	  et	  al.,	  2012).	  
1.2.4 Basal-­‐like	  	  
This	   subtype	   represents	   10-­‐20%	   of	   all	   breast	   cancers.	   Basal-­‐like	   tumours	   are	  mainly	  
infiltrating	   ductal	   carcinomas	   with	   high	   lymph	   node	   involvement	   and	   metastatic	  
potential	   (Eroles	   et	   al.,	   2012).	   The	   most	   important	   characteristic	   of	   this	   tumour	  
subtype	  is	  the	  absence	  of	  all	  three	  breast	  cancer	  biomarkers	  ER,	  PR	  and	  HER2	  (Boyle,	  
2012;	  Eroles	  et	  al.,	  2012).	  This	  is	  why	  they	  are	  also	  often	  referred	  to	  as	  triple	  negative	  
breast	   cancers	   (TNBC).	   Triple-­‐negative	   breast	   basal-­‐like	   cancers	   are	   also	   positive	   for	  
EGFR	  and	  CK5/6	  (Li	  et	  al.,	  2013).	  Basal-­‐like	  cancers	  are	  usually	  histologically	  high	  grade	  
tumours,	  and	  treatment	  is	  usually	  with	  chemotherapy.	  Poly-­‐ADP	  ribose-­‐	  polymerase-­‐1	  
(PARP-­‐1)	  inhibitors	  are	  currently	  being	  developed	  to	  treat	  this	  subset	  of	  tumours,	  but	  
are	  currently	  only	  being	  used	  in	  clinical	  trials	  (Eroles	  et	  al.,	  2012).	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1.2.5 Normal	  breast-­‐like	  
About	  5-­‐10%	  of	  breast	  carcinomas	  have	  been	  classified	  under	   the	  normal	  breast-­‐like	  
subtype	  (Eroles	  et	  al.,	  2012).	  Normal	  breast-­‐like	  breast	  cancers	  are	  negative	  for	  ER,	  PR	  
and	  HER2,	  but	  unlike	   the	  triple-­‐negative	  breast	  cancer	  subtype,	  are	  also	  negative	   for	  	  
CK5/6	   and	   EGFR	   (Eroles	   et	   al.,	   2012).	   Normal	   breast-­‐like	   breast	   cancers	   are	   poorly	  
characterised	  and	  are	  very	  rare	  (Sørlie	  et	  al.,	  2001;	  Eroles	  et	  al.,	  2012).	  Some	  studies	  
hypothesize	   that	   this	   subtype	   is	   only	   a	   technical	   artefact	   derived	   from	   a	   high	  
contamination	   of	   normal	   tissue	   during	   the	   preparation	   of	   tissue	   microarrays.	   It	   is	  
difficult	   to	   establish	   a	   clinical	   significance	   of	   the	   normal	   breast-­‐like	   breast	   cancer	  
subtype	  due	  to	  their	  rarity	  (Eroles	  et	  al.,	  2012).	  
1.2.6 Claudin-­‐low	  
About	  12-­‐14%	  of	  breast	  cancers	  are	  found	  under	  this	  subtype	  (Eroles	  et	  al.,	  2012).	  The	  
claudin-­‐low	  breast	  cancer	  subtype	  is	  characterized	  by	  a	  low	  expression	  of	  certain	  genes	  
which	   play	   a	   crucial	   role	   in	   the	   formation	   of	   tight	   junctions	   and	   in	   cell	   adhesion.	  
Examples	  of	  these	  genes	  are	  claudin	  -­‐3,	  -­‐4,	  -­‐7	  cingulin,	  occludin	  and	  E-­‐cadherin,	  hence	  
the	  name	  claudin-­‐low	  (Perou,	  2011).	  This	  subtype	  is	  characterised	  by	  a	  high	  expression	  
of	   immune	   cells.	   Claudin-­‐low	   tumours	   also	   express	   a	   low	   level	   of	   genes	   which	   are	  
related	  to	  cell	  proliferation,	  yet	  this	  subtype	  belongs	  to	  a	  poor	  prognosis	  group	  (Eroles	  
et	   al.,	   2012;	   Perou,	   2011).	   Claudin-­‐low	   breast	   tumours	   are	   relatively	   high	   grade	  
infiltrating	   ductal	   carcinomas.	   Immunohistochemically,	   Claudin-­‐low	   tumours	   are	  
mostly	   triple	   negative,	   and	   treatment	   of	   patients	   is	   mainly	   with	   neoadjuvant	  
chemotherapy.	   This	  new	  classification	  of	  breast	   cancers	   is	   still	   being	   researched	  and	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has	  not	  yet	  been	   fully	  applied	   in	  clinical	   settings	  due	   to	  a	   lack	  of	   standardization	   for	  








































Luminal	  A	   50-­‐60%	   ER+,	   PR+,	  
HER2-­‐	  
Low	   Excellent	  






Claudin-­‐low	   12-­‐14%	   ER-­‐,	  PR-­‐,	  HER2-­‐	   High	   Poor	  
Table	  1.1:	  Molecular	  subtypes	  of	  HER2	  and	  their	  characteristic	  features.	  Adapted	  and	  used	  with	  








Figure	  1.1	  (A)	  Kaplan–Meier	  curves	  of	  disease-­‐free	  survival	  and	  overall	  survival	  based	  on	  UNC337	  
database.	  Dark	  blue,	  luminal	  A;	  light	  blue,	  luminal	  B;	  red,	  basal-­‐like;	  pink,	  HER2-­‐enriched;	  yellow,	  
Claudin-­‐low.	  (B)	  Distribution	  of	  ER	  and	  HER2	  in	  the	  different	  subtypes	  of	  breast	  cancer	  based	  on	  mRNA	  
expression.	  [Source	  and	  permissions:	  (Eroles	  et	  al.,	  2012)].	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1.3 Discovery	  of	  the	  Human	  Epidermal	  Growth	  Factor	  Receptor	  
2	  (HER2)	  
The	   Human	   Epidermal	   Growth	   Factor	   Receptor	   2	   (HER2)	   is	   a	   proto-­‐oncogene	  which	  
belongs	   to	   the	   Human	   Epidermal	   Growth	   Factor	   Receptor	   (HER/EGFR)	   family	   of	  
transmembrane	  receptor	  tyrosine	  kinases	  (Dean-­‐Colomb	  &	  Esteva,	  2008;	  Normanno	  et	  
al.,	  2006).	  The	  EGFR	  family	  of	  genes	  consists	  of	  HER1	  (EGFR	  /	  c-­‐erbB-­‐1),	  HER2	  (c-­‐erbB-­‐2	  
/	   verb-­‐B2	   /	   Neu),	   HER3	   (c-­‐erbB-­‐3),	   and	   HER4	   (c-­‐erbB-­‐4)	   (Shah	   &	   Chen,	   2010;	   Wan,	  
Sazani	   &	   Kole,	   2009).	   Aberrant	   expression	   or	   functioning	   of	   the	   epidermal	   growth	  
factor	  family	  has	  been	  implicated	  in	  the	  development	  and	  evolution	  of	  various	  cancers	  
(Baselga	  &	  Swain,	   2009).	   The	  HER2/Neu	   oncogene	  was	   first	   characterised	   in	  1981	   in	  
experiments	   using	   genetically	  modified	  mice	   (Sińczak-­‐Kuta	  et	   al.,	   2007;	   Siegel	  et	   al.,	  
1999).	   	  Neu,	   the	   rat	   homologue	   of	  HER2,	   was	   identified	   as	   a	   transforming	   gene	   in	  
transfection	   experiments	   using	   genomic	   DNA	   isolated	   from	   chemically	   induced	  
neuroblastoma	  models	   (Marchini	  et	  al.,	   2011;	  Sińczak-­‐Kuta	  et	  al.,	   2007;	  Siegel	  et	  al.,	  
1999;	   Jackson	   et	   al.,	   2013).	   Single	   point	   mutations	   in	   the	   transmembrane	   region	  
activate	  the	  neu	  oncogene	  by	  converting	  a	  valine	  residue	  to	  glutamic	  acid	  (Siegel	  et	  al.,	  
1999).	   This	   mutation	   in	   the	   transmembrane	   domain	   results	   in	   increased	   ligand-­‐
independent	  dimerization	  causing	  tyrosine	  kinase	  activity.	  The	  human	  homolog	  of	  the	  
Neu	   gene	   (HER2)	   was	   identified	   and	   isolated	   due	   to	   its	   homology	   with	   the	   Neu	  
oncogene.	   ERBB2	   is	   the	   official	   name	   for	   HER2	   provided	   by	   the	   HUGO	   Gene	  
Nomenclature	   Committee	   for	   the	   v-­‐erb-­‐b2	   erythroblastic	   leukemia	   viral	   oncogene	  
homolog	  2	  gene	  (Wolff	  et	  al.,	  2007).	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The	  HER2	  gene	  is	  located	  on	  the	  long	  arm	  of	  human	  chromosome	  17	  (17	  q21-­‐q22)	  and	  
encodes	  a	  185kDa	  tyrosine	  kinase	  receptor	  (Freudenberg	  et	  al.,	  2009;	  Nuti	  et	  al.,	  2011)	  
that	   is	  constitutively	  active	  as	  a	  dimer	  and	  shares	  extensive	  homology	  with	  the	  other	  
three	   members	   of	   the	   EGFR	   family	   (Castiglioni	   et	   al.,	   2006);	   all	   Human	   Epidermal	  
Growth	   factor	   receptors	   have	   an	   extracellular	   ligand-­‐binding	   domain,	   a	   short	  
hydrophobic	  transmembrane	  region	  and	  a	  cytoplasmic	  domain	  with	   intrinsic	   tyrosine	  
kinase	  catalytic	  activity	  (Sińczak-­‐Kuta	  et	  al.,	  2007;	  Hynes	  &	  Lane,	  2005)	  (Figure	  1.2).	  	  
About	  10-­‐25%	  of	  human	  breast	  carcinomas	  are	  positive	  for	  HER2	  (Koletsa	  et	  al.,	  2008;	  
Scaltriti	   et	   al.,	   2007).	   	   The	   overexpression	   or	   gene	   amplification	   of	   HER2	   has	   been	  
observed	   in	   many	   other	   human	   epithelial	   cancers	   including	   colorectal,	   ovarian,	  
endometrial,	  prostate,	  pancreatic,	  oral,	   lung,	  and	  gastric	  carcinomas	   (Freudenberg	  et	  
al.,	  2009;	  Gebhardt,	  Zänker	  &	  Brandt,	  1998;	  Nuti	  et	  al.,	  2011;	  Blok	  et	  al.,	  2013;	  Fuse,	  
2011),	  and	  is	  known	  to	  be	  associated	  with	  an	  unfavourable	  prognosis.	  HER2	  positivity	  
in	   breast	   cancers	   is	   associated	   with	   a	   more	   aggressive	   tumour	   phenotype	   with	  
increased	   cell	   proliferation	   and	  metastatic	   potential	   (Dean-­‐Colomb	  &	   Esteva,	   2008),	  
earlier	   recurrence,	   significantly	   lower	   disease-­‐free	   and	   overall	   survival	   rates,	   shorter	  
time	  to	  relapse,	  and	  overall	  poor	  prognosis	  (Doherty	  et	  al.,	  1999a;	  Freudenberg	  et	  al.,	  
2009;	  Shah	  &	  Chen,	  2010).	  	  
1.4 HER2	  signalling	  pathways	  
The	  Human	  Epidermal	  Growth	   Factor	  Receptor	   (HER/EGFR)	   tyrosine	   kinase	   family	   of	  
transmembrane	  proteins	  are	  activated	   following	  binding	  with	  peptide	  growth	   factors	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of	  the	  EGF-­‐family	  of	  proteins	  (Normanno	  et	  al.,	  2006).	  The	  EGFRs	  play	  a	  crucial	  role	  in	  
normal	   physiology	   and	   evidence	   also	   suggests	   that	   the	   EGFR	   family	   of	   receptors	   is	  
involved	  in	  the	  pathogenesis	  and	  progression	  of	  different	  carcinoma	  types	  (Normanno	  
et	  al.,	  2006;	  Hynes	  &	  MacDonald,	  2009).	  Epidermal	  growth	  factor	  receptors	  also	  play	  a	  
role	   in	   embryogenesis,	   and	   are	   important	   factors	   in	   tissue	   remodelling	   and	   renewal	  
throughout	   adult	   life.	   Epidermal	   Growth	   Factor	   Receptors	   1	   and	   2	   (EGFRs	   1	  &	   2)	   in	  
particular	  are	  mutated	  in	  many	  epithelial	  cancers,	  and	  clinical	  studies	  suggest	  that	  they	  
play	   roles	   in	   the	   development	   and	   progression	   of	   various	   cancer	   types	   (Hynes	   &	  
MacDonald,	  2009).	  Thirteen	  cognate	  ligands	  have	  been	  characterized	  that	  bind	  to	  the	  
HER	   receptors,	  with	   the	   exception	   of	  HER2	  which	   has	   no	   known	   ligand.	   The	   cellular	  
mechanism	  of	  HER2	  activation	  is	  therefore	  not	  completely	  understood	  (Shah	  &	  Chen,	  
2010).	  The	  HER	  proteins	  remain	  in	  an	  inactive	  form,	  assuming	  a	  tethered	  conformation	  
until	  they	  are	  activated	  on	  ligand	  binding,	  but	  HER2	  remains	  constitutively	  active	  and	  
can	   therefore	   induce	   transformation	   in	   a	   ligand-­‐independent	   way	   (Alvarez	   &	  
Hortobagyi,	  2013;	  Nuti	  et	  al.,	  2011).	  Upon	  ligand	  binding	  to	  the	  extracellular	  domain,	  
homo-­‐	  or	  heterodimerization	  of	  the	  HER2	  receptor	  with	  itself	  or	  other	  members	  of	  the	  
EGFR	  family	  leads	  to	  phosphorylation	  of	  residues	  from	  the	  intracellular	  domain	  of	  the	  
HER2	   receptor	   and	   consequent	   activation	   of	   the	   HER2	   protein	   resulting	   in	   the	  
recruitment	  of	   signalling	  molecules	   from	  the	  cytoplasm	  and	   the	  activation	  of	   several	  
signalling	   pathways	   (Alvarez	   &	   Hortobagyi,	   2013).	   Downstream	   of	   HER2,	  
phosphorylation	  results	  in	  the	  recruitment	  of	  signalling	  molecules	  from	  the	  cytoplasm	  
and	  the	  induction	  of	  several	  potent	  intracellular	  signalling	  pathways	  which	  result	  in	  cell	  
differentiation,	   cell	   migration,	   signal	   transduction,	   cell	   motility,	   cell	   adhesion,	  
increased	  cell	  proliferation,	  protease	  expression	  and	  activation,	  and	  a	  cascade	  of	  other	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events	   which	   lead	   to	   functional	   changes	   in	   both	   embryonic	   and	   adult	   tissues	  
(Zagozdzon,	  Gallagher	  &	  Crown,	  2011;	  Gebhardt,	   Zänker	  &	  Brandt,	   1998;	  Nuti	  et	  al.,	  
2011;	   Shah	   &	   Chen,	   2010).	   The	   downstream	   signalling	   pathway	   which	   is	   activated	  
following	  HER2	  dimerization	   is	   significantly	   influenced	  by	   the	  pattern	  of	  dimerization	  
(Tai,	  Mahato	  &	  Cheng,	  2010).	  Different	  signalling	  cascades	  can	  potentially	  be	  initiated	  
depending	  on	   the	  dimeric	   combination	  of	  HER2	  with	   itself	   or	   other	  members	  of	   the	  
HER	  family.	  
	  
Figure	   1.2	   Schematic	   representation	   of	  HER2.	  HER2	   (purple)	   can	   form	   heterodimers	   as	   pictured	  with	  
EGFR	   (orange),	   HER3	   (red),	   as	   well	   as	   HER4	   (not	   pictured).	   EGFR	   (orange)	   assumes	   a	   tethered	  
conformation	   in	   the	   absence	   of	   a	   ligand.	   HER2	   remains	   active	   and	   is	   naturally	   ready	   for	   ligand	  
dimerization.	  	  
	  
Two	  of	   the	  most	   studied	  downstream	   signalling	   pathways	   in	   EGFR	   signalling	   are	   the	  
phosphoinositide-­‐3-­‐kinase	   (PI3K/AKT)	   and	   the	   mitogen	   activated	   protein	   kinase	  
(MAPK)	  cascades.	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1.4.1. Phosphoinositide-­‐3-­‐kinase	  (PI3K/AKT)	  cascade	  
	  The	  PI3K/AKT	  pathway	  is	  arguably	  the	  most	  significant	  pathway	  activated	  downstream	  
of	   HER2	   phosphorylation	   in	   cancer.	   The	   PI3K/AKT	   lipid	   kinase	   activity	   is	   stimulated	  
when	   HER2	   signals	   in	   conjunction	   with	   HER3.	   Apart	   from	   the	   HER2	   +	   HER3	  
heterodimer,	   it	   is	   also	   possible	   to	   induce	   the	   PI3K/AKT	   cascade	   by	   tyrosine-­‐
phosphorylated	   HER3	   homodimerization.	   This	   is	   because	   HER3	   possesses	   numerous	  
binding	   domains	   which	   can	   interact	   with	   the	   regulatory	   subunit	   p85	   of	   PI3K	   (Tai,	  
Mahato	   &	   Cheng,	   2010;	   Hynes	   &	  MacDonald,	   2009).	   Homodimers	   containing	   HER3	  
also	  have	  the	  potential	  to	  activate	  the	  AKT	  kinase	  via	  the	  PI3K	  lipid	  kinase.	  At	  the	  cell	  
membrane,	   Phosphatidylinositol	   (3,4,5)-­‐trisphosphate	   (PIP3)-­‐bound	   AKT	   becomes	  
phosphorylated,	   resulting	   in	   the	   activation	   of	   the	   mechanistic	   target	   of	   rapamycin	  
(mTOR)	   (Emde,	   Köstler	   &	   Yarden,	   2012;	   Pohlmann,	  Mayer	   &	  Mernaugh,	   2009).	   The	  
activation	   of	   mTOR	   induces	   several	   intracellular	   functions,	   interactions	   with	  
transcription	   factors,	   activation	   of	   metabolic	   pathways,	   apoptosis	   and	   angiogenesis,	  
which	  result	  in	  cell	  proliferation,	  invasion	  and	  survival	  (Pohlmann,	  Mayer	  &	  Mernaugh,	  
2009).	   Following	   the	   activation	   of	   AKT,	   PIP3	   is	   dephosphorylated	   by	   the	   tumour	  
suppressor	  gene	  phosphatase	  and	  tensin	  homolog	  (PTEN)	  to	  PIP2,	  which	  makes	  PTEN	  a	  
negative	   regulator	   of	   the	   PI3K/AKT	   signalling	   cascade	   (Figure	   1.3).	   PTEN	   is	   a	   protein	  
encoded	   by	   the	   PTEN	   gene,	   and	   functions	   as	   a	   tumour	   suppressor	   gene	   (Nahta	   &	  
O’Regan,	   2010).	   PTEN	   is	   important	   in	   the	   PI3K/AKT	   pathway	   because	   it	   inhibits	   the	  
downstream	   signalling	   of	   P13K	   (Saal	   et	   al.,	   2008).	   In	   normal	   signalling	   of	   the	   EGFR	  
receptors,	   the	  PI3K/AKT	  pathway	   induces	  cell	  survival	  and	   inhibits	  apoptosis	   (Jackson	  
et	  al.,	  2013).	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Figure	   1.3	   Schematic	   representation	   of	   the	   PI3K/AKT/mTOR	   pathway.	   Following	   ligand	   binding,	  HER2	  
dimerizes	  with	  activated	  HER3	  resulting	  in	  PI3K/AKT/mTOR	  signalling.	  
	  
1.4.2. Mitogen	  Activated	  Protein	  Kinase	  (MAPK)	  cascade	  
This	  is	  also	  known	  as	  the	  RAS/RAF/MEK/MAPK	  pathway.	  Unlike	  the	  PI3K/AKT	  pathway,	  
the	  MAPK	  pathway	  can	  be	  activated	  by	  all	  dimerizations	  involving	  HER2	   (HER1/HER2,	  
HER2/HER2,	   HER2/HER3,	   and	   HER2/HER4)	   (Tai,	   Mahato	   &	   Cheng,	   2010).	   In	   this	  
cascade,	   the	   adaptor	   protein	   known	   as	   Growth	   Factor	   Receptor	   Bound	   Protein	   2	  
(GRB2)	   which	   recognises	   tyrosine-­‐phosphorylated	   sites	   on	   the	   activated	   receptor,	  
binds	  to	  the	  guanine	  nucleotide	  exchange	  factor	  Son	  of	  Sevenless	  (SOS).	  The	  GRB2/SOS	  
complex	   binding	   to	   the	   receptor	   activates	   SOS,	   resulting	   in	   a	   loss	   of	   Guanosine	  
Diphosphate	   (GPD)	   from	   inactive	   RAS.	   Free	   RAS	   is	   then	   activated	   by	   binding	   to	  
Guanosine-­‐5’-­‐Triphosphate	   (GTP).	   RAS/GTP	   complex	   then	   binds	   to	   activate	   Raf-­‐1	  
15	  	  
(MAP3K).	   Raf-­‐1	   can	   then	   activate	   MEK1	   (MAP2K1)	   and	   MEK2	   (MAP2K2)	   which	   are	  
essential	  for	  downstream	  signalling	  of	  RAS	  and	  Raf-­‐1.	  The	  activation	  of	  MEK	  results	  in	  
the	   phosphorylation	   of	   ERK	   (Figure	   1.4).	   ERK	   activation	   is	   crucial	   to	   certain	  
physiological	   functions	   in	   the	   cell,	   including	   cell	   cycle	   control,	   differentiation,	  
migration,	   apoptosis	   and	   angiogenesis	   (Pohlmann,	   Mayer	   &	   Mernaugh,	   2009).	   The	  
pathway	  also	  serves	  in	  stimulating	  cell	  proliferation	  (Jackson	  et	  al.,	  2013).	  
	  
	  
Figure	   1.4	   Schematic	   representation	   of	   the	   RAS/RAF/MEK/MAPK	   cascade.	   The	  MAPK	  pathway	   can	   be	  
activated	  by	  dimerization	  of	  HER2	  with	  HER1,	  HER3	  or	  HER4.	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1.5 HER2	  as	  a	  prognostic	  factor	  in	  breast	  cancer	  
Gene	  amplification	  of	  HER2	  is	  the	  main	  mechanism	  by	  which	  abnormally	  high	  levels	  of	  
the	   185kDa	   glycoprotein	   are	   found	   in	   HER2	   overexpressed	   tumours	   (Wolff	   et	   al.,	  
2007).	   It	   is	   now	   recommended	   that	   the	   HER2	   status	   is	   determined	   for	   all	   invasive	  
breast	  cancer	  patients	  (Dean-­‐Colomb	  &	  Esteva,	  2008).	  Determination	  of	  HER2	  status	  is	  
important	  for	  a	  number	  of	  reasons.	  HER2	  positivity	  is	  associated	  with	  poor	  prognosis	  in	  
patients	  with	  early	  breast	  cancer	  who	  do	  not	   receive	  any	  adjuvant	  systemic	   therapy.	  
This	   makes	   HER2	   status	   a	   crucial	   factor	   in	   determining	   the	   type	   of	   treatment	   to	  
administer	   to	   patients,	   particularly	   in	   cases	   where	   adjuvant	   therapy	   might	   be	  
beneficial	  (Wolff	  et	  al.,	  2007).	  HER2	  positivity	   is	  known	  to	  be	  associated	  with	  relative	  
resistance	   to	   endocrine	   therapy,	   e.g.	   tamoxifen.	  HER2	   status	   has	   also	   been	   recently	  
associated	  with	   resistance	  or	   sensitivity	   to	   various	   chemotherapeutic	   agents	   such	   as	  
nonathracycline	   and	  nontaxane.	  Conversely,	   studies	  have	   shown	   that	  HER2	   positivity	  
predicts	   a	   favourable	   response	   to	   anthracycline-­‐containing	   chemotherapy	   regimens.	  
HER2	   status	   may	   also	   play	   a	   role	   in	   predicting	   response	   to	   paclitaxel	   (Wolff	   et	   al.,	  
2007).	  More	  importantly,	  HER2	  positivity	  is	  known	  to	  predict	  a	  favourable	  response	  to	  
Trastuzumab	  (Herceptin®,	  Genentech,	  Inc.,	  South	  San	  Francisco,	  CA,	  USA;	  Hoffmann-­‐La	  
Roche	   Ltd.,	   Basel,	   Switzerland),	   a	   humanised	   monoclonal	   antibody	   that	   targets	   the	  
extracellular	  domain	  of	  HER2	  and	  inhibits	  tumour	  growth	  in	  vitro	  and	  in	  vivo	  (Saini	  et	  
al.,	  2011).	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1.6 Testing	  for	  HER2	  status	  
Studies	   have	   shown	   a	   good	   correlation	   in	   the	   protein	   overexpression,	   gene	  
amplification	  and	  mRNA	  levels	  of	  HER2.	  This	  allows	  for	  reliable	  testing	  for	  HER2	  status	  
in	   cancer	   cells	   by	   immunistochemistry	   and	   FISH.	   These	   two	   methods	   are	   currently	  
recommended	  for	  testing	  HER2	  status	  in	  breast	  cancer	  patients	  (Vogel,	  2010;	  Wolff	  et	  
al.,	  2007).	  	  
1.6.1. Testing	  for	  HER2	  status	  at	  the	  protein	  level	  
1.6.1.1. Immunohistochemistry	  
Immunohistochemistry	   is	   currently	   the	   most	   widely	   used	   primary	   technique	   in	   the	  
determination	  of	  HER2	  status	  (Moelans	  et	  al.,	  2011).	  The	  use	  of	  immunohistochemical	  
methods	  in	  testing	  for	  HER2	  in	  breast	  cancer	  allows	  tumours	  to	  be	  classified	  based	  on	  
semi-­‐quantitative	   methods	   of	   evaluation	   of	   HER2	   protein	   expression,	   such	   as	   the	  
mouse	   monoclonal	   antibody	   clone	   CB11	   (Novocastra	   Laboratories,	   Newcastle	   upon	  
Tyne,	   England),	   the	   Rabbit	   monoclonal	   antibody	   clone	   SP3	   (LabVision	   corporation,	  
Runcorn,	   England),	   the	   Rabbit	   monoclonal	   antibody	   clone	   4D5	   (Ventana	   Medical	  
Systems,	   Tuscon,	   Arizona),	   and	   the	   HercepTest	   (Dako,	   Glostrup,	   Denmark)	   which	   is	  
based	   on	   the	   DAKO	   A0485	   rabbit	   polyclonal	   antibody	   (Rhodes	   et	   al.,	   2010;	   Vogel,	  
2010;	  Wolff	  et	  al.,	  2007;	  van	  der	  Vegt	  et	  al.,	  2009).	  Tumours	  are	  graded	  0	  to	  3+	  using	  
the	   HercepTest	   score,	   an	   algorithm	   by	  which	   tumours	   are	   scored	   based	   on	   staining	  
intensity	  and	  percentage	  of	  tumour	  cells	  stained.	  The	  HercepTest	  guidelines	  are	  used	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to	   grade	   tumours	   as	   0	   (negative),	   1+	   (weak	   and	   incomplete	  membrane	   staining),	   2+	  
(complete	  non-­‐uniform	  membrane	  staining	  or	  with	  a	  weak	  intensity	  in	  more	  than	  10%	  
of	  the	  tumour	  cells)	  or	  3+	  (complete	  strong-­‐positive	  membrane	  staining	  in	  more	  than	  
30%	  of	  tumour	  cells)	  (Moelans	  et	  al.,	  2011).	  	  Patients	  with	  IHC	  scores	  of	  0	  and	  1+	  are	  
considered	   negative	   for	   HER2	   and	   therefore	   not	   eligible	   for	   Trastuzumab	   therapy.	  
Tumours	  with	  IHC	  scores	  of	  2+	  are	  considered	  to	  be	  equivocal	  cases,	  as	  several	  studies	  
have	  shown	  that	  such	  tumours	  can	  be	  found	  to	  have	  HER2	  gene	  amplification.	  Patients	  
with	  an	  IHC	  score	  of	  3+	  are	  considered	  to	  be	  a	  definite	  HER2	  positivity,	  and	  patients	  in	  
this	  group	  are	   considered	  eligible	   for	  Trastuzumab	   treatment	   (Moelans	  et	  al.,	   2011).	  
The	   use	   of	   immunohistochemistry	   in	   testing	   for	  HER2	   status	   in	   patients	   is	   however	  
laden	   with	   a	   number	   of	   drawbacks.	   Quality	   control	   and	   standardization	   of	   tests	   is	  
critical	   in	   eliminating	   inter-­‐observer	   variability.	   In	   contrast	   to	   FISH,	   IHC	   is	   prone	   to	  
staining	   artefacts	  which	  may	   be	   caused	   by	   inappropriate	   tissue	   handling.	   Subjective	  
interpretation	  of	  the	  intensity	  of	  membrane	  staining	  may	  also	  pose	  a	  major	  obstacle	  in	  
the	   interpretation	   of	   IHC	   results	   (Moelans	   et	   al.,	   2011;	   Vogel,	   2010).	   In	   cases	   with	  
equivocal	   IHC	  2+	   score,	  determination	  of	   treatment	  approach	   is	  usually	  after	   further	  
analysis	   of	   the	   tumour	   by	   other	   methods	   of	   testing	   such	   as	   Fluorescence	   in	   situ	  
Hybridization	  (FISH)	  and	  chromogenic	  in	  situ	  hybridization	  (CISH).	  	  
1.6.1.2. The	  Enzyme-­‐Linked	  Immunosorbant	  Assay	  (ELISA)	  
The	  Enzyme-­‐Linked	  Immunosorbant	  Assay	  (ELISA)	  is	  used	  to	  measure	  protein	  levels	  in	  
serum.	  The	  use	  of	  ELISA	   in	   testing	   for	  HER2	   status	  measures	   the	  amount	  of	  HER2	   in	  
serum	  extracellular	  domain.	  Matrix	  metalloproteinases	  cleaved	  to	   the	  HER2	   receptor	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protein	   can	   be	   detected	   in	   the	   extracellular	   domain	   that	   is	   released	   into	   the	  
circulation.	  	  Elevated	  serum	  ECD	  levels	  (≥	  15ng/ml)	  is	  associated	  with	  poor	  prognosis,	  
progressive	  metastasis,	   and	  a	  poor	   response	   to	   treatment.	  However,	  not	  all	  patients	  
with	  HER2	  positive	  breast	  cancers	  appear	  to	  have	  elevated	  serum	  ECD	  levels,	  therefore	  
the	  use	  of	  this	  method	  of	  testing	  in	  determination	  of	  treatment	  is	  not	  recommended	  in	  
clinical	  settings	  (Moelans	  et	  al.,	  2011).	  
1.6.2. Testing	  for	  HER2	  status	  at	  the	  DNA	  level	  
1.6.2.1. Fluorescence	  In	  Situ	  Hybridization	  (FISH)	  
Fluorescence	   in	   situ	   hybridization	   is	   a	   cytogenetic	   technique	   in	   which	   fluorescently	  
labelled	   DNA	   probes	   are	   used	   to	   detect	   and	   visualise	   a	   specific	   DNA	   sequence	  with	  
which	   they	   share	   a	   high	   degree	   of	   complementarity.	   Dual-­‐colour	   FISH	   (Vysis	  
Pathvysion,	   DAKO	   PharmDx)	   is	   the	   FDA-­‐approved	   FISH	   testing	   kit,	   which	   hybridizes	  
complementary	  HER2	   DNA	  on	   slides,	   and	   the	   resulting	   probes	   are	   visualised	  using	   a	  
fluorescence	  microscope.	   In	   the	   current	   guidelines	   for	  HER2	   testing	  by	   FISH,	   a	  HER2	  
gene	  signals	  to	  chromosome	  17	  signals	  ratio	  (FISH	  ratio)	  of	  ≤2:2	  is	  considered	  a	  normal	  
HER2	  expression	  (Wolff	  et	  al.,	  2007).	  A	  FISH	  ratio	  of	  ≥2.2	  counted	  in	  a	  minimum	  of	  20	  
tumour	  cells,	  and	   in	  at	   least	  2	   invasive	   tumour	  areas,	   is	  considered	  positive	   for	  gene	  
amplification.	  In	  equivocal	  cases	  of	  FISH	  assay,	  it	  is	  recommended	  that	  additional	  cells	  
are	   counted	   or	   the	   test	   is	   repeated.	   In	   some	   cases,	   an	   IHC	   test	  may	   be	   required	   to	  
confirm	  true	  equivocality.	  Due	   to	   the	  complexity	  of	   the	  FISH	   technique,	  and	   the	   fact	  
that	   the	   scoring	   process	   is	   very	   time	   consuming,	   it	   is	   not	   a	   very	   practical	   primary	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screening	  tool.	  In	  many	  clinical	  settings,	  the	  FISH	  technique	  is	  only	  used	  to	  determine	  
treatment	  decisions	  in	  patients	  with	  equivocal	  IHC	  2+	  score	  (Moelans	  et	  al.,	  2011).	  
1.6.2.2. Chromogenic	  In	  Situ	  Hybridization	  (CISH)	  
The	   Chromogenic	   in	   situ	   hybridization	   technique	   is	   a	   method	   of	   HER2	   testing	  
developed	  by	  Tanner	  et	  al.	  as	  an	  alternative	  to	  FISH.	  CISH	  was	  approved	  by	  the	  FDA	  in	  
2008.	   CISH	   detects	   the	   HER2	   gene	   copies	   using	   a	   conventional	   immunoperoxidase	  
reaction.	  This	  method	  of	  visualization	  of	  HER2	  allows	  scoring	  with	  a	  conventional	  light	  
microscope.	   Using	   this	   method,	   a	   scoring	   system	   has	   been	   established	   where	   an	  
average	   copy	   number	   of	   >10	   or	   with	   big	   clusters	   in	   more	   than	   50%	   of	   the	   tumour	  
nuclei,	  is	  considered	  HER2	  amplification	  (Tanner	  et	  al.,	  2000).	  A	  minimum	  of	  30	  tumour	  
cells	  are	  counted.	  The	  CISH	  method	  has	  also	  been	  shown	  to	  correlate	  well	  with	  FISH	  
and	   IHC	  methods	   (Moelans	   et	   al.,	   2011).	  Most	   available	   CISH	   assays	   only	   score	   the	  
HER2	  copy	  number,	  but	  recently,	  a	  new	  dual-­‐colour	  CISH	  (Dako	  duo	  CISH	  kit)	  assay	  has	  
been	   developed	   which	   allows	   for	   the	   detection	   of	   a	   HER2	   probe	   (red)	   and	   a	  
chromosome	  17	  probe	  (blue),	  therefore	  allowing	  for	  the	  assessment	  of	  the	  HER2	  gene	  
ratio	  relative	  to	  chromosome	  17	  signals	  (Moelans	  et	  al.,	  2011).	  
1.6.2.3. Silver	  In	  Situ	  Hybridization	  (SISH)	  
The	  SISH	  technique	  is	  used	  for	  determination	  of	  HER2	  gene	  expression	  (Jacquemier	  et	  
al.,	   2013).	   SISH	   combines	   the	  accuracy	  of	   the	   FISH	   technique	  and	   the	  morphological	  
control	  of	  the	  IHC	  technique,	  with	  the	  use	  of	  opaque	  silver,	  instead	  of	  fluorescent	  spot-­‐
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like	   signals.	   The	   resulting	   signal	   is	   a	   permanent	   result	   that	   can	   be	   visualised	   by	   an	  
ordinary	   light	  microscope.	   The	   SISH	   technique	   is	   relatively	   new,	   and	   though	   studies	  
have	   shown	   a	   high	   concordance	   between	   FISH	   and	   CISH	   techniques,	   further	  
independent	  validation	   is	   recommended	  before	   the	  SISH	   test	   can	  be	  used	   in	   routine	  
clinical	   settings	   (Gómez-­‐Martin	  et	   al.,	   2012;	   Jacquemier	  et	   al.,	   2013;	   Shousha	  et	   al.,	  
2009).	  
1.6.3. Testing	  for	  HER2	  status	  at	  the	  RNA	  level	  
1.6.3.1. Quantitative	   Real-­‐Time	   Reverse	   Transcription	  
Polymerase	  Chain	  Reaction	  (qRT-­‐PCR)	  
Due	   to	   the	   relative	   instability	  of	  RNA	  compared	   to	  DNA,	  and	   the	  severe	  degradation	  
caused	   by	   cross-­‐linking	   during	   fixation,	   RNA	   samples	   isolated	   from	   Formalin-­‐fixed	  
paraffin-­‐embedded	   (FFPE)	   samples,	   the	   qRT-­‐PCR	  method	   is	   not	   often	   used	   in	  HER2	  
testing	   in	   clinical	   settings.	   This	  method,	   however,	   has	   been	   shown	   to	   correlate	  well	  
with	   IHC	  and	  FISH	  techniques,	  even	   in	  RNA	  templates	   isolated	   from	  FFPE	  material.	  A	  
very	   important	  use	  of	  qRT-­‐PCR	   in	   cancer	   testing	   is	   the	  Oncotype	  DX	  assay	   (Genomic	  
health,	  USA),	  a	  method	  by	  which	  the	  likelihood	  of	  disease	  recurrence	  in	  women	  with	  
breast	  cancer	  is	  predicted.	  A	  recurrence	  score	  is	  obtained	  after	  analysing	  tumour	  cells	  
using	  a	  panel	  of	  21	  genes,	  which	  include	  HER2,	  ER	  and	  PR	  (Moelans	  et	  al.,	  2011).	  
The	  optimal	  method	  of	  testing	  for	  HER2	  in	  breast	  cancer	  remains	  controversial	  despite	  
the	   development	   of	   various	   reliable	   tests.	   Most	   organisations	   rely	   on	   HER2	   3+	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positivity	  by	  immunohistochemistry	  as	  the	  preferred	  method	  for	  selecting	  patients	  for	  
Trastuzumab	   therapy.	   (Vogel,	  2010).	  The	   IHC	  technique	  has	  been	  shown	  to	  correlate	  
well	  with	   the	   FISH	   technique,	  with	   only	   equivocal	   cases	   needing	   confirmatory	   tests,	  
usually	   carried	   out	   by	   FISH	   (Meijer	   et	   al.,	   2011).	   Therefore	   screening	   of	   newly	  
diagnosed	  breast	  cancers	  is	  mostly	  performed	  by	  immunohistochemistry	  (Vogel,	  2010).	  
Accurate	   testing	   for	   HER2	   is	   important	   as	   false	   positive	   tests	   could	   lead	   to	   the	  
administration	  of	  an	  expensive	  (£25,000	  -­‐	  £35,000	  per	  patient	  per	  year)	  and	  ineffective	  
treatment	  with	  very	   serious	   side	  effects;	  due	   to	   the	  cardiotoxicity	  of	   the	  drug,	   some	  
patients	   who	   undergo	   Trastuzumab	   treatment	   are	   likely	   to	   develop	   cardiac	  
dysfunction	   (Minami,	   Matsumoto	   &	   Horiuchi,	   2010;	   Moelans	   et	   al.,	   2011).	   A	   false	  
negative	   test	   on	   the	   other	   hand,	   would	   deprive	   the	   patient	   of	   an	   important	  
therapeutic	  option	  (Moelans	  et	  al.,	  2011).	  
1.7 Therapies	  in	  HER2	  positive	  cancer	  
The	   current	   therapy	   for	   breast	   cancer	   patients	   with	   early	   and	   metastatic	   disease,	  
involves	  the	  use	  of	  multiple	  agents.	  Endocrine	  therapies	  are	  administered	  to	  patients	  
with	  hormone	  receptor-­‐positive	  disease,	  anti-­‐HER2	  therapies	  for	  HER2-­‐overespressing	  
tumours,	   and	   the	   poly-­‐ADP-­‐ribose	   polymerase	   (PARP)	   inhibitors	   are	   currently	   being	  
developed	  in	  clinical	  trials,	  to	  treat	  patients	  with	  breast	  cancer	  gene	  1	  or	  2	  (BRCA1/2)-­‐
mutated	   tumours	   (Awada,	   Bozovic-­‐Spasojevic	   &	   Chow,	   2012;	   Eroles	   et	   al.,	   2012).	  
Accurate	  assessment	  of	  the	  HER2	  status	  of	  all	  invasive	  ductal	  breast	  carcinomas	  (IDC)	  is	  
essential	   in	  determining	  the	  appropriate	  treatment	  regimen	  for	  individual	  cases.	   	  The	  
inhibition	  of	  growth	  factor	  receptors	  can	  be	  achieved	  either	  by	  the	  use	  of	  monoclonal	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antibodies	  which	  bind	  to	  the	  extracellular	  epitopes	  found	  in	  tumour	  cells,	  or	  the	  use	  of	  
small	   tyrosine	   kinase	   inhibitors	   (TKIs)	   directed	   to	   extracellular	   epitopes	   and	  
intracellular	   signalling	   pathways	   (Alvarez	   &	   Hortobagyi,	   2013).	   These	   two	  
complementary	   approaches	   have	   become	   part	   of	   the	   standard	   of	   care	   for	   patients	  
with	  HER2	   positive	  breast	   cancer.	  A	  number	  of	   chemotherapeutic	   targets	  have	  been	  
approved	  by	   the	  US	   Food	   and	  Drug	   agency	   (FDA)	   for	   use	   in	   the	   treatment	  of	  HER2-­‐
positive	  breast	  cancer.	  
1.7.1. Trastuzumab	  treatment	  for	  patients	  with	  HER2	  positive	  
invasive	  breast	  cancer	  
Perhaps	  the	  most	  important	  reason	  for	  determining	  HER2	  status	  in	  patients	  is	  for	  the	  
appropriate	  administration	  of	  the	  humanized	  anti-­‐HER2	  monoclonal	  antibody	  therapy	  
Trastuzumab	  to	  patients	  with	  invasive	  breast	  cancer	  that	  overexpress	  HER2	  (Bartlett	  et	  
al.,	  2001;	  Vogel,	  2010).	  Trastuzumab	  was	  approved	  for	  use	  in	  September	  1998,	  in	  the	  
treatment	  of	  metastatic	  HER2-­‐positive	  breast	   cancer.	   	   In	   January	  2008,	  Trastuzumab	  
was	  approved	  for	  use	  as	  first-­‐line	  treatment	  for	  patients	  with	  early	  stage	  HER2-­‐positive	  
breast	   cancer	   (Piccart-­‐Gebhart	   et	   al.,	   2005;	   Romond	   et	   al.,	   2005).	   More	   recently,	  
Trastuzumab	  is	  also	  used	  in	  in	  the	  treatment	  of	  metastatic,	  unresectable	  HER2-­‐positive	  
gastric	  and	  gastro-­‐oesophageal	  junction	  cancer	  (Bang	  et	  al.,	  2010).	  Trastuzumab	  is	  also	  
administered	   in	   both	  metastatic	   and	   adjuvant	   settings	   and	   is	   currently	   administered	  
with	  chemotherapies	  involving	  paclitaxel	  and	  docetaxel	  which	  results	  in	  increased	  time	  
to	   disease	   progression,	   and	   overall	   survival	   compared	  with	   Herceptin	   therapy	   alone	  
(Kang	  et	  al.,	  2008).	  	  
24	  	  
The	   Trastuzumab	   antibody	   consists	   of	   two	   antigen-­‐specific	   sites	   that	   bind	   to	   the	  
extracellular	   domain	   of	   HER2,	   resulting	   in	   the	   inhibition	   of	   HER2	   and	   apoptosis	   of	  
tumour	  cells	  overexpressing	  HER2	  (Vogel,	  2010;	  Geyer	  et	  al.,	  2006),	  and	  the	  inhibition	  
of	  the	  intracellular	  pathways	  involved	  in	  HER2	  activation	  (Stern,	  2012)	  (Figure	  1.5).	  The	  
exact	  mechanism	  by	  which	  Trastuzumab	  exerts	  its	  antitumor	  activity	  has	  still	  not	  been	  
fully	  elucidated.	  Several	  possible	  mechanisms	  have	  been	  proposed;	  these	   include	  the	  
activation	   of	   antibody-­‐dependent	   cellular	   cytotoxicity,	   inhibition	   of	   angiogenesis,	  
blockage	   of	   proteolytic	   cleavage	   of	   the	   HER2	   extracellular	   domain	   and	   consequent	  
downregulation	  of	  HER2	   receptors,	  disruption	  of	  downstream	  proliferative	  pathways,	  
inhibition	  of	  cell	  cycle	  progression,	  inhibition	  of	  signal	  transduction	  in	  the	  intracellular	  
domain	   of	   HER2,	   and	   the	   inhibition	   of	   repair	   of	   DNA	   damage	   caused	   by	   cancer	  
treatment	  (Spector	  &	  Blackwell,	  2009;	  Awada,	  Bozovic-­‐Spasojevic	  &	  Chow,	  2012).	  	  
The	   Initial	   approval	   of	  Trastuzumab	   in	   the	   treatment	   of	  HER2	   overexpressing	   breast	  
cancers,	  was	  based	  on	  studies	  in	  patients	  with	  metastatic	  breast	  cancer	  (Dean-­‐Colomb	  
&	  Esteva,	  2008).	  A	  phase	  III	  clinical	  trial	  by	  Slamon	  et	  al.	   (2001)	  compared	  the	  use	  of	  
Trastuzumab	  plus	  various	  chemotherapeutic	  agents	  as	  a	  first-­‐line	  treatment,	  with	  the	  
use	  of	   chemotherapy	   alone	   in	  metastatic	   breast	   cancer.	   This	   study	   found	   that	   there	  
was	   a	   significant	   improvement	   in	   overall	   survival	   (25.1	   vs.	   20.3	  months)	   and	   overall	  
response	  rate	  (50	  vs.	  32%),	  and	  a	  significantly	  longer	  median	  progression-­‐free	  survival	  
(6.9	  vs.	  3.0	  months).	  	  These	  findings	  resulted	  in	  a	  62%	  reduction	  in	  the	  risk	  of	  disease	  
progression	  (Slamon	  et	  al.,	  2001).	  Based	  on	  the	  results	  of	  the	  study,	  Trastuzumab	  was	  
approved	  with	   paclitaxel	   as	   a	   first-­‐line	   treatment	   of	  HER2-­‐overexpressing	  metastatic	  
breast	  cancer	   (Alvarez	  &	  Hortobagyi,	  2013).	  Several	   independent	  randomized	  studies	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have	  also	  shown	  that	  the	  addition	  of	  Trastuzumab	  to	  chemotherapy	  reduced	  the	  rate	  
of	  recurrence	  by	  50%	  in	  women	  with	  HER2-­‐positive	  early	  breast	  cancer.	  In	  2005,	  four	  
clinical	   trials	   in	  patients	  with	  HER2	  overexpressing	  early	  breast	   cancer	   compared	   the	  
effects	  administration	  of	  Trastuzumab	  as	  an	  adjuvant	  versus	  observation.	  The	  results	  
showed	  that	  the	  recurrence	  rate	  of	  patients	  was	  reduced	  by	  a	  third,	  and	  the	  	  mortality	  
rate	  was	   reduced	   by	   half	   (Wolff	   et	   al.,	   2007).	   On	   the	   basis	   of	   these	   results,	   the	   UK	  
National	   Institute	   for	   Health	   and	   Care	   Excellence	   (NICE)	   and	   the	   US	   Food	   and	   Drug	  
Administration	   (FDA)	   and	   the	   European	   Medicines	   Agency	   (EMA)	   approved	   the	  
adjuvant	  use	  of	  Trastuzumab	  with	  chemotherapy	  in	  patients	  with	  HER2	  overexpressing	  
early	   breast	   cancer	   (Pivot	   et	   al.,	   2013;	  Wolff	   et	   al.,	   2007;	   Emde,	   Köstler	   &	   Yarden,	  
2012;	  Goddard	  et	  al.,	  2012).	  	  
1.7.2. Lapatinib	  
In	   March	   2007,	   Lapatinib	   (Tykerb,	   GlaxoSmithKline,	   Philadelphia,	   PA,	   USA)	   was	  
approved	   for	  use	   in	   the	  metastatic	  HER2-­‐positive	  breast	  cancers.	  Lapatinib	   is	  a	   small	  
molecule	  reversible	  dual	  EGFR/HER1	  and	  HER2	   tyrosine	  kinase	   inhibitor	  administered	  
in	   combination	   with	   capecitabine	   for	   the	   treatment	   of	   advanced	   metastatic	   HER2-­‐
positive	   breast	   cancers	   where	   the	   patients	   had	   been	   given	   prior	   therapy	   including	  
anthracycine,	   a	   taxane,	   and	   Trastuzumab,	   and	   where	   these	   therapies	   have	   failed	  
(Geyer	  et	  al.,	   2006;	  Awada,	  Bozovic-­‐Spasojevic	  &	  Chow,	  2012;	  Wolff	  et	  al.,	   2007).	   In	  
January	  2010,	  Lapatinib,	   in	  combination	  with	  Letrozole	  (Femara®),	  was	  also	  approved	  
for	   the	   treatment	  of	  HER2-­‐positive	  breast	   cancer	  patients	  whose	   tumours	  were	   also	  
hormone	   receptor-­‐positive,	   and	   for	  whom	  hormonal	   therapy	   is	   indicated	   (Alvarez	  &	  
Hortobagyi,	  2013).	  Lapatinib	  binds	  to	  the	  intracellular	  tyrosine	  kinase	  domains	  of	  HER1	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and	  HER2,	  and	  selectively	  inhibits	  HER1	  or	  HER2	  overexpressing	  tumour	  cells,	  resulting	  
in	  the	  inhibition	  of	  phosphorylation,	  and	  the	  inhibition	  of	  downstream	  pathways	  which	  
lead	   to	   cell	   proliferation	  and	   cell	   survival	   (Awada,	  Bozovic-­‐Spasojevic	  &	  Chow,	  2012)	  
(figure	  1.5).	  	  
1.7.3. Pertuzumab	  	  
In	  June	  2012,	  pertuzumab	  was	  approved	  for	  use	  in	  combination	  with	  Trastuzumab	  and	  
docetaxel,	  in	  the	  treatment	  of	  patients	  with	  HER2	  positive	  breast	  cancer	  who	  had	  not	  
received	  prior	  HER2	   therapy	  or	   chemotherapy	   for	  metastatic	   disease	   (Baselga	  et	   al.,	  
2012).	  	  
Pertuzumab	   is	   an	   anti	   HER2	   antibody	   that	   binds	   to	   subdomain	   II	   of	   the	   HER2	  
extracellular	  domain	  (Franklin	  et	  al.,	  2004).	  Pertuzumab	  functions	  in	  the	  prevention	  of	  
HER2	   dimerization	   with	   ligand-­‐activated	   HER2	   receptors,	   mostly	   HER3	   (Baselga	   &	  
Swain,	  2009;	  Agus	  et	  al.,	  2002).	  Trastuzumab	   is	  directed	  towards	   ligand-­‐independent	  
HER2	  signalling	  (HER2/HER2	  interactions),	  while	  Pertuzumab	  interferes	  with	  activation	  
of	  HER2	  via	   ligand-­‐dependent	  HER3-­‐mediated	  signalling	   (Scheuer	  et	  al.,	  2009)	   (figure	  
1.5).	   A	   combinatorial	   therapy	   involving	   Trastuzumab	   and	   pertuzumab	   in	   HER2	  
overexpressed	   breast	   cancer	   has	   been	   associated	   with	   significant	   antitumor	   activity	  
(Scheuer	  et	  al.,	  2009;	  Nahta,	  Hung	  &	  Esteva,	  2004).	  	  	  
Other	   chemotherapeutic	   agents	   including	   Trastuzumab	   Emtansine	   (T-­‐DM1),	   and	  
Neratinib,	  have	  shown	  significant	  activity	  in	  the	  inhibition	  of	  cell	  membrane	  receptors	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in	   clinical	   trials,	   but	   have	   not	   yet	   been	   approved	   for	   clinical	   practice	   (Alvarez	   &	  
Hortobagyi,	  2013).	  	  
	  
Figure	   1.5	   Schematic	   representation	   of	   the	   mechanisms	   of	   action	   of	   current	   therapies	   for	   HER2	  
overexpressing	   breast	   cancer.	   Downstream	   signalling	   is	   inhibited	   by	   monoclonal	   antibodies	  
Trastuzumab	   and	   pertuzumab,	  which	   inhibit	   dimerization	   by	   binding	   to	   subdomains	   IV	   and	   II	   of	   HER	  
receptors	  respectively.	  Lapatinib,	  a	  small-­‐molecule	  tyrosine	  kinase	  inhibitor,	  inhibits	  phosphorylation	  by	  
binding	  to	  the	  intracellular	  kinase	  domain	  of	  HER2	  receptors.	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1.8 Challenges	   and	   unmet	   needs	   in	   the	   treatment	   of	   HER2	  
positive	  breast	  cancer	  
Although	   the	   administration	   of	   Trastuzumab-­‐based	   treatment	   has	   become	   the	  
standard	  of	  care	  for	  patients	  with	  HER2	  positive	  metastatic	  breast	  cancer,	  for	  reasons	  
that	  are	  unclear,	  many	  patients	  will	  either	  not	  respond	  to	  Trastuzumab	  treatment,	  or	  
eventually	   progress	   despite	   treatment	   (Awada,	   Bozovic-­‐Spasojevic	   &	   Chow,	   2012;	  
Koletsa	  et	  al.,	  2008).	  It	  is	  estimated	  that	  up	  to	  40%	  of	  patients	  with	  metastatic	  breast	  
cancer	   do	   not	   respond	   to	   Trastuzumab	   or	   combinatorial	   therapies	   which	   include	  
Trastuzumab	   (Awada,	   Bozovic-­‐Spasojevic	   &	   Chow,	   2012).	   Patients	   who	   achieve	   an	  
initial	  response	  to	  Herceptin	  plus	  chemotherapy	  generally	  acquire	  resistance	  within	  1	  
year	  (Freudenberg	  et	  al.,	  2009;	  Awada,	  Bozovic-­‐Spasojevic	  &	  Chow,	  2012;	  Kang	  et	  al.,	  
2008).	  As	  a	  result,	  significant	  efforts	  have	  been	  applied	  to	  elucidating	  the	  mechanisms	  
underlying	  Herceptin	  resistance,	  and	  finding	  other	  therapies	  besides	  Herceptin	  for	  the	  
treatment	  of	  HER2	  positive	  breast	  cancer.	  	  
Development	  of	  resistance	  to	  HER2	  therapies	  poses	  a	  serious	  concern,	  and	  ultimately	  
results	   in	   shorter	   time	   to	   tumour	  progression,	  and	   limited	  overall	   survival.	  There	  are	  
several	   mechanisms	   by	   which	   HER2	   overexpressing	   tumour	   cells	   may	   develop	  
resistance	  to	  HER2	  therapies.	  Cross-­‐talk	  between	  intracellular	  signalling	  pathways	  and	  
redundancy	   in	   growth	   factor	   receptors	   have	   been	   implicated	   in	   the	   development	   of	  
resistance	   in	   most	   patients	   with	   HER2-­‐positive	   breast	   cancer.	   For	   example,	  
Trastuzumab	   may	   be	   ineffective	   in	   inhibiting	   PI3K	   due	   to	   lateral	   activation	   of	   the	  
pathway	  by	  other	  members	  of	  the	  HER	  family	  (i.e.	  HER1	  and	  HER3),	  thereby	  leading	  to	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continuing	   cell	   proliferation	   (Kerbel,	   2009).	   Alterations	   in	   receptor-­‐antibody	  
interactions	   may	   lead	   to	   resistance,	   either	   through	   mutations	   in	   HER2	   that	   disrupt	  
binding,	  the	  masking	  of	  antigens	  on	  the	  tumour	  cell	  surface	  through	  glycoproteins	  such	  
as	  MUC-­‐4,	  or	  the	  overexpression	  of	  truncated	  isoforms	  of	  HER2,	  e.g.	  p95	  that	  lacks	  the	  
extracellular	   domain,	   and	   therefore	   does	   not	   have	   a	   Trastuzumab	   binding	   site	  
(Sperinde	  et	  al.,	  2010).	  In	  addition,	  mutations	  in	  PTEN	  which	  result	  in	  loss	  of	  function,	  
or	  activating	  mutations	  in	  PI3K,	  may	  lead	  to	  enhanced	  phosphorylation	  and	  signalling	  
of	  AKT	  which	  is	  downstream	  of	  HER2,	  therefore	  bypassing	  any	  HER2-­‐directed	  therapy,	  
and	   resulting	   in	   cellular	   proliferation	   of	  HER2	   (Coughlin	   et	   al.,	   2010).	   Mutations	   or	  
conditions	   that	   lead	   to	   the	   loss	   of	   tumour	   suppressor	   gene	  Cyclin-­‐dependent	   kinase	  
inhibitor	  1B	  (p27)	  may	  contribute	  to	  Trastuzumab	   resistance.	  The	  phosphorylation	  of	  
the	  p27	  gene	  prevents	   the	  degradation	  of	  Trastuzumab	  and	   leads	  to	  cell	  cycle	  arrest	  
(Bedard,	   de	   Azambuja	   &	   Cardoso,	   2009).	   The	   p27	   gene	   is	   therefore	   crucial	   in	   the	  
efficiency	  of	  Trastuzumab	  via	  the	   inhibition	  of	  HER2.	   In	  addition,	  the	  amplification	  or	  
overexpression	  of	  cyclin	  E	  will	   result	   in	   increased	  proliferation	  and	   increased	  tumour	  
growth,	   which	   may	   subsequently	   result	   in	   resistance	   and	   decreased	   sensitivity	   to	  
Trastuzumab	  (Scaltriti	  et	  al.,	  2011).	  
Due	   to	   shortcomings	   with	   current	   targeted	   therapies	   such	   as	   Trastuzumab	   and	  
Lapatinib,	   a	   variety	   of	   novel	   and	   improved	   targets	   are	   being	   investigated	   for	   the	  
treatment	  of	  HER2	  positive	  breast	  cancer,	  many	  of	  which	  have	  the	  potential	  to	  address	  
the	  unmet	  needs	  of	  current	  treatment	  regimens	  (Awada,	  Bozovic-­‐Spasojevic	  &	  Chow,	  
2012).	  Some	  characteristics	  of	   ideal	  novel	  targets	  would	  include	  significant	  antitumor	  
activity,	  good	  tolerability,	  a	  limited	  propensity	  for	  the	  development	  of	  drug	  resistance,	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good	   selectivity	   for	   the	   chosen	   therapeutic	   targets,	   potent	   inhibition	   of	   commonly	  
expressed	  molecular	  targets,	  and	  such	  treatments	  would	  display	  irreversible	  binding	  to	  
its	   molecular	   targets,	   thereby	   producing	   longer-­‐lasting	   effects	   (Awada,	   Bozovic-­‐
Spasojevic	  &	  Chow,	  2012).	  	  Recently,	  several	  agents	  have	  been	  developed	  which	  have	  
the	   potential	   to	   inhibit	   HER2	   in	   breast	   tumours,	   either	   as	   monotherapy	   or	   in	  
combination	  with	  other	   therapies.	   These	  novel	   therapies	   include	   the	   tyrosine	   kinase	  
inhibitors	  neratinib	  (HKI-­‐272)	  and	  afatinib	  (bibw-­‐2992),	  and	  the	  anti-­‐HER2	  monoclonal	  
antibodies	   pertuzumab	   and	  Trastuzumab-­‐MCC-­‐DM1	   (T-­‐DM1)(Jones	  &	   Buzdar,	   2009).	  
The	   use	   of	   agents	   that	   target	   molecular	   pathways	   such	   as	   the	   Vascular	   Endothelial	  
Growth	  Factor	   (VEGF)	   receptor,	  mammalian	   target	  of	   rapamycin	   (mTOR),	  PI3	   kinase,	  
insulin	  growth	   factor	   receptors	   (IGFRs),	  HSP-­‐90	  and	  other	   important	  kinases	   (Awada,	  
Bozovic-­‐Spasojevic	  &	  Chow,	  2012)	  may	  also	  be	  useful	  as	  alternative	  targets	   for	  HER2	  
therapy.	  However,	   innovative	  clinical	  studies	  using	  well	  characterised	  clinical	  subjects	  
will	   be	   required	   in	   order	   to	   establish	   the	   true	   clinical	   value	   of	   these	   potential	   novel	  
anti-­‐HER2	  targets	  (Awada,	  Bozovic-­‐Spasojevic	  &	  Chow,	  2012).	  
1.9 Alternative	  Splicing	  
RNA	  splicing	  is	  a	  process	  in	  the	  nucleus	  by	  which	  introns	  are	  removed	  from	  pre-­‐mRNA	  
and	  exons	  are	  ligated	  together,	  converting	  pre-­‐mRNA	  to	  mature	  mRNA	  (Watson	  et	  al.,	  
2008).	   Some	  pre-­‐mRNAs	   in	   individual	   genes	  may	  be	  differentially	   spliced,	   generating	  
multiple	  alternative	  mature	  mRNA	  products	  from	  a	  common	  mRNA	  precursor,	  known	  
as	   isoforms.	   Alternative	   splicing	   is	   the	   process	   by	   which	   more	   than	   one	   mRNA	   is	  
produced	   by	   a	   single	   pre-­‐mRNA,	   leading	   to	   the	   production	   of	   several	   structurally	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distinct	   protein	   isoforms,	   which	   can	   have	   diverse	   functions	   (Garcia-­‐Blanco,	   2005).	  
Alternative	  splicing	  is	  a	  key	  post-­‐transcriptional	  mechanism	  by	  which	  the	  expression	  of	  
multiple	  protein	  products	  from	  a	  single	  gene	  can	  be	  controlled	  (Li	  et	  al.,	  2006)	  and	  is	  
considered	  as	  one	  of	   the	  key	  generators	  of	  proteomic	  diversity	   (Ladomery,	  Harper	  &	  
Bates,	   2007);	   alternative	   splicing	   increases	   the	   protein	   diversity	   without	   increasing	  
genome	   size,	   and	   therefore	   forms	   one	   of	   the	   most	   significant	   components	   of	   the	  
complexity	   of	   the	   human	   genome	   (Modrek	   &	   Lee,	   2002).	   It	   is	   estimated	   that	  
alternative	  splicing	  can	  occur	   in	  up	  to	  75%	  of	  all	  human	  genes	   (Watson	  et	  al.,	  2008).	  
The	  number	  of	  different	  variants	  a	  given	  gene	  can	  encode	  by	  alternative	  splicing	  varies	  
from	   two	   to	   thousands.	   For	  example,	   the	   rat	  Slo	  gene	  encodes	  a	  potassium	  channel	  
which	   is	  expressed	   in	  neurons,	  and	  has	   the	  capacity	   to	  encode	  up	  to	  500	  alternative	  
transcripts	   of	   the	   gene,	   and	   one	  Drosphilia	  melanogaster	   gene	   has	   the	   potential	   to	  
encode	  up	  to	  38,000	  products	  as	  a	  result	  of	  alternative	  splicing	  (Watson,	  et	  al.,	  2008).	  	  
In	  the	  majority	  of	  human	  genes,	  alternative	  splicing	  may	  give	  rise	  to	  transcript	  variants	  
and/or	  protein	  isoforms	  that	  can	  vary	  distinctly	  in	  structure	  and	  functional	  properties	  
(Figure	  1.6).	   For	  example,	   an	  alternative	   splice	   variant	  of	  VEGF	   gives	   rise	   to	  multiple	  
protein	   isoforms,	   which	   display	   either	   pro-­‐angiogenic	   or	   anti-­‐angiogenic	   activities	  
(Nowak	  et	  al.,	  2008;	  Ladomery,	  Harper	  &	  Bates,	  2007).	  	  
Alternative	  splicing	   is	   the	  most	  plausible	  solution	   for	   the	  miscorrelation	  between	  the	  
number	  of	  genes	  transcribed	  in	  eukaryotic	  cells	  and	  the	  number	  of	  proteins	  translated	  




Figure	  1.6	  Schematic	  representation	  of	  alternative	  splicing.	  Due	  to	  alternative	  splicing,	  a	  single	  gene	  can	  
produce	  more	  than	  one	  transcript,	  which	  can	  be	  translated	  into	  different	  protein	  isoforms.	  
	  
Alternative	   splicing	   plays	   various	   important	   roles	   in	   the	   cell,	   chief	   of	   which	   is	   to	  
increase	  the	  diversity	  of	  the	  proteome	  and	  transcriptome	  by	  allowing	  the	  generation	  
and	   expression	   of	   multiple	   mRNA	   products	   from	   a	   single	   gene.	   Due	   to	   alternative	  
splicing,	  the	  coding	  capacity	  of	  the	  human	  genome	  is	  greatly	  increased	  (Tazi,	  Bakkour	  
&	   Stamm,	   2009),	   leading	   to	   an	   increased	   complexity	   of	   the	   transcriptome	   and	  
proteome	  (Stamm	  et	  al.,	  2005).	  This	   increased	  complexity	  of	  the	  human	  genome	  has	  
clear	   repercussions	   for	   the	   regulation	  of	  gene	  expression	   in	  many	  organisms	  and	   for	  
the	   balance	   between	  human	  health	   and	  disease	   (Garcia-­‐Blanco,	   2005;	   Stamm	  et	   al.,	  
2005).	   Today,	   alternative	   splicing	   is	   increasingly	   linked	   with	   the	   aetiology	   of	   cancer	  
(Ladomery,	  Harper	  &	  Bates,	  2007).	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Regulation	  of	  alternative	  splicing	  
A	  number	  of	   factors	  are	  known	  to	  play	  a	  crucial	   role	   in	  alternative	  splicing.	  Of	   these	  
known	   factors,	   the	  most	   studied	   are	  RNA-­‐binding	   proteins	   and	   transcription	   factors.	  
RNA-­‐binding	   proteins,	   also	   known	   as	   regulatory	   proteins,	   play	   a	  wide	   role	   in	  mRNA	  
biogenesis	   (David	  &	  Manley,	   2008).	  When	   bound	   to	   exons,	   Serine	   and	   Arginine-­‐rich	  
(SR)	   proteins	   tend	   to	   promote	   exon	   inclusion,	   while	   heterogeneous	   nuclear	  
ribonuclear	   proteins	   (hnRNPs)	  modulate	   exon	   skipping	   (David	  &	  Manley,	   2008).	   Pre-­‐
mRNA	   splicing	   is	   catalysed	   by	   the	   spliceosome,	   a	   ribonuclearprotein	   complex	  
composed	  of	  five	  small	  nuclear	  ribonuclearprotein	  particles	  (hnRNPs),	  and	  a	  number	  of	  
accessory	   polypeptides,	   in	   a	   sequential	   and	   highly	   coordinated	   pathway	   (Smith	   &	  
Valcárcel,	  2000).	  	  
The	   spliceosome	  begins	   its	   function	   by	   recognising	   the	   consensus	   elements	   on	   both	  
ends	  of	  the	   intron;	  the	  U1	  Small	  nuclear	  ribonucleoprotein	  (snRNP)	  recognises	  the	  5’	  
splice	   site,	   while	   the	   65	   kDa	   subunit	   of	   the	   U2	   snRNP	   (U2AF65)	   binds	   to	   the	  
polypyrimidine	  tract,	  and	  the	  35kDa	  subunit	  of	  the	  U2	  (U2AF35)	  binds	  to	  the	  3’	  splice	  
site.	   Bridging	   interactions	   between	   U1	   snRNP	   bound	   to	   the	   5’	   splice	   site	   and	   U2AF	  
bound	  to	  the	  3’	  splice-­‐site	  region	  are	  known	  to	  be	  modulated	  by	  SR	  proteins	  (Smith	  &	  
Valcárcel,	   2000).	   The	   SR	   proteins	   are	   involved	   in	   both	   constitutive	   and	   regulated	  
splicing	   (Ladomery,	   Harper	   &	   Bates,	   2007).	   SR	   proteins	   contain	   N-­‐terminal	   RNA	  
recognition	   motifs,	   which	   mediate	   binding	   to	   the	   pre-­‐mRNA.	   Their	   C-­‐terminal	  
recognise	   exonic	   splice	   enhancers	   (ESEs)	   and	   through	   protein-­‐protein	   interactions,	  
bind	  to	  the	  snRNP	  U2AF35	  and	  U1	  snRNP,	  therefore	  promoting	  U1	  and	  U2AF	  binding	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to	   splice	   sites	   (Smith	   &	   Valcárcel,	   2000;	   Ladomery,	   Harper	   &	   Bates,	   2007).	   Smaller	  
regulatory	   complexes	   also	   play	   a	   role	   in	   achieving	   cell-­‐type-­‐specific	   splicing;	   exonic	  
splice	   enhancers	   (ESEs)	   or	   silencers	   (ESSs)	   promote	   or	   inhibit	   exon	   inclusion	   of	  
proximal	   exons,	   while	   intronic	   splice	   enhancers	   (ISEs)	   or	   silencers	   (ISSs)	   enhance	   or	  
inhibit	   the	  use	  of	  exon	   from	  an	   intronic	   location,	   respectively	   (Wang	  &	  Burge,	  2008;	  
Smith	   &	   Valcárcel,	   2000).	   Apart	   from	   the	   functional	   role	   of	   regulatory	   proteins,	  
changes	   in	   their	   expression	   levels	   or	   post-­‐transcriptional	   changes	   may	   alter	   their	  
activities,	  providing	  a	  means	  for	  the	  regulation	  of	  alternative	  splicing	  (David	  &	  Manley,	  
2008).	   For	   example,	   hnRNPA1	   which	   functions	   in	   the	   inclusion	   of	   many	   alternative	  
exons,	  may	  become	  phosphorylated	  upon	  osmotic	   shock,	   resulting	   in	   its	   cytoplasmic	  
accumulation,	  which	  may	   in	   turn	   lead	   to	  changes	   in	  alternative	  splicing	   (Allemand	  et	  
al.,	  2005).	  	  
Transcription	   factors	  have	  also	  been	   studied,	   and	  may	  have	  a	  potential	   influence	  on	  
alternative	   splicing,	   either	   by	   influencing	   the	   concentration	   of	   direct	   regulators	   of	  
alternative	   splicing	   (e.g.	   SR	   proteins	   and	   snRNPs),	   or	   by	   altering	   the	   rate	   of	   RNA	  
polymerase	   II	   elongation,	   leading	   to	   indirect	   effects	   on	   alternative	   splicing.	   It	   is	  
therefore	   important	   to	   identify	   the	   tissue-­‐specific	   changes	   in	   transcription	   factor	  
expression	  during	  splicing,	  and	  the	  instances	  in	  which	  these	  changes	  alter	  patterns	  of	  
alternative	  splicing.	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1.9.1. The	  role	  of	  alternative	  splicing	  in	  the	  development	  of	  cancer	  
The	   abnormal	   generation	   of	   mRNA	   splice	   variants	   has	   been	   implicated	   in	   the	  
oncogenic	  tendencies	  of	  several	  important	  biomarkers	  to	  include	  vascular	  endothelial	  
growth	   factor	   (VEGF)	   and	   Wilms	   Tumour	   1	   (WT1);	   with	   evidence	   accumulating	   to	  
support	   the	   theory	   that	   some	   splice	   variants	   are	   more	   oncogenic	   than	   others.	   This	  
evidence	   is	   used	   to	   explain	   why	   in	   some	   studies	  WT1	   appears	   to	   act	   as	   a	   tumour	  
suppressor,	  whilst	  in	  others	  it	  appears	  to	  be	  operating	  as	  an	  oncogene.	  Many	  protein	  
isoforms	   produced	   via	   alternative	   splicing	   are	   tightly	   regulated	   during	   normal	  
development,	   but	   may	   be	   misregulated	   in	   cancer	   cells.	   Aberrant	   expression	   of	  
alternative	  splice	  variants	  in	  many	  genes	  has	  been	  linked	  with	  disease	  progression	  and	  
prognosis,	   and	   cancer	   cells	   may	   manipulate	   the	   mechanisms	   that	   regulate	   drug	  
resistance	  and	  patient	  survival	  (Pal,	  Gupta	  &	  Davuluri,	  2012).	  Recent	  studies	  have	  also	  
demonstrated	  that	  the	  modulation	  of	  alternative	  transcript	  expression	  in	  various	  genes	  
may	   impede	   tumour	  growth	  and	  act	  as	  a	  model	   for	   targeting	  disease	  at	   the	   isoform	  
level	   (Pal,	   Gupta	  &	  Davuluri,	   2012).	   There	   are	   various	  modes	   of	   alternative	   splicing.	  
The	  most	   common	   types	   include	   competing	  5’	   splice	   sites,	   competing	  3’	   splice	   sites,	  
cassette	   exons,	  mutually	   exclusive	   exons,	   and	   retained	   introns	   (Ladomery,	  Harper	  &	  




Figure	  1.7	  Modes	  of	  alternative	  splicing	  showing	  exon	  skipping,	  alternative	  5’	  and	  3’	  splice	  sites,	  intron	  
retention	  and	  mutually	  exclusive	  exons	  (adapted	  	  from	  Ladomery,	  Harper	  &	  Bates,	  2007	  and	  used	  with	  
permission	  of	  the	  author).	  
	  
1.10 Alternative	  splicing	  of	  HER2	  and	  HER2	  Splice	  Isoforms	  
1.10.1. Herstatin	  
1n	  1999,	  Doherty	   et	   al.	   described	   a	   truncated	   alternative	  HER2	   transcript	  which	   is	   a	  
secreted	  protein	  of	  ≈68kDa	  with	  growth	  inhibitory	  properties.	  Herstatin	   is	  a	  naturally	  
occurring	  HER2	  protein	  and	  is	  generated	  from	  alternative	  HER2	  mRNA	  transcripts	  that	  
retain	  the	  intron	  8	  (Doherty	  et	  al.,	  1999b).	  Herstatin	  is	  a	  soluble	  protein,	  which	  can	  be	  
secreted	   from	   cells	   it	   has	   been	   produced	   by,	   and	   lacks	   a	   transmembrane	   domain	  
(Koletsa	  et	  al.,	  2008).	  Herstatin,	  also	  described	  as	  p68	  HER2,	  and	  dimercept,	  delineates	  
340	  amino	  acid	  residues	  identical	  to	  subdomain	  I	  and	  II	  of	  the	  extracellular	  domain	  of	  
p185	  HER2.	   The	   extracellular	   domain	   precedes	   a	   unique	   C-­‐terminal	   sequence	   of	   79	  
amino	  acids	  encoded	  by	  intron	  8,	  which	  functions	  as	  a	  receptor	  binding	  domain	  (Figure	  
1.8).	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Herstatin	   is	   expressed	   in	   foetal	   kidney	   and	   liver,	   and	   in	   normal	   tissues,	   and	   is	  
considered	  as	  a	  growth	   regulatory	   factor	  during	  normal	  development	   (Kolesta	  et	  al.,	  
2008).	   Herstatin	   mRNA	   and	   protein	   have	   been	   shown	   to	   be	   expressed	   in	   the	  
noncancerous	   breast	   tissue,	   in	   areas	   adjacent	   to	   breast	   carcinomas	   (Kolesta	   et	   al.,	  
2008).	   Recent	   evidence	   suggests	   that	   Herstatin	   has	   a	   potential	   significance	   in	   the	  
regulation	  of	  the	  wild	  type	  (p185)	  HER2	  in	  normal	  and	  malignant	  development,	  due	  to	  
its	  specific	  inhibitory	  effect	  (Doherty	  et	  al.,	  1999).	  When	  bound	  to	  p185HER2,	  Herstatin	  
disrupts	   the	   dimerization	   of	   HER2	   with	   itself	   and	   other	   HER2	   full	   length	   receptor	  
homologues,	   and	   results	   in	   a	   noticeably	   reduced	   tyrosine	   phosphorylation	   of	   HER2	  
(Wang	  et	  al.,	  2013).	  Herstatin	  may	  therefore	  have	  tumour-­‐supressing	  activity	  of	  down-­‐
regulating	  the	  expression	  of	  p185HER2	  through	  the	  inhibition	  of	  receptor	  dimerization	  
and	  the	  consequent	  inhibition	  of	  tumour	  formation	  (Jackson	  et	  al.,	  2013).	  	  
Herstatin	  has	  also	  been	  shown	  to	  bind	  to	  EGFR,	  HER3	  and	  HER4,	  and	  in	  a	  	  way	  similar	  
to	  pertuzumab,	  blocks	  homomeric	  and	  heteromeric	  receptor	   interactions	  (Justman	  &	  
Clinton,	   2002;	   Koletsa	   et	   al.,	   2008).	   More	   so,	   In	   a	   similar	   manner	   to	   Trastuzumab,	  
binding	  of	  Herstatin	  to	  the	  extracellular	  domain	  of	  HER2	  leads	  to	  degradation	  of	  HER2	  
receptor	   and	   endocytosis	   (Wang	   et	   al.,	   2013).	   Herstatin	   specifically	   blocks	   dimer	  
phosphorylation	   by	   disrupting	   HER2/HER3	   and	   EGFR/HER2	   dimers.	   Although	   the	  
majority	  of	  tumours	  express	  Herstatin	  mRNA,	  the	  Herstatin	  protein	  is	  absent	  in	  75%	  of	  
breast	   cancers.	   This	   may	   be	   because	   the	   cancer	   cells	   are	   protected	   by	   an	   intrinsic	  




Figure	  1.8	  Schematic	  representation	  of	  Herstatin	  showing	  the	  retention	  of	  intron	  8.	  
	  
1.10.2. HER2∆16	  
An	  alternative	  splice	  form	  of	  the	  human	  HER2	  containing	  an	  in-­‐frame	  skipping	  of	  exon	  
16,	  a	  48bp	  cassette	  exon,	  has	  been	  detected	  in	  human	  breast	  cancers	  (Kwong	  &	  Hung,	  
1998;	   Castiglioni	   et	   al.,	   2006).	   This	   splice	   variant,	   designated	   HER2Δ16encodes	   a	  
receptor	  that	  lacks	  the	  amino-­‐acids	  encoded	  by	  exon	  16,	  which	  is	  a	  small	  region	  of	  the	  
extracellular	  domain	  of	  HER2	  (Jackson	  et	  al.,	  2013;	  Mitra	  et	  al.,	  2009)	  (Figure	  1.9).	  Exon	  
16	   immediately	   precedes	   the	   transmembrane	   domain	   and	   contains	   two	   cysteine	  
residues,	  and	  lacks	  the	  amino	  acids	  634	  –	  649	  in	  domain	  IV	  of	  the	  HER2	  extracellular	  
domain	  (Wang	  et	  al.,	  2013;	  Kwong	  &	  Hung,	  1998).	  The	  resultant	  loss	  of	  these	  cysteine	  
residues	  in	  the	  extracellular	  domain	  of	  HER2	  leads	  to	  a	  change	  in	  the	  conformation	  of	  
the	   HER2	   receptor	   extracellular	   domain	   promoting	   the	   homodimerization	   of	   stable	  
receptors	  capable	  of	  transforming	  cells,	  via	  the	  formation	  of	  disulphide	  bonds	  (Jackson	  
et	   al.,	   2013;	   Castiglioni	   et	   al.,	   2006).	   HER2∆16	   is	   purported	   to	   constitute	   a	   more	  
aggressive	  HER2	  variant	  compared	  to	  the	  wild	  type,	  p185	  HER2,	  and	   is	  said	  to	  play	  a	  
crucial	  role	  in	  the	  malignant	  transformation	  and	  disease	  progression	  of	  HER2	  positive	  
breast	  cancers.	  This	  suggests	  that	  patients	  expressing	  HER2∆16	  may	  benefit	  from	  more	  
aggressive	   therapy.	   HER2∆16	   has	   also	   been	   linked	   to	   Trastuzumab	   resistance,	  
advocating	   the	  use	  of	   tyrosine	  kinase	   inhibitors	  as	  an	  alternative	   therapy.	  Studies	  by	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Castiglioni	  et	  al.	  show	  that	  the	  HER2∆16	  splice	  variant	  comprises	  about	  9%	  of	  the	  total	  
HER2	  mRNA	  of	  a	  collection	  of	  46	  breast	  carcinomas	  tested,	  with	  HER2	  expression	  levels	  
ranging	   from	  0	   to	   3+,	   as	   determined	   by	   the	  HercepTest.	   	   These	   studies	   showed	   the	  
exon	  16	  skipped	  HER2	  variant	  to	  have	  much	  stronger	  transformation	  activity	  than	  the	  
wild	  type	  HER2	  (Castiglioni	  et	  al.,	  2006).	   	  Mitra	  et	  al.	  report	  that	  HER2∆16	  expression	  
promotes	   cell	   invasion	   and	   Trastuzumab	   resistance	   through	   direct	   coupling	   of	  
HER2∆16	  to	  Src	  kinase	  (Mitra	  et	  al.,	  2009).	  There	   is	  evidence	  that	  alternative	  splicing	  
leading	   to	   cassette	   exons	   within	   the	   extracellular	   domain	   of	   some	   growth	   factor	  
receptors	   provides	   a	   unique	  mechanism	   for	   the	   generation	   of	   novel	   isoforms	  which	  
may	  encode	  potentially	  active	  molecules	  (Baek	  et	  al.,	  2004;	  Collesi	  et	  al.,	  1996;	  Li	  et	  al.,	  
1995).	  For	  this	  reason,	  the	  HER2∆16	  variant	  represents	  a	  constitutively	  active	  form	  of	  
HER2	   similar	   to	   the	   mutated	   gene	   (Marchini	   et	   al.,	   2011).	   This	   provides	   further	  
evidence	   to	   the	   theory	   that	  mutations	   in	   splice	   variants	   affect	   the	   progression	   from	  
normal	  breast	   cells	   to	   invasive	   cells,	   rather	   than	   increase	   in	   receptor	  numbers	  alone	  
(Castiglioni	  et	  al.,	  2006).	  Therefore,	  a	  better	  understanding	  of	  the	  involvement	  of	  HER2	  
splice	   variants	   in	   the	   response	  or	   resistance	   to	   current	   therapies	   targeting	   the	  HER2	  
receptor	   might	   be	   crucial	   in	   improving	   response	   rates	   in	   patients	   with	   HER2	  
overexpressing	  cancers	  (Castiglioni	  et	  al.,	  2006).	  
	  
	  
Figure	  1.9	  Schematic	  representation	  of	  HER2∆16	  showing	  the	  cassette	  exon	  on	  exon	  16.	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1.10.3. P100	  HER2	  	  
The	  p100	  HER2	  transcript	  was	  first	  described	  by	  Scott	  et	  al.	  as	  a	  spliced	  variant	  of	  HER2	  
which	   encodes	   a	   2.3kb	   protein	   constituting	   only	   the	   extracellular	   domain	   of	   the	   full	  
length	   protein	   (Scott	   et	   al.,	   1993;	   Jackson	   et	   al.,	   2013).	   P100	  HER2	   arises	   via	   an	   in-­‐
frame	  stop	  codon	  which	  results	  from	  the	  retention	  of	  intron	  15,	  and	  has	  been	  found	  to	  
interfere	  with	  oncogenic	  activity,	  with	  the	  capacity	  to	  inhibit	  cell	  proliferation	  (Jackson	  
et	  al.,	  2013)	  (Figure	  1.10).	  The	  5’	  end	  of	  the	  p100	  HER2	  gene	  is	  a	  2.1kb	  segment	  of	  the	  
truncated	  HER2	  transcript	  homologous	  to	  the	  5’	  end	  of	  the	  full	  length	  HER2	  transcript,	  
while	   the	  3’	  end	  diverges	   to	   reveal	  an	  exonic	  extension	  with	  an	   in-­‐frame	  stop	  codon	  
and	  a	  poly(A)	  addition	   site	   (Scott	  et	  al.,	   1993).	   The	  alternative	  polyadenylaton	   signal	  
permits	  reading	  into	  the	  intron	  which	  results	  in	  the	  translation	  of	  a	  100kDa	  isoform	  of	  
HER2.	  The	  truncated	  HER2	  transcript	  encodes	  a	  100-­‐kDa	  variant	  of	  the	  full	  length	  185-­‐
kDa	   transmembrane	   receptor	   that,	  with	   the	  exception	  of	  20	  C-­‐terminal	   amino	  acids,	  
contains	  the	  entire	  HER2	  extracellular	  domain	  (Scott	  et	  al.,	  1993).	  Further	  exploration	  
into	   the	  role	  of	  p100	  HER2	   revealed	   that	   this	   secreted	  truncated	   form	  of	  HER2	  gives	  
rise	  to	  a	  decrease	   in	  the	  downstream	  signal	  transduction	  pathway	  such	  as	  the	  MAPK	  
cascade.	  Being	  a	  secreted	  protein,	  the	  p100	  HER2	   isoform	  may	  also	  serve	  as	  a	  serum	  





Figure	  1.10	  Schematic	  representation	  of	  p100	  HER2	  showing	  the	  retention	  of	  intron	  15.	  
	  
	  
1.11 Hypothesis	  and	  objectives	  of	  this	  Study	  
1.11.1. Hypothesis	  	  
Studies	   have	   shown	   the	   existence	   of	   alternative	   splice	   variants	   of	   HER2,	   and	   in	  
addition,	   that	  HER2	   splice	   variants	  may	   serve	   various	   crucial	   functions	   in	   continuing	  
disease	   progression	   of	   HER2	   overexpressed	   or	   amplified	   breast	   carcinomas	   despite	  
current	  therapies.	  The	  lack	  of	  activating	  mutations	  in	  HER2	  positive	  breast	  cancers	  and	  
the	  high	  proportion	  of	  patients	  who	  do	  not	  respond	  to	  current	  therapies,	  suggests	  that	  
it	   is	   not	   only	   the	   total	   number	   of	  HER2	   receptors	   that	   is	   responsible	   for	   malignant	  
transformations	   in	   the	   cell.	   The	   expression	   of	   alternative	   splice	   variants	   of	   HER2	  
resulting	   in	   protein	   isoforms	   with	   potent	   cellular	   functions,	   may	   lead	   to	   the	  
development	   of	   specific	   assays	   to	   include	   splice-­‐variant	   status	   of	   certain	   important	  
isoforms,	   in	   the	   aim	   of	   improving	   diagnosis	   and	   treatment.	   Mutations	   in	   the	  
oncoprotein,	   in	  particular	  small	  deletions	   in	  the	  extracellular	  domain,	  may	  also	  result	  
in	   the	   formation	  of	  disulphide	  bonds.	  Current	   investigations	   into	   the	   three	   identified	  
naturally	  occurring	  HER2	  splice	  variants	  (HER2∆16,	  Herstatin	  	  and	  p100	  HER2)	  has	  been	  
geared	   on	   developing	   new	   therapeutic	   strategies	   to	   tackle	   issues	   with	   treatment	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resistance	   and	   to	   further	   understand	   impact	   of	  HER2	   overexpression	  with	   particular	  
focus	  on	  these	  splice	  variants	  (Jackson	  et	  al.,	  2013).	  
The	   hypothesis	   of	   this	   study	   is	   that	   in	   addition	   to	   the	   previously	   identified	   roles	   of	  
HER2	   alternative	   splice	   variants	   in	   the	   progression	   and	   continued	   transformation	   of	  
invasive	   breast	   cancer,	   currently	   unidentified	   alternative	   splice	   variants	   may	   be	   a	  
contributing	  factor	  in	  the	  poor	  response	  of	  patients	  to	  current	  treatment	  regimes.	  The	  
discovery	   of	   novel	   alternative	   splice	   variants	   may	   lead	   to	   identification	   of	   HER2	  
isoforms	  which	  play	  crucial	  roles	  in	  the	  induction	  or	  inhibition	  of	  HER2	  signalling.	  The	  
use	   of	   these	   splice	   variants	   in	   the	   manipulation	   of	   HER2	   signalling	   may	   be	   of	  
therapeutic	  benefit	  to	  patients	  diagnosed	  with	  HER2	  positive	  breast	  cancers.	  	  	  
	  
1.11.2. Objectives	  
1. To	   develop	   specific	   standard	   RT-­‐PCR	   primers	   for	   the	   detection	   of	   novel	   splice	  
isoforms	  of	  HER2	  in	  invasive	  breast	  cancer	  cell	  lines.	  
2. To	  verify	  the	  identity	  of	  amplified	  PCR	  products	  by	  DNA	  sequencing.	  
3. To	  identify	  the	  functions	  of	  novel	  splice	  variants,	  relating	  splice	  variant	  expression	  
to	  clinical	  parameters,	  using	  bioinformatics	  analysis.	  
4. To	  identify	  the	  expression	  of	  novel	  splice	  variants	  of	  HER2	  in	  clinical	  breast	  cancer	  
samples	  categorised	  with	  0	  to	  3+	  by	  immunohistochemistry.	  
5. To	   develop	   double	   dye	   (Taqman)	   probes	   for	   the	   detection	   of	   novel	   alternative	  
HER2	  splice	  variants	  by	  quantitative	  real-­‐time	  PCR.	  
6. To	   study	   the	   regulation	   of	   HER2	   and	   HER2	   splice	   variants	   by	   manipulating	   cell	  
culture	  conditions,	  e.g.	  induction	  of	  hypoxia.	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7. To	  study	  the	  effects	  of	  tyrosine	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  
regulation	  of	  HER2	  and	  HER2	  alternative	  splice	  variants.	  
8. To	   develop	   siRNAs	   to	   knockdown	   certain	   splice	   factors	  which	  may	   be	   known	   to	  
play	   a	   role	   in	  HER2	   splicing,	   and	   to	   relate	   the	   effects	   of	   gene	   silencing	   on	   the	  














CHAPTER	  2. GENERAL	  MATERIALS	  AND	  METHODS	  
2.1. Antigen	  Retrieval	  Immunohistochemistry	  	  
2.1.1. 	  Buffers	  used	  in	  Immunohistochemistry	  
Sodium	  Citrate	  buffer	  (pH	  6.0)	  was	  used	  as	  the	  antigen	  retrieval	  buffer.	  0.1M	  Sodium	  
Citrate	  buffer	  was	  freshly	  prepared	  by	  adding	  29.4g	  of	  Sodium	  Citrate	  and	  54ml	  of	  1M	  
HCl	  to	  10L	  of	  distilled	  water	  and	  stirring	  vigorously.	  The	  pH	  value	  of	  the	  buffer	  solution	  
was	  adjusted	  using	  a	  pH	  meter	  by	  adding	  a	  few	  drops	  of	   freshly	  prepared	  1M	  HCl	  or	  
0.1M	  NaOH	   solution	   to	   obtain	   the	   desired	   value.	   The	   buffer	  was	   then	   stored	   at	   4°C	  
(Kong	  et	  al.,	  2006).	  	  
TRIS	   Buffered	   Saline	   (TBS)	   pH7.4	   was	   used	   as	   the	   washing	   buffer.	   0.005M	   TBS	   was	  
prepared	  by	  adding	  80g	  of	  Sodium	  Chloride,	  6.05g	  of	  TRIS	  and	  44ml	  of	  1M	  HCl	  to	  10L	  







ANTIBODY	  CLONE	   SPECIFICITY	   SOURCE	   CONCENTRATION	  
SP3	   HER2	   Labvision	  
Corporation,	  UK	  
0.6	  µg/mL	  











PGR636	   PR	   Dako	  Uk	  Ltd	   0.5	  µg/mL	  
Table	  2.1	  Antibodies	  used	  in	  immunohistochemistry,	  their	  specificities	  and	  concentrations.	  
	  
2.1.2. 	  Antigen	  retrieval	  microwave	  heating	  technique	  
Tissue	  sections	  5	  microns	  thick	  mounted	  on	  slides	  were	  prepared	  for	  antigen	  retrieval	  
by	  deparaffinising	   in	   two	   changes	  of	  Histoclear	   (5	  minutes	  each),	   rehydrating	   in	   two	  
changes	  of	  100%	  Industrial	  methylated	  spirit	  (3	  minutes	  each)	  and	  rinsing	  in	  tap	  water	  
for	   a	   few	   minutes.	   The	   sections	   were	   treated	   with	   3%	   hydrogen	   peroxide	   to	   block	  
endogenous	   peroxidise	   for	   5	   minutes,	   and	   rinsed	   thoroughly	   in	   distilled	   water.	   The	  
slides	   were	   then	   placed	   in	   a	   plastic	   slide	   rack	   and	   transferred	   into	   a	   plastic	   jar	  
containing	   the	   antigen	   retrieval	   buffer	   solution	   and	   the	   slide	   rack	   was	   completely	  
covered	  in	  antigen	  retrieval	  buffer	  solution.	  	  The	  plastic	  jar	  was	  covered	  with	  a	  loose-­‐
fitting	  cap	  and	  the	  slides	  were	  heated	  in	  a	  microwave	  oven	  at	  a	  temperature	  of	  100°C.	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The	   duration	   of	   heating	   was	   25	   minutes	   in	   Sodium	   Citrate	   buffer	   (pH	   6.0).	   After	  
heating	   the	   sections	   were	   washed	   and	   cooled	   to	   room	   temperature	   in	   running	   tap	  
water	  and	  rinsed	  in	  TBS	  before	  immunostaining	  (Hayat,	  2002).	  
2.1.3. 	  Immunohistochemical	  staining	  methods	  
All	   immunohistochemical	   assays	   were	   performed	   at	   room	   temperature	   (20-­‐25°C).	  
Although	   most	   automated	   immonhistochemical	   systems	   suggest	   that	   conducting	  
immunohistochemical	  staining	  at	  4°C	  may	  improve	  antigenicity,	  in	  most	  instances,	  the	  
use	  of	   room	  temperature	   is	  generally	  acceptable	  and	  has	  been	  known	   to	  give	  highly	  
reproducible	  results	  (Vogel,	  1901).	  Antibodies	  used	  for	  immunohistochemical	  staining	  
are	  listed	  in	  table	  2.1.	  The	  Vector	  Elite	  ABC	  system	  for	  immunohistochemistry,	  with	  a	  
peroxidase	   label	   (Vector	  Labs,	  Uk)	  was	  used	  as	   the	  detection	  kit.	  Diaminobenzidine	   -­‐	  
DAB	  (Dako	  Uk	  Ltd)	  was	  used	  to	  visualise	  the	  labelled	  antibodies.	  	  
The	   sections	   were	   incubated	   in	   normal	   goat	   serum	   for	   5	   minutes	   to	   prevent	   non-­‐
specific	   binding	   of	   the	   antibodies,	   and	   then	   incubated	   in	   primary	   antibody	   for	   60	  
minutes.	  After	  staining	  with	  the	  primary	  antibody,	  sections	  were	  then	  incubated	  with	  a	  
linking	   secondary	   biotinyilated	   antibody	   for	   30	  minutes.	   Sections	  were	  washed	   after	  
each	   stage	   with	   TBS	   at	   pH	   7.4.	   The	   slides	   were	   then	   incubated	   in	   the	   enzyme-­‐
conjugated	   ABC	   label	   for	   30	   minutes,	   rinsed	   in	   TBS	   and	   washed	   in	   distilled	   water.	  
Conjugation	  of	  the	  primary	  antibody	  with	  biotin	  is	  a	  method	  of	  labelling	  which,	  due	  to	  
the	  high	  affinity	  of	  avidin	  to	  biotin,	  enables	  the	  visualization	  of	  proteins	  when	  bound	  to	  
fluorescent	  or	  enzyme-­‐labelled	  avidin.	  The	  resulting	  avidin-­‐biotin	  (ABC)	  complex	  forms	  
a	   stable	   complex,	   and	   is	   a	   highly	   sensitive	   method	   for	   detection	   of	   the	   primary	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antibody.	  Finally	  the	  sections	  were	  treated	  with	  the	  chromogen	  3,3’	  diaminobenzidine	  
(DAB)	   for	   10	   minutes,	   washed	   in	   running	   tap	   water,	   counterstained	   in	   Harris’	  
haematoxylin	  for	  2	  minutes,	  differentiated	  in	  1%	  acid	  alcohol	  for	  a	  few	  seconds,	  left	  to	  
blue	  in	  running	  tap	  water	  and	  dehydrated	  in	  alcohol,	  cleared	  and	  mounted	  in	  DPX	  for	  
examination	  under	  a	  microscope	  (Hayat,	  2002).	  	  
2.1.4. 	  Evaluation	  of	  Immunohistochemistry	  results	  
Slides	   were	   examined	   using	   Nikon	   Eclipse	   50i	   microscope.	   Photomicrographs	   were	  
taken	  with	  a	  Nikon	  Digital	  Sight	  DS-­‐UI	  camera.	  	  
2.2. Cell	  culture	  
Human	   breast	   and	   ovarian	   cancer	   cell	   lines	   were	   obtained	   from	   the	   European	  
Collection	   of	   Cell	   Cultures	   (ECACC;	   Salisbury,	   UK)	   and	   the	   American	   Type	   Culture	  
Collections	   (ATCC;	  Middlesex,	   UK).	   	   In	   order	   to	   eliminate	   contaminants	   arising	   from	  
high	  passage	  numbers,	  all	  six	  cell	  line	  stocks	  were	  frozen	  down	  at	  passages	  5	  to	  10,	  and	  
cells	  were	  cultured	  up	  to	  a	  maximum	  of	  10	  passages	  before	  being	  replaced	  by	  frozen	  
stocks	   (van	   Staveren	   et	   al.,	   2009).	   The	   cell	   lines	   were	   cultured	   in	   their	   respective	  
growth	   media	   in	   cell	   culture	   flasks	   according	   to	   their	   manufacturers’	  
recommendations,	  in	  a	  humidified	  atmosphere.	  	  
All	  cell	  culture	  media	  were	  supplemented	  with	  10%	  Foetal	  Bovine	  Serum	  (Biosera,	  UK),	  
2mM	   L-­‐Glutamine	   (Lonza,	   UK)	   and	   100u/ml	   penicillin-­‐streptomycin	   solution	   (Lonza,	  
UK).	  All	  cells	  lines	  were	  adhering	  cells.	  Upon	  reaching	  confluence,	  cells	  were	  washed	  in	  
48	  	  
Phosphate	   Buffered	   Saline	   (PBS)	   and	   removed	   from	   the	   bottom	   of	   the	   flasks	   by	  
trypsinization	  in	  1x	  trypsin/EDTA	  solution	  (Lonza,	  UK)	  (Goren	  et	  al.,	  2010).	  	  
	  
Table	  2.2	  Cell	  line	  models	  used	  in	  cell	  culture	  studies	  and	  their	  culture	  conditions.	  
	  
The	   cell	   lines	   used	   in	   this	   study	   represent	   samples	   with	   varying	   levels	   of	   HER2	  
expression,	  and	  were	  therefore	  considered	  a	  good	  model	  for	  HER2	  expression	  analysis,	  
based	  on	  the	  repository	  of	  cells	  available	  for	  selection.	  
2.3. RNA	  extraction	  
2.3.1 RNA	  extraction	  from	  cell	  cultures	  
Total	   RNA	   was	   extracted	   from	   cells	   using	   TRI	   reagent	   (Ambion,	   UK),	   a	   monophasic	  
solution	  of	  phenol,	  guanidine	  isothiocyanate,	  and	  other	  proprietary	  components	  which	  






SKOV3	   Ovarian	  Cancer	   HER2	  3+	   McCoy’s	   5A	  
Medium	  
(Lonza,	  UK)	  
37°C,	  5%	  CO2	  
SKBR3	   Breast	  Cancer	   HER2	  3+	   McCoy’s	   5A	  
Medium	  
(Lonza,	  UK)	  
37°C,	  5%	  CO2	  
BT-­‐20	   Breast	  Cancer	   HER2	  -­‐	   DMEM	  
(Lonza,	  UK)	  
37°C,	  5%	  CO2	  
MCF-­‐7	   Breast	  Cancer	   HER2	  -­‐	   DMEM	  
(Lonza,	  UK)	  
37°C,	  5%	  CO2	  
MDA-­‐MB-­‐453	   Breast	  Cancer	   HER2	  2+	   DMEM	  
(Lonza,	  UK)	  
37°C,	  5%	  CO2	  
MDA-­‐MB-­‐361	   Breast	  Cancer	   HER2	  2+	   DMEM	  
(Lonza,	  UK)	  
37°C,	  5%	  CO2	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facilitate	  the	  isolation	  of	  a	  variety	  of	  RNA	  species	  of	  large	  or	  small	  molecular	  size	  (Mita	  
et	  al.,	  2007).	  Cells	  were	  washed	  twice	   in	  PBS,	  and	  1ml	  TRI	  reagent	  was	  added	  to	  the	  
cells.	   The	   cells	  were	   removed	   from	   the	   flasks	   or	   plates	   by	   scraping	   to	   one	   side;	   the	  
resulting	  lysate	  was	  then	  removed	  and	  placed	  in	  a	  1.5ml	  eppendorf	  and	  incubated	  for	  
5	   minutes	   at	   room	   temperature,	   0.2ml	   chloroform	   (Sigma,	   UK)	   was	   added	   to	   the	  
lysates	   and	   the	   suspension	   was	   mixed	   by	   inversion	   and	   incubated	   at	   room	  
temperature	  for	  15	  minutes.	  The	  suspension	  was	  then	  centrifuged	  at	  12,000xg	  for	  15	  
minutes	   at	   4°C,	   after	   which	   the	   aqueous	   phase	   was	   transferred	   into	   fresh	   micro	  
centrifuge	   tubes.	   To	   pellet	   the	   RNA	   0.5ml	   of	   isopropanol	   was	   added	   to	   each	  micro	  
centrifuge	   tube	   and	   mixed	   thoroughly	   by	   vortexing.	   The	   mixture	   was	   incubated	   at	  
room	  temperature	  for	  10	  minutes	  and	  then	  centrifuged	  at	  12,000xg	  for	  8	  minutes	  at	  
room	   temperature.	   The	   resulting	   supernatant	   was	   carefully	   removed	   and	   the	   RNA	  
pellet	   was	   washed	   by	   adding	   1ml	   of	   75%	   ethanol	   and	   centrifuged	   at	   7,500xg	   for	   5	  
minutes	   (Doherty	  et	   al.,	   1999b).	   After	   removal	   of	   the	   supernatant,	   the	   RNA	  was	   air	  
dried	  and	  resuspended	  in	  20-­‐50µl	  of	  nuclease	  free	  water,	  depending	  on	  the	  size	  of	  the	  
pellet.	  The	  RNA	  suspension	  was	  incubated	  for	  5	  minutes	  at	  55°C	  on	  a	  heating	  block	  to	  
completely	  dissolve	  the	  RNA	  pellet.	  The	  resulting	  RNA	  was	  then	  stored	  at	  -­‐80°C.	  
2.3.2 RNA	  extraction	  from	  Formalin	  Fixed,	  Paraffin	  Embedded	  
(FFPE)	  samples	  
Fourteen	  FFPE	  samples	  were	  kindly	  supplied	  by	  Dr	  Muhammed	  Sohail	  (Department	  of	  
Histopathology,	  United	  Hospitals	  Bristol	  Foundation	  Trust,	  Bristol	  Royal	  Infirmary,	  UK).	  
The	  department	  of	  histopathology	  holds	  a	  general	  pathology	  accreditation	  awarded	  by	  
the	  Clinical	  Pathology	  Accreditation	  (UK)	  Ltd.	  The	  criteria	  for	  selection	  of	  breast	  cancer	  
tissue	  were	  based	  on	  the	   tissues	  being	  HER2	  2+	  or	  3+	  as	  determined	  by	  HercepTest.	  
50	  	  
10µm	   thick	   sections	   were	   cut	   from	   selected	   blocks	   of	   breast	   cancer	   which	   were	  
confirmed	   to	   be	   HER2	   2+	   and	   3+	   by	   immunohistochemistry,	   as	   determined	   by	  
HercepTest	   carried	   out	   by	   the	   Bristol	   Royal	   infirmary	   laboratory.	   Total	   RNA	   was	  
extracted	   from	   FFPE	   samples	   using	   the	   RNEasy	   FFPE	   kit	   (Qiagen,	   UK)	   according	   to	  
manufacturer’s	  protocols,	  with	  the	  following	  modifications:	  Four	  10µm	  thick	  sections	  
were	  placed	  in	  1.5ml	  eppendorf	  tubes	  and	  deparaffinised	  by	  adding	  1ml	  of	  Histoclear,	  
vortexing	   for	   10	   seconds	   and	   centrifuging	   at	   full	   speed	   for	   2	   minutes	   to	   bring	   the	  
samples	   to	   the	   bottom	   of	   the	   tubes.	   The	   supernatant	   was	   then	   removed	   and	  
discarded.	  To	   remove	   the	  Histoclear,	  1ml	  of	  100%	  ethanol	  was	  added	   to	   the	  pellets,	  
mixed	  by	  vortexing	  and	  centrifuged	  at	  full	  speed	  for	  2	  minutes.	  The	  supernatant	  was	  
removed	  and	  discarded,	  and	  the	  pellets	  were	  incubated	  at	  room	  temperature	  for	  10-­‐
15	  minutes	  to	  completely	  dry	  the	  pellet,	  thereby	  removing	  residual	  ethanol.	  150µL	  of	  
buffer	   PKD	   was	   added	   to	   the	   tubes;	   the	   solution	   was	   mixed	   by	   vortexing,	   and	  
centrifuged	   for	   1	   minute	   at	   11,000xg.	   10µl	   of	   Proteinase	   K	   was	   then	   added	   to	   the	  
lower,	  clear	  phase	  containing	  the	  RNA,	  mixed	  by	  gently	  pipetting,	  incubated	  overnight	  
at	  15°C,	  and	  then	  for	  15	  minutes	  at	  80°C.	  This	  step	  is	  crucial	  for	  reversal	  of	  cross	  links	  
to	   ensure	   optimal	   performance	   in	   downstream	   applications	   such	   as	   qRT-­‐PCR.	   The	  
lower,	  clear	  phase	  was	  then	  transferred	  to	  new	  2ml	  microcentrifuge	  tubes,	  incubated	  
on	   ice	   for	  3	  minutes,	  and	  then	  centrifuged	   for	  15	  minutes	  at	  20,000xg.	  The	  resulting	  
supernatant	   was	   transferred	   into	   fresh	  microcentrifuge	   tubes.	   To	   treat	   for	   genomic	  
DNA	   contamination,	   16µL	  DNAse	  booster	   and	   10µL	  DNAse	   I	   solution	  were	   added	   to	  
the	  tubes	  and	  incubated	  for	  15minutes	  at	  room	  temperature.	  320ml	  of	  buffer	  RBC	  was	  
added	  to	  the	  tubes	  to	  adjust	  the	  binding	  conditions,	  and	  mixed	  by	  vortexing.	  700ml	  of	  
ethanol	  was	  added	  to	  the	  tubes,	  and	  mixed	  by	  pipetting.	  The	  sample	  was	  then	  passed	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through	   an	   RNeasy	  MinElute	   spin	   column	  placed	   in	   a	   2	  ml	   collection	   tube.	   The	   spin	  
column	   was	   then	   centrifuged	   at	   8,000xg	   for	   15	   seconds	   and	   the	   flow-­‐through	   was	  
discarded.	   This	   step	   was	   repeated	   until	   the	   entire	   sample	   was	   passed	   through	   the	  
MinElute	  spin	  column.	  500ml	  of	  buffer	  RPE	  was	  then	  added	  to	  the	  spin	  columns	  and	  
centrifuged	  at	  8,000xg	   for	  15	  seconds	  and	  the	   flow-­‐through	  was	  discarded.	  500ml	  of	  
buffer	  RPE	  was	  again	  added	  to	  the	  spin	  columns	  to	  wash	  the	  spin	  column	  membrane,	  
centrifuged	  at	  8,000xg	   for	  2	  minutes,	  and	  the	   flow-­‐through	  discarded	  along	  with	   the	  
collection	   tube.	  The	  spin	  column	  was	   then	   transferred	   into	   fresh	  collection	   tube	  and	  
centrifuged	   at	   full	   speed	   for	   5	   minutes.	   This	   step	   is	   necessary	   to	   ensure	   that	   the	  
residual	  ethanol	  on	  the	  membranes	  of	  the	  spin	  columns	  is	  removed.	  The	  spin	  columns	  
were	  then	  placed	  in	  fresh	  1.5ml	  microcentrifuge	  tubes	  and	  20µL	  of	  RNase-­‐free	  water	  
was	   added	   to	   the	   column	   membrane.	   After	   incubating	   for	   5	   minutes	   at	   room	  
temperature,	  the	  spin	  columns	  were	  centrifuged	  for	  1	  minute	  at	  full	  speed	  to	  elute	  the	  
RNA	  (Abramovitz	  et	  al.,	  2008).	  
2.3.3 Assessment	  of	  RNA	  yield	  and	  quality	  
The	   yield	   and	   quality	   of	   isolated	   RNA	  was	   determined	   using	   a	   Nanodrop	   1000A	   UV	  
spectrophotometer	   (Thermo	   Fisher	   Scientific,	   USA).	   RNA	   concenttrations	   for	   the	   cell	  
lines	   used	   in	   this	   study	   can	   be	   found	   in	   Table	   3.1.	   The	   Nanodrop	   UV	  
spectrophotometer	  is	  used	  for	  analysing	  nucleic	  acid	  concentrations	  and	  the	  purity	  of	  
nucleic	  acid	  samples	  with	  high	  accuracy	  using	  as	  small	  as	  1µl	  of	  sample	  volume.	  A	  ratio	  
of	  ~1.8	  of	  sample	  absorbance	  at	  260/280	  nm	  was	  considered	  pure	  for	  RNA	  samples.	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2.4. Reverse	  Transcription	  Polymerase	  Chain	  Reaction	  (RT-­‐PCR)	  
2.4.1. 	  First-­‐Strand	  Synthesis	  of	  cDNA	  
Prior	   to	   first	   strand	  synthesis	   total	  RNA	  was	   treated	   for	  genomic	  DNA	  contamination	  
with	   RQ1	   RNAse-­‐free	   DNAse	   (Promega,	   UK).	   1µg	   of	   RNA	   was	   diluted	   up	   to	   8µl	   in	  
nuclease	  free	  water	  and	  incubated	  with	  1µl	  RQ1	  RNAse-­‐free	  DNAse	  10x	  reaction	  buffer	  
and	   1µl	   RQ1	   RNAse-­‐free	   DNAse	   for	   30	   minutes	   at	   37°C.	   The	   DNAse	   reaction	   was	  
terminated	   by	   the	   addition	   of	   RQ1	   DNAse	   stop	   solution	   and	   heating	   to	   65°C	   for	   10	  
minutes.	  First-­‐strand	  cDNA	  synthesis	  was	  then	  performed	  using	  equal	  amounts	  of	  total	  
RNA	  by	  incubating	  with	  random	  hexamers	  (Qiagen	  UK)	  at	  65°C	  for	  5	  minutes	  and	  then	  
cooling	   immediately	   on	   ice.	   The	   reverse	   transcriptase	   buffer,	   dNTP	   mix,	   RNase	  
inhibitor	   and	  Omniscript	   reverse	   transcriptase	   (Qiagen,	  UK)	  were	   then	   added	   to	   the	  
reaction	   and	   incubated	   at	   37°C	   for	   60	   minutes.	   To	   ensure	   that	   subsequent	   PCR	  
amplification	  was	  derived	   from	  RNA	  and	  not	  genomic	  DNA	  or	  other	   contaminants,	  a	  
no-­‐RT	   control	   was	   included	   in	   every	   reverse	   transcription	   experiment	   (Bustin	   et	   al.,	  
2009).	   The	  yield	  and	  quality	  of	   cDNA	   synthesized	  was	  determined	  using	  a	  Nanodrop	  
1000A	  UV	  spectrophotometer	  (Thermo	  Fisher	  Scientific,	  USA).	  A	  ratio	  of	  ~1.8	  of	  sample	  
absorbance	  at	  260/280nm	  was	  considered	  pure	  for	  cDNA	  samples.	  
2.4.2. 	  Standard	  Reverse	  Transcription	  Polymerase	  Chain	  Reaction	  
(RT-­‐PCR)	  
Standard	   PCR	   reactions	   of	   20µl	   volumes	   consisted	   of	   1x	   green	   GoTaq®	   Flexi	   Buffer;	  
2µM	  MgCL2;	  0.2µM	  of	  each	  dNTP;	  0.5µM	  of	  each	  primer;	  1.25U	  GoTaq®	  Hotstart	  DNA	  
polymerase	  and	  ~200ng	   template	  cDNA.	  All	   standard	  PCR	  reagents	  were	  supplied	  by	  
Promega	   UK.	   For	   control	   amplifications	   cDNA	  was	   replaced	   by	   nuclease	   free	  water.	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Cycling	  was	  performed	  using	  a	  PTC200	  Peltier	  Thermal	  Cycler	  (MJ	  research,	  USA)	  using	  
the	  following	  conditions:	  hotstart	  at	  95°C	  for	  2	  minutes	  followed	  by	  35	  cycles	  of	  95°C	  
for	   1	   minute	   (denaturing),	   54-­‐64°C	   for	   1	   minute	   (annealing),	   72°C	   for	   1	   minute	  
(extending),	   and	   a	   final	   extension	   of	   5	  minutes	   at	   72°C.	   A	   soaking	   cycle	   of	   4°C	  was	  
included	   to	  hold	   the	   tubes	  after	   amplification,	  prior	   to	   storage	  at	   -­‐20°C	   (Hillig	  et	  al.,	  
2012).	  
2.4.3. 	  Agarose	  gel	  electrophoresis	  
RT-­‐PCR	   products	   were	   separated	   using	  molecular	   grade	   Agarose	   (Bioline	   UK).	   A	   2%	  
Agarose	  gel	  was	  prepared	  by	  dissolving	  Agarose	  powder	  in	  1x	  TAE	  buffer	  and	  heating	  
in	   a	   microwave	   until	   the	   Agarose	   powder	   was	   dissolved	   in	   the	   buffer.	   Ethidium	  
bromide	  (10mg/ml;	  Sigma-­‐Aldrich,	  UK)	  was	  added	  to	  a	  final	  concentration	  of	  0.5µg/ml	  
and	   the	  molten	  Agarose	   solution	  was	  poured	   into	   a	   gel	   tray	   and	   left	   to	   set	   at	   room	  
temperature	  for	  15	  minutes.	  DNA	  samples	  were	  loaded	  onto	  the	  gel	  and	  subjected	  to	  
electrophoresis	  at	  120V	  for	  1	  hour	  20	  minutes.	  DNA	  hyperladder	  (Bioline	  UK)	  was	  run	  
simultaneously	  to	  allow	  estimation	  of	  DNA	  fragment	  sizes.	  DNA	  was	  visualised	  under	  
UV	  light	  on	  a	  MiniBis	  gel	  documentation	  system	  (Berthold	  Technologies,	  Germany).	  
2.5. Cloning	  of	  RT-­‐PCR	  products	  for	  sequencing	  
2.5.1. 	  Gel	  extraction	  and	  purification	  of	  PCR	  products	  
100µl	  reactions	  of	  PCR	  products	  destined	  for	  cloning	  were	  separated	  on	  a	  3%	  Agarose	  
gel	  and	  the	  bands	  excised	  from	  the	  gel	  prior	  to	  purification	  using	  a	  sterile	  scalpel.	  PCR	  
products	   were	   purified	   using	   Qiaquick	   Gel	   Extraction	   Kit	   (Qiagen	   UK)	   (Lukas	   et	   al.,	  
2001).	  The	  excised	  gel	  bands	  were	  transferred	  to	  micro	  centrifuge	  tubes	  and	  weighed.	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Three	  volumes	  of	  buffer	  QG	  were	  added	  to	  one	  gel	  volume,	  incubated	  at	  50°C	  for	  10	  
minutes	   and	   vortexed	   every	   2-­‐3	  minutes	   until	   the	   gel	   was	   completely	   dissolved.	   To	  
increase	   the	   DNA	   yield,	   1	   gel	   volume	   of	   isopropanol	   was	   added	   to	   the	   sample	   and	  
mixed	   by	   inverting	   the	   tube	   several	   times.	   	   To	   bind	   the	   DNA,	   the	   sample	  was	   then	  
transferred	  to	  a	  Qiaquick	  spin	  column,	  placed	   in	  a	  collection	  tube	  and	  centrifuged	  at	  
10,000xg	   for	   1	  minute	   and	   the	   flow-­‐through	  was	  discarded,	   500µl	   of	   buffer	  QG	  was	  
added	   to	   the	   spin	   column	  and	   centrifuged	   at	   10,000	   x	   g	   for	   1	  minute	   and	   the	   flow-­‐
through	  discarded.	  To	  wash	  the	  DNA,	  750µl	  of	  buffer	  PE	  was	  added	  to	  the	  column	  and	  
centrifuged	  at	  10,000	  x	  g	  for	  1	  minute.	  To	  remove	  residual	  ethanol,	  the	  flow-­‐through	  
was	   discarded	   and	   the	   spin	   column	   was	   centrifuged	   for	   an	   additional	   1	   minute	   at	  
10,000	   x	   g.	   To	   elute	   the	  DNA	   the	  Qiaquick	   column	  was	   transferred	   to	   a	   fresh	   1.5ml	  
micro	  centrifuge	  tube	  and	  10µl	  of	  buffer	  EB	  was	  added	  to	  the	  column	  and	  incubated	  
for	  about	  1	  minute	  and	  centrifuged	  at	  10,000	  x	  g	  for	  1	  minute.	  The	  purified	  DNA	  was	  
stored	  at	  4°C.	  
2.5.2. 	  Preparation	  of	  LB	  broth	  and	  LB/Agar	  plates	  with	  
ampicillin/IPTG/X-­‐GAL	  
LB	  broth	  medium	  was	  prepared	  by	   suspending	  20g	  of	   LB	  power	   (Sigma	  UK)	   in	   1L	   of	  
distilled	   water	   and	   sterilized	   by	   autoclaving.	   LB/Agar	   plates	   were	   prepared	   by	  
suspending	  20g	  of	  LB	  powder	  (Sigma	  UK)	  and	  15g	  of	  Agar	  (Sigma	  UK)	  in	  1L	  of	  distilled	  
water	   and	   sterilized	   by	   autoclaving.	   The	   LB	   +	   Agar	   mixture	   was	   cooled	   to	  
approximately	   50°C	   and	   stock	   solutions	   of	   IPTG,	   X-­‐GAL	   and	   ampicillin	   (bioline,	   UK)	  
were	  added	  to	  the	  LB	  +	  Agar	  mixture	  to	  a	   final	  concentration	  of	  100µg/ml	  each,	  and	  
then	  mixed	   by	   inversion	   (Doherty	   et	   al.,	   1999b).	   The	  mixture	  was	   then	   poured	   into	  
petri	  dishes	  and	  cooled	  until	  solid.	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2.5.3. 	  Ligation	  into	  pGEM-­‐T	  Easy	  vector	  
The	  pGEM®-­‐T	  Easy	  Vector	  system	  (Promega,	  UK)	  is	  a	  convenient	  system	  for	  cloning	  of	  
PCR	  products.	  The	  pGEM-­‐T	  Easy	  vector	  is	  prepared	  by	  digestion	  with	  EcoRV	  and	  adding	  
a	  3’	  terminal	  thymidine	  terminal	  overhang	  to	  both	  ends	  to	  prevent	  recircularisation	  of	  
the	   vector	   and	   enable	   insertion	   of	   PCR	   products	   generated	   using	   thermostable	  
polymerases	  that	  add	  a	  deoxyadenosine	  to	  the	  3’	  end	  of	  amplified	  PCR	  products.	  The	  
high	   copy	   number	   pGEM®-­‐T	   Easy	   Vector	   contains	   T7	   and	   SP6	   RNA	   polymerase	  
promoters	  flanking	  an	  alpha	  peptide	  multiple	  cloning	  region,	  which	  when	  inactivated,	  
allows	  recombinant	  clones	  to	  be	  identified	  by	  blue/white	  screening	  on	  indicator	  plates.	  	  
The	   ligation	   reaction	   consisted	   of	   1µl	   (50ng)	   pGEM-­‐T®	   Easy	   Vector,	   5µl	   2x	   T4	   DNA	  
Ligase	  rapid	   ligation	  buffer,	  1µl	   (3	  Weiss	  units/µl)	  T4	  DNA	  Ligase	  and	  3µl	  gel	  purified	  
PCR	  product.	   The	   reactions	  were	   incubated	  overnight	  at	  4°C	   to	  produce	  a	  maximum	  
number	  of	  transformants.	  	  
2.5.4. 	  Transformation	  into	  JM109	  High	  Efficiency	  Competent	  E.	  
coli	  cells	  
PCR	  ligation	  reactions	  were	  inserted	  into	  JM109	  High	  Efficiency	  Competent	  E.	  Coli	  cells	  
(Promega,	  UK).	  50µl	  of	  cells	  were	  added	  to	  fresh	  microcentrifuge	  tubes	  and	  incubated	  
on	  ice	  for	  20	  minutes	  with	  2µl	  of	  each	  ligation	  reaction.	  Cells	  were	  heat-­‐shocked	  in	  a	  
water	  bath	  at	  42°C	  for	  50	  seconds	  and	  then	  placed	  on	   ice	  for	  2	  minutes.	  950µl	  of	  LB	  
broth	   was	   added	   to	   the	   cells	   then	   incubated	   at	   37°C	   for	   1.5	   hours	   with	   shaking.	  
Transformed	  cells	  were	  then	  grown	  overnight	  on	  LB	  plates	  with	  ampicillin/IPTG/X-­‐GAL	  
at	   37°C.	   Single	   white	   E.	   coli	   colonies	   were	   selected	   and	   used	   to	   inoculate	   5ml	   LB	  
medium	  containing	  100µg/ml	  ampicillin	  and	  incubated	  overnight	  at	  37°C	  with	  shaking.	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2.5.5. 	  Extraction	  of	  plasmid	  DNA	  
Plasmids	   were	   extracted	   from	   E.	   coli	   cells	   using	   The	   PureYield™	   Plasmid	   miniprep	  
system	  (Promega	  UK).	  The	  PureYield™	  Plasmid	  Miniprep	  System	  is	  designed	  to	  purify	  
plasmid	   DNA	   from	   an	   overnight	   culture	   of	   bacteria	   transformed	   with	   a	   high-­‐copy	  
number	  plasmid.	  Cells	  were	  pelleted	  by	  centrifugation	  at	  10,000xg	  for	  5	  minutes	  and	  
the	   supernatant	   discarded.	   Cells	  were	   resuspended	   in	   600µl	   of	   nuclease	   free	  water,	  
lysed	  by	  adding	  100µl	  of	  cell	  lysis	  buffer,	  and	  mixed	  by	  inverting	  the	  tube	  several	  times.	  
Lysis	  was	  terminated	  by	  adding	  350µl	  of	  neutralization	  solution	  and	  the	  solution	  was	  
thoroughly	  mixed	   by	   inversion.	   The	   reaction	  was	   then	   centrifuged	   at	   10,000xg	   for	   3	  
minutes	  to	  pellet	  the	  debris	  resulting	  from	  lysis.	  The	  supernatant	  was	  then	  transferred	  
to	  a	  PureYield™	  Mini	  column	  and	  centrifuged	  at	  10,000xg	  for	  15	  seconds	  and	  the	  flow	  
through	   discarded.	   The	   column	   was	   then	   washed	   by	   adding	   200µl	   of	   Endotoxin	  
Removal	  Wash	  (ERB)	  to	  the	  mini	  column	  and	  centrifuged	  at	  10,000xg	  for	  15	  seconds,	  
and	   then	   adding	   400µl	   of	   column	   wash	   solution	   (CWS)	   to	   the	   mini	   column	   and	  
centrifuging	  at	  10,000xg	  for	  30	  seconds.	  The	  resulting	  DNA	  was	  eluted	  by	  adding	  30µl	  
of	  Elution	  Buffer	  directly	  to	  the	  mini	  column	  matrix	  and	  incubating	  for	  1	  minute.	  The	  
column	  was	  then	  transferred	  to	  a	  fresh	  1.5ml	  tube	  and	  centrifuged	  at	  10,000xg	  for	  30	  
seconds.	  The	  eluted	  purified	  plasmid	  DNA	  was	  quantified	  using	  a	  Nanodrop	  1000A	  UV	  
spectrophotometer	  (Thermo	  Fisher	  Scientific,	  USA)	  and	  then	  stored	  at	  -­‐20°C.	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2.6. Quantitative	  real-­‐time	  PCR	  (qRT-­‐PCR)	  	  
2.6.1. 	  Quantitative	  real-­‐time	  PCR	  amplifications	  
Primers	   and	   probes	   for	   qRT-­‐PCR	  were	   designed	   by	   Primer	   Deisgn	  UK.	   The	   amplicon	  
lengths	  for	  all	  primer	  sets	  were	  90-­‐150	  base	  pairs.	  All	  PCR	  reactions	  were	  performed	  
using	  a	  Step	  One	  Plus™	  Real-­‐Time	  PCR	  system	  (Life	  Technologies,	  UK).	  Real-­‐time	  PCR	  
reactions	   were	   set	   up	   using	   Sensifast	   Probe	   Hi-­‐Rox	   and	   Sensifast	   SYBR	   Hi-­‐Rox	   kits	  
(Bioline,	   UK).	   25ng	   cDNA	  was	   used	   for	   each	   reaction	   containing	   1x	   Sensifast	  master	  
mix,	  primers	   (400nM	  each),	  probe	   (100nM)	  and	  nuclease	   free	  water	   (up	  to	  20ul).	  All	  
reactions	  were	  set	  up	  in	  triplicate	  in	  a	  96	  well	  plate.	  The	  cycling	  conditions	  comprised	  
polymerase	  activation	  for	  2	  minutes	  at	  95°C,	  followed	  by	  40	  cycles	  of	  denaturation	  at	  
95°C	  for	  5	  minutes,	  and	  annealing	  at	  60°C	  for	  15	  seconds.	  For	  SYBR	  green	  chemistry,	  
the	  specificity	  of	  the	  primers	  was	  determined	  using	  a	  melt	  curve	  analysis	  by	  increasing	  
the	  cycling	  temperature	  in	  one	  degree	  increments,	  starting	  at	  50°C,	  for	  40	  cycles	  of	  10	  
seconds	   each.	   The	   efficiency	   of	   the	   primers	   was	   also	   determined	   using	   a	   standard	  
curve.	   Six	   serial	   doubling	   dilutions	   of	   pooled	   cDNA	   samples	   were	   run	   in	   triplicate	  
alongside	  the	  main	  reaction.	  CT	  values	  were	  plotted	  against	  arbitrary	  log	  values	  on	  an	  
excel	  spreadsheet	  using	  a	  scatter	  plot.	  R2	  values	  of	  ≥0.96	  were	  accepted	  for	  correlation	  
efficiency	  (Derveaux,	  Vandesompele	  &	  Hellemans,	  2010).	  	  
2.6.2. 	  Calculations	  	  
CT	  values	  were	  automatically	  determined	  by	  the	  Step	  One	  Plus™	  Real-­‐Time	  PCR	  system	  
(Life	  Technologies,	  UK).	  Relative	  expression	  of	  target	  mRNA	  in	  different	  samples	  were	  
normalised	   to	  a	   set	  of	   reference	  genes	  using	   the	  Relative	  Standard	  Curve	  method.	  A	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standard	  curve	  was	  set	  up	  for	  each	  primer	  set	  by	  running	  six	  serial	  doubling	  dilutions	  
of	   pooled	   cDNA	   in	   triplicate	   alongside	   the	   main	   reactions.	   The	   standard	   curve	   was	  
determined	  using	  the	  equation:	  
y	  =	  mx+c.	  
The	  CT	  (y)	  values	  generated	  from	  the	  real-­‐time	  PCR	  reaction	  was	  then	  used	  to	  derive	  
the	  following	  equation:	  
x	  =	  [(y-­‐c)/-­‐m)]	  
Once	   the	   x	   values	  were	  derived,	   they	  were	   then	   converted	   to	   real	  numbers	  by	  anti-­‐
logging,	  normalised	  against	  a	  set	  of	  reference	  genes,	  and	  the	  fold	  difference	  between	  
control	   and	   experimental	   samples	   were	   calculated	   (Emir,	   2011).	   The	   statistical	  
significance	  of	  the	  fold	  difference	  between	  two	  samples	  was	  determined	  by	  student’s	  
t-­‐test.	  
2.6.3. 	  Normalisation	  of	  real-­‐time	  qRT-­‐PCR	  
The	   use	   of	   quantitative	   real-­‐time	   PCR	   in	   gene	   expression	   analysis	   has	   become	  
increasingly	   important	   in	   biological	   research.	   Due	   to	   the	   sensitivity	   of	   the	   qRT-­‐PCR	  
assay,	   accurate	   normalization	   of	   data	   is	   necessary	   to	   ensure	   that	   changes	   in	   gene	  
expression	  from	  sample	  to	  sample	  are	  not	  due	  to	  errors	  like	  variations	  in	  sample	  size,	  
pipetting	  errors	  or	  errors	  in	  the	  reverse	  transcription	  step.	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The	   use	   of	   reference	   genes	   as	   endogenous	   controls	   in	   qRT-­‐PCR	   is	   one	   of	   the	  most	  
common	  methods	  used	  in	  the	  normalization	  of	  qRT-­‐PCR	  data.	  However,	  the	  expression	  
of	   reference	  genes	  may	  vary	   considerably	  between	  experiments	  as	  no	   single	  gene	   is	  
stably	   expressed	   from	   sample	   to	   sample	   or	   under	   all	   experimental	   conditions.	  
Randomly	   selecting	   a	   reference	   gene	   of	   choice	   may	   lead	   to	   large	   errors	   in	   data	  
analysis;	  therefore	  it	  is	  essential	  to	  identify	  a	  reference	  gene	  or	  a	  set	  of	  genes	  from	  a	  
set	  of	   candidate	   genes,	   that	   are	  most	   stably	   expressed	   in	  every	  experimental	  model	  
(Derveaux,	   Vandesompele	   &	   Hellemans,	   2010;	   Vandesompele	   et	   al.,	   2002;	  
Romanowski	  et	  al.,	  2007;	  Andersen,	  Jensen	  &	  Ørntoft,	  2004;	  Bustin	  et	  al.,	  2009).	  	  
Two	  different	  methods	  of	  reference	  gene	  selection	  were	  used	  in	  this	  project:	  
• GenormPLUS	   (Ghent,	   Belgium):	   the	   GenormPLUS	   algorithm	   calculates	   the	   most	  
stably	  expressed	  reference	  gene	  or	  set	  of	  reference	  genes	  from	  a	  set	  of	  genes	  
based	   on	   the	   geometric	   mean	   of	   a	   number	   of	   housekeeping	   genes	  
(Vandesompele	  et	  al.,	  2002).	  
• Normfinder	   (Molecular	   Diagnostics	   Laboratory,	   Denmark):	   The	   normfinder	  
algorithm	  ranks	  a	  set	  of	  candidate	  reference	  genes	  according	  to	  their	  stability	  
in	  a	  given	  experimental	  design	  (Andersen,	  Jensen	  &	  Ørntoft,	  2004).	  	  
	  
A	  set	  of	  12	  candidate	  reference	  genes	  were	  chosen	  for	  use	  in	  the	  selection	  of	  optimal	  
reference	  genes	  for	  the	  normalisation	  of	  qRT-­‐PCR	  (Table	  2.3).	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GENE	  NAME	   DESIGNATION	   ACCESSION	  	   FUNCTION	  
18s	  Ribosomal	  RNA	   18S	   NM_10098	  
	  
Protein	  translation	  
Beta	  actin	   ACTB	   NM_001101	   Cytoskeletal	   protein	  
involved	   in	   cell	   motility,	  
structure,	  and	  integrity.	  










B2M	   NM_004048	   Beta-­‐chain	   of	   major	  
histocompatibility	  
complex	   class	   I	  
molecules	   involved	   in	  
the	   presentation	   of	  
peptide	   antigens	   to	   the	  
immune	  system.	  
Cytochrome	  c-­‐1	   CYC1	   NM_001916	   Electron	   transport	   in	  
mitochondrial	  
respiratory	  chain	  
Eukaryotic	   translation	  
initiation	  factor	  4A2	  
E1F4A2	   NM_001967	   Initiation	  of	  translation	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GAPDH	   NM_002046	   Oxidoreductase	   in	  
glycolysis	  
Ribosomal	  protein	  L13A	   RPL13A	   NM_012423	   Protein	  synthesis	  	  
Succinate	  
dehydrogenase	  complex,	  
subunit	  A,	  flavoprotein	  
SDHA	   NM_004168	   Mitochondrial	  
respiration	  
Topoisomerase	  DNA	  I	   TOP1	   NM_003286	   Control	  and	  alteration	  of	  
DNA	   topology	   during	  
transcription	  




activation	  protein,	  zeta	  
YWHAZ	   NM_145690	   Mediation	   of	   signal	  
transduction	  
Table	  2.3:	  Reference	  genes	  used	  for	  qRT-­‐PCR	  and	  their	  functions	  in	  normal	  physiology.	  	  
2.7. Protein	  analysis	  
2.7.1. 	  Protein	  extraction	   	   	  
Protein	  extraction	  was	  carried	  out	  using	  Radioimmunoprecipitation	  assay	   (RIPA)	   lysis	  
buffer	  (Fisher,	  UK).	  Cells	  grown	  in	  monolayer	  were	  washed	  twice	  with	  cold	  PBS.	  500µL	  
of	   RIPA	   buffer,	   supplemented	  with	   protease	   and	   phosphatase	   inhibitors	   (sigma,	   UK)	  
was	  added	  to	  a	  75cm2	  flask	  or	  5x106	  cells	  and	  kept	  on	  ice	  for	  5	  minutes	  with	  occasional	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swirling	  of	  the	  flask	  for	  uniform	  spreading.	  The	  lysate	  was	  then	  removed	  from	  the	  flask	  
by	   scraping	   to	   gather	   to	   one	   side,	   and	   transferred	   into	   a	   microcentrifuge	   tube.	   To	  
increase	  yield,	  the	  lysates	  ware	  homogenised	  by	  taking	  the	  homogenate	  up	  and	  down	  
20	  times	  using	  a	  21G	  needle.	  The	  homogenate	  was	  then	  centrifuged	  at	  13,000	  rpm	  for	  
15	  minutes	  at	  4°C	  to	  pellet	  the	  cell	  debris.	  The	  supernatant	  was	  then	  transferred	  to	  a	  
fresh	  microcentrifuge	  tube	  and	  stored	  at	  -­‐80°C.	  
2.7.2. 	  Protein	  quantification	   	   	   	  
Protein	  concentration	  was	  determined	  using	  the	  Cooomassie	  Blue	  dye	  binding	  method	  
for	  protein	  estimation	  (Bradford	  Method)	  (Siegel	  et	  al.,	  1999).	  This	  assay	  is	  based	  on	  an	  
absorbance	  shift	  of	  the	  coomassie	  blue	  G	  dye	  when	  it	  binds	  to	  proteins.	  The	  increase	  in	  
absorbance	   at	   595nm	   is	   proportional	   to	   the	   amount	   of	   bound	   dye	   and	   thus,	   the	  
concentration	  of	  protein	  present	  in	  the	  sample.	  	  
A	  stock	  dye	  solution	  was	  prepared	  dissolving	  330mg	  of	  coomassie	  blue	  G	  dye	  in	  100ml	  
phosphoric	   acid/ethanol	   (2:1)	   mixture.	   The	   working	   dye	   solution	   was	   prepared	   by	  
mixing	   1.5ml	   of	   stock	   dye	   reagent,	   4ml	   of	   phosphoric	   acid,	   1.9ml	   of	   ethanol	   and	  
making	  up	   to	  50ml	   in	  distilled	  water.	  A	  protein	   standard	  was	  prepared	  by	  dissolving	  
albumin	  in	  deionised	  water	  to	  a	  final	  concentration	  of	  1µg/µL.	  Reactions	  were	  carried	  
out	  in	  triplicate	  in	  a	  96	  well	  plate	  and	  the	  absorbance	  was	  measured	  at	  560nm.	  
2.7.3. 	  SDS	  PAGE	  
Proteins	   were	   separated	   using	   a	   criterion	   XT	   system	   (Bio-­‐rad,	   UK).	   Samples	   were	  
thawed	  on	   ice	   from	   frozen	  and	  20µg	  of	  protein	   lysates	  were	  mixed	  with	  4x	  NuPAGE	  
LDS	  sample	  buffer	  diluted	  to	  1x	  in	  distilled	  water	  (Life	  Technologies,	  UK),	  and	  made	  up	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to	  20µl	  volume	  in	  distilled	  water.	  The	  concentration	  of	  protein	  for	  SDS	  was	  determined	  
following	   the	   general	   protocols	   for	   western	   blotting	   by	   the	   Bio-­‐rad	   systems.	   The	  
mixture	  was	  heated	  to	  95°C	  for	  5	  minutes	  prior	  to	  being	  loaded	  onto	  a	  criterion	  XT	  4%-­‐
12%	   Bis-­‐Tris	   pre-­‐cast	   gel	   (Bio-­‐rad,	   UK).	   The	   Criterion	   gel	   system	   (Bio-­‐rad,	   UK)	   was	  
assembled	  according	  to	  manufacturer’s	  instructions	  and	  filled	  with	  1	  litre	  of	  1x	  XT-­‐MES	  
running	  buffer	  (Life	  Technologies,	  UK).	  The	  criterion	  XT	  pre-­‐cast	  gel	  was	  inserted	  into	  
the	  gel	   tank	  and	  10µl	  HyperPAGE	   II	  broad	  range	  pre	  stained	  protein	  marker	   (Bioline,	  
UK)	  was	  loaded	  to	  the	  first	  well.	  Samples	  were	  loaded	  to	  subsequent	  wells	  and	  run	  at	  
120	  volts	  for	  1-­‐2	  hours.	  	  
2.7.4. 	  Western	  blot	  analysis	  	  
Following	   SDS	   PAGE,	   Polyvinylidene	   fluoride	   (PVDF)	   membrane	   (GE	   Healthcare,	   UK)	  
was	  cut	  to	  appropriate	  size	  and	  activated	  by	  immersing	  in	  methanol	  for	  2	  minutes.	  The	  
membrane	  was	  then	  rinsed	  in	  distilled	  water	  and	  then	  left	  to	  equilibrate	  in	  1x	  transfer	  
buffer	   (20x	   Nupage	   transfer	   buffer,	   5%	   methanol	   in	   distilled	   water).	   The	   gel	   and	  
membrane	   were	   then	   transferred	   onto	   a	   Criterion	   blotter	   (Bio-­‐Rad,	   UK)	   and	   the	  
proteins	   were	   transferred	   at	   50	   volts	   at	   4°C	   for	   1	   hour.	   Following	   transfer	   the	  
membranes	  were	  transferred	  to	  blocking	  solution	  [5%	  (w/v)	  non-­‐fat	  dry	  milk	  solution,	  
0.02%	  (v/v)	  Tween	  20	  (Life	  Technologies,	  UK)	  in	  PBS]	  for	  1	  hour	  at	  room	  temperature	  
with	  rocking.	   	  After	  blocking,	  the	  membranes	  were	   incubated	  in	  primary	  antibody	  (in	  
5%	   non-­‐fat	   dry	   milk	   solution)	   at	   4°C	   overnight.	   Following	   incubation	   in	   primary	  
antibody,	  the	  membrane	  was	  washed	  3	  times	  with	  PBS-­‐T	  at	  room	  temperature	  for	  15	  
minutes	   each	  with	   rocking.	   The	   PBS-­‐T	  was	   then	   removed	   and	   the	  membranes	  were	  
incubated	   in	   HRP-­‐linked	   secondary	   antibody	   (Santa	   Cruz	   Biotechnology,	   UK)	   for	   45	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minutes	  at	  room	  temperature.	  The	  membranes	  were	  then	  washed	  3	  times	  with	  PBS-­‐T	  
at	   room	   temperature	   for	   15	  minutes	   each	  with	   rocking,	   and	   then	   rinsed	   in	   distilled	  
water	  (Al	  Okail,	  2010).	  Table	  6.1	  shows	  a	  list	  of	  antibodies	  used	  in	  western	  blotting	  and	  
their	  specificities.	  
After	   washing	   the	  membranes,	   HRP-­‐chemiluminescent	   substrate	   was	   applied	   to	   the	  
membranes	   and	   the	   bands	   were	   visualised	   in	   a	   dark	   room	   by	   developing	   on	   a	   film	  
(Amersham	  Hyperfilm	  ECL;	  GE	  Healthcare).	  
2.8. RNAi	  methods	  	   	   	   	   	   	   	  
2.8.1. 	  siRNA	  transfection	  of	  cells	  	  	  
Cells	  were	  prepared	  for	  transfection	  by	  seeding	  in	  2ml	  antibiotic	  free	  media	  in	  6-­‐well	  
plates	  at	  a	  density	  of	  0.6x106	  for	  24	  hours.	  On	  the	  day	  of	  transfection,	  cells	  were	  serum	  
starved	   in	   Opti-­‐MEM®	   I	   Reduced	   Serum	  Media	   (Life	   Technologies,	   UK)	   for	   2	   hours.	  
siRNA	  transfection	  was	  then	  carried	  out	  using	  siGENOME	  siRNA	  smartpool	  SRPK1	  and	  
SRSF1	   (Thermoscientific,	   UK)	   and	   siGENOME	   Non-­‐Targeting	   siRNA	   Pool	   #2	   as	   a	  
negative	   control.	  Dharmafect	  2	   transfection	   reagent	   (Thermoscientific,	  UK)	  was	  used	  
(Sahlberg	   et	   al.,	   2013).	   siRNA	   transfection	   was	   carried	   out	   according	   to	   the	  
manufacturer’s	  guidelines	  with	  the	  following	  modifications:	  	  
A	  2mM	  siRNA	  solution	  was	  prepared	  by	  diluting	  in	  1X	  siRNA	  Buffer	  (Thermoscientific,	  
UK).	   In	   separate	   tubes,	   100nM	   siRNA	   and	   Dharmafect	   2	   transfection	   reagent	   were	  
diluted	   using	   Opti-­‐Mem	   1	  medium.	   Contents	   of	   each	   tube	   were	   carefully	   mixed	   by	  
pipetting	  up	  and	  down	  and	  incubated	  for	  5	  minutes	  at	  room	  temperature.	  The	  content	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of	  both	  tubes	  were	  then	  carefully	  mixed	  together	  by	  carefully	  pipetting	  up	  and	  down.	  
The	  final	  mixture	  was	  then	  incubated	  for	  20	  minutes	  at	  room	  temperature	  to	  allow	  the	  
formation	  of	  transfection	  complexes.	  Prior	  to	  adding	  the	  transfection	  reagents	  to	  the	  
cells,	  cell	  culture	  medium	  was	  removed	  from	  the	  cells	  and	  fresh	  opti-­‐Mem	  I	  was	  added	  
to	  the	  cells,	  and	  then	  the	  appropriate	  transfection	  mix	  was	  added	  to	  the	  cells	  at	  a	  final	  
concentration	  of	  100nM	  siRNA	  and	  6µl	  Dharmafect	  2	  reagent	  per	  well.	  Cells	  were	  then	  
incubated	   for	   6	   hours	   to	   allow	   the	   transfection	   reagents	   to	   permeate	   the	   cell	  
membranes.	  After	  6	  hours	  of	  transfection,	  the	  transfection	  reagent	  was	  removed	  from	  
the	  cells	  and	  replaced	  with	  antibiotic	  free	  medium,	  and	  the	  cells	  were	  then	  incubated	  
for	  24-­‐48	  hours	  before	  protein	  or	  RNA	  extraction.	  All	  knockdowns	  were	  carried	  out	  in	  
triplicate,	   with	   each	   replicate	   performed	   on	   a	   different	   passage	   of	   cells.	   A	   mock	  







CHAPTER	  3. DISCOVERY	  OF	  HER2	  AND	  HER2	  ALTERNATIVE	  
SPLICE	  VARIANTS	  IN	  BREAST	  AND	  OVARIAN	  CANCER	  CELL	  LINES	  
3.1 Introduction	  
Amplification	  of	  the	  HER2	  oncogene	  is	  one	  of	  the	  genetic	  abnormalities	  in	  breast	  tissue	  
associated	  with	   the	  progression	   from	  normal	  breast	  epithelia	   to	   invasive	  cancer	  cells	  
(Castiglioni	  et	  al.,	  2006).	  HER2	  testing	  is	  essential	  for	  the	  appropriate	  administration	  of	  
the	   humanized	   anti-­‐HER2	   monoclonal	   antibody	   therapy	   Trastuzumab	   (Herceptin	   ®,	  
Genetech,	   South	   San	   Francisco,	   CA)	   to	   invasive	   breast	   cancer	   patients	   with	   HER2	  
overexpression	   or	   gene	   amplification	   (Bartlett	   et	   al.,	   2001;	   Dean-­‐Colomb	   &	   Esteva,	  
2008).	  However,	   the	  discovery	  of	  alternative	  splice	  variants	  of	  HER2	  potentially	  adds	  
extra	   complexity	   in	  mediating	   patient	   response	   to	  HER2	   therapies	   as	   different	  HER2	  
splice	  variants	  may	  have	  differing	  biological	  properties	  (Mitra	  et	  al.,	  2009;	  Marchini	  et	  
al.,	   2011).	   Research	   studies	   suggest	   that	   expression	   and	   secretion	   of	   aberrant	  HER2	  
splice	   variants	   can	   interfere	   with	   the	   oncogenic	  HER2	   activity	   (Aigner	   et	   al.,	   2001).	  
Whereas	  the	  wild	  type	  p185	  HER2	   is	  associated	  with	  pro-­‐oncogenic	  receptor	  activity,	  
resulting	  in	  poor	  prognosis	  and	  disease	  progression	  if	  overexpressed	  or	  over	  amplified	  
in	  breast	  cancer,	  the	  HER2	  isoforms	  Herstatin	  and	  p100	  HER2	  are	  thought	  to	  have	  anti-­‐
oncogenic	   function	  by	   inhibiting	   receptor	  dimerization	  and	   subsequently	   inactivating	  
signal	  transduction	  pathways	  (Wang	  et	  al.,	  2013).	  Also,	  the	  HER2	  exon	  16	  immediately	  
precedes	  the	  transmembrane	  domain	  and	  contains	  two	  cysteine	  residues.	  The	  loss	  of	  
exon	  16	  in	  HER2Δ16	  therefore	  leads	  to	  a	  change	  in	  the	  conformation	  of	  HER2	  receptor	  
extracellular	   domain	   that	   promotes	   intermolecular	   disulphide	   bonding,	   thereby	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promoting	   the	   formation	   of	   constitutively	   activated	   HER2	   homodimers	   capable	   of	  
transforming	   cells	   (Castiglioni	   et	   al.,	   2006).	   Therefore	   it	   may	   be	   of	   significant	  
prognostic	  value	  to	  determine	  the	  HER2	  variant	  status	  of	  patients	  with	  invasive	  breast	  
cancer.	  The	  recommended	  methods	  for	  testing	  HER2	  status	   in	  breast	  cancer	  patients	  
are	  Immunohistochemistry	  and	  Fluorescence	  In-­‐situ	  Hybridization	  (FISH)	  (Wolff	  et	  al.,	  
2007),	   and	  more	   recently,	   Silver	   in-­‐situ	   hybridization	   (SISH)	   is	   also	   being	   used	   as	   an	  
alternative	  to	  the	  FISH	  technique	  (Moelans	  et	  al.,	  2011).	  With	  growing	  evidence	  of	  the	  
potential	  involvement	  of	  alternative	  splice	  variants	  as	  biomarker	  candidates	  in	  cancer	  
diagnosis	   (Lukas	  et	  al.,	  2001;	  Marchini	  et	  al.,	  2011;	  Omenn,	  Yocum	  &	  Menon,	  2010),	  
the	   discovery	   of	   novel	   alternative	   splice	   variants	   of	  HER2	   and	   their	   potential	   role	   in	  
disease	   progression	   or	   resistance	   to	   Trastuzumab	   may	   be	   crucial	   in	   developing	  
potential	   novel	  methods	   of	   testing	   and	   treatment	   of	  HER2	   in	   patients	  with	   invasive	  
breast	  cancer.	  	  	  	  
Objectives	  
1. To	   detect	   HER2	   protein	   expression	   in	   breast	   cancer	   cell	   lines	   by	  
immunohistochemistry.	  
2. To	  detect	  HER2Δ16	  in	  HER2	  overexpressing	  breast	  and	  ovarian	  cancer	  cell	  lines.	  
3. To	  design	  PCR	  primers	  for	  the	  detection	  of	  HER2	  and	  possibly	  novel	  HER2	  splice	  
variants	  in	  cell	  lines	  by	  RT-­‐PCR.	  
4. To	   sequence	   the	   HER2	   cDNA	   and	   HER2	   splice	   variants	   following	   RT-­‐PCR	  
amplification.	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3.2 Methods	  	  
3.2.1 Antigen	  Retrieval	  for	  Immunohistochemistry	  
Antigen	   retrieval	   was	   performed	   prior	   to	   Immunohistochemical	   staining	   in	   SKBR3	  
(HER2	   3+;	   ER-­‐;	   PR-­‐),	   BT-­‐20	   (HER2-­‐;	   ER-­‐;	   PR-­‐)	   and	  MCF-­‐7	   (HER2-­‐,	   ER+;	   PR+)	   cell	   lines.	  
Breast	   cancer	   cells	   mounted	   on	   slides	   were	   stained	   with	   monoclonal	   antibodies	   to	  
HER2	  (SP3;	  CB11),	  Oestrogen	  Receptors	  (6F11),	  and	  Progesterone	  Receptors	  (PGR636)	  
(Table	  3.1).	  
3.2.2 HER2	  primer	  design	  for	  RT-­‐PCR	  
The	   polymerase	   chain	   reaction	   (PCR)	   is	   a	   reliable	   method	   used	   to	   amplify	   specific	  
genes	   of	   interest,	   or	   sections	   of	   a	   gene	   (Schrader	   et	   al.,	   2012).	   Specific	   primer	  
sequences	  corresponding	  to	  a	  specific	  gene	  of	  interest	  are	  used	  to	  amplify	  sections	  of	  
DNA,	  with	  the	  use	  of	  DNA	  polymerase,	  enabling	  the	  generation	  of	  unlimited	  copies	  of	  a	  
small	  fragment	  of	  DNA	  (Joshi	  &	  Deshpande,	  2011;	  Schrader	  et	  al.,	  2012).	  	  
The	  open	  reading	  frame	  of	  HER2	  mRNA	  as	  predicted	  by	  the	  ExPASY	  translate	  tool	  was	  
amplified	  by	  PCR	  using	  12	  sets	  of	  sequence-­‐specific	  primers	  (Figure	  3.1).	  The	  primers	  
were	   designed	   using	   OligoPerfectTM	   Designer	   (Invitrogen,	   UK).	   The	   nucleotide	  
sequences	  used	  for	  the	  primer	  design	  were	  based	  on	  HER2	  ncbi	  GenBank®	  accession	  
number	  NM_004448	  (NCBI,	  2010).	  NP1,	  NP2,	  NP5	  and	  NP6	  primer	  sequences	  for	  the	  
amplification	   of	  HER2∆16	  were	   obtained	   from	   Kwong	  &	   Hung	   (1998).	   Primers	   were	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synthesized	  by	  Eurofins	  MWG	  Operon	  (Ebesberg,	  Germany).	  Primer	  sequences	  for	  all	  
primers	  used	  in	  HER2	  amplification	  are	  listed	  in	  Appendix	  A.	  	  
	  
Figure	  3.1:	  Design	  of	  HER2-­‐specific	  RT-­‐PCR	  primers	  for	  used	  to	  amplify	  HER2	  cDNA.	  Arrows	  indicate	  
positions	  of	  primers	  in	  target	  exons.	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3.2.3 DNA	  sequencing	  	  
All	  DNA	  products	  isolated	  and	  purified	  from	  RT-­‐PCR	  analysis	  were	  sequenced	  using	  the	  
Sanger	  method	   of	   DNA	   sequencing	   to	   confirm	   that	   the	   insert	   sequences	  were	   from	  
HER2	  mRNA.	  DNA	  sequencing	  was	  performed	  at	  three	  independent	  locations:	  
• University	  of	  the	  West	  of	  England:	  Plasmid	  DNA	  templates	  were	  supplied	  at	  a	  
concentration	  of	  200ng/μl	  in	  a	  total	  volume	  of	  10μl.	  The	  sequencing	  reactions	  
consisted	  of	  8	  μl	  of	  1	   x	  BigDye	  Terminator	   v.	  3.1	   ready	   reaction	  mix	   (Applied	  
Biosystems,	   UK),	   3	   μl	   of	   dilution	   buffer	   (Applied	   Biosystems),	   3.2	   pmol	   of	  
primer,	  and	  0.2	  μg	  of	  template	  DNA	  in	  a	  final	  reaction	  volume	  of	  20	  μl.	  Cycling	  
conditions	   included	  an	   initial	  one	  minute	  denaturation	   step	  at	  96°C,	   followed	  
by	  25	  cycles	  at	  96°C	  for	  10	  seconds,	  50°C	  for	  5	  seconds,	  and	  60°C	  for	  4	  minutes,	  
and	  a	  final	  extension	  at	  15°C	  for	  10	  minutes.	  Samples	  were	  electrophoresed	  on	  
an	  Applied	  Biosystems	  3730xl	  automated	  DNA	  sequencing	  instrument,	  using	  37	  
cm	  capillary	  arrays	  and	  POP-­‐7	  polymer.	  	  Sequencing	  of	  plasmids	  was	  performed	  
using	  T7	  and	  SP6	  promoter	  primers.	  Data	  were	  analyzed	  using	  PE-­‐Biosystems	  
version	  3.7	  of	  Sequencing	  Analysis.	  	  
• MWG	  operon:	  50-­‐100ng/µl	  of	  plasmid	  DNA	  in	  a	  final	  volume	  of	  15µl	  was	  sent	  
to	   MWG	   operon	   for	   commercial	   single	   strand	   sequencing	   using	   T7	   and	   SP6	  
promoter	  primers.	  
• University	  of	  Exeter:	   following	  agarose	  gel	  electrophoresis,	  DNA	  was	  obtained	  
directly	  from	  the	  agarose	  gel	  by	  stabbing	  the	  bands	  with	  a	  p20	  pipette	  tip	  while	  
being	  visualised	  with	   the	  UV	  transilluminator.	  The	  DNA	  was	   then	  re-­‐amplified	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by	  RT-­‐PCR,	  using	  the	  same	  primers	  used	  for	  the	  initial	  PCR	  amplification,	  tagged	  
with	  M13	  primers	  (primer	  sequences	  are	  listed	  in	  appendix	  A),	  under	  the	  same	  
cycling	   conditions	   as	   the	   initial	   PCR	   reaction.	   The	   resulting	   re-­‐PCR	   products	  
were	  then	  sequenced	  at	  the	  University	  of	  Exeter.	  
3.2.4 Analysis	  of	  sequencing	  results	  
All	   sequenced	   plasmid	   DNA	   templates	   were	   analysed	   by	   first	   identifying	   SP6	   or	   T7	  
promoter	   primer	   sequences,	   and	   M13	   primer	   sequences,	   and	   then	   identifying	   the	  
insert	   sequences.	   The	   plasmid	   insert	   sequences	   were	   entered	   into	   NCBI	   Nucleotide	  
Basic	   Local	   Alignment	   Search	   Tool	   (BLASTN)	   to	   confirm	   that	   they	   were	   actual	  HER2	  
mRNA	   sequences	   (NCBI,	   2010).	   After	   sequences	   were	   confirmed	   to	   be	  HER2,	   insert	  
sequences	  were	  then	  aligned	  using	  Clustal	  Omega	  Multiple	  Sequence	  Alignment	  Tool	  
(European	   Bioinformatics	   Institute,	   2010)	   with	   the	   reference	   HER2	   sequence	   to	  
determine	   homology	   between	   sequences	   obtained	   from	   GenBank	   and	   sequences	  
obtained	  from	  cloned	  inserts	  of	  PCR	  amplified	  products.	  	  
3.3 Results	  
3.3.1 Detection	  of	  HER2	  protein	  in	  cell	  lines	  by	  
Immunohistochemistry	  
Immunohistochemistry	  was	  performed	  to	  give	  a	  general	  overview	  of	  HER2	  expression	  
in	  cell	  lines.	  Three	  breast	  cancer	  cell	  lines;	  SKBR3	  (HER2	  3+;	  ER-­‐;	  PR-­‐),	  BT-­‐20	  (HER2-­‐;	  ER-­‐
;	  PR-­‐)	  and	  MCF-­‐7	  (HER2-­‐,	  ER+;	  PR+)	  were	  used	  for	  immunohistochemical	  analysis.	  The	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antibodies	  used	   for	  detection	  of	  HER2	   bind	   to	   the	  extracellular	  domain	  while	   the	  ER	  
and	  PR	   antibodies	  bind	   to	   the	  nucleus.	  HER2	   antibodies	   are	  not	   known	   to	  bind	   to	   a	  
specific	  HER2	   isoform,	  and	  may	   therefore	  be	  positive	   to	   the	  generic	  wild-­‐type	  HER2,	  
regardless	  of	  any	   isoforms	  which	  may	  be	  co	  expressed	  in	  the	  same	  cells.	  Monoclonal	  
antibodies	  used	  in	  this	  study	  and	  their	  specificities	  are	  listed	  in	  Table	  3.1.	  	  
SKBR-­‐3	   cell	   line:	   Immunohistochemical	   analysis	   of	   SKBR3	   cell	   line	   showed	   the	  
presence	  of	  membrane	  staining	  with	  SP3	  and	  CB11	  monoclonal	  antibodies	  (Figures	  3.2	  
and	   3.3),	   which	   is	   indicative	   of	   HER2	   positivity.	   The	   absence	   of	   nuclear	   staining	   of	  
SKBR3	   cells	   with	   6F11	   and	   PGR636	   antibodies	   (Figures	   3.4	   and	   3.5)	   show	   negative	  
results	  for	  Oestrogen	  and	  Progesterone	  receptors	  respectively.	  
BT-­‐20	  cell	  line:	  Immunohistochemical	  analysis	  of	  BT-­‐20	  cell	  line	  showed	  the	  absence	  
of	  membrane	   staining	  with	   SP3	   and	   CB11	   antibodies	   (Figures	   3.2	   and	   3.3),	   which	   is	  
indicative	  of	  HER2	   negativity.	   The	  absence	  of	  nuclear	   staining	  of	  BT-­‐20	   cell	   line	  with	  
6F11	   and	   PGR636	   antibodies	   (Figures	   3.4	   and	   3.5)	   is	   also	   indicative	   of	   negativity	   of	  
oestrogen	  and	  progesterone	  receptors	  respectively.	  	  	  	  	  	  	  
MCF-­‐7	   cell	   line:	   Immunohistochemical	   analysis	   of	   MCF-­‐7	   cell	   line	   showed	   the	  
absence	   of	  membrane	   staining	  with	   SP3	   and	   CB11	   antibodies	   (Figures	   3.2	   and	   3.3),	  
which	   is	   indicative	  of	  HER2	  negativity.	  The	  presence	  of	  nuclear	  staining	   in	  MCF-­‐7	  cell	  
line	  with	  CB11	  and	  PGR636	  antibodies	  (Figures	  3.4	  and	  3.5)	   is	   indicative	  of	  oestrogen	  
and	   progesterone	   receptor	   positivity,	   respectively.	   Negative	   controls	   used	   in	  
immunohistochemistry,	  stained	  negative	  for	  SP3	  antibody	  (Figure	  3.6).	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The	   results	   obtained	   from	   immunohistochemistry	   correlate	  well	  with	   previous	  HER2	  
studies	   on	   the	   cell	   lines	   used	   in	   this	   study	   (Rhodes	   et	   al.,	   2010)	   However,	   overall	  
protein	   expression	   as	   determined	   by	   IHC	  may	   not	   be	   conclusive	   in	   determining	   the	  
patients’	   splice	   variant	   status,	   and	   therefore	   may	   not	   be	   sufficient	   in	   predicting	  	  
patients’	  response	  to	  treatment.	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Figure	   3.2:	   Immunohistochemical	   staining	   of	   cell	   lines	   SKBR3	   (A),	   BT-­‐20	   (B)	   and	  MCF-­‐7	   (C)	   using	   SP3	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Figure	  3.3:	   Immunohistochemical	   staining	  of	   cell	   lines	   SKBR3	   (A),	  BT-­‐20	   (B)	   and	  MCF-­‐7	   (C)	  using	  CB11	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Figure	  3.4:	   Immunohistochemical	   staining	  of	   cell	   lines	   SKBR3	   (A),	   BT-­‐20	   (B)	   and	  MCF-­‐7	   (C)	   using	  6F11	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Figure	  3.5:	  Immunohistochemical	  staining	  of	  cell	  lines	  SKBR3	  (A),	  BT-­‐20	  (B)	  and	  MCF-­‐7	  (C)	  using	  PGR636	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Figure	  3.6:	  Negative	  controls	  used	  in	  immunohistochemistry	  showing	  cell	  lines	  SKBR3	  (A),	  BT-­‐20	  (B)	  and	  
MCF-­‐7	  (C)	  using	  SP3,	  CB11	  and	  6F11	  monoclonal	  antibodies	  respectively	  (magnification:	  x	  40).	  
	  
3.3.2 Detection	  of	  HER2	  mRNA	  expression	  in	  cell	  lines	  by	  RT-­‐	  PCR	  	  
The	  Polymerase	  Chain	  Reaction	  provides	  a	  rapid	  and	  sensitive	  method	  for	  amplifying	  a	  
specific	  segment	  of	  complementary	  DNA	  (cDNA)	  produced	  by	  reverse-­‐transcription	  of	  
RNA	   extracted	   from	   cells	   or	   tissues,	   making	   it	   possible	   to	   delineate	   a	   template	  
sequence	  or	  a	  specific	  region	  of	  a	  gene	  of	  interest.	  The	  specified	  sequence	  corresponds	  
to	  the	  amplicon	  size	  of	  the	  PCR	  product.	  PCR	  has	  also	  been	  used	  to	  identify	  alternative	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splice	   isoforms	   in	   genes	   where	   products	   which	   do	   not	   correspond	   to	   the	   expected	  
amplicon	  size	  have	  been	  obtained.	  	  
RT-­‐PCR	  analysis	  of	  cell	  lines	  shows	  that	  there	  are	  numerous	  potential	  alternative	  splice	  
variants	   in	  HER2.	   In	  addition	   to	   the	  already	  published	  exon	  16	  deleted	  HER2	   isoform	  
using	   primer	   pairs	   NP1/NP2	   and	   NP5/NP6	   (Figures	   3.15	   and	   3.16)	   (Kwong	   &	   Hung,	  
1998),	  multiple	  bands	  were	  observed	   in	  exons	  12-­‐15	  with	  primers	  E12F/E15R	  (Figure	  
3.10),	  exons	  15-­‐19	  with	  primers	  E15F/E19R,	  and	  exons	  19-­‐22	  with	  primers	  E19F/E22R	  
(Figure	  3.12).	  To	  ensure	  that	  the	  RT-­‐PCR	  results	  were	  from	  actual	  HER2	  mRNA	  and	  not	  
genomic	  DNA,	  all	  RNA	  templates	  were	  treated	  with	  RQ1	  RNAse-­‐Free	  DNAse	  (Promega,	  
UK).	  As	  an	  added	  control,	  a	  no	  RT	  template	  was	  added	  to	  each	  reverse	   transcription	  
reaction,	   and	   the	   template	   was	   PCR	   amplified	   along	   with	   the	   experimental	   cDNA	  
samples.	  RT-­‐PCR	  results	  are	  representative	  of	  three	  biological	  repeats.	  	  
	  
Figure	  3.7:	  RT-­‐PCR	  amplification	  of	  HER2	  exons	  3-­‐6	   (primer	  pair	  E3F+E6R)	  using	  all	   six	  cell	   lines,	  and	  a	  
negative	  (no	  RT)	  control.	  SKOV3,	  SKBR3	  and	  MDA-­‐MB-­‐453	  show	  expected	  band	  sizes	  at	  478	  base	  pairs.	  




Figure	  3.8:	  RT-­‐PCR	  amplification	  of	  HER2	  exons	  6-­‐9	   (primer	  pair	  E6F+E9R)	  using	  all	   six	  cell	   lines,	  and	  a	  
negative	   (no	   RT)	   control.	   SKOV3,	   SKBR3	   and	  MDA-­‐MB-­‐453	   show	   expected	   band	   sizes	   at	   441bp	   base	  




Figure	  3.9:	  RT-­‐PCR	  amplification	  of	  HER2	  exons	  9-­‐12	  (primer	  pair	  E9F+E12R)	  using	  all	  six	  cell	  lines,	  and	  a	  
negative	  (no	  RT)	  control.	  SKOV3,	  SKBR3	  and	  MDA-­‐MB-­‐453	  show	  expected	  band	  sizes	  at	  454	  base	  pairs.	  




Figure	  3.10:	  RT-­‐PCR	  amplification	  of	  HER2	  exons	  12-­‐15	   (primer	  pair	  E12F+E15R)	  using	  all	   six	   cell	   lines,	  
and	  a	  negative	  (no	  RT)	  control.	  SKOV3,	  SKBR3	  and	  MDA-­‐MB-­‐453	  show	  expected	  band	  sizes	  at	  432	  base	  
pairs,	   and	   MDA-­‐MB-­‐453	   shows	   two	   unexpected	   additional	   bands,	   indicative	   of	   potential	   novel	  




Figure	  3.11:	  RT-­‐PCR	  amplification	  of	  HER2	  exons	  15-­‐19	   (primer	  pair	  E15F+E19R)	  using	  all	   six	   cell	   lines,	  
and	  a	  negative	  (no	  RT)	  control.	  SKOV3,	  SKBR3	  and	  MDA-­‐MB-­‐453	  show	  expected	  band	  sizes	  at	  480	  base	  
pairs;	  SKOV-­‐3,	  SKBR-­‐3,	  and	  MDA-­‐MB-­‐453	  show	  one	  unexpected	  additional	  band,	  indicative	  of	  potential	  
novel	  alternative	  splice	  variants.	  Each	  rung	  of	  the	  hyperladder	  IV	  represents	  100bp.	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Figure	  3.12:	  RT-­‐PCR	  amplification	  of	  HER2	  exons	  19-­‐22	   (primer	  pair	  E19F+E22R)	  using	  all	   six	   cell	   lines,	  
and	  a	  negative	  (no	  RT)	  control.	  SKOV3,	  SKBR3	  and	  MDA-­‐MB-­‐453	  show	  expected	  band	  sizes	  at	  450	  base	  
pairs;	   SKOV3	  and	  MDA-­‐MB-­‐453	   shows	   two	  unexpected	  additional	  bands,	   indicative	  of	  potential	   novel	  




Figure	  3.13:	  RT-­‐PCR	  amplification	  of	  HER2	  exons	  22-­‐25	   (primer	  pair	  E22F+E25R)	  using	  all	   six	   cell	   lines,	  
and	  a	  negative	  (no	  RT)	  control.	  SKOV3	  and	  MDA-­‐MB-­‐453	  show	  expected	  band	  sizes	  at	  489	  base	  pairs.	  




Figure	  3.14:	  RT-­‐PCR	  amplification	  of	  HER2	  exons	  25-­‐27	   (primer	  pair	  E25F+E27R)	  using	  all	   six	   cell	   lines,	  
and	  a	  negative	  (no	  RT)	  control.	  SKOV3	  and	  MDA-­‐MB-­‐453	  show	  expected	  band	  sizes	  at	  450	  base	  pairs.	  




Figure	  3.15:	  RT-­‐PCR	  amplification	  of	  HER2	  exons	  16-­‐18	  (primer	  pair	  NP1+NP2)	  using	  all	  six	  cell	  lines,	  and	  
a	  negative	  (no	  RT)	  control.	  SKOV3,	  SKBR3,	  MDA-­‐MB-­‐453	  and	  MDA-­‐MB-­‐361	  show	  expected	  band	  sizes	  at	  
266	  base	  pairs;	  MDA-­‐MB-­‐453	  and	  MDA-­‐MB-­‐361	  show	  one	  expected	  additional	  band	  at	  approx.	  224bp.	  




Figure	  3.16:	  RT-­‐PCR	  amplification	  of	  HER2	  exons	  16-­‐18	  (primer	  pair	  NP5+NP6)	  using	  all	  six	  cell	  lines,	  and	  
a	  negative	  (no	  RT)	  control.	  SKOV3,	  SKBR3,	  MDA-­‐MB-­‐453	  and	  MDA-­‐MB-­‐361	  show	  expected	  band	  sizes	  at	  
146	  base	  pairs;	  SKBR3	  shows	  one	  additional	  band	  at	  approximately	  104bp.	  Each	  rung	  of	  the	  hyperladder	  
IV	  represents	  100bp.	  	  
Quality	  control	  results	  for	  cDNA	  and	  RNA	  templates	  used	  for	  the	  assessment	  of	  HER2	  








SAMPLE	   ng/µl	   260/280	  
SKOV3	   1019.6	   1.99	  
SKBR3	   696.8	   1.95	  
BT-­‐20	   441.2	   1.90	  
MCF-­‐7	   501.7	   1.93	  
MDA-­‐MB-­‐453	   494.3	   1.94	  
MDA-­‐MD-­‐361	   432.2	   1.92	  
	  
Table	  3.1:	  RNA	  concentrations	  and	  absorbance	  at	  260/280	  for	  each	  cell	  line.	  The	  ratio	  of	  absorbance	  at	  
260/280	  is	  used	  to	  assess	  the	  purity	  of	  RNA	  and	  DNA.	  A	  ratio	  of	  ~2.0	  and	  ~1.8	  is	  generally	  accepted	  as	  
‘pure’	  for	  RNA	  and	  DNA	  respectively.	  
	  
SAMPLE	   ng/µL	   260/280	  
SKOV3	   1718.3	   1.8	  
SKBR3	   1709.9	   1.8	  
BT-­‐20	   2036.4	   1.77	  
MCF-­‐7	   1764.7	   1.78	  
MDA-­‐MB-­‐453	   1666.8	   1.79	  
MDA-­‐MD-­‐361	   1661.3	   1.78	  
	  
Table	  3.2:	  cDNA	  concentrations	  and	  absorbance	  at	  260/280	  for	  each	  cell	  line.	  The	  ratio	  of	  absorbance	  at	  
260/280	  is	  used	  to	  assess	  the	  purity	  of	  RNA	  and	  DNA.	  A	  ratio	  of	  ~2.0	  and	  ~1.8	  is	  generally	  accepted	  as	  
‘pure’	  for	  RNA	  and	  DNA	  respectively.	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3.3.3 Analysis	  of	  HER2	  cDNA	  amplicon	  sequences	  
To	  ensure	  that	  the	  results	  obtained	  from	  the	  sequences	  were	  actual	  HER2	  mRNA,	  the	  
sequences	   were	   entered	   into	   NCBI	   Nucleotide	   Basic	   Local	   Alignment	   Search	   Tool	  
(BLASTN)	   after	   which	   the	   insert	   sequences	   were	   then	   aligned	   to	   the	   full	   HER2	  
sequence	  using	  Clustal	  Omega	   to	  determine	  homology	  between	   sequences	  obtained	  
from	  GenBank	  and	  sequences	  obtained	  from	  cloned	  inserts	  of	  PCR	  amplified	  products.	  
Bioinformatic	   analysis	   was	   then	   carried	   out	   on	   the	   regions	   of	   the	   HER2	   gene	   with	  
potential	  alternative	  splice	  variants	  observed	  as	  loss	  of	  entire	  exons	  (cassette	  exons)	  or	  
loss	  of	  part	  of	  an	  exon	  (alternative	  3’	  or	  5’	  splice	  sites).	  Full	  sequence	  alignment	  of	  the	  
rest	   of	   the	   HER2	   exons	   resulting	   from	   the	   RT-­‐PCR	   products	   which	   did	   not	   show	  








HER2	  Exons	  12-­‐15;	  top	  band	  (Primers	  E12F	  +	  E15R)	  
	  
Figure	   3.17:	   Sequence	   alignment	   of	   HER2	   insert	   with	   the	   reference	   HER2	   exons	   12-­‐15	   using	   Clustal	  
Omega.	   The	   alignment	   shows	   the	   expected	   gene	   sequence	   for	   the	   region	   amplified	   in	   the	   top	   band	  














HER2	  Exons	  12-­‐15;	  bottom	  band	  (Primers	  E12F	  +	  E15R)	  
	  
Figure	   3.18:	   Sequence	   alignment	   of	   HER2	   insert	   with	   the	   wild	   type	   HER2	   exons	   12-­‐15	   using	   Clustal	  
Omega.	   The	   alignment	   shows	   the	   deletions	   in	   the	   gene	   sequence	   for	   the	   region	   amplified	   in	   the	   top	  







HER2	  Exons	  15-­‐19;	  top	  band	  (Primers	  E15F	  +	  E19R)	  
	  
Figure	   3.19:	   Sequence	   alignment	   of	   HER2	   insert	   with	   the	   wild	   type	   HER2	   exons	   15-­‐19	   using	   Clustal	  
Omega.	   The	   alignment	   shows	   the	   expected	   gene	   sequence	   for	   the	   region	   amplified	   in	   the	   top	   band	  







HER2	  Exons	  15-­‐19;	  lower	  band	  (Primers	  E15F	  +	  E19R)	  
	  
Figure	   3.20:	   Sequence	   alignment	   of	   HER2	   insert	   with	   the	   wild	   type	   HER2	   exons	   15-­‐19	   using	   Clustal	  
Omega.	   The	   alignment	   shows	   the	   deletions	   in	   the	   gene	   sequence	   for	   the	   region	   amplified	   in	   the	   top	  
band	  using	  primer	  pairs	  E15F	  +	  E19R.	  This	  deletion	  corresponds	  with	  the	  use	  of	  an	  alternative	  3’	  splice	  







HER2	  Exons	  15-­‐18;	  top	  band	  (Primers	  NP1	  +	  NP2)	  
	  
Figure	  3.21:	  Sequence	  alignment	  of	  HER2	   exons	  15-­‐18	  using	  Clustal	  Omega.	  The	  alignment	   shows	   the	  








HER2	  Exons	  15-­‐18;	  bottom	  band	  (Primers	  NP1	  +	  NP2)	  
	  
Figure	   3.22:	   Sequence	   alignment	   of	   HER2	   exons	   15-­‐18	   using	   Clustal	   Omega.	   The	   alignment	   shows	  
deletions	   in	   the	  gene	  sequence	   for	   the	   region	  amplified	   in	   the	  bottom	  band	  using	  primer	  pairs	  NP1	  +	  







HER2	  Exons	  15-­‐17;	  Top	  band	  (Primers	  NP5	  +	  NP6)	  
	  
Figure	  3.23:	  Sequence	  alignment	  of	  HER2	   exons	  15-­‐17	  using	  Clustal	  Omega.	  The	  alignment	   shows	   the	  







HER2	  Exons	  15-­‐17;	  Bottom	  band	  (Primers	  NP5	  +	  NP6)	  
	  
Figure	  3.24:	  Sequence	  alignment	  of	  HER2	  exons	  15-­‐17	  using	  Clustal	  Omega.	  The	  alignment	  shows	  
deletions	  in	  the	  gene	  sequence	  for	  the	  region	  amplified	  in	  the	  bottom	  band	  using	  primer	  pairs	  NP5	  +	  
NP6.	  This	  deletion	  corresponds	  to	  the	  skipping	  of	  exon	  16.	  
Of	  all	  the	  additional	  bands	  observed	  in	  RT-­‐PCR	  experiments,	  only	  the	  bands	  obtained	  
with	   E12F+E15R,	   E15F+E19R,	   NP1+NP2	   and	   NP5+NP6	   were	   successfully	   sequenced.	  
Additional	   bands	   were	   observed	   with	   primer	   pairs	   E19F+E22R,	   and	   E12F+E15R.	  
Sequencing	  of	  these	  bands,	  however,	  did	  not	  produce	  reliable	  results.	  This	  may	  have	  
been	   as	   a	   result	   of	   inadequate	   template	   concentrations	   required	   for	   the	   reliable	  
sequencing	  of	  plasmids	  or	  artefacts	  produced	   in	   the	  cDNA	  amplification	  process.	  RT-­‐
PCR	   amplification	   of	   exons	   1	   and	   2	   did	   not	   produce	   bands	   after	   agarose	   gel	  
electrophoresis.	   Sequence	   alignments	   for	   all	   other	   primer	   pairs	   for	   the	   HER2	   gene	  
where	  additional	  bands	  were	  not	  observed,	  can	  be	  found	  in	  Appendix	  A.	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3.4 Summary	  	  
Analyses	   of	   SKBR3,	   BT-­‐20	   and	  MCF-­‐7	   cell	   lines	   by	   immunohistochemistry	   show	   that	  
HER2	   is	  expressed	   in	  SKBR-­‐3	  cell	   lines,	  and	  not	   in	  BT-­‐20	  and	  MCF-­‐7	  cell	   lines.	  This	   is	  
consistent	  with	  published	   studies	  on	   the	  HER2	   expression	   in	   these	   cell	   lines	   (Figures	  
3.2-­‐3.6).	   Immunohistochemical	   testing	   of	   breast	   tumours	   is	   a	   reliable	   method	   of	  
testing	  for	  HER2	  status	  in	  breast	  cancer	  patients.	  However,	  overall	  protein	  expression	  
as	   determined	   by	   IHC	  may	   not	   be	   conclusive	   in	   determining	   a	   patient’s	   response	   to	  
treatment.	  	  
RT-­‐PCR	  analysis	   of	   cell	   lines	   shows	   that	   there	   are	  novel	   alternative	   splice	   variants	   in	  
HER2.	   In	  addition	  to	  the	  already	  published	  exon	  16	  deleted	  HER2	   isoform,	  two	  novel	  
splice	  variants	  of	  HER2	  have	  been	  successfully	  characterised;	  a	  cassette	  exon	   in	  exon	  
13,	  in	  which	  the	  entire	  exon	  is	  skipped,	  and	  an	  alternative	  5’	  splice	  site	  in	  exon	  18,	  in	  
which	  the	  42	  bases	  corresponding	  with	  14	  amino	  acids	  at	  the	  3’	  end	  of	  the	  exon	  have	  







CHAPTER	  4. BIOINFORMATIC	  ANALYSIS	  OF	  HER2	  AND	  HER2	  
ALTERNATIVE	  SPLICE	  VARIANTS	  
4.1 Introduction	  	  
The	   Human	   Epidermal	   Growth	   Factor	   Receptor	   2	   (HER2)	   gene	   (accession	   number	  
NM_004448)	   was	   first	   isolated	   in	   1985	   (Coussens	   et	   al.,	   1985;	   Semba	   et	   al.,	   1985;	  
Bargmann,	  Hung	  &	  Weinberg,	  1986)	  in	  rat	  NIH3T3	  cells	  as	  an	  oncogene	  called	  neu,	  and	  
shown	  to	  reside	  on	  chromosome	  17	  (Figure	  4.1).	  HER2	  is	  classified	  as	  one	  of	  the	  most	  
important	   genes	   in	   human	   cancer,	   because	   of	   its	   frequent	   amplification	   in	   cancers	  
such	  as	  breast	  carcinomas	  (Shih	  et	  al.,	  1981).	  Schechter	  et	  al	   (1985)	  showed	  that	  the	  
neu	  gene	  encoded	  a	  protein	  of	  relative	  molecular	  mass	  185,000	  (p185)	   (Schechter	  et	  
al.,	   1985).	   The	   neu	   gene	   was	   found	   to	   share	   significant	   similarity	   to	   the	   avian	  
erythroblastosis	   virus	   (v-­‐erbB),	   and	   was	   homologous	   with	   the	   cellular	   gene	   (c-­‐erbB)	  
which	  encodes	  EGFR	  (Downward	  et	  al.,	  n.d.;	  Vennström	  &	  Bishop,	  1982;	  Yamamoto	  et	  
al.,	  1983).	  Schechter	  et	  al	   (1985)	  also	  demonstrated	  that	   the	  homology	  between	  the	  
proteins	  encoded	  by	  the	  neu	  and	  c-­‐erbB	  genes	  were	   limited	  to	  the	  kinase	  domain	  of	  
the	  EGFR	   protein,	   and	   the	   human	   v-­‐erbB-­‐related	   sequence	  was	   then	   identified,	   and	  
shown	   to	   be	   distinct	   from	   EGFR	   	   (Yamamoto	   et	   al.,	   2011).	   The	   HER2	   nucleic	   acid	  
sequence	  is	  approximately	  4.8kb	  long,	  the	  open	  reading	  frame	  encodes	  a	  1255	  amino	  
acid	  protein	  approximately	  185kDa	  in	  mass.	  An	  extensive	  bioinformatic	  analysis	  of	  the	  
HER2	   gene	   and	   protein	   structure	   is	   available	   on	   databases	   such	   as	   ScanProsite,	  
UniprotKB	  and	  NCBI.	  With	  the	  discovery	  of	  novel	  splice	  variants	  of	  HER2	  as	  described	  
in	   chapter	   2,	   the	  use	  of	   bioinformatics	  was	   interrogated	   to	   investigate	   the	  potential	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functional	  and	  structural	  differences	  between	  alternative	  splice	  variants	  of	  HER2,	  and	  
the	  regulation	  of	  splicing	  in	  the	  HER2	  gene.	  
4.2 Objectives	  
1. To	  review	  the	  literature	  and	  databases	  on	  the	  bioinformatics	  of	  HER2	  gene	  and	  
protein.	  
2. To	   use	   bioinformatics	   to	   analyse	   the	   functional	   properties	   of	   the	   wild-­‐type	  
HER2	  gene.	  
3. To	  use	  bioinformatics	  to	  understand	  the	  role	  and	  function	  of	  HER2	  alternative	  
splice	  variants	  in	  comparison	  to	  the	  wild-­‐type	  HER2.	  
4.3. Methods	  	  
4.3.1 HER2	  sequence	  retrieval	  
The	   HER2	   mRNA	   sequence	   was	   obtained	   using	   NCBI	   Refseq®,	   a	   genetic	   sequence	  
database	   which	   contains	   an	   annotated	   collection	   of	   all	   publicly	   available	   DNA	  
sequences.	  HER2	   exons	   were	   configured	   using	   the	   Friendly	   Alternative	   Splicing	   and	  
Transcripts	   DataBase	   (FastDB;	   GenoSplice	   technology,	   Paris).	   The	   HER2	   protein	  
sequence	  was	  obtained	  using	   the	  UniprotKB	  blast	   tool,	   a	  database	  which	   consists	  of	  
high	  quality	  and	   freely	  accessible	   resource	  of	  protein	   sequences	  and	   their	   functional	  
information.	   The	   HER2	   protein	   sequence	   was	   also	   derived	   from	   the	   HER2	   RNA	  
sequence	  using	  the	  ExPASy	  translate	  tool	  (Swiss	  Institute	  of	  Bioinformatics).	  The	  HER2	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open	   reading	   frame	   was	   predicted	   using	   ExPASy	   Translate	   Tool	   and	   the	   NCBI	   ORF	  
finder.	  	  
4.3.2 Alignment	  of	  HER2	  transcript	  variants	  and	  isoforms	  
HER2	   transcript	   variants	   and	  HER2	   isoforms	   obtained	   from	   the	   NCBI	   database	  were	  
aligned	  using	  the	  Clustal	  Omega	  multiple	  sequence	  alignment	  tool	  (Appendix	  B).	  Novel	  
HER2	  splice	  variants	  and	  their	  isoforms	  characterised	  during	  this	  study	  were	  aligned	  in	  
comparison	  with	  the	  HER2	  transcript	  variant	  1	  mRNA	  (Accession	  number	  NM_004448)	  
using	  the	  Clustal	  Omega	  multiple	  sequence	  alignment	  tool	  (Appendix	  B).	  	  
4.3.3 Analysis	   of	   potential	   splice	   factor	   binding	   sites	   in	   HER2	  
alternative	  splice	  variants.	  
SpliceAid,	   a	   database	   of	   experimentally	   assessed	   human	   RNA	   target	   sequences	  
(introni.it,	   2013),	   was	   used	   to	   identify	   motifs	   that	   may	   predict	   the	   pattern	   of	   RNA	  
splicing	  by	  identifying	  splice	  factors	  which	  are	  involved	  in	  HER2	  splicing.	  The	  SpliceAid	  
database	  was	  used	  to	  predict	  binding	  motifs	  for	  exonic	  splice	  enhancers	  (ESE),	  Intronic	  
splice	   silencers	   (ISS),	   exonic	   splice	   silencers	   (ESS)	   and	   Intronic	   splice	   enhancers	   (ISE)	  
within	  the	  alternatively	  spliced	  exons	  and	  their	  flanking	  introns.	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4.3.4 Structural	   and	   functional	   characterisation	   of	   the	   wild-­‐type	  
HER2	  protein	  	  
Structural	   and	   functional	   characterisation	   of	   the	  wild-­‐type	  HER2	   protein	  was	   carried	  
out	   by	   entering	   the	   amino	   acid	   sequence	   of	   HER2	   isoform	   1	   (accession	   number	  
P02464)	  into	  various	  bioinformatic	  databases;	  this	  variant	  encodes	  the	  longest	  protein	  
isoform,	   and	   has	   been	   chosen	   as	   the	   ‘canonical’	   HER2	   sequence.	   All	   comparative	  
analyses	  in	  this	  study	  have	  been	  made	  in	  reference	  to	  it.	  The	  HER2	  protein	  sequence	  
analysis	  was	  carried	  out	  using	  UniprotKB,	  and	  the	  prediction	  of	  HER2	  domain	  structure	  
and	   function	   was	   obtained	   using	   ScanProsite.	   The	   Protein	   Families	   (Pfam)	   database	  
(Wellcome	   trust,	   Sanger	   Institute,	   Cambridge)	   was	   used	   to	   predict	   the	   functional	  
domains	   of	  HER2	   and	   their	   amino	   acid	   sequences.	   The	   secondary	   structure	   of	  HER2	  
was	   predicted	   using	   the	   PSIPRED	  programme.	   The	  HER2	  protein	   sequence	  was	   then	  
entered	   into	   the	   Protein	   Homology/Analogy	   Recognition	   Engine	   V	   2.0	   (Phyre2)	  
programme	   to	   predict	   its	   tertiary	   structure.	   ProtParam	   was	   used	   to	   predict	   the	  
molecular	  weight,	  half-­‐life	  and	  amino	  acid	  composition	  of	  HER2.	  	  
4.4. Results	  	  
4.4.1 HER2	  RNA	  sequence	  analysis	  	  
The	   NCBI	   Genbank®	   nucleotide	   search	   using	   the	   search	   term	   ‘HER2’	   returned	   the	  
following	  results:	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• Definition:	   V-­‐erb-­‐b2	   avian	   erythroblastic	   leukemia	   viral	   oncogene	   homolog	   2	  
(ERBB2),	  transcript	  variant	  1,	  mRNA.	  
• Accession:	  NM_004448.	  
• Source	  organism:	  Homo	  sapiens.	  
• Location:	  17q12.	  
• Genomic	   sequence:	   17;	   NC_000017.11	   (39688140...39728662)	   reference	  
GRCH38	  p13	  primary	  assembly.	  
HER2	   is	   flanked	   upstream	   by	   post-­‐GPI	   attachment	   to	   proteins	   3	   (PGAP3)	   and	  
migration	  and	   invasion	  enhancer	  1	  (MIEN1),	  and	  downstream	  by	  titin-­‐cap	  (TCAP),	  
Phenylethanolamine	  N-­‐methyltransferase	  (PNMT),	  microRNA	  4728	  (MIR4728),	  and	  
growth	  factor	  receptor-­‐bound	  protein	  7	  (GRB7)	  (Figure	  4.1).	  	  
	  
	  





Six	  transcript	  variants	  of	  HER2	  mRNA	  were	  obtained	  from	  the	  NCBI	  database;	  	  
1. Homo	   sapiens	   v-­‐erb-­‐b2	   Avian	   Erythroblastic	   Leukaemia	   Viral	  
Oncogene	  Homolog	  2	  (ERBB2),	  Transcript	  Variant	  1,	  mRNA	  (Accession	  
number	   NM_004448):	   This	   4,664	   base	   pair	   transcript	   encodes	   a	   protein	  
known	  as	  HER2	  isoform	  a,	  which	  represents	  the	  longest	  HER2	  protein	  isoform.	  
2. Homo	   sapiens	   v-­‐erb-­‐b2	   Avian	   Erythroblastic	   Leukaemia	   Viral	  
Oncogene	  Homolog	  2	  (ERBB2),	  Transcript	  Variant	  2,	  mRNA	  (Accession	  
number	  NM_001005862):	  The	  HER2	  transcript	  variant	  2	  is	  4,889	  base	  pairs	  
long	   and	   encodes	   a	   protein	   known	   as	  HER2	   isoform	   b.	   The	  HER2	   transcript	  
variant	  2	  lacks	  a	  portion	  of	  the	  5’	  coding	  region,	  and	  initiates	  translation	  at	  a	  
downstream	   start	   codon,	   resulting	   in	   a	   shorter	   N	   terminus,	   compared	   to	  
isoform	  a.	  
3. Homo	  sapiens	  v-­‐erb-­‐b2	  Avian	  Erythroblastic	  Leukaemia	  Viral	  Oncogene	  
Homolog	   2	   (ERBB2),	   Transcript	   Variant	   3,	   mRNA	   (Accession	   number	  
NM_001289936;	   XM_006721766):	   The	   HER2	   transcript	   variant	   3	   is	   4,940	  
base	   pairs	   long	   and	   encodes	   a	   protein	   known	   as	  HER2	   isoform	   c.	   Unlike	   the	  
transcript	  variant	  1,	  the	  HER2	  transcript	  variant	  3	  has	  an	  alternative	  5’	  UTR	  and	  
5’	  coding	  region,	  resulting	  in	  an	  isoform	  with	  a	  shorter	  N-­‐terminus	  compared	  to	  
isoform	  a.	  	  
4. Homo	  sapiens	  v-­‐erb-­‐b2	  Avian	  Erythroblastic	  Leukaemia	  Viral	  Oncogene	  
Homolog	   2	   (ERBB2),	   Transcript	   Variant	   4,	   mRNA	   (Accession	   number	  
NM_001289937):	  The	  HER2	   transcript	   variant	  4	   is	  4,411	  base	  pairs	   long	  and	  
encodes	  a	  protein	  known	  as	  the	  HER2	   isoform	  d.	   this	  variant	   lacks	  an	  exon	   in	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the	   3’	   coding	   region,	   resulting	   in	   a	   translational	   frame	   shift.	   The	   resulting	  
protein	  isoform	  has	  a	  distinct	  and	  shorter	  c-­‐terminus	  compared	  to	  isoform	  a.	  	  
5. Homo	  sapiens	  v-­‐erb-­‐b2	  Avian	  Erythroblastic	  Leukaemia	  Viral	  Oncogene	  
Homolog	   2	   (ERBB2),	   Transcript	   Variant	   5,	   mRNA	   (Accession	   number	  	  
NM_001289938):	  The	  HER2	   transcript	   variant	  5	   is	  2,590	  base	  pairs	   long	  and	  
encodes	   a	   protein	   known	   as	   the	   HER2	   isoform	   e.	   this	   variant	   has	   multiple	  
coding	  differences,	  and	  differs	  in	  the	  5’	  and	  3’	  UTRs,	  compared	  to	  variant	  1.	  The	  
resulting	   isoform	   has	   a	   shorter	   N-­‐terminus	   and	   a	   truncated	   C-­‐terminus,	  
compared	  to	  isoform	  a.	  	  
6. Homo	  sapiens	  v-­‐erb-­‐b2	  Avian	  Erythroblastic	  Leukaemia	  Viral	  Oncogene	  
Homolog	   2	   (ERBB2),	   Transcript	   Variant	   6,	   long	   non-­‐coding	   RNA	  
(Accession	  number	  NR_110535):	  This	  4,998	  base	  pair	  transcript	  variant	  has	  
an	   alternative	   5’	   splice	   site	   compared	   to	   the	  HER2	   transcript	   variant	   1.	   The	  
HER2	  variant	  6	   is	  designated	  as	  a	  non-­‐coding	  RNA	  because	  use	  of	  the	  5'-­‐most	  
expected	   translation	   start	   codon	   renders	   the	   transcript	   a	   candidate	   for	  
nonsense-­‐mediated	  mRNA	  decay	  (NMD).	  
	  The	   RNA	   sequences	   of	   all	   six	  HER2	   transcript	   variants	  were	   compared	   using	   Clustal	  
Omega	  multiple	  sequence	  alignment	  tool	  (Appendix	  B).	  
4.4.2 HER2	  protein	  sequence	  analysis	  
Four	  isoforms	  of	  HER2	  were	  obtained	  from	  the	  NCBI	  database.	  The	  protein	  sequences	  
of	  the	  above	  HER2	  transcripts	  were	  also	  derived	  from	  their	  mRNA	  sequences	  using	  the	  
Expasy	  Translate	  tool.	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1. HER2	  isoform	  1	  (accession	  number	  P042626;	  P04626-­‐1)	  is	  a	  1255	  amino	  acid	  
protein,	   encoded	   by	   Homo	   sapiens	   v-­‐erb-­‐b2	   Avian	   Erythroblastic	   Leukaemia	  
Viral	   Oncogene	   Homolog	   2	   (ERBB2),	   Transcript	   Variant	   1,	   mRNA	   (Accession	  
number	  NM_004448).	  This	   isoform	  is	  chosen	  as	  the	  putative	  (wild-­‐type)	  HER2	  
sequence.	   All	   positional	   and	   comparative	   analyses	   of	   HER2	   and	   HER2	   splice	  
isoforms	  are	  made	  with	  reference	  to	  this	  isoform.	  
2. HER2	  isoform	  2	  (accession	  number	  P04626-­‐2)	  is	  611	  amino	  acids	  long,	  and	  is	  
also	   known	   as	   CTF-­‐611.	   This	   isoform	   is	   produced	   by	   alternative	   initiation	   at	  
Met-­‐611	  of	  isoform	  1,	  and	  is	  missing	  amino	  acids	  1-­‐610	  of	  the	  canonical	  HER2	  
isoform	  1	  sequence.	  
3. HER2	  isoform	  3	  (accession	  number	  P04626-­‐3)	  is	  569	  amino	  acids	  long,	  and	  is	  
also	   known	   as	   CTF-­‐687.	   This	   isoform	   is	   produced	   by	   alternative	   initiation	   at	  
Met-­‐687	   of	   isoform	   1,	   and	   is	   missing	   amino	   acids	   1-­‐687	   compared	   to	  HER2	  
isoform	  1.	  
4. HER2	   isoform	  4	   (accession	  number	   P04626-­‐4)	   is	   a	   1240	   amino	   acid	   protein	  
produced	   by	   alternative	   splicing	   of	   the	   5’	   end	   of	   isoform	   1.	   The	   alternative	  
splicing	   of	   this	   HER2	   isoform	   produces	   replaces	   amino	   acids	   1-­‐23	  
(MELAALCRWGLLLALLPPGAAST…)	   with	   a	   shorter,	   8-­‐amino	   acid	   sequence	  
(MPRGSWKP…).	  	  
The	  protein	  sequences	  of	  all	  HER2	  isoforms	  obtained	  from	  NCBI,	  as	  well	  as	  sequences	  
derived	   from	   HER2	   transcript	   variants,	   were	   compared	   using	   the	   Clustal	   Omega	  
multiple	  sequence	  alignment	  tool	  (Appendix	  B).	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4.4.3 Structural	   and	   functional	   characterisation	   of	   the	   wild-­‐type	  
HER2	  (isoform	  1)	  
The	   analyses	   of	   HER2	   isoform	   1	   (P04626)	   sequence	   for	   structural	   and	   functional	  
properties	   predicted	   a	   1255	   amino	   acid	   protein	   with	   a	   protein	   kinase	   region	   at	  
residues	  720-­‐987aa;	  2417-­‐2438nt,	   an	  ATP	  nucleotide	  binding	   region	  at	   residues	  726-­‐
734;	  2438-­‐2461nt,	  an	  ATP	  binding	   site	  at	  735aa;	  2462-­‐2465nt,	  and	  an	  active	   (proton	  
acceptor)	  site	  at	  845aa;	  2794-­‐2797nt.	  	  Further	  analysis	  of	  HER2	  protein	  structure	  using	  
the	  UniprotKB	  analysis	  tool	  also	  predicted	  the	  signal	  peptide	  at	  1-­‐22aa;	  260-­‐325nt,	  the	  
receptor	   tyrosine	   kinase	   domain	   at	   23-­‐1255aa;	   326-­‐4664nt,	   the	   transmembrane	  
domain	  at	  653-­‐675aa;	  2215-­‐2284nt,	  and	  the	  cytoplasmic	  domain	  at	  676-­‐1255aa,	  2285-­‐
4664nt.	   The	   nuclear	   localisation	   signalling	   region	   is	   predicted	   at	   676-­‐689aa;	   2285-­‐
2326nt	   (KPNB1	   and	   EEA1	   activation	   site),	   and	   a	   PIK3C2B	   activation	   site	   at	   1195-­‐
1197aa;	  3842-­‐3851nt.	  
Inputting	   the	  HER2	   RNA	   sequence	   into	   the	   Pfam	   programme	   returned	   four	   distinct	  
domains	   in	   the	   extracellular	   region	   of	  HER2	   and	   one	   domain	   in	   the	   tyrosine	   kinase	  
region	  (Figure	  4.2).	  	  
• Receptor	  L	  domain:	  This	  domain	  constitutes	  subdomains	   I	  and	   III	  of	   the	  HER2	  
ECD	   (residues	   52-­‐173;	   336-­‐468,	   respectively).	   The	   HER2	   receptor	   L	   domain	  
makes	   up	   the	   bilobal	   ligand	   binding	   site,	   each	   domain	   consisting	   of	   a	   single-­‐
stranded	  right	  hand	  β-­‐helix	  (Garrett	  et	  al.,	  1998).	  
• Furin-­‐like	   cysteine	   rich	   domain:	   This	   domain	   constitutes	   subdomain	   III	   of	   the	  
HER2	  ECD	  (residues	  183-­‐343),	  and	   is	  usually	   found	   in	  eukaryotic	  proteins	  that	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are	  involved	  in	  signal	  transduction	  by	  receptor	  tyrosine	  kinases	  (Raz,	  Schejter	  &	  
Shilo,	  1991).	  
• Growth	   factor	   receptor	  domain:	  This	  domain	  constitutes	  subdomain	   IV	  of	   the	  
HER2	  ECD	  (residues	  510-­‐643).	   Interaction	  between	  the	  growth	  factor	  receptor	  
domain	   and	   the	   furin-­‐like	   domain	   regulates	   the	   binding	   of	   ligands	   to	   the	  
receptor	  L	  domains	  (Cho	  &	  Leahy,	  2002).	  	  
• Protein	   tyrosine	   kinase	   domain:	   Tyrosine	   kinases	   are	   a	   subclass	   of	   protein	  
kinases.	   This	   domain	   (residues	   720-­‐976)	   constitutes	   an	   enzyme	   that	   can	  
transfer	  a	  phosphate	  group	  from	  ATP	  to	  a	  protein	  in	  the	  cell,	  functioning	  as	  an	  
‘on’	  or	  ‘off	  switch	  in	  a	  variety	  of	  cellular	  functions	  (Hanks	  &	  Quinn,	  1991;	  Hanks	  
&	  Hunter,	  1995;	  Hunter	  &	  Plowman,	  1997).	  	  
	  
	  
Figure	  4.2	  Schematic	  of	  Pfam	  output	  showing	  HER2	  functional	  domains	  and	  their	  positions.	  
The	  PSIPRED	  programme	  predicted	  the	  following	  HER2	  secondary	  structure:	  α-­‐helix	  (2-­‐
14aa),	  β-­‐strand	  (26-­‐27aa),	  α-­‐helix	  (39-­‐48aa),	  β-­‐strand	  (54-­‐57aa,	  60-­‐64aa,	  78-­‐81aa,	  83-­‐
88aa,	   100-­‐103aa,	   112-­‐117aa,	   139-­‐140aa),	   α-­‐helix	   (147-­‐148aa),	   β-­‐strand	   (153-­‐155aa,	  
181-­‐184aa),	   α-­‐helix	   (237-­‐241aa),	   β-­‐strand	   (272-­‐273aa,	   279-­‐281aa,	   304-­‐305aa,	   312-­‐
313aa,	   321-­‐323aa,	   354-­‐356aa),	   α-­‐helix	   (360-­‐362aa),	   β-­‐strand	   (368-­‐371aa,	   374-­‐377aa,	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404-­‐414aa,	  429-­‐432aa,	  434-­‐437aa,	  440-­‐446aa,	  451-­‐453aa,	  460-­‐461aa,	  466-­‐468aa,	  493-­‐
495aa,	   655-­‐660aa,	   663-­‐667aa),	   α-­‐helix	   (671-­‐687aa,	   709-­‐714aa),	   β-­‐strand	   (720-­‐726aa,	  
732-­‐741aa,	  747-­‐755aa),	  α-­‐helix	  (761-­‐775aa),	  β-­‐strand	  (781-­‐789aa,	  794-­‐799aa),	  α-­‐helix	  
(805-­‐812aa,	  819-­‐832aa,	  842-­‐849aa),	  β-­‐strand	  (858-­‐861aa,	  877-­‐879aa,884-­‐885aa,	  887-­‐
888aa),	  α-­‐helix	  (889-­‐895aa),	  β-­‐strand	  (911-­‐916),	   	  α-­‐helix	  (933-­‐936aa,	  949-­‐959aa,	  969-­‐
980aa),	  β-­‐strand	   (987-­‐988aa).	  The	   intervening	  sequences	  are	   random	  coils	   (appendix	  
A).	  	  
The	  Phyre2	  programme	  predicted	   the	  3D	  structure	  of	   the	  HER2	  protein,	   showing	   the	  
positions	  of	  the	  α-­‐helices	  and	  the	  β-­‐strands	  (Figure	  4.3).	  	  
ProtParam	   predicted	   HER2	   to	   have	   a	   molecular	   weight	   of	   137910.5Da	   and	   an	  
estimated	   half-­‐life	   of	   30	   hours.	   The	   amino	   acid	   composition	   of	   the	  HER2	   protein	   as	  




Figure	   4.3	   Phyre2	   output	   showing	   the	   3D	   structure	   of	  HER2.	   The	   image	   is	   coloured	   by	   rainbow	   from	  









AMINO	  ACID	  	   OCCURRENCE	   PERCENTAGE	  	  
Ala	  (A)	   83	   6.60%	  
Arg	  (R)	  	  	   71	   5.70%	  
Asn	  (N)	  	  	  	  	  	   41	   3.30%	  
Asp	  (D)	  	   65	   5.20%	  
Cys	  (C)	  	  	  	  	  	  	   59	   4.70%	  
Gln	  (Q)	  	  	  	  	  	  	  	  	   62	   4.90%	  
Glu	  (E)	  	   77	   6.10%	  
Gly	  (G)	  	   101	   8.00%	  
His	  (H)	  	  	  	  	  	  	   35	   2.80%	  
Ile	  (I)	  	   44	   3.50%	  
Leu	  (L)	  	  	  	   138	   11.00%	  
Lys	  (K)	  	  	  	   39	   3.10%	  
Met	  (M)	  	  	  	  	   23	   1.80%	  
Phe	  (F)	  	  	  	  	  	  	   35	   2.80%	  
Pro	  (P)	  	  	   109	   8.70%	  
Ser	  (S)	  	  	  	  	  	  	   73	   5.80%	  
Thr	  (T)	  	  	  	  	  	   67	   5.30%	  
Trp	  (W)	  	  	  	  	  	   15	   1.20%	  
Tyr	  (Y)	  	  	  	  	  	  	  	  	   35	   2.80%	  
Val	  (V)	  	  	  	  	   83	   6.60%	  
Table	  4.1	  HER2	  amino	  acid	  composition	  as	  predicted	  by	  ProtParam.	  	  
	  
4.4.4 Analysis	  of	  potential	  splice	  factor	  binding	  sites	  
HER2	  DNA	  sequences	  representing	  alternative	  spliced	  exons	  and	  their	  flanking	  introns	  




Figure	  4.4	  SpliceAid	  output	  for	  the	  analysis	  of	  splice	  factor	  binding	  motifs	  in	  exon	  13	  and	  50	  base	  pairs	  
into	   the	   flanking	   introns.	   In	   exon	   13	   skipping,	   binding	   motifs	   that	   facilitate	   exon	   skipping	   are	  
considerably	  more	  than	  those	  which	  facilitate	  exon	  inclusion.	  Positive	  scores	  represent	  target	  sequences	  
that	  facilitate	  exon	  definition;	  exonic	  splice	  enhancer	  (ESE)	  and	  intronic	  splice	  silencer	  (ISS)	  motifs,	  and	  
negative	  scores	  represent	  target	  sequences	  that	  facilitate	  intron	  definition;	  exonic	  splice	  silencers	  (ESS)	  
and	   intronic	   splice	   enhancer	   (ISE)	  motifs.	   Target	  RNA	   sequences	   for	   splice	   factors	   are	   represented	  by	  
histogram.	   Bars	   have	   variable	   heights	   and	  widths	   related	   to	   the	   binding	   affinity.	   The	  missing	   exon	   is	  





Figure	  4.5	  SpliceAid	  output	  for	  the	  analysis	  of	  splice	  factor	  binding	  motifs	  in	  exon	  16	  and	  50	  base	  pairs	  
into	  the	  flanking	  introns.	  In	  exon	  16	  skipping,	  binding	  motifs	  that	  facilitate	  exon	  skipping	  are	  present	  in	  
equal	  numbers	  as	  those	  which	  facilitate	  exon	  inclusion.	  Positive	  scores	  represent	  target	  sequences	  that	  
facilitate	   exon	   definition;	   exonic	   splice	   enhancer	   (ESE)	   and	   intronic	   splice	   silencer	   (ISS)	   motifs,	   and	  
negative	  scores	  represent	  target	  sequences	  that	  facilitate	  intron	  definition;	  exonic	  splice	  silencers	  (ESS)	  
and	   intronic	   splice	   enhancer	   (ISE)	  motifs.	   Target	  RNA	   sequences	   for	   splice	   factors	   are	   represented	  by	  
histogram.	   Bars	   have	   variable	   heights	   and	  widths	   related	   to	   the	   binding	   affinity.	   The	  missing	   exon	   is	  
highlighted	  in	  the	  DNA	  sequence.	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Figure	  4.6	  SpliceAid	  output	  for	  the	  analysis	  of	  splice	  factor	  binding	  motifs	  in	  exon	  16	  and	  50	  base	  pairs	  
into	  the	  flanking	  introns.	   In	  exon	  13	  skipping,	  binding	  motifs	  that	  facilitate	  exon	  skipping	  are	  relatively	  
more	   than	   those	   which	   facilitate	   exon	   inclusion.	   Positive	   scores	   represent	   target	   sequences	   that	  
facilitate	   exon	   definition;	   exonic	   splice	   enhancer	   (ESE)	   and	   intronic	   splice	   silencer	   (ISS)	   motifs,	   and	  
negative	  scores	  represent	  target	  sequences	  that	  facilitate	  intron	  definition;	  exonic	  splice	  silencers	  (ESS)	  
and	   intronic	   splice	   enhancer	   (ISE)	  motifs.	   Target	  RNA	   sequences	   for	   splice	   factors	   are	   represented	  by	  
histogram.	  Bars	  have	  variable	  heights	  and	  widths	  related	  to	  the	  binding	  affinity.	  The	  missing	  part	  of	  exon	  
18	  is	  highlighted	  in	  the	  DNA	  sequence.	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4.4.5 Post-­‐translational	  modification	  of	  HER2	  protein	  
Post-­‐translational	  modification	   is	   an	   enzymatic	   process	   of	   covalently	   altering	   one	   or	  
more	   amino	   acids	   in	   a	   protein	   by	   either	   addition	   of	   functional	   groups	   or	   proteins,	  
proteolytic	   cleavage	   of	   regulatory	   subunits	   or	   degradation	   of	   entire	   proteins.	   Post-­‐
translational	  modifications	  occur	   after	   translation	   from	  mRNA,	   and	   after	   the	  protein	  
has	   been	   released	   from	   the	   ribosome.	   Post-­‐translational	   modifications	   increase	   the	  
functional	  diversity	  of	  the	  proteome	  and	  are	  therefore	  critical	   in	  cell	  biology.	  Various	  
post-­‐translational	   modifications	   include	   phosphorylation/autophosphorylation,	  
glycosylation,	   ubiquitination,	   nitrosylation,	   methylation,	   acetylation,	   lipidation	   and	  
proteolysis.	   The	   only	   researched	   post-­‐translational	   modification	   of	   HER2	   that	   was	  
found	   at	   this	   time	  was	   Autophosphorylation.	   In	  HER2,	   phosphorylation	   increases	   on	  
the	   tyrosine	   residues	   following	  dimerisation.	  Autophosphorylation	  of	  HER2	   occurs	   in	  
trans;	   receptor	   dimerisation	   occurs	   when	   one	   subunit	   of	   the	   dimeric	   receptor	  
phosphorylates	   tyrosine	   residues	   on	   the	   other	   subunit	   (Deng	   et	   al.,	   2007;	   Li	   et	   al.,	  
2007).	  	  
4.4.6 Structural	   and	   functional	   characterisation	   of	   novel	   HER2	  
isoforms	  
In	   order	   to	   predict	   the	   structural	   and	   functional	   differences	   between	   the	   wild-­‐type	  
HER2	   and	   novel	   HER2	   transcript	   variants	   identified	   in	   this	   study,	   a	   comparative	  
bioinformatic	   analysis	   was	   carried	   out	   on	   individual	   transcripts	   and	   their	   resulting	  
protein	  isoforms.	  The	  previously	  identified	  HER2∆16	  transcript	  (Kwong	  &	  Hung,	  1998)	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was	  also	  analysed.	  All	  three	  splice	  variants	  of	  HER2	  are	  similar	  to	  the	  full	  length	  HER2	  
transcript	  except	  for	  the	  skipping	  of	  exons	  13	  and	  16,	  and	  an	  alternative	  5’	  splice	  site	  in	  
exon	   18,	   respectively.	   Analysis	   of	   the	   protein	   isoforms	   of	   these	   splice	   variants	   will	  
predict	   structural	   differences	   which	   may	   lead	   to	   functional	   changes	   in	   the	   HER2	  
isoforms.	  	  
4.4.6.1. Additional	  band	  produced	  by	  primers	  E15F/E19R	  give	  
rise	   to	  a	   loss	  of	   the	  HER2	  ATP	  binding	  pocket,	  and	  a	  novel	  HER2	  
splice	  variant	  HER2∆ATP	  	  
The	   cDNA	   sequence	   of	   the	   multiple	   bands	   obtained	   using	   primer	   pairs	   E15F/E19R	  
(Figures	  3.22	  and	  3.24)	  were	  aligned	  using	  Clustal	  Omega	  multiple	  sequence	  alignment	  
tool,	  and	  revealed	  a	  deletion	  of	  42	  base	  pairs	  (lower	  band)	  compared	  to	  the	  wild-­‐type	  
HER2	  (top	  band)	  (Figure	  3.11).	  The	  amino	  acid	  sequences	  of	  both	  bands	  were	  obtained	  
using	  ExPASy	  translate	  tool,	  and	  revealed	  an	  in-­‐frame	  deletion	  of	  14	  amino	  acids.	  The	  
structural	  and	  functional	  changes	  were	  compared	  to	  the	  HER2	  isoform	  1	  (P04626),	  and	  
revealed	  the	  deletions	  in	  the	  lower	  HER2	  amplicon	  to	  be	  the	  loss	  of	  amino	  acids	  724-­‐
737	  in	  the	  kinase	  domain	  of	  the	  HER2	  protein,	  which	  corresponds	  to	  the	  ATP	  binding	  
domain	  (the	  ATP	  binding	  domain	  is	  represented	  by	  amino	  acids	  726-­‐734).	  This	  analysis	  
revealed	   a	   novel	   splice	   isoform	   containing	   a	   deletion	   of	   the	   3’	   end	   of	   exon	   18,	   and	  
more	  specifically,	  the	  deletion	  of	  the	  entire	  ATP	  binding	  pocket	  (Figure	  4.8).	  This	  novel	  




Figure	   4.7	   Analysis	   of	   cDNA	   and	   amino	   acid	   sequences	   of	   multiple	   bands	   obtained	  
using	  primer	  pair	  E15F/E19R.	  
4.4.6.2. Additional	   band	   produced	   by	   primers	   E12F/E15R	  
gives	  rise	  to	  the	  loss	  of	  the	  HER2	  extracellular	  domain,	  and	  a	  novel	  
HER2	  splice	  variant	  HER2∆ECD	  .	  	  
The	   cDNA	   sequence	   of	   the	   multiple	   bands	   obtained	   using	   primer	   pairs	   E12F/E15R	  
(Figures	  3.18	  and	  3.20)	  were	  aligned	  using	  Clustal	  Omega	  multiple	  sequence	  alignment	  
tool,	  and	  revealed	  a	  deletion	  of	  133	  base	  pairs	  (lower	  band)	  compared	  to	  the	  wild-­‐type	  
HER2	   (top	  band)	   (Figure	  3.10).	   The	  amino	  acid	   sequence	  of	   the	  additional	   band	  was	  
obtained	  using	  ExPASy,	  and	   revealed	  a	   truncated	  645	  amino	  acid	  HER2	   isoform.	  This	  
truncated	  HER2	  shows	  a	  loss	  in	  amino	  acids	  1-­‐610	  in	  the	  extracellular	  domain	  of	  HER2.	  
Further	  analysis	  using	  ScanProsite	  and	  uniprotKB	   revealed	   that	   this	  novel	  alternative	  
splice	   variant	   encodes	   a	   HER2	   protein	   with	   conserved	   active	   binding	   sites	   in	   the	  
transmembrane	  domain	  of	  HER2,	  but	  with	  a	  loss	  of	  644	  amino	  acids	  upstream	  of	  HER2	  
(HER2∆ECD	   	   consists	  652	  amino	  acids).	  This	  novel	  HER2	  alternative	  splice	  variant	  has	  
been	  designated	  HER2∆ECD	  	  (Figure	  4.9).	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Figure	   4.8	   Analysis	   of	   cDNA	   and	   amino	   acid	   sequences	   of	  multiple	   bands	   obtained	   using	   primer	   pair	  
E12F/E15R.	  
4.4.6.3. Additional	   bands	   produced	   using	   primer	   pairs	  
NP1/NP2	   and	   NP5/NP6	   give	   rise	   to	   the	   HER∆16	   isoform	  
corresponding	   to	   the	   loss	   of	   subdomain	   IV	   of	   the	   HER2	  
extracellular	  domain	  
Both	   NP1/NP2	   and	   NP5/NP6	   primer	   sets	   have	   been	   used	   previously	   to	   identify	   the	  
HER2∆16	   splice	   variant	   (Kwong	   &	   Hung,	   1998).	   Although	   this	   isoform	   has	   been	  
identified	   in	   previous	   studies,	   the	   present	   study	   identifies	   the	   expression	   of	   this	  
isoform	  in	  SKOV3,	  SKBR3,	  and	  MDA-­‐MB-­‐453	  and	  MDA-­‐MB-­‐361	  cell	  lines.	  Expression	  in	  
these	   cell	   lines	   has	   not	   been	   previously	   documented.	   Also,	   the	   splicing	  mechanisms	  
underlying	  the	  deletion	  of	  exon	  16	  have	  not	  been	  elucidated.	  The	  alignment	  of	  cDNA	  
sequences	  of	  both	  primer	  pairs	  confirms	  the	  expression	  of	  an	  alternative	  HER2	  isoform	  
in	  addition	  to	  the	  wild-­‐type	  HER2.	  This	  isoform	  shows	  a	  loss	  of	  exon	  16,	  and	  has	  been	  
shown	   to	   have	   increased	   transformation	   activity	   when	   expressed	   in	   HER2	   positive	  
breast	   cancers	   (Kwong	  &	  Hung,	   1998).	   Bioinformatics	   analysis	   using	   scanprosite	   and	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uniprotkb	   revealed	   a	   1239	   conserved	   peptide	   with	   active	   structural	   functions	   (ATB	  
binding	  domain,	  and	  tyrosine	  kinase	  domain).	  The	  cassette	  exon	  occurs	  in	  amino	  acids	  
634-­‐649,	  which	  constitute	  a	  portion	  of	  subdomain	  IV	  of	  the	  extracellular	  domain	  of	  the	  
wild-­‐type	  HER2	  protein	  (Figure	  4.10).	  	  
	  
Figure	  4.9	  Analysis	   of	   cDNA	  and	  amino	  acid	   sequences	  of	  multiple	  bands	  obtained	  using	  primer	  pairs	  
NP1/NP2	  and	  NP5/NP6.	  
Using	   the	   information	   generated	   from	   the	   analyses	   of	   the	   HER2	   splice	   variants,	   a	  
schematic	   was	   drawn	   comparing	   cDNA	   and	   protein	   sequences	   generated	   by	   the	  
different	  splice	  variants.	  
4.5. Analysis	  of	  new	  5’	  splice	  site	  boundaries	  for	  HER2∆ATP	  
The	  loss	  of	  42	  nucleotides	  gives	  rise	  to	  the	  loss	  of	  exactly	  14	  amino	  acids.	  The	  resulting	  
new	  5’	  splice	  site	  boundaries	  for	  HER2∆ATP	  were	  analysed	  in	  relation	  to	  the	  vertebrate	  
splice	  site	  consensus.	  
In	  the	  full	  length	  HER2	  mRNA,	  exon	  18	  splices	  into	  exon	  19	  in	  this	  order:	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…TCTACAAGGGCATCTGG…	  
In	  the	  new	  HER2∆ATP	  mRNA,	  exon	  18	  splices	  into	  exon	  19	  in	  this	  order:	  
…GAGGAAGGGCATCTGG…	  
The	  vertebrate	  5’	  splice	  site	  consensus	  is:	  
…MAGGURAGU…	  
Where:	  
M=A	  or	  C	  
R=A	  or	  G	  
U=C	  or	  U	  (T)	  (Elliot	  &	  Ladomery,	  2011)	  
Therefore,	   the	   alternative	   5’	   splice	   site	   AAG	   fits	   the	   consensus	   MAG,	   which	  
indicates	   that	   the	   new	   5’	   splice	   site	   in	   HER2∆ATP	   is	   a	   true	   isoform	   with	  
conserved	  vertebrate	  5’	  splice	  site.	  
4.6. Summary	  	  
The	  structural	  and	  functional	  characterisation	  of	  HER2	  gives	  a	  better	  understanding	  of	  
the	   function	   of	   the	   HER2	   protein,	   as	   well	   as	   the	   effects	   of	   alternative	   splicing	   in	  
changing	  the	  function	  of	  the	  protein	  through	  change	  in	  structure.	  	  
• The	   loss	  of	  exon	  13	  gives	  rise	  to	  HER2∆ECD	   ,	  a	  645	  amino	  acid	  protein	  with	  a	  
loss	   of	   the	   entire	   HER2	   extracellular	   binding	   domain,	   and	   consequently	   a	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potential	   loss	  of	  all	   signalling	  properties,	  as	   the	  HER2	   signalling	  domains	  have	  
been	   lost	   in	   translation.	   This	   loss	   may	   potentially	   result	   in	   the	   loss	   of	   the	  
binding	   sites	   of	  HER2,	   therefore	   conferring	   resistance	  of	  HER2∆ECD	   	   to	  HER2	  
therapies	  targeted	  at	  the	  HER2	  extracellular	  domain.	  	  
• The	  loss	  of	  exon	  16	  constitutes	  the	  loss	  of	  HER2	  to	  translate	  amino	  acids	  634	  to	  
649,	   which	   is	   predicted	   to	   be	  within	   the	   region	   containing	   domain	   IV	   of	   the	  
HER2	  extracellular	  domain.	  The	  HER2	  ECD	  domain	   IV	   is	  predicted	  to	  start	  and	  
end	  at	  amino	  acids	  510	  and	  643,	  respectively,	  and	  is	  designated	  as	  the	  growth	  
factor	  receptor	  binding	  domain	  of	  HER2	  isoform	  1	  (P04626).	  The	  loss	  of	  exon	  16	  
is	   therefore	   likely	   to	   alter	   the	   binding	   sites	   of	  HER2,	   conferring	   resistance	   to	  
HER2	  ECD-­‐targeted	  therapies.	  	  
• The	  utilization	  of	  the	  alternative	  5’	  splice	  site	  of	  HER2∆ATP	  results	  in	  the	  loss	  of	  
amino	  acids	  722-­‐735	  	  in	  the	  protein	  tyrosine	  kinase	  domain	  of	  HER2	  (the	  HER2	  
protein	  tyrosine	  kinase	  domain	  spans	  amino	  acids	  720-­‐976).	  As	  the	  HER2	  ECD	  
remains	  intact,	  HER2∆ATP	  would	  still	  be	  capable	  of	  dimerization;	  however,	  the	  
loss	  of	   amino	  acids	   in	   the	   tyrosine	   kinase	   region	  may	   inhibit	   phosphorylation	  
and	  subsequent	  activation	  of	  downstream	  signalling	  pathways.	  
• HER2∆ATP	  is	  identified	  here	  as	  a	  true	  isoform	  with	  an	  alternative	  5’	  splice	  site	  




CHAPTER	  5. EXPRESSION	   OF	  HER2	   AND	  HER2	   ALTERNATIVE	  
SPLICE	   VARIANTS	   IN	   NORMAL	   HUMAN	   TISSUES	   AND	   HUMAN	  
BREAST	  TUMOURS	  	  
5.1 Introduction	  
Established	   human	   cancer	   cell	   lines	   derived	   from	   tumours	   are	   frequently	   used	   as	   in	  
vitro	  tumour	  models	  for	  human	  cancers,	  and	  have	  been	  used	  to	  significantly	  advance	  
the	  understanding	  of	  cancer	  biology	  (Domcke	  et	  al.,	  2013).	  Human	  lesions	  obtained	  at	  
surgery	   represent	   the	   real	   state	   of	   the	   tumour	   in	   vivo,	   and	   can	   be	   used	   to	   derive	  
certain	  useful	  information	  such	  as	  their	  pathology,	  gene	  or	  biomarker	  expression,	  and	  
metabolism.	   However,	   they	   only	   represent	   one	   time	   point	   in	   the	   evolution	   of	   the	  
tumour,	  and	  therefore	  do	  not	  lend	  themselves	  to	  much	  experimentation	  (van	  Staveren	  
et	  al.,	  2009).	  Human	  cell	  lines	  are	  an	  example	  of	  good	  experimental	  models	  as	  they	  are	  
known	   to	   retain	   the	  hallmarks	  of	   cancer	   cells,	   are	  easy	   to	  propagate	  and	  genetically	  
manipulate,	   and	   can	   produce	   reproducible	   results	   when	   used	   under	   well-­‐defined	  
experimental	   conditions,	   even	   after	   numerous	   passages	   (van	   Staveren	   et	   al.,	   2009).	  
The	  use	  of	   cell	   lines	   in	  breast	   cancer	   studies	  has	   resulted	   in	  a	  wealth	  of	   information	  
about	  deregulation	  of	  proliferation,	  migration	  and	  apoptosis,	  as	  well	  as	  the	  genes	  and	  
signalling	  pathways	  that	  regulate	  these	  processes	  (Vargo-­‐Gogola	  &	  Rosen,	  2007;	  Neve	  
et	   al.,	   2006).	   However,	   gene	   expression	   profiles	   may	   sometimes	   be	   altered	   by	  
activating	  mutations	  of	  kinases	  in	  cell	  lines	  which	  may	  not	  be	  present	  in	  primary	  breast	  
tumours	  (van	  Staveren	  et	  al.,	  2009).	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The	  discovery	  of	  new	  alternative	  splice	  variants	  of	  HER2	  in	  HER2	  positive	  breast	  cancer	  
cell	   lines	   in	   this	   study	   gives	   rise	   to	   a	   need	   for	   further	   exploration	   of	   these	   splice	  
variants	   in	   human	   samples	   from	   a	   normal	   tissue	   panel	   and	   clinical	   cases	   of	   HER2	  
positive	  breast	  cancer.	  
The	  use	  of	  a	  normal	  tissue	  panel	  and	  HER2	  positive	  breast	  tumour	  samples	  to	  test	  for	  
HER2	   expression	   in	   this	   study	  was	   in	  order	   to	   investigate	   tumour-­‐specificity	  of	  HER2	  
alternative	  splice	  variants,	  particularly	  HER2ΔATP	  and	  HER2ΔECD.	   In	  a	  study	  by	  Mitra	  
et	  al	  (2009),	  a	  panel	  of	  18	  normal	  tissues	  showed	  no	  expression	  of	  HER2Δ16.	  However	  
HER2Δ16	   was	   detected	   in	   51%	   of	   a	   cohort	   of	   85	   primary	   invasive	   breast	   tumours.	  
HER2Δ16	  is	  therefore	  said	  to	  be	  a	  tumour-­‐specific	  HER2	  oncogene	  (Mitra	  et	  al.,	  2009).	  	  
For	   the	   benefit	   of	   this	   chapter,	   only	   the	   exons	  which	   have	   been	   confirmed	   to	   have	  
alternative	  splice	  variants	  were	  analysed	   for	   the	  expression	  of	  HER2	  and	  HER2	   splice	  
variant	  expression	  in	  human	  samples.	  qPCR	  probes	  were	  designed	  to	  target	  the	  wild-­‐
type	  HER2	  gene	  and	  to	  detect	  expression	  of	  HER2ΔECD,	  HER2Δ16	  and	  HER2ΔATP	  .	  
5.2 Objectives	  
1. To	   investigate	   the	  expression	  of	  HER2	   and	  HER2	   alternative	   splice	   variants	   in	  
normal	  tissues.	  
2. To	   investigate	   the	   expression	   of	   HER2	   and	   novel	   HER2	   alternative	   splice	  
variants	   in	   HER2	   positive	   human	   breast	   cancer	   tissues	   which	   have	   been	  
processed	   by	   freezing,	   and	   samples	   which	   have	   been	   processed	   by	   formalin	  
fixation	  and	  embedded	  in	  paraffin	  wax	  (FFPE).	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3. To	  compare	   the	  expression	  of	  HER2	  and	  novel	  HER2	   splice	  variants	   in	  normal	  
tissues	  and	  human	  breast	  cancer	  tissues.	  
5.3 Methods	  	  
Standard	  RT-­‐PCR	  primers	  listed	  in	  Table	  A	  1	  were	  used	  in	  the	  amplification	  of	  exons	  12-­‐
15,	  exons	  15-­‐19,	  and	  exons	  16-­‐18.	  Taqman	  probes	  for	  the	  detection	  of	  HER2	  and	  HER2	  
splice	   variants	   by	   quantitative	   real-­‐time	   PCR	   were	   designed	   by	   Primer	   Design	  
(Southampton,UK).	  Primer	  sequences	  are	  listed	  in	  Table	  5.1.	  
PRIMER	  NAME	   SENSE	  PRIMER	   ANTISENSE	  PRIMER	   PRODUCT	  	  
LENGTH	  
ERBB2	  (Global)	   ACCTTCCTTCCTGCTTGAGT	   GCCTCAGAATCCACAAAGACT	   94	  
ERBB2_ex13del	   CCAGAGGACGAGTGTGGAG	   CGGTCCAAAACAGGTCACTG	   120	  
ERBB2_ex16del	   CAACTGCACCCACTCCCCT	   CCAAGACCACGACCAGCAG	   71	  
ERBB2_ex18del	   GGAGCTGAGGAAGGGCAT	   GGCTTTGGGGGATGTGTTTT	   94	  
Table	  5.1	  Primer	  sequences	  for	  the	  detection	  of	  HER2	  and	  HER2	  splice	  variants	  by	  qRT-­‐PCR.	  
5.3.1 Analysis	   of	   cDNA	   samples	   from	   a	   normal	   tissue	   panel	   for	   the	  
expression	  of	  HER2	  and	  HER2	  alternative	  splice	  variants	  	  
A	   panel	   of	   ten	   BioBank	   human	   cDNA	   samples	   consisting	   of	   normal	   tissues	   was	  
obtained	  from	  Primer	  Design	  (Southampton,	  UK).	  The	  BioBank	  is	  a	  high	  quality	  source	  
of	   cDNA	   validated	   for	   use	   in	   real-­‐time	   PCR	   experiments.	   The	   cDNA	   is	   reverse	  
transcribed	   from	   high	   quality,	   DNAse	   treated	   RNA,	   from	   a	   variety	   of	   tissues	   or	   cell	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cultures,	  using	  an	  optimised	  blend	  of	  oligo-­‐dT	  and	  random	  nonamer	  primers.	  BioBank	  
cDNA	   is	   therefore	   free	   of	   genomic	   DNA	   and	   PCR	   inhibitors	   and	   covers	   the	   widest	  
possible	  range	  of	  RNA	  and	  mRNA	  transcripts	  in	  the	  specified	  tissue	  or	  cell	  line.	  BioBank	  
cDNA	  is	  useful	  for	  expression	  profiling	  of	  newly	  identified	  genes,	  and	  also	  as	  a	  positive	  











The	  panel	  of	  normal	  tissues	  for	  used	  HER2	  testing	  was	  based	  on	  the	  repository	  of	  cDNA	  
samples	  available	  for	  selection.	  To	  eliminate	  variations	  in	  results,	  tissues	  used	  were	  all	  
treated	   from	   RNA	   extraction	   to	   reverse	   transcription,	   using	   the	   same	   protocol	   and	  
processed	  at	  the	  same	  time.	  Positive	  control	  primers	  were	  also	  supplied	  with	  the	  tissue	  
samples,	  which	  detect	  18s	  ribosomal	  RNA.	  The	  tissue	  samples	  from	  the	  normal	  tissue	  
panel	  were	   tested	   for	   the	   expression	   of	  HER2	   and	  HER2	   splice	   variants	   by	   standard	  
PCR.	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5.3.2 Analysis	   of	   frozen	   clinical	   samples	   from	   HER2	   positive	  
breast	   tumours	   for	   the	  expression	  of	  HER2	  and	  HER2	  alternative	  
splice	  variants	  
RNA	   samples	   from	   three	   matched	   invasive	   ductal	   carcinomas	   and	   adjacent	   normal	  
tissues	  were	  obtained	  from	  the	  Wales	  cancer	  bank	  (Cardiff,	  UK).	  RNA	  extracted	  from	  
frozen	   blocks	   is	   of	   high	   quality	   for	   use	   in	   techniques	   such	   as	   expression	  microarray	  
systems.	  The	  RNA	  extraction	  was	  carried	  out	  by	  the	  Wales	  cancer	  bank	  using	  a	  Qiagen	  
kit	   or	   Trizol®	   method.	   RNA	   was	   supplied	   as	   5µg	   in	   50µl	   aliquots.	   RNA	   quality	   was	  
assessed	   by	   260/230	   and	   260/280	   ratio	   using	   a	   nanospectrophotometer,	   and	   then	  
subjected	  to	  quality	  assurance	  by	  Agilent	  Bioanalyser.	  Table	  5.2	  shows	  a	  minimum	  data	  
set	   for	   all	   three	   frozen	   samples,	  which	   includes	   the	   age	  of	   the	  patient,	   tumour	   type	  
and	  grade,	  size	  of	  tumour	  and	  HER2	  status.	  For	  the	  purpose	  of	  this	  study,	  the	  samples	  
were	  designated	  01A,	  02A	  and	  03A	  for	  the	  breast	  tumours	  and	  01B,	  02B	  and	  02B	  for	  



















Tumour	   Receptor	  Status	  
RR6BL0
000141	  
(01)	   48	   F	  
Invasive	  
Ductal	  





(02)	   51	   M	  
Invasive	  
Ductal	  





(03)	   43	   F	  
Invasive	  
Ductal	  





Table	  5.2	  Minimum	  data	  set	  for	  frozen	  samples	  from	  invasive	  ductal	  carcinomas	  obtained	  from	  the	  
Wales	  cancer	  bank	  (Cardiff,	  UK).	  For	  anonymity	  and	  data	  protection,	  samples	  were	  designated	  numeric	  
codes	  for	  the	  purpose	  of	  identification.	  
Following	  gDNA	  treatment	  and	  reverse	  transcription,	  the	  RNA	  samples	  obtained	  from	  
the	   frozen	   breast	   tumours	  were	   tested	   for	   the	   expression	   of	  HER2	   and	  HER2	   splice	  
variants	  by	  standard	  PCR	  and	  real-­‐time	  PCR.	  	  	  
124	  	  
5.3.3 Analysis	   of	   formalin	   fixed	   and	   paraffin	   embedded	   (FFPE)	  
clinical	   samples	   from	   HER2	   positive	   breast	   tumours	   for	   the	  
expression	  of	  HER2	  and	  HER2	  alternative	  splice	  variants.	  
Total	   RNA	  was	   extracted	   from	  FFPE	   samples	   using	   the	  RNEasy	   FFPE	   kit	   (Qiagen,	  UK)	  
according	  to	  manufacturer’s	  protocols.	  After	  RNA	  extraction	  and	  quantification,	  700ng	  
of	  RNA	  was	  reverse	  transcribed	  to	  cDNA	  using	  Maxima	  H	  Minus	  Reverse	  Transcriptase	  
(ThermoScientific,	  UK)	  according	  to	  the	  manufacturer’s	  guidelines.	  The	  resulting	  cDNA	  
was	   then	   diluted	   1:10	   and	   RT-­‐PCR	   was	   performed	   using	   GoTaq	   Hotstart	   Taq	  
Polymerase	   (Promega,	   UK)	   using	   the	   following	   thermal	   cycler	   program:	   hotstart	   at	  
95°C	  for	  2	  minutes	  followed	  by	  39	  cycles	  of	  95°C	  for	  1	  minute	  (denaturing),	  56°C	  for	  1	  
minute	  (annealing),	  72°C	  for	  30	  seconds	  (extending),	  and	  a	  final	  extension	  of	  5	  minutes	  
at	  72°C.	  A	  soaking	  cycle	  of	  4°C	  was	  included	  to	  hold	  the	  tubes	  after	  amplification,	  prior	  
to	  agarose	  gel	  electrophoresis,	  or	  storage	  at	  -­‐20°C.	  
5.4 Results	  
5.4.1 Expression	  of	  HER2	  and	  HER2	  alternative	  splice	  variants	  in	  
cDNA	  samples	  from	  a	  normal	  tissue	  panel	  	  
Amplification	  of	  HER2ΔECD:	  Figure	  5.1	  shows	  RT-­‐PCR	  amplification	  of	  HER2ΔECD	  in	  
normal	  human	  tissues.	  All	  tissue	  types	  (1-­‐4,	  6-­‐10)	  except	  liver	  (5),	  express	  the	  wild-­‐type	  
HER2,	  but	  not	  HER2ΔECD.	  Liver	  tissue	  (5)	  does	  not	  appear	  to	  express	  either	  the	  wild-­‐
type	  HER2	  or	  HER2ΔECD.	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Figure	  5.1:	  RT-­‐PCR	  amplification	  of	  wild	   type	  HER2	   and	  HER2ΔECD	   (primer	  pair	  E12F+E15R)	   in	  normal	  
human	  tissue	  cDNA	  (1-­‐10),	  using	  MDA-­‐MB-­‐453	  cell	  line	  as	  a	  positive	  control.	  Hyperladder	  IV	  was	  used	  as	  
the	  DNA	  marker.	  The	  expected	  amplicon	  sizes	  for	  the	  wild-­‐type	  HER2	  and	  HER2ΔECD	  were	  432	  and	  299	  
base	  pairs	  respectively.	  Each	  rung	  of	  the	  hyperladder	  IV	  represents	  100bp.	  	  	  	  	  	  	  	  	  	  	  	  
	  Amplification	  of	  HER2ΔATP:	  Figure	  5.2	  shows	  RT-­‐PCR	  amplification	  of	  HER2ΔATP	  in	  
normal	  tissues.	  All	  tissue	  types	  (1-­‐4,	  6-­‐10)	  except	  liver	  (5),	  appear	  to	  express	  the	  wild	  
type	  HER2,	  but	  not	  HER2ΔATP.	  In	  addition	  to	  the	  top	  band	  which	  represents	  the	  wild	  
type	  HER2,	  Adipose,	  cervix,	   colon,	  kidney,	  ovary	  and	  placenta	  also	  show	  the	  smaller,	  
lower	  bands	  which	   represent	  HER2ΔATP.	   Liver	   tissue	   (5)	  does	  not	   appear	   to	  express	  
either	  the	  wild	  type	  HER2	  or	  HER2ΔATP.	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Figure	  5.2:	  RT-­‐PCR	  amplification	  of	  wild	   type	  HER2	   and	  HER2ΔATP	   (primer	  pair	   E15F+E19R)	   in	  normal	  
human	  tissue	  RNA	  (1-­‐10),	  using	  MDA-­‐MB-­‐453	  cell	  line	  as	  a	  positive	  control.	  Hyperladder	  IV	  was	  used	  as	  
the	  DNA	  marker.	  The	  expected	  amplicon	  sizes	  for	  the	  wild-­‐type	  HER2	  and	  HER2ΔATP	  were	  480	  and	  438	  
base	  pairs	  respectively.	  Each	  rung	  of	  the	  hyperladder	  IV	  represents	  100bp.	  	  	  	  	  	  	  	  	  	  	  	  
	  
Amplification	   of	  HER2Δ16:	   Figure	   5.3	   shows	   RT-­‐PCR	   amplification	   of	  HER2Δ16	   in	  
normal	  tissues.	  All	  tissue	  types	  (1-­‐4,	  6-­‐10)	  except	  liver	  (5),	  express	  the	  wild	  type	  HER2,	  
but	  not	  HER2Δ16.	  Liver	  tissue	  (5)	  does	  not	  appear	  to	  express	  either	  the	  wild	  type	  HER2	  
or	  HER2Δ16.	  	  
Figure	   5.3:	   RT-­‐PCR	   amplification	   of	   wild	   type	   HER2	   and	   HER2Δ16	   (primer	   pair	   NP5+NP6)	   in	   normal	  
human	  tissue	  RNA	  (1-­‐10),	  using	  MDA-­‐MB-­‐453	  cell	  line	  as	  a	  positive	  control.	  Hyperladder	  V	  was	  used	  as	  
the	  DNA	  marker.	  The	  expected	  amplicon	  sizes	  for	  the	  wild-­‐type	  HER2	  and	  HER2Δ16	  were	  146	  and	  104	  
base	  pairs	  respectively.	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Figure	  5.4:	  RT-­‐PCR	  amplification	  of	  18s	  in	  normal	  human	  tissue	  cDNA	  and	  MDA-­‐MB-­‐453	  cell	  line.	  
Amplicon	  size	  is	  approximately	  88bp.	  Each	  rung	  of	  the	  hyperladder	  IV	  represents	  100bp.	  	  	  	  	  	  	  	  	  	  	  	  
A	  negative	  (no	  RT)	  control	  was	  also	  included	  in	  all	  PCR	  experiments	  to	  ensure	  that	  PCR	  
amplification	  was	  derived	  from	  RNA	  and	  not	  genomic	  DNA	  or	  other	  contaminants.	  All	  
experiments	  were	  run	  in	  triplicate	  to	  ensure	  reproducibility.	  
	  
5.4.2 Expression	  of	  HER2	  and	  HER2	  alternative	  splice	  variants	  in	  
cDNA	  obtained	  from	  frozen	  clinical	  samples	  
Amplification	  of	  wild-­‐type	  HER2:	  	  
Figure	   5.5	   shows	   the	   relative	   expression	   of	   the	   wild-­‐type	   HER2	   in	   frozen	   clinical	  
samples.	  qPCR	  analysis	  shows	  HER2	  expression	  to	  be	  generally	  higher	   in	  the	  tumours	  
than	  in	  the	  matched	  normal	  tissues.	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Figure	  5.5:	  qPCR	  analysis	  of	  the	  expression	  of	  wild-­‐type	  HER2	  cDNA	  in	  clinical	  samples.	  Each	  histogram	  
bar	   is	   representative	   of	   one	   sample	   and	   three	   replicates	   (n=3).	   The	   x	   axis	   represents	   the	   individual	  
samples	  (01A,	  02A	  and	  03A),	  and	  their	  matched	  normal	  breast	  tissue	  (01B,	  02B	  and	  03B).	  The	  error	  bars	  
represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
Amplification	  of	  HER2ΔECD:	  Figure	  5.6	  shows	  RT-­‐PCR	  amplification	  of	  the	  wild-­‐type	  
HER2	  and	  HER2ΔECD	  in	  cDNA	  obtained	  from	  frozen	  clinical	  samples.	  All	  three	  tumours	  
samples	  express	  the	  wild	  type	  HER2,	  but	  not	  HER2ΔECD.	  Figure	  5.7	  shows	  the	  relative	  
expression	  of	  HER2ΔECD	  in	  the	  clinical	  samples	  by	  qRT-­‐PCR.	  
	  
Figure	   5.6:	   RT-­‐PCR	   amplification	   of	   wild	   type	  HER2	   and	  HER2ΔECD	   (primer	   pair	   E12F+E15R)	   in	   cDNA	  
obtained	   from	   frozen	   tumours,	  using	  MDA-­‐MB-­‐453	  cell	   line	  as	  a	  positive	  control.	  The	   samples	  named	  
01A,	   02A	   and	  03A	   represent	   breast	   tumours,	  while	   01B,	   02B	   and	  03B	   represent	   the	  matched	  normal	  
breast	   tissue	   from	   the	   same	   patient,	   respectively.	   Hyperladder	   IV	  was	   used	   as	   the	   DNA	  marker.	   The	  
expected	   amplicon	   sizes	   for	   the	   wild-­‐type	   HER2	   and	   HER2ΔECD	   were	   432	   and	   299	   base	   pairs	  
respectively.	  Each	  rung	  of	  the	  hyperladder	  IV	  represents	  100bp.	  	  	  	  	  	  	  	  


























Figure	   5.7:	   qPCR	   analysis	   of	   the	   expression	   of	   HER2ΔECD	   in	   clinical	   samples.	   Each	   histogram	   bar	   is	  
representative	  of	  one	   sample	  and	   three	   replicates	   (n=3).	   The	  x	  axis	   represents	   the	   individual	   samples	  
(01A,	   02A	   and	   03A),	   and	   their	   matched	   normal	   breast	   tissue	   (01B,	   02B	   and	   03B).	   The	   error	   bars	  
represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
Amplification	  of	  HER2ΔATP:	  Figure	  5.8	  shows	  RT-­‐PCR	  amplification	  of	  the	  wild-­‐type	  
HER2	  and	  HER2ΔATP	  in	  cDNA	  obtained	  from	  frozen	  clinical	  samples.	  All	  three	  tumours	  
samples	  express	  the	  wild	  type	  HER2,	  but	  not	  HER2ΔATP.	  Figure	  5.9	  shows	  the	  relative	  
expression	  of	  HER2ΔATP	  in	  the	  clinical	  samples	  by	  qRT-­‐PCR.	  
	  
Figure	   5.8:	   RT-­‐PCR	   amplification	   of	   wild	   type	   HER2	   and	   HER2ΔATP	   (primer	   pair	   E15F+E19R)	   in	   RNA	  
samples	  obtained	  from	  frozen	  tumours,	  using	  MDA-­‐MB-­‐453	  cell	   line	  as	  a	  positive	  control.	  The	  samples	  
named	   01A,	   02A	   and	   03A	   represent	   breast	   tumours,	  while	   01B,	   02B	   and	   03B	   represent	   the	  matched	  
normal	  breast	  tissue	  from	  the	  same	  patient,	  respectively.	  Hyperladder	  IV	  was	  used	  as	  the	  DNA	  marker.	  
The	   expected	   amplicon	   sizes	   for	   the	   wild-­‐type	   HER2	   and	   HER2ΔATP	   were	   480	   and	   438	   base	   pairs	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Figure	   5.9	   qPCR	   analysis	   of	   the	   expression	   of	   HER2ΔATP	   in	   clinical	   samples.	   Each	   histogram	   bar	   is	  
representative	  of	  one	   sample	  and	   three	   replicates	   (n=3).	   The	  x	  axis	   represents	   the	   individual	   samples	  
(01A,	   02A	   and	   03A),	   and	   their	   matched	   normal	   breast	   tissue	   (01B,	   02B	   and	   03B).	   The	   error	   bars	  
represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
Amplification	  of	  HER2Δ16:	  Figure	  5.10	  shows	  RT-­‐PCR	  amplification	  of	  the	  wild-­‐type	  
HER2	  and	  HER2Δ16	  in	  cDNA	  obtained	  from	  frozen	  clinical	  samples.	  All	  three	  tumours	  
samples	  express	   the	  wild	   type	  HER2,	  but	  not	  HER2Δ16.	  Figure	  5.9	  shows	  the	  relative	  
expression	  of	  HER2ΔATP	  in	  the	  clinical	  samples.	  
	  
Figure	   5.10:	   RT-­‐PCR	   amplification	   of	   wild	   type	  HER2	   and	  HER2Δ16	   (primer	   pair	   NP1	   +	   NP2)	   in	   cDNA	  
samples	  obtained	  from	  frozen	  tumours,	  using	  MDA-­‐MB-­‐453	  cell	   line	  as	  a	  positive	  control.	  The	  samples	  
named	   01A,	   02A	   and	   03A	   represent	   breast	   tumours,	  while	   01B,	   02B	   and	   03B	   represent	   the	  matched	  
normal	  breast	  tissue	  from	  the	  same	  patient,	  respectively.	  Hyperladder	  IV	  was	  used	  as	  the	  DNA	  marker.	  
The	   expected	   amplicon	   sizes	   for	   the	   wild-­‐type	   HER2	   and	   HER2Δ16	   were	   266	   and	   218	   base	   pairs	  
respectively.	  Each	  rung	  of	  the	  hyperladder	  IV	  represents	  100bp.	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Figure	  5.11:	  qPCR	  analysis	  of	  the	  expression	  of	  HER2Δ16	  in	  clinical	  samples.	  Each	  histogram	  bar	  is	  
representative	  of	  one	  sample	  and	  three	  replicates	  (n=3).	  The	  x	  axis	  represents	  the	  individual	  samples	  
(01A,	  02A	  and	  03A),	  and	  their	  matched	  normal	  breast	  tissue	  (01B,	  02B	  and	  03B).	  The	  error	  bars	  
represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
	  
Figure	  5.12:	  RT-­‐PCR	  amplification	  of	  18s	  in	  normal	  human	  tissue	  RNA	  and	  MDA-­‐MB-­‐453	  cell	  line.	  Each	  
rung	  of	  the	  hyperladder	  IV	  represents	  100bp.	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5.4.3 Expression	  of	  HER2	  and	  HER2	  splice	  variants	  in	  formalin	  
fixed	  and	  paraffin	  embedded	  (FFPE)	  clinical	  samples.	  
SAMPLE	   HER2	  STATUS	   ng/µl	   260/280	  
11	   2+	   19.09	   1.79	  
15B	   2+	   284.52	   1.94	  
21B	   3+	   86.69	   1.93	  
24B	   3+	   140.99	   1.89	  
27B	   3+	   367.41	   1.93	  
28C	   3+	   359.44	   1.95	  
31A	   2+	   179.75	   1.98	  
34B	   3+	   135.91	   1.94	  
35	   2+	   367.66	   1.92	  
36B	   3+	   289.44	   1.94	  
43A	   2+	   535.65	   2	  
53B	   3+	   385.82	   1.91	  
75A	   2+	   144.81	   1.91	  
86	   2+	   111.84	   1.93	  
Table	  5.3:	  HER2	  status,	  quantification	  and	  integrity	  of	  RNA	  obtained	  from	  FFPE	  samples.	  For	  anonymity	  
and	  data	  protection,	  samples	  were	  designated	  numeric	  codes	  for	  the	  purpose	  of	  identification.	  
133	  	  
Amplification	  of	  HER2ΔECD:	  Figure	  5.13	  shows	  RT-­‐PCR	  amplification	  of	  the	  wild-­‐
type	  HER2	  and	  HER2ΔECD	  in	  cDNA	  obtained	  from	  FFPE	  clinical	  samples.	  When	  
matched	  against	  MDA-­‐MB-­‐453	  as	  a	  positive	  control,	  PCR	  amplification	  shows	  wild-­‐type	  
HER2	  expressed	  in	  samples	  21B,	  28C,	  35	  and	  36B,	  and	  HER2ΔECD	  expressed	  in	  samples	  
15B,	  21b,	  28C	  and	  36B.	  	  
	  
Figure	  5.13:	  RT-­‐PCR	  amplification	  of	  wild	  type	  HER2	  and	  HER2ΔECD	  (primer	  pair	  E12F+E15R)	  in	  cDNA	  
obtained	  from	  FFPE	  clinical	  samples,	  using	  MDA-­‐MB-­‐453	  cell	  line	  as	  a	  positive	  control.	  The	  numbers	  
above	  the	  lanes	  (11,	  15B,	  21B,	  24B,	  27B,	  28C,	  31A,	  34B,	  35,	  36B,	  43A,	  53B,	  75A,	  and	  86)	  represent	  
individual	  patient	  samples.	  The	  red	  lines	  are	  to	  aid	  in	  identification	  of	  expected	  amplicons.	  Hyperladder	  
V	  was	  used	  as	  the	  DNA	  marker.	  The	  expected	  amplicon	  sizes	  for	  the	  wild-­‐type	  HER2	  and	  HER2ΔECD	  







Amplification	  of	  HER2ΔATP:	  Figure	  5.14	  shows	  RT-­‐PCR	  amplification	  of	  the	  wild-­‐
type	  HER2	  and	  HER2ΔATP	  in	  cDNA	  obtained	  from	  FFPE	  clinical	  samples.	  When	  
matched	  against	  MDA-­‐MB-­‐453	  as	  a	  positive	  control,	  PCR	  amplification	  shows	  wild-­‐type	  
HER2	  expressed	  in	  samples	  28C,	  34B,	  35	  and	  36B,	  and	  HER2ΔATP	  expressed	  in	  sample	  
36B.	  
Figure	  5.14:	  RT-­‐PCR	  amplification	  of	  wild	  type	  HER2	  and	  HER2ΔATP	  (primer	  pair	  E15F+E19R)	  in	  cDNA	  
obtained	  from	  FFPE	  clinical	  samples,	  using	  MDA-­‐MB-­‐453	  cell	  line	  as	  a	  positive	  control.	  The	  numbers	  
above	  the	  lanes	  (11,	  15B,	  21B,	  24B,	  27B,	  28C,	  31A,	  34B,	  35,	  36B,	  43A,	  53B,	  75A,	  and	  86)	  represent	  
individual	  patient	  samples.	  The	  red	  lines	  are	  to	  aid	  in	  identification	  of	  expected	  amplicons.	  Hyperladder	  
V	  was	  used	  as	  the	  DNA	  marker.	  The	  expected	  amplicon	  sizes	  for	  the	  wild-­‐type	  HER2	  and	  HER2ΔATP	  were	  








Amplification	  of	  HER2Δ16:	  Figure	  5.15	  shows	  RT-­‐PCR	  amplification	  of	  the	  wild-­‐type	  
HER2	   and	   HER2Δ16	   in	   cDNA	   obtained	   from	   FFPE	   clinical	   samples.	   When	   matched	  
against	  MDA-­‐MB-­‐453	   as	   a	   positive	   control,	   PCR	   amplification	   shows	  wild-­‐type	  HER2	  
expressed	   in	   samples	   15B,	   21B,	   27B,	   28C,	   34B,	   35,	   36B,	   43A,	   53B	   and	   75A,	   and	  
HER2Δ16	  expressed	  in	  samples	  15B,	  21B,	  28C,	  34B,	  35,	  36B,	  43A	  and	  53B.	  
Figure	  5.15:	  RT-­‐PCR	  amplification	  of	  wild	   type	  HER2	  and	  HER2Δ16	  (primer	  pair	  NP1	  and	  NP2)	   in	  cDNA	  
obtained	   from	   FFPE	   clinical	   samples,	   using	  MDA-­‐MB-­‐453	   cell	   line	   as	   a	   positive	   control.	   The	   numbers	  
above	   the	   lanes	   (11,	   15B,	   21B,	   24B,	   27B,	   28C,	   31A,	   34B,	   35,	   36B,	   43A,	   53B,	   75A,	   and	   86)	   represent	  
individual	  patient	  samples.	  The	  red	  lines	  are	  to	  aid	  in	  identification	  of	  expected	  amplicons.	  Hyperladder	  
V	  was	  used	  as	  the	  DNA	  marker.	  The	  expected	  amplicon	  sizes	  for	  the	  wild-­‐type	  HER2	  and	  HER2Δ16	  were	  
266	  and	  218	  base	  pairs	  respectively.	  
Figure	  5.16:	  RT-­‐PCR	  amplification	  of	  18s	  in	  cDNA	  obtained	  from	  FFPE	  clinical	  samples,	  using	  MDA-­‐MB-­‐
453	  cell	  line	  as	  a	  positive	  control.	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5.5 	  Summary	  	  
The	  use	  of	  cell	  line	  models	  in	  the	  investigation	  of	  alternative	  splicing	  in	  invasive	  breast	  
and	   ovarian	   cancer	   cell	   lines	   in	   this	   study	   has	   led	   to	   the	   discovery	   of	   novel	   splice	  
variants	   in	   invasive	   cancer.	   However,	   it	   is	   also	   important	   to	   correlate	   these	   findings	  
with	  expression	  in	  human	  samples.	  The	  discovery	  of	  HER2	  alternative	  splice	  variants	  in	  
human	   tissues	   particularly	   HER2	   positive	   cases	   of	   breast	   cancer,	   may	   lead	   to	  
establishing	  a	  potential	  clinical	  significance	  of	  these	  new	  alternative	  splice	  variants.	  	  
The	   use	   of	   qRT-­‐PCR	   in	   this	   study	   was	   in	   order	   to	   give	   a	   general	   overview	   of	   the	  
expression	  of	  HER2	   and	  HER2	   alternative	   splice	   variants	   in	   tissue	   samples,	   alongside	  
the	  standard	  RT-­‐PCR.	  Due	  to	  the	  absence	  of	  a	  control	  sample,	  it	  is	  not	  conclusive	  in	  this	  
study	  the	  tissue-­‐specific	  changes	  in	  the	  expression	  levels	  of	  HER2	  and	  HER2	  alternative	  
splice	   variants.	   It	   is	   also	   important	   to	   note	   that	   the	   detection	   by	   qRT-­‐PCR	   of	  HER2	  
expression	   and	   tissue-­‐specific	   changes	   in	   HER2	   expression,	   though	   they	   may	   seem	  
statistically	  significant,	  may	  only	  be	  minute	  changes	  which	  can	  only	  be	  verified	  by	  the	  
use	  of	  a	  tissue	  control	  and	  absolute	  quantification	  of	  HER2	  expression	  in	  the	  controls	  
to	  compare	  to	  the	  expression	  in	  the	  tissues	  tested.	  To	  summarise:	  
• In	   this	   study,	   alternative	   splice	   variant	  HER2Δ16	  was	   not	   detected	   in	   normal	  
human	   tissues	   (Figure	   5.3).	   This	   finding	   is	   in	   accordance	  with	   current	   reports	  
(Mitra	  et	  al.,	  2009).	  The	  newly	   identified	  HER2Δ13	  splice	  variant	  was	  also	  not	  
detected	   in	   normal	   human	   tissues.	   However,	   the	   HER2ΔATP	   splice	   variant	  
appears	  to	  be	  expressed	  in	  normal	  tissues.	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• The	  newly	  identified	  alternative	  splice	  variants	  HER2ΔECD	  and	  HER2ΔATP	  were	  
also	  found	  to	  be	  expressed	  in	  clinical	  samples	  of	  breast	  carcinomas	  which	  were	  
processed	  by	  formalin	  fixation	  (Figures	  5.13	  and	  5.14).	  	  
• In	  accordance	  with	  findings	  by	  Mitra	  et	  al	  (2009),	  this	  study	  has	  identified	  the	  
expression	  of	   the	  HER2Δ16	   splice	   variant	   in	  HER2	   positive	  breast	   cancer,	   and	  












CHAPTER	  6. REGULATION	   OF	   HER2	   AND	   HER2	   SPLICE	  
VARIANTS	  IN	  CELL	  LINE	  MODELS	  
6.1. Introduction	  	  
The	   regulation	   of	   normal	  mRNA	   splicing	   is	   dependent	   on	   the	   recognition	   of	   intron-­‐
exon	  boundaries,	  the	  removal	  of	  intervening	  introns,	  and	  the	  ligation	  of	  exons	  by	  the	  
spliceosome	  (Fackenthal	  &	  Godley,	  2008).	   	   In	  cancer	  cells,	   the	   fidelity	  of	   this	  process	  
may	  be	  altered	  by	  defects	  in	  several	  splicing	  mechanisms	  (Skotheim	  &	  Nees,	  2007).	  In	  
some	   cases	   of	   misregulation	   of	   splicing,	   the	   aberrant	   mRNAs	   and	   their	   encoded	  
proteins	   confer	   unique	   functions	   to	   the	   expressing	   cancer	   cells,	   and	   have	   unique	  
properties	   that	   alter	   the	   growth	   and	   differentiation	   properties,	   and	   other	   cellular	  
characteristics	   of	   the	   cell	   (Kim,	   Goren	   &	   Ast,	   2008)	   .	   The	   regulation	   of	   alternative	  
splicing	   is	   still	   being	   widely	   investigated	   and	   remains	   incompletely	   understood.	   It	   is	  
suggested	   that	   the	   disruption	   of	   splicing	   regulatory	   proteins	   may	   play	   a	   role	   in	  
alternative	   splicing	   (Kim,	   Goren	   &	   Ast,	   2008).	   Serine	   and	   arginine-­‐rich	   (SR)	   proteins	  
control	  the	  functions	  of	  exonic	  splice	  enhancers	  (ESEs),	  which	  are	  purine-­‐rich	  cis-­‐acting	  
elements	  that	  promote	  splicing	  of	  nearby	  sequences	  (Fackenthal	  &	  Godley,	  2008).	  High	  
levels	   of	   phosphorylation	   of	   SR	   proteins	   are	   also	   thought	   to	   play	   a	   role	   in	   inhibiting	  
splicing	  (Gui	  et	  al.,	  1994).	  Bioinformatic	  analysis	  of	  binding	  sites	  for	  novel	  HER2	  splice	  
variants	   and	  HER∆16	   in	   chapter	   4	   revealed	   potential	   splice	   factor	   binding	  motifs	   for	  
ASF/SF2	   (SRSF2),	  which	   is	   a	   splice	   factor	   in	   the	   cytoplasm	  phosphorylated	  by	   the	   SR	  
protein	  SRPK1.	  The	  SRPK1	  protein	  kinase	  is	  also	  involved	  in	  RNA	  transcript	  processing,	  
and	  increased	  levels	  of	  SRPK1	  have	  been	  known	  to	  play	  a	  role	  in	  the	  development	  of	  
certain	  cancers	  such	  as	  chronic	  myelogenous	   leukemia	   (CML),	  colonic	  and	  pancreatic	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carcinomas	  (Salesse,	  Dylla	  &	  Verfaillie,	  2004;	  Hayes,	  Carrigan	  &	  Miller,	  2007).	  There	  is	  
also	   evidence	   that	   SRPK1	   plays	   an	   important	   role	   in	   the	   regulation	   and	   of	   Vascular	  
Endothelial	  Growth	  Factor	  Receptor	   (VEGF),	  and	   is	  one	  of	   the	   factors	   responsible	   for	  
the	   balance	   between	   the	   pro-­‐	   and	   anti-­‐	   angiogenic	   isoforms	   of	   VEGF	   (Nowak	  et	   al.,	  
2008).	   In	   this	   chapter	   the	  SR	  protein	  SRSF1	   (ASF/SF2)	   and	   it	  phosphorylating	  protein	  
kinase	  SRPK1	  were	  investigated	  by	  siRNA	  knockdown,	  to	  determine	  their	  involvement	  
in	   the	   regulation	  of	  HER2	  and	  HER2	  alternative	  splice	  variants	  using	  cell	   line	  models.	  	  
Other	  factors	  were	  also	  investigated,	  including	  the	  role	  of	  Hypoxia	  Inducible	  Factor	  1α	  
(HIF1-­‐α),	  and	  the	  role	  of	  Splice	  factor	  kinases.	  HIF1-­‐α	  is	  known	  to	  function	  as	  a	  tumour	  
suppressor	   in	  breast	  cancer	  cells	  (Chiavarina	  et	  al.,	  2010),	  and	  can	  be	  induced	  by	  the	  
use	  of	  hypoxia	  mimetic	  factors	  such	  as	  Cobalt	  Chloride	  (Vengellur	  &	  LaPres,	  2004).	  The	  
HIF1-­‐α	   protein	   is	   a	   transcription	   factor	   subunit	   with	   intrinsic	   cellular	   response	   to	  
hypoxia.	   HIF1-­‐α	   is	   known	   to	   be	   upregulated	   by	   hypoxia,	   and	   is	   known	   as	   a	   gold	  
standard	   in	   the	   detection	   of	   hypoxia	   (Vordermark,	   Brown	  &	  Phil,	   2003;	   Lekas	  et	   al.,	  
n.d.;	  Ke	  &	  Costa,	  2006).	  
The	  role	  of	  splice	  factor	  kinases	  was	  investigated	  by	  the	  use	  of	  protein	  kinase	  inhibitors	  
to	  the	  protein	  kinase	  inhibitors	  of	  interest.	  The	  selection	  protein	  kinases	  tested	  in	  this	  
study	  were	  based	  on	  an	  available	  repository	  of	  protein	  kinases	  which	  have	  been	  shown	  
to	  be	  related	  to	  certain	  mammalian	  cancers,	  or	  have	  been	  shown	  to	  regulate	  certain	  
factors	  which	  play	  a	  role	  in	  cancer.	  Current	  group	  research	  interests	  have	  been	  focused	  
on	   investigating	   the	   roles	   of	   these	   protein	   kinase	   inhibitors	   in	   various	   cancer	   types	  
including	   prostate	   cancer	   and	   leukaemia.	   The	   kinase	   inhibitors	   investigated	   in	   this	  
study	   include	  SRPIN340,	  TG003	  and	   INDY.	  SRPIN340	   is	  a	   selective	   inhibitor	  of	  SRPK1.	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TG003	   is	   a	   CDC2-­‐like	   kinase	   inhibitor.	   The	   CDC2-­‐like	   kinase	   is	   a	   member	   of	   an	  
evolutionary	   conserved	   family	   of	   dual-­‐specificity	   kinases	   belonging	   to	   the	   Cyclin-­‐
dependent	   (CDK),	  Mitogen-­‐activated	   (MAPK),	   Glycogen	   synthase	   (GSK)	   and	   CDK-­‐like	  
kinases	   (CMGC)	   (Jain	  et	  al.,	  2014;	  Rodgers	  et	  al.,	  2010).	  CDC2-­‐like	  kinases	  have	  been	  
shown	  to	  alter	   the	  regulation	  of	  SR	  proteins	  both	   in	  vitro	  and	   in	  vivo	   (Rodgers	  et	  al.,	  
2010).	  Though	  a	  high	   level	   regulator	  of	  alternative	  splicing	  via	  phosphorylation	  of	  SR	  
domains	   on	   splice	   factors,	   the	   connection	   between	   CDC2-­‐like	   kinases	   and	   breast	  
cancer	  has	  not	  been	  previously	  studied.	  	  
INDY	   is	   an	   inhibitor	   of	   the	   Dual-­‐specificity	   tyrosine-­‐(Y)-­‐phosphorylation	   regulated	  
kinase	  1A	  (DYRK1A),	  a	  protein	  kinase	  that	   is	  a	  member	  of	   the	  highly	  conserved	  dual-­‐
specificity	   tyrosine	   phosphorylation	   regulated	   kinase	   (DYRK)	   family	   (Courcet	   et	   al.,	  
2012).	  DYRK1A	  modulates	  alternative	  splicing	  by	  phosphorylating	  splice	  factor	  SRSF6.	  It	  
is	  also	  known	  to	  phosphorylate	  serine,	  threonine	  and	  tyrosine	  residues	  in	  its	  sequence.	  
In	   addition,	   DYRK1A	   participates	   in	   multiple	   biological	   pathways,	   including	   the	  
phosphorylation	  of	  ASF	  and	  the	  splicing	  factor	  SF3b1/SAP155	  (Courcet	  et	  al.,	  2012).	  
6.2. Methods	  	  
6.2.1 Treatment	  of	  cells	  with	  protein	  kinase	  inhibitors	  	  
To	   study	   the	  effect	   of	   protein	   kinases	  on	  HER2	   and	  HER2	   alternative	   splice	   variants,	  
MDA-­‐MB-­‐453,	   SKBR3	  and	  BT-­‐20	   cells	  were	  used	   to	   investigate	   the	  effects	  of	  protein	  
kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY.	  Stock	  solutions	  were	  prepared	  by	  diluting	  
in	  DMSO.	  1µl	  of	  DMSO	  was	  also	  added	  to	  each	  well	  of	   the	  untreated	  cells	   to	  ensure	  
that	   the	   changes	   in	   the	   cells	   after	   treatments	  are	  not	  due	   to	  DMSO	   in	   treated	   cells.	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Protein	   kinase	   inhibitors	   were	   added	   to	   cells	   according	   to	   the	   manufacturer’s	  
guidelines	   at	   a	   final	   concentration	   of	   10µM,	   in	   complete	   cell	   culture	   media,	   and	  
incubated	   for	   24	   and	   48	   hours,	   prior	   to	   RNA	   extraction,	   reverse	   transcription,	   and	  
qPCR	  analysis.	  In	  addition	  to	  untreated	  cells,	  two	  negative	  controls	  were	  also	  added	  to	  
the	  treatment;	  SRPIN349	  was	  used	  as	  a	  negative	  control	  for	  SRPIN340,	  and	  TG009	  was	  
used	  as	  a	  negative	  control	  for	  TG003.	  
6.2.2 Treatment	   of	   cells	   with	   hypoxia	   mimetic	   factor	   Cobalt	  
Chloride	  (CoCl2)	  
Cells	  were	  treated	  with	  CoCl2	  to	  investigate	  the	  effects	  of	  hypoxia	  stimulated	  by	  CoCl2	  
in	   breast	   cancer	   cell	   line	   MDA-­‐MB-­‐453	   and	   SKBR3.	   A	   100mM	   stock	   solution	   was	  
prepared	   by	   dissolving	   CoCl2	   powder	   in	   sterile	   distilled	   water.	   CoCl2	   was	   added	   to	  
complete	  cell	  culture	  media	  at	  final	  concentrations	  of	  100µM,	  200µM,	  300µM,	  400µM	  
and	   500µM.	   Cells	  were	   incubated	   for	   24	   hours	   under	   normal	   cell	   culture	   conditions	  
before	  RNA	  extraction,	  reverse	  transcription	  and	  qPCR	  analysis.	  HIF1-­‐α  accumulation	  in	  
cells	   following	  CoCl2	   treatment	  have	  been	  seen	  to	   increase	  within	  only	  6-­‐12	  hours	   in	  
western	   blot	   experiments	   (Ke	   &	   Costa,	   2006;	   Al	   Okail,	   2010).	   Moreover,	   treatment	  
with	  CoCl2	   for	   longer	  than	  24	  hours	   in	  this	  study	  resulted	  in	  a	  high	  level	  of	  cell	  death	  
which	  may	  be	  due	  to	  the	  high	  toxicity	  of	  CoCl2	  to	  the	  cells	  (Al	  Okail,	  2010).	  The	  24	  hour	  
time	  point	  was	  chosen	  for	  all	  CoCl2	  treatments.	  However	  the	  effects	  of	  different	  time	  
points	  have	  not	  been	  carried	  out	  within	  the	  scope	  of	  this	  project.	  
142	  	  
6.2.3 siRNA	   silencing	   of	   SRPK1	   	   and	   SRSF1	   in	   MDA-­‐MB-­‐453	   and	  
SKBR3	  cell	  lines	  	  
MDA-­‐MB-­‐453	   and	   SKBR3	   cell	   lines	   were	   used	   to	   investigate	   the	   effects	   of	   siRNA	  
knockdown	  of	  SRPK1	  and	  SRSF1	  on	  the	  expression	  of	  HER2	  and	  the	  HER2	  alternative	  
splice	   variants	   of	   interest.	   MDA-­‐MB-­‐453	   cell	   line	   was	   used	   for	   SRPK1	   and	   SRSF1	  
knockdown	   because	   it	   showed	   reliable	   expression	   of	  HER2	   and	  HER2	   splice	   variants	  
and	   is	  a	  reliable	  source	  of	  DNA	  material	   for	  sequencing.	  SKBR3	  cell	   line	  was	  used	  for	  
SRPK1	   and	   SRSF1	   knockdowns	   because	   it	   is	  HER2	   3+	   by	   immunohistochemistry,	   and	  
represents	   the	   highest	   clinical	   expression	   of	   HER2	   based	   on	   tests	   used	   in	   HER2	  
diagnosis.	  	  
Cells	   were	   seeded	   onto	   6-­‐well	   tissue	   culture	   plates	   at	   a	   density	   of	   0.6x106	   the	   day	  
before	  transfection,	  and	  allowed	  to	  adhere	  overnight	  in	  their	  respective	  media	  +	  10%	  
Foetal	   Bovine	   Serum	   (FBS)	   +	   2mM	   L-­‐Glutamine,	   without	   antibiotics.	   On	   the	   day	   of	  
transfection,	   cells	   were	   serum-­‐starved	   for	   two	   hours	   in	   Opti-­‐MEM	   I	   reduced-­‐serum	  
medium	   (Life	   Technologies,	   UK).	   Transfection	   was	   carried	   out	   using	   Dharmafect	  
transfection	   reagent	   (Dharmacon,	   UK)	   at	   a	   volume	   of	   6µl	   per	   well.	   Smartpool	  
siGENOME	   siRNAs	   targeted	   against	   SRPK1	   and	   SRSF1	   were	   used	   at	   a	   final	  
concentration	   of	   100nM.	   Smartpool	   siGENOME	   siRNA	   consists	   of	   a	   set	   of	   4	   siRNAs	  
provided	  as	  a	  single	  reagent,	  providing	  the	  advantaged	  of	  high	  specificity	  and	  potency.	  
Total	  RNA	  was	  extracted	  from	  the	  cells	  24	  and	  48	  hours	  post	  transfection,	  followed	  by	  
reverse	  transcription	  and	  qRT-­‐PCR.	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6.2.4 Western	  blot	  analysis	  
To	  confirm	  changes	  in	  protein	  expression	  following	  transfection,	  siRNA	  knockdowns	  of	  
SRPK1	  and	  SRSF1	  in	  MDA-­‐MB-­‐453	  cells	  were	  studied	  using	  western	  blot	  analysis.	  MDA-­‐
MB-­‐453	  cells	  were	  used	  for	  this	  assay	  due	  to	  its	  reliability	  in	  expressing	  HER2	  and	  HER2	  
alternative	   splice	   variants	   earlier	   in	   this	   study.	   Cells	  were	   transfected	   for	   24	   and	   48	  
hours	   prior	   to	   protein	   extraction.	   SRPK1	   mouse	   monoclonal	   antibody	   clone	   EE-­‐
13:sc100443	   and	   ASF/SF2	   (SRSF1)	   mouse	   monoclonal	   antibody	   clone	   96:sc33652	  
(Santa	   Cruz	   Biotechnology)	   were	   used	   as	   primary	   antibodies	   to	   SRPK1	   and	   SRSF1,	  
respectively.	  β-­‐actin	  was	  used	  as	  a	  loading	  control.	  	  
Antibody	  Clone	   Specificity	   Source	   Concentration	  
	  










β-­‐actin	   Santa	   Cruz	  
Biotechnology	  
0.1µg/mL	  
Table	  6.1:	  Antibodies	  used	  in	  Western	  blotting	  and	  their	  specificities	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6.2.5 Real-­‐time	   qPCR	   analysis	   of	   HER2,	   HER2	   alternative	   splice	  
variants,	  SRPK1	  and	  SRSF1.	  	  
Real-­‐time	   qPCR	   analysis	   was	   performed	   following	   treatment	   of	   cells	   with	   protein	  
kinase	   inhibitors	   and	   Cobalt	   Chloride,	   and	   following	   transfection	   of	   cells	  with	   SRPK1	  
and	  SRSF1	  siRNAs.	  Double-­‐dye	  probes	  were	  used	  for	  the	  detection	  of	  HER2	  and	  HER2	  
alternative	   splice	   variant	   expression	   (Table	   5.1).	   Primers	   for	   the	   detection	   of	   SRPK1,	  
SRSF1	  and	  HIF1-­‐α	  by	  sybr	  green	  chemistry	  were	  designed	  by	  primer	  design	  UK	  (Table	  
6.2).	  Real-­‐time	  qPCR	  assays	  were	  normalised	  against	  the	  most	  stable	  of	  12	  reference	  
genes,	  using	  the	  Normfinder	  algorithm.	  
	  
Table	  6.2:	  SRPK1,	  SRSF1	  and	  HIF1-­‐α	  primer	  sequences.	  
	  
	  
Primer	  name	   5’-­‐3’	  sequence	   Product	  length	  
SRSF1	  sense	  	   GATGGAATTGTGTTTTGCGTTTT	   	  
101bp	  SRSF1	  antisense	  	   CATCTACTCGTGCTGAATCCTT	  
SRPK1	  sense	   ACAAGCAAGAAGAATCAGAGAGT	   	  
124bp	  SRPK1	  antisense	   	  	  CGTTCCATAAGCGTTTGATCC	  
HIF1-­‐α	  	  sense	   TGCCACATCATCACCATATAGAG	   	  
132bp	  HIF1-­‐α	  	  antisense	   TGACTCAAAGCGACAGATAACA	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6.3. Results	  	  
6.3.1 Inhibition	  of	  SRPK1	  by	  SRPIN340	  modulates	   the	  expression	  
of	  HER2	  and	  HER2	  alternative	  splice	  variants	  in	  MDA-­‐MB-­‐453	  cell	  
line	  
Gene	  name	   Stability	  value	  
	   	   	  18S	   0.072	  
	  
Best	  gene	   GAPDH	  
ACTB	   0.079	  
	  
Stability	  
value	   0.035	  
ATP5B	   0.113	  
	   	   	  B2M	   0.138	  
	   	   	  CYC1	   0.119	  
	   	   	  E1F4A2	   0.155	  
	   	   	  GAPDH	   0.035	  
	   	   	  RPLI3A	   0.079	  
	   	   	  SDHA	   0.171	  
	   	   	  TOP1	   0.073	  
	   	   	  UBC	   0.119	  
	   	   	  YWHAZ	   0.153	  
	   	   	  Table	   6.3:	   Normfinder	   output	   for	   the	   selection	   of	   an	   optimal	   reference	   gene	   in	   MDA-­‐MB-­‐453	   cells	  
treated	  with	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY.	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6.3.1.1. MDA-­‐MB-­‐453	  cell	  line	  
The	  untreated	  samples	  were	  used	  as	  a	  calibrator	  to	  measure	  the	  fold	  change	  at	  24	  and	  
48	  hours	  post-­‐treatment,	  using	  GAPDH	  as	  a	  normalisation	  factor	  (Table	  6.3).	  	  
6.3.1.1.1. Changes	  in	  the	  expression	  of	  wild-­‐type	  HER2	  following	  
treatment	  with	  protein	  kinase	  inhibitors	  
There	  was	  no	  significant	  change	  in	  the	  expression	  wild-­‐type	  HER2	  after	  treatment	  for	  
24	   hours	   with	   SRPIN340	   (fold	   change	   =	   0.94;	   p≥0.05),	   TG003	   (fold	   change	   =	   1.07;	  
p≥0.05)	  and	  INDY	  (fold	  change	  =	  1.07;	  p≥0.05).	  Negative	  controls	  SRPIN340	  and	  TG009	  
also	  showed	  no	  change	  in	  expression	  after	  24	  hours	  (fold	  change	  =	  0.97;	  p≥0.05;	  and	  
1.12;	   p≥0.05,	   respectively)	   (Figure	   6.1).	   After	   48	   hours,	   a	   significant	   increase	   was	  
observed	  in	  the	  expression	  of	  the	  wild-­‐type	  HER2	  following	  SRPIN340	  treatment	  (fold	  
change	  =	  0.26;	  p<0.05).	  No	  significant	  change	  was	  observed	  in	  the	  wild-­‐type	  HER2	  after	  
treatment	   with	   TG003	   and	   INDY	   (fold	   change	   =	   0.93;	   p≥0.05;	   and	   1.28;	   p≥0.05,	  
respectively).	   Negative	   controls	   SRPIN349	   and	   TG009	   also	   showed	   no	   significant	  
change	  in	  the	  expression	  of	  wild-­‐type	  HER2	  following	  treatment	  for	  48	  hours	  of	  MDA-­‐





Figure	  6.1:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  wild-­‐type	  HER2	  in	  MDA-­‐
MB-­‐453	  cells	  24	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  
consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  was	  run	  on	  a	  
different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
	  
Figure	  6.2:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  wild-­‐type	  HER2	  in	  MDA-­‐
MB-­‐453	  cells	  24	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  
consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  was	  run	  on	  a	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6.3.1.1.2. Changes	   in	   the	   expression	   of	   HER2∆ECD	   	   following	  
treatment	  with	  protein	  kinase	  inhibitors	  
There	  was	  no	  significant	  change	   in	   the	  expression	  HER2∆ECD	   	  after	   treatment	   for	  24	  
hours	  with	  SRPIN340	   (fold	   change	   =	   1.0;	   p≥0.05),	  TG003	   (fold	   change	   =	   1.0;	   p≥0.05)	  
and	   INDY	   (fold	   change	   =	   1.21;	   p≥0.05).	   Negative	   controls	   SRPIN340	   and	   TG009	   also	  
showed	  no	  change	  in	  expression	  after	  24	  hours	  (fold	  change	  =	  0.92;	  p≥0.05;	  and	  1.14;	  
p≥0.05,	  respectively)	  (Figure	  6.3).	  After	  48	  hours,	  a	  significant	  increase	  was	  observed	  in	  
the	  expression	  of	   the	  HER2∆ECD	   	   following	  SRPIN340	   treatment	   (fold	  change	  =	  0.13;	  
p<0.05).	   A	   slight	   reduction	   in	   the	   expression	   of	   HER2∆ECD	   	   was	   observed	   after	  
treatment	   with	   TG003	   and	   INDY	   (fold	   change	   =	   0.4;	   p≥0.05;	   and	   0.42;	   p≥0.05,	  
respectively).	   These	   changes,	   however,	   are	   not	   statistically	   significant.	   Negative	  
controls	  SRPIN349	  and	  TG009	  also	  showed	  no	  significant	  change	   in	  the	  expression	  of	  
wild-­‐type	  HER2	  following	  treatment	  for	  48	  hours	  of	  MDA-­‐MB-­‐453	  cells	  (fold	  change	  =	  




Figure	  6.3:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  HER2∆ECD	  	  alternative	  
splice	  variant	  in	  MDA-­‐MB-­‐453	  cells	  24	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  




Figure	  6.4:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  HER2∆ECD	  	  alternative	  
splice	  variant	  in	  MDA-­‐MB-­‐453	  cells	  48	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	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6.3.1.1.3. Changes	   in	   the	   expression	   of	   HER2∆16	   following	  
treatment	  with	  protein	  kinase	  inhibitors	  
There	   was	   no	   significant	   change	   in	   the	   expression	  HER2∆16	   after	   treatment	   for	   24	  
hours	   with	   SRPIN340	   (fold	   change	   =	   1.12;	   p≥0.05)	   and	   TG003	   (fold	   change	   =	   1.1;	  
p≥0.05).	  A	  slight	  reduction	  was	  observed	  following	  treatment	  with	  INDY	  (fold	  change	  =	  
1.53;	   p≥0.05).	   Negative	   controls	   SRPIN340	   and	   TG009	   also	   showed	   no	   change	   in	  
expression	  after	  24	  hours	  (fold	  change	  =	  0.98;	  p≥0.05;	  and	  1.23;	  p≥0.05,	  respectively)	  
(Figure	  6.5).	  After	  48	  hours,	   a	   significant	   increase	  was	  observed	   in	   the	  expression	  of	  
the	   HER2∆16	   following	   SRPIN340	   treatment	   (fold	   change	   =	   0.13;	   p<0.01).	   A	   slight	  
reduction	  in	  the	  expression	  of	  HER2∆16	  was	  observed	  after	  treatment	  with	  TG003	  and	  
INDY	   (fold	   change	   =	   0.5;	   p≥0.05;	   and	   0.42;	   p≥0.05,	   respectively).	   These	   changes,	  
however,	  are	  not	   statistically	   significant.	  Negative	  controls	  SRPIN349	   and	  TG009	   also	  
showed	  no	  significant	  change	  in	  the	  expression	  of	  wild-­‐type	  HER2	  following	  treatment	  
for	   48	   hours	   of	   MDA-­‐MB-­‐453	   cells	   (fold	   change	   =	   1.0;	   p≥0.05;	   and	   0.9;	   p≥0.05,	  
respectively)	  (Figure	  6.6).	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Figure	   6.5:	   Effect	   of	   protein	   kinase	   inhibitors	  SRPIN340,	  TG003	   and	   INDY	   on	   the	  HER2∆16	   alternative	  
splice	  variant	  in	  MDA-­‐MB-­‐453	  cells	  24	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  




Figure	   6.6:	   Effect	   of	   protein	   kinase	   inhibitors	  SRPIN340,	  TG003	   and	   INDY	   on	   the	  HER2∆16	   alternative	  
splice	  variant	  in	  MDA-­‐MB-­‐453	  cells	  48	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	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6.3.1.1.4. Changes	   in	   the	   expression	   of	   HER2∆ATP	   following	  
treatment	  with	  protein	  kinase	  inhibitors	  
There	  was	   no	   significant	   change	   in	   the	   expression	  HER2∆ATP	   after	   treatment	   for	   24	  
hours	   with	   SRPIN340	   (fold	   change	   =	   1.0;	   p≥0.05)	   and	   TG003	   (fold	   change	   =	   0.96;	  
p≥0.05).	  A	  slight	  increase	  was	  observed	  following	  treatment	  with	  INDY	  (fold	  change	  =	  
1.31;	   p≥0.05).	   Negative	   controls	   SRPIN340	   and	   TG009	   also	   showed	   no	   change	   in	  
expression	  after	  24	  hours	  (fold	  change	  =	  0.96;	  p≥0.05;	  and	  1.16;	  p≥0.05,	  respectively)	  
(Figure	  6.7).	  After	  48	  hours,	   a	   significant	   increase	  was	  observed	   in	   the	  expression	  of	  
the	  HER2∆ATP	   following	   SRPIN340	   treatment	   (fold	   change	   =	   0.13;	   p<0.01).	   A	   slight	  
increase	  in	  the	  expression	  of	  HER2∆ATP	  was	  observed	  after	  treatment	  with	  TG003	  and	  
INDY	   (fold	   change	   =	   0.4;	   p≥0.05;	   and	   0.42;	   p≥0.05,	   respectively).	   These	   changes,	  
however,	  are	  not	   statistically	   significant.	  Negative	  controls	  SRPIN349	   and	  TG009	   also	  
showed	  no	  significant	  change	  in	  the	  expression	  of	  wild-­‐type	  HER2	  following	  treatment	  
for	   48	   hours	   of	   MDA-­‐MB-­‐453	   cells	   (fold	   change	   =	   1.0;	   p≥0.05;	   and	   0.9;	   p≥0.05,	  




Figure	  6.7:	  Effect	  of	  protein	  kinase	   inhibitors	  SRPIN340,	  TG003	  and	   INDY	  on	  the	  HER2∆ATP	  alternative	  
splice	  variant	  in	  MDA-­‐MB-­‐453	  cells	  24	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  




Figure	  6.8:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  HER2∆ECD	  	  alternative	  
splice	  variant	  in	  MDA-­‐MB-­‐453	  cells	  48	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	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6.3.1.2 SKBR3	  cell	  line	  
The	  untreated	  cells	  were	  used	  as	  a	  calibrator	  to	  measure	  the	  fold	  change	  at	  24	  and	  48	  
hours	  post-­‐treatment,	  using	  ATP5B	  as	  a	  normalisation	  factor	  (Table	  6.4).	  	  
Gene	  name	   Stability	  value	  
	  
	  
	  18S	   0.099	  
	  
Best	  gene	   ATP5B	  
ACTB	   0.110	  
	  
Stability	  
value	   0.067	  
ATP5B	   0.067	  
	  
	   	  
B2M	   0.080	  
	  
	   	  
CYC1	   0.098	  
	   	   	  E1F4A2	   0.119	  
	   	   	  GAPDH	   0.102	  
	   	   	  RPLI3A	   0.151	  
	   	   	  SDHA	   0.178	  
	   	   	  TOP1	   0.085	  
	   	   	  UBC	   0.170	  
	   	   	  YWHAZ	   0.080	  
	   	   	  
Table	  6.4:	  Normfinder	  output	  for	  the	  selection	  of	  an	  optimal	  reference	  gene	  in	  SKBR3	  cells	  treated	  with	  
protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY.	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6.3.1.2.1 The	  expression	  of	  wild-­‐type	  HER2	  following	  treatment	  
with	  protein	  kinase	  inhibitors	  
There	  was	  no	  significant	  change	  in	  the	  expression	  wild-­‐type	  HER2	  after	  treatment	  for	  
24	   hours	   with	   SRPIN340	   (fold	   change	   =	   0.94;	   p≥0.05),	   TG003	   (fold	   change	   =	   1.09;	  
p≥0.05)	  and	  INDY	  (fold	  change	  =	  0.87;	  p≥0.05).	  Negative	  controls	  SRPIN340	  and	  TG009	  
also	   showed	  no	  change	   in	  expression	  after	  24	  hours	   (fold	   change	  =	  0.9;	  p≥0.05;	  and	  
0.91;	   p≥0.05,	   respectively)	   (Figure	   6.9).	   After	   48	  hours,	   there	  was	   also	  no	   significant	  
change	   in	   the	   expression	   of	   the	  wild-­‐type	  HER2	   following	   treatment	   with	   SRPIN340	  
(fold	  change	  =	  0.8;	  p≥0.05),	  TG003	  (fold	  change	  =	  1.1;	  p≥0.05)	  and	  INDY	  (fold	  change	  =	  
1.0;	  p≥0.05).	  Negative	  controls	  SRPIN349	  and	  TG009	  also	  showed	  no	  significant	  change	  
in	  the	  expression	  of	  wild-­‐type	  HER2	  following	  treatment	  for	  48	  hours	  of	  MDA-­‐MB-­‐453	  
cells	  (fold	  change	  =	  0.8;	  p≥0.05;	  and	  0.9;	  p≥0.05,	  respectively)	  (Figure	  6.10).	  
	  
Figure	  6.9:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  wild-­‐type	  HER2	  in	  SKBR3	  
cells	   24	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	   average	   of	   9	   samples	  
consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  was	  run	  on	  a	  

































Figure	   6.10:	   Effect	   of	   protein	   kinase	   inhibitors	   SRPIN340,	   TG003	   and	   INDY	   on	   the	   wild-­‐type	  HER2	   in	  
SKBR3	  cells	  48	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  
consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  was	  run	  on	  a	  
different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
6.3.1.2.2 The	  expression	  of	  HER2∆ECD	  	  following	  treatment	  with	  
protein	  kinase	  inhibitors	  
There	  was	  no	  significant	  change	   in	   the	  expression	  HER2∆ECD	   	  after	   treatment	   for	  24	  
hours	  with	  SRPIN340	   (fold	   change	   =	   1.0;	   p≥0.05),	  TG003	   (fold	   change	   =	   1.2;	   p≥0.05)	  
and	   INDY	   (fold	   change	   =	   1.2;	   p≥0.05).	   Negative	   controls	   SRPIN340	   and	   TG009	   also	  
showed	  no	   change	   in	   expression	  after	   24	  hours	   (fold	   change	  =	  1.0;	   p≥0.05;	   and	  1.2;	  
p≥0.05,	  respectively)	  (Figure	  6.11).	  After	  48	  hours,	  there	  was	  also	  no	  significant	  change	  
in	   the	   expression	   of	  HER2∆ECD	   	   following	   treatment	   with	   SRPIN340	   (fold	   change	   =	  
0.75;	  p≥0.05),	  TG003	  (fold	  change	  =	  0.75;	  p≥0.05)	  and	  INDY	  (fold	  change	  =	  1.0;	  p≥0.05).	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expression	  of	  HER2∆ECD	  	  following	  treatment	  for	  48	  hours	  of	  MDA-­‐MB-­‐453	  cells	  (fold	  
change	  =	  0.8;	  p≥0.05;	  and	  1.1;	  p≥0.05,	  respectively)	  (Figure	  6.12).	  
	  
Figure	  6.11:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  HER2∆ECD	  	  alternative	  
splice	   variant	   in	   SKBR3	   cells	   24	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  


































Figure	  6.12:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  HER2∆ECD	  	  alternative	  
splice	   variant	   in	   SKBR3	   cells	   48	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  
replicate	  was	  run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  
values.	  
	  
6.3.1.2.3 The	   expression	   of	  HER2∆16	   following	   treatment	  with	  
protein	  kinase	  inhibitors	  
There	   was	   no	   significant	   change	   in	   the	   expression	  HER2∆16	   after	   treatment	   for	   24	  
hours	  with	  SRPIN340	   (fold	   change	   =	   0.8;	   p≥0.05),	  TG003	   (fold	   change	   =	   1.0;	   p≥0.05)	  
and	   INDY	   (fold	   change	   =	   0.9;	   p≥0.05).	   Negative	   controls	   SRPIN340	   and	   TG009	   also	  
showed	  no	   change	   in	   expression	  after	   24	  hours	   (fold	   change	  =	  0.8;	   p≥0.05;	   and	  0.9;	  
p≥0.05,	  respectively)	  (Figure	  6.13).	  After	  48	  hours,	  there	  was	  also	  no	  significant	  change	  
in	   the	  expression	  of	  HER2∆16	  following	  treatment	  with	  SRPIN340	   (fold	  change	  =	  1.0;	  
p≥0.05),	   TG003	   (fold	   change	   =	   1.1;	   p≥0.05)	   and	   INDY	   (fold	   change	   =	   0.8;	   p≥0.05).	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expression	   of	  HER2∆16	   following	   treatment	   for	   48	   hours	   of	  MDA-­‐MB-­‐453	   cells	   (fold	  
change	  =	  0.8;	  p≥0.05;	  and	  0.8;	  p≥0.05,	  respectively)	  (Figure	  6.14).	  
	  
Figure	  6.13:	  Effect	  of	  protein	  kinase	   inhibitors	  SRPIN340,	  TG003	  and	   INDY	  on	  the	  HER2∆16	  alternative	  
splice	   variant	   in	   SKBR3	   cells	   24	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  






































Figure	  6.14:	  Effect	  of	  protein	  kinase	   inhibitors	  SRPIN340,	  TG003	  and	   INDY	  on	  the	  HER2∆16	  alternative	  
splice	   variant	   in	   SKBR3	   cells	   48	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  
replicate	  was	  run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  
values.	  
	  
6.3.1.2.4 The	  expression	  of	  HER2∆ATP	  following	  treatment	  with	  
protein	  kinase	  inhibitors	  
There	  was	   no	   significant	   change	   in	   the	   expression	  HER2∆ATP	   after	   treatment	   for	   24	  
hours	  with	  SRPIN340	   (fold	  change	  =	  0.96;	  p≥0.05),	  TG003	   (fold	  change	  =	  1.1;	  p≥0.05)	  
and	   INDY	   (fold	   change	   =	   1.1;	   p≥0.05).	   Negative	   controls	   SRPIN340	   and	   TG009	   also	  
showed	  no	   change	   in	   expression	  after	   24	  hours	   (fold	   change	  =	  0.9;	   p≥0.05;	   and	  1.0;	  
p≥0.05,	  respectively)	  (Figure	  6.15).	  After	  48	  hours,	  there	  was	  also	  no	  significant	  change	  
in	  the	  expression	  of	  HER2∆ATP	  following	  treatment	  with	  SRPIN340	  (fold	  change	  =	  1.0;	  
p≥0.05),	   TG003	   (fold	   change	   =	   1.0;	   p≥0.05)	   and	   INDY	   (fold	   change	   =	   0.9;	   p≥0.05).	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expression	  of	  HER2∆ATP	  following	  treatment	  for	  48	  hours	  of	  MDA-­‐MB-­‐453	  cells	  (fold	  
change	  =	  1.0;	  p≥0.05;	  and	  1.0;	  p≥1.0,	  respectively)	  (Figure	  6.16).	  
	  
Figure	  6.15:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  HER2∆ATP	  alternative	  
splice	   variant	   in	   SKBR3	   cells	   24	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  



































Figure	  6.16:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  HER2∆ATP	  alternative	  
splice	   variant	   in	   SKBR3	   cells	   48	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  
replicate	  was	  run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  
values.	  
	  
6.3.1.3 BT-­‐20	  cell	  line	  
The	  untreated	  cells	  were	  used	  as	  a	  calibrator	  to	  measure	  the	  fold	  change	  at	  24	  and	  48	  
hours	   post-­‐treatment,	   using	   B2M	   as	   a	   normalisation	   factor	   (Table	   6.5).	   Due	   to	   the	  
significant	   changes	   observed	   in	   MDA-­‐MB-­‐453	   cells,	   triple-­‐negative	   BT-­‐20	   cells	   were	  
treated	  with	  protein	  kinase	  inhibitors	  to	  investigate	  whether	  the	  changes	  in	  expression	  
of	  HER2	   and	  HER2	   alternative	   splice	   variants	   were	   specific	   to	  MDA-­‐MB-­‐453	   cells	   or	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Gene	  name	   Stability	  value	  
	  
	   	  
18S	   0.160	  
	  
Best	  gene	   B2M	  
ACTB	   0.141	  
	  
Stability	  
value	   0.100	  
ATP5B	   0.160	  
	   	   	  B2M	   0.100	  
	   	   	  CYC1	   0.176	  
	   	   	  E1F4A2	   0.118	  
	   	   	  GAPDH	   0.171	  
	   	   	  RPLI3A	   0.151	  
	   	   	  TOP1	   0.346	  
	   	   	  UBC	   0.214	  
	   	   	  YWHAZ	   0.115	  
	   	   	  
Table	  6.5:	  Normfinder	  output	  for	  the	  selection	  of	  an	  optimal	  reference	  gene	  in	  BT-­‐20	  cells	  treated	  with	  
protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY.	  
	  
6.3.1.3.1 The	  expression	  of	  wild-­‐type	  HER2	  following	  treatment	  
with	  protein	  kinase	  inhibitors	  
There	  was	  no	  significant	  change	  in	  the	  expression	  wild-­‐type	  HER2	  after	  treatment	  for	  
24	  hours	  with	  SRPIN340	  (fold	  change	  =	  0.82;	  p≥0.05).	  An	  increased	  expression	  in	  wild-­‐
type	  HER2	   expression	  was	   observed	   following	   treatment	  with	  TG003	   and	   INDY	   (fold	  
change	   =	   0.04;	   p<0.01;	   0.03;	   p<0.01,	   respectively).	   Negative	   controls	   SRPIN340	   and	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TG009	  also	  showed	  no	  change	  in	  expression	  after	  24	  hours	  (fold	  change	  =	  0.8;	  p≥0.05;	  
and	   0.7;	   p≥0.05,	   respectively)	   (Figure	   6.17).	   After	   48	   hours,	   there	  was	   no	   significant	  
change	   in	   the	   expression	   of	   the	  wild-­‐type	  HER2	   following	   treatment	   with	   SRPIN340	  
(fold	  change	  =	  1.1;	  p≥0.05),	  TG003	  (fold	  change	  =	  1.1;	  p≥0.05)	  and	  INDY	  (fold	  change	  =	  
0.9;	  p≥0.05).	  Negative	  controls	  SRPIN349	  and	  TG009	  also	  showed	  no	  significant	  change	  
in	  the	  expression	  of	  wild-­‐type	  HER2	  following	  treatment	  for	  48	  hours	  of	  MDA-­‐MB-­‐453	  
cells	  (fold	  change	  =	  1.2;	  p≥0.05;	  and	  0.9;	  p≥0.05,	  respectively)	  (Figure	  6.18).	  
	  
	  
Figure	  6.17:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  wild-­‐type	  HER2	  in	  BT-­‐
20	   cells	   24	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	   average	   of	   9	   samples	  
consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  was	  run	  on	  a	  



































Figure	  6.18:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  wild-­‐type	  HER2	  in	  BT-­‐
20	   cells	   48	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	   average	   of	   9	   samples	  
consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  was	  run	  on	  a	  
different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
6.3.1.3.2 The	  expression	  of	  HER2∆ECD	  	  following	  treatment	  with	  
protein	  kinase	  inhibitors	  
There	  was	  no	  significant	  change	   in	   the	  expression	  HER2∆ECD	   	  after	   treatment	   for	  24	  
hours	  with	  SRPIN340	   (fold	   change	   =	   1.3;	   p≥0.05),	  TG003	   (fold	   change	   =	   0.8;	   p≥0.05)	  
and	   INDY	   (fold	   change	   =	   0.7;	   p≥0.05).	   Negative	   controls	   SRPIN340	   and	   TG009	   also	  
showed	  no	   change	   in	   expression	  after	   24	  hours	   (fold	   change	  =	  1.0;	   p≥0.05;	   and	  1.0;	  
p≥0.05,	  respectively)	  (Figure	  6.19).	  After	  48	  hours,	  there	  was	  also	  no	  significant	  change	  
in	  the	  expression	  of	  HER2∆ECD	  	  following	  treatment	  with	  SRPIN340	  (fold	  change	  =	  0.7;	  
p≥0.05),	   TG003	   (fold	   change	   =	   0.9;	   p≥0.05)	   and	   INDY	   (fold	   change	   =	   0.8;	   p≥0.05).	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expression	  of	  HER2∆ECD	  	  following	  treatment	  for	  48	  hours	  of	  MDA-­‐MB-­‐453	  cells	  (fold	  
change	  =	  1.1;	  p≥0.05;	  and	  1.0;	  p≥0.05,	  respectively)	  (Figure	  6.20).	  
	  
	  
Figure	  6.19:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  HER2∆ECD	  	  alternative	  
splice	  variant	  in	  BT-­‐20	  cells	  24	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  
of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  


































Figure	  6.20:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  HER2∆ECD	  	  alternative	  
splice	  variant	  in	  BT-­‐20	  cells	  48	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  
of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  
was	  run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
6.3.1.3.3 Changes	   in	   the	   expression	   of	   HER2∆16	   following	  
treatment	  with	  protein	  kinase	  inhibitors	  
There	   was	   no	   significant	   change	   in	   the	   expression	  HER2∆16	   after	   treatment	   for	   24	  
hours	   with	   SRPIN340	   (fold	   change	   =	   1.3;	   p≥0.05)	   and	   TG003	   (fold	   change	   =	   0.8;	  
p≥0.05).	  An	  increase	  in	  the	  expression	  of	  HER2∆16	  was	  seen	  after	  24	  hour	  treatment	  
with	  INDY	  (fold	  change	  =	  0.6;	  p≥0.05).	  Negative	  controls	  SRPIN340	  and	  TG009	  showed	  
no	   change	   in	   expression	   after	   24	   hours	   (fold	   change	   =	   0.8;	   p≥0.05;	   and	   0.9;	   p≥0.05,	  
respectively)	   (Figure	   6.21).	   After	   48	   hours,	   there	   was	   no	   significant	   change	   in	   the	  
expression	  of	  HER2∆16	  following	  treatment	  with	  SRPIN340	  (fold	  change	  =	  0.9;	  p≥0.05),	  
TG003	   (fold	   change	   =	   1.1;	   p≥0.05)	   and	   INDY	   (fold	   change	   =	   1.0;	   p≥0.05).	   Negative	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HER2∆16	   following	   treatment	   for	   48	  hours	   of	  MDA-­‐MB-­‐453	   cells	   (fold	   change	  =	   0.9;	  
p≥0.05;	  and	  1.0;	  p≥0.05,	  respectively)	  (Figure	  6.22).	  
	  
Figure	  6.21:	  Effect	  of	  protein	  kinase	   inhibitors	  SRPIN340,	  TG003	  and	   INDY	  on	  the	  HER2∆16	  alternative	  
splice	  variant	  in	  BT-­‐20	  cells	  24	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  
of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  




































Figure	  6.22:	  Effect	  of	  protein	  kinase	   inhibitors	  SRPIN340,	  TG003	  and	   INDY	  on	  the	  HER2∆16	  alternative	  
splice	  variant	  in	  BT-­‐20	  cells	  48	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  
of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  
was	  run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
6.3.1.3.4 Changes	   in	   the	   expression	   of	   HER2ΔATP	   following	  
treatment	  with	  protein	  kinase	  inhibitors	  	  
There	  was	   no	   significant	   change	   in	   the	   expression	  HER2∆ATP	   after	   treatment	   for	   24	  
hours	   with	   SRPIN340	   (fold	   change	   =	   1.0;	   p≥0.05)	   and	   TG003	   (fold	   change	   =	   0.98;	  
p≥0.05).	   An	   increase	   in	   the	   expression	   HER2∆ATP	   was	   observed	   after	   24	   hour	  
treatment	  with	   INDY	   (fold	   change	   =	   0.058;	   p≥0.05)	   Negative	   controls	   SRPIN340	   and	  
TG009	  also	  showed	  no	  change	  in	  expression	  after	  24	  hours	  (fold	  change	  =	  1.1;	  p≥0.05;	  
and	   0.9;	   p≥0.05,	   respectively)	   (Figure	   6.23).	   After	   48	   hours,	   there	   was	   also	   no	  
significant	  change	  in	  the	  expression	  of	  HER2∆ATP	  following	  treatment	  with	  SRPIN340	  
(fold	  change	  =	  1.0;	  p≥0.05),	  TG003	  (fold	  change	  =	  0.98;	  p≥0.05)	  and	  INDY	  (fold	  change	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change	  in	  the	  expression	  of	  HER2∆ATP	  following	  treatment	  for	  48	  hours	  of	  MDA-­‐MB-­‐
453	  cells	  (fold	  change	  =	  0.97;	  p≥0.05;	  and	  0.84;	  p≥1.0,	  respectively)	  (Figure	  6.24).	  
	  
	  
Figure	  6.23:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  HER2∆ATP	  alternative	  
splice	  variant	  in	  BT-­‐20	  cells	  24	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  
of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  





































Figure	  6.24:	  Effect	  of	  protein	  kinase	  inhibitors	  SRPIN340,	  TG003	  and	  INDY	  on	  the	  HER2∆ATP	  alternative	  
splice	  variant	  in	  BT-­‐20	  cells	  48	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  
of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  
was	  run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
6.3.2 Induction	   of	   hypoxia	   by	   hypoxia	   mimetic	   factor	   Cobalt	  
Chloride	   (CoCl2)	   inhibits	   the	   expression	   of	   HER2	   and	   HER2	  
alternative	  splice	  variants	  in	  SKBR3	  cell	  line.	  
The	  untreated	  cells	  were	  used	  as	  a	  calibrator	  to	  measure	  the	  fold	  change	  at	  24	  and	  48	  
hours	  post-­‐treatment,	  using	  ACTB	  as	  a	  normalisation	  factor	  (Table	  6.6).	  No	  results	  are	  
shown	  for	  the	  CoCl2	  induction	  of	  hypoxia	  in	  MDA-­‐MB-­‐453	  cell	  lines	  because	  the	  MDA-­‐
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Gene	  name	   Stability	  value	  
	  
	   	  
18S	   0.355	  
	  
Best	  gene	   ACTB	  
ACTB	   0.203	  
	  
Stability	  value	   0.203	  
ATP5B	   0.398	  
	   	   	  B2M	   0.233	  
	   	   	  CYC1	   0.207	  
	   	   	  E1F4A2	   0.289	  
	   	   	  GAPDH	   0.438	  
	   	   	  RPLI3A	   0.284	  
	   	   	  SDHA	   0.494	  
	   	   	  TOP1	   0.258	  
	   	   	  UBC	   0.482	  
	   	   	  YWHAZ	   0.281	  
	   	   	  
Table	  6.6:	  Normfinder	  output	  for	  the	  selection	  of	  an	  optimal	  reference	  gene	  in	  SKBR3	  cells	  treated	  with	  
Cobalt	  Chloride.	  
	  
6.3.2.1. Changes	   in	   HIF1-­‐α	   expression	   after	   treatment	   of	  
SKBR3	  cells	  with	  Cobalt	  Chloride	  for	  24	  and	  48	  hours	  
After	  24	  hours,	  and	  taking	  the	  untreated	  cells	  as	  1,	  a	  significant	  increase	  was	  observed	  
in	   the	   expression	   of	  HIF1-­‐α	  with	   100µM	   (fold	   change	   =	   0.59;	   p<0.001),	   200µM	   (fold	  
change	  =	  0.59;	  p<0.001),	  300µM	  (fold	  change	  =	  0.58;	  p<0.001),	  400µM	  (fold	  change	  =	  
0.6;	   p<0.01),	   and	   500µM	   (fold	   change	   =	   0.7;	   p<0.01)	   concentrations	   of	   CoCl2	   (Figure	  
6.25).	  
173	  	  
After	   48	   hours,	   a	   significant	   reverse	   of	   this	   effect	   is	   observed;	   HIF1-­‐α	   expression	  
significantly	   reduces	   after	   treatment	   with	   100µM	   (fold	   change	   =	   2.15;	   p<0.0001),	  
200µM	  (fold	  change	  =	  2.0;	  p<0.0001),	  300µM	  (fold	  change	  2.9;	  p<0.0001),	  400µM	  (fold	  
change	  =	  4.9;	  p<0.0001),	  and	  500µM	  (fold	  change	  =	  5.3;	  p<0.0001)	  concentrations	  of	  
CoCl2	  (Figure	  6.26).	  
	  
Figure	  6.25:	  Effect	  of	  Cobalt	  chloride	  treatment	  on	  HIF1-­‐α	  gene	  in	  SKBR3	  cells	  24	  hours	  after	  treatment.	  
Each	  histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  
three	  biological	   replicates.	  Each	  biological	   replicate	  was	   run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  
represent	  the	  standard	  deviations	  of	  the	  CT	  values.	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Figure	  6.26:	  Effect	  of	  Cobalt	  chloride	  treatment	  on	  HIF1-­‐α	  gene	  in	  SKBR3	  cells	  48	  hours	  after	  treatment.	  
Each	  histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  
three	  biological	   replicates.	  Each	  biological	   replicate	  was	   run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  
represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
6.3.2.2. Changes	   in	   the	   expression	   of	   HER2	   and	   HER2	  
alternative	   splice	   variants	   after	   treatment	   of	   SKBR3	   cells	   with	  
Cobalt	  Chloride	  for	  24	  and	  48	  hours	  
Treatment	   of	   HER2-­‐positive	   SKBR3	   cells	   with	   hypoxia	   mimetic	   CoCl2	   resulted	   in	   a	  
significant	  reduction	   in	  the	  expression	  of	  HER2	  and	  HER2	   splice	  variants.	  At	  24	  hours	  
post-­‐treatment,	   a	   significant	   decrease	   in	   expression	   was	   observed	   in	   the	   wild-­‐type	  
HER2	  (fold	  change	  =	  6.38;	  p<0.0001)	  (	  
	  
Figure	   6.27),	  HER2∆ECD	   	   (fold	   change	   =	   4.39;	   p<0.001)	   (Figure	   6.28),	  HER2∆16	   (fold	  
change	   =	   5.14;	   p<0.001)	   (Figure	   6.29),	   and	  HER2∆ATP	   (fold	   change	   =	   5.13;	   p<0.001)	  
(Figure	  6.30).	  At	  48	  hours	  post-­‐treatment,	  the	  same	  significant	  decrease	  in	  expression	  
****	   ****	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was	   observed	   in	   the	   wild-­‐type	   HER2	   (fold	   change	   =	   6.49;	   p<0.0001)	   (Figure	   6.31),	  
HER2∆ECD	   	  (fold	  change	  =	  2.76;	  p<0.0001)	  (Figure	  6.32),	  HER2∆16	  (fold	  change	  =	  2.9;	  
p<0.0001)	  (Figure	  6.33),	  and	  HER2∆ATP	  (fold	  change	  =	  2.9;	  p<0.0001)	  (Figure	  6.34).	  
	  
	  
Figure	   6.27:	   Effect	   of	   Cobalt	   Chloride	   treatment	   on	   the	  wild-­‐type	  HER2	   in	   SKBR3	   cells	   24	   hours	   after	  
treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  
repeats	  of	   three	  biological	   replicates.	  Each	  biological	   replicate	  was	  run	  on	  a	  different	  passage	  of	  cells.	  




Figure	  6.28:	  Effect	  of	  Cobalt	  Chloride	   treatment	  on	   the	  HER2∆ECD	   	   alternative	  splice	  variant	   in	  SKBR3	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consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  was	  run	  on	  a	  
different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
	  
Figure	  6.29:	  Effect	  of	  Cobalt	  Chloride	  treatment	  on	  the	  HER2∆16	  alternative	  splice	  variant	  in	  SKBR3	  cells	  
24	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  
three	   technical	   repeats	   of	   three	   biological	   replicates.	   Each	   biological	   replicate	  was	   run	   on	   a	   different	  
passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
	  
Figure	   6.30:	   Effect	   of	   Cobalt	   Chloride	   treatment	   on	   the	  HER2∆ATP	   alternative	   splice	   variant	   in	   SKBR3	  
cells	   24	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	   average	   of	   9	   samples	  
consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  was	  run	  on	  a	  





























































Figure	   6.31:	   Effect	   of	   Cobalt	   Chloride	   treatment	   on	   the	  wild-­‐type	  HER2	   in	   SKBR3	   cells	   48	   hours	   after	  
treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  
repeats	  of	   three	  biological	   replicates.	  Each	  biological	   replicate	  was	  run	  on	  a	  different	  passage	  of	  cells.	  
Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
	  
Figure	  6.32:	  Effect	  of	  Cobalt	  Chloride	   treatment	  on	   the	  HER2∆ECD	   	   alternative	  splice	  variant	   in	  SKBR3	  
cells	   48	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	   average	   of	   9	   samples	  
consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  was	  run	  on	  a	  






























































Figure	  6.33:	  Effect	  of	  Cobalt	  Chloride	  treatment	  on	  the	  HER2∆16	  alternative	  splice	  variant	  in	  SKBR3	  cells	  
48	  hours	  after	  treatment.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  
three	   technical	   repeats	   of	   three	   biological	   replicates.	   Each	   biological	   replicate	  was	   run	   on	   a	   different	  
passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
	  
Figure	   6.34:	   Effect	   of	   Cobalt	   Chloride	   treatment	   on	   the	  HER2∆ATP	   alternative	   splice	   variant	   in	   SKBR3	  
cells	   48	   hours	   after	   treatment.	   Each	   histogram	   bar	   is	   representative	   of	   an	   average	   of	   9	   samples	  
consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  was	  run	  on	  a	  
different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	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6.3.3. The	   effects	   of	   SRPK1	   and	   SRSF1	   knockdown	   on	   the	  
expression	  of	  HER2	  and	  HER2	  alternative	  splice	  variants	  in	  HER2-­‐
positive	  MDA-­‐MB-­‐453	  and	  SKBR3	  breast	  cancer	  cell	  lines.	  
Cells	  transfected	  with	  a	  non-­‐targeting	  siRNA	  were	  used	  as	  a	  calibrator	  to	  measure	  the	  
fold	  change	  at	  24	  and	  48	  hours	  post-­‐treatment,	  using	  RPLI3A	  as	  a	  normalisation	  factor	  





	   	  
18S	   0.217	  
	  
Best	  gene	   RPLI3A	  
ACTB	   0.119	  
	  
Stability	  value	   0.030	  
ATP5B	   0.334	  
	   	   	  B2M	   0.269	  
	   	   	  CYC1	   0.184	  
	   	   	  E1F4A2	   0.168	  
	   	   	  GAPDH	   0.760	  
	   	   	  RPLI3A	   0.030	  
	   	   	  SDHA	   0.179	  
	   	   	  TOP1	   0.093	  
	   	   	  UBC	   0.048	  
	   	   	  YWHAZ	   0.089	  
	   	   	  
Table	  6.7:	  Normfinder	  output	  for	  the	  selection	  of	  an	  optimal	  reference	  gene	  in	  MDA-­‐MB-­‐453	  and	  SKBR3	  
cells	  after	  siRNA	  knockdown	  of	  SRPK1	  and	  SRSF1	  splice	  factors.	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6.3.3.1 Confirmation	  of	  SRPK1	  and	  SRSF1	  knockdown	  in	  MDA-­‐
MB-­‐453	  cells	  
At	  both	  24	  and	  48	  hours	  post-­‐transfection,	  a	  significant	  knockdown	  was	  observed	  for	  
both	  SRPK1	  and	  SRSF1	  in	  MDA-­‐MB-­‐453	  cells.	  Using	  non-­‐targeting	  siRNA	  as	  a	  calibrator,	  
a	   24	   hour	   transfection	   produced	   a	   reduction	   in	   SRPK1	   mRNA	   of	   1.7fold	   (±	   0.42;	  
p<0.0001)	  (Figure	  6.35),	  and	  a	  reduction	  in	  SRSF1	  mRNA	  of	  0.76	  fold	  (±	  0.63;	  p<0.01)	  
(Figure	  6.37),	  and	  a	  48	  hour	  transfection	  produced	  a	  reduction	  in	  SRPK1	  mRNA	  of	  2.0	  
fold	  (±0.05;	  p<0.0001)	  (Figure	  6.36),	  and	  in	  SRSF1	  of	  1.8	  fold	  (±0.34;	  p<0.0001)	  (Figure	  
6.38).	  
	  
Figure	  6.35:	  Knockdown	  of	  SRPK1	  mRNA	  in	  MDA-­‐MB-­‐453	  cells	  after	  transfection	  with	  SRPK1	  smartpool	  
siGENOME	  siRNA;	  a	  mixture	  of	  four	  separate	  siRNAs	  supplied	  in	  a	  single	  tube.	  MDA-­‐MB-­‐453	  cells	  were	  
transfected	  with	   100nM	  of	   either	   a	   non-­‐targeting	   siRNA	   or	   SRPK1-­‐specific	   siRNA	   for	   24	   hours	   before	  
RNA	   extraction,	   reverse	   transcription	   and	   qPCR	   analysis.	   Each	   histogram	   bar	   is	   representative	   of	   an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  









































Figure	  6.36:	  Knockdown	  of	  SRPK1	  mRNA	  in	  MDA-­‐MB-­‐453	  cells	  after	  transfection	  with	  SRPK1	  smartpool	  
siGENOME	  siRNA;	  a	  mixture	  of	  four	  separate	  siRNAs	  supplied	  in	  a	  single	  tube.	  MDA-­‐MB-­‐453	  cells	  were	  
transfected	  with	   100nM	  of	   either	   a	   non-­‐targeting	   siRNA	   or	   SRPK1-­‐specific	   siRNA	   for	   48	   hours	   before	  
RNA	   extraction,	   reverse	   transcription	   and	   qPCR	   analysis.	   Each	   histogram	   bar	   is	   representative	   of	   an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  




Figure	  6.37:	  Knockdown	  of	  SRSF1	  mRNA	  in	  MDA-­‐MB-­‐453	  cells	  after	  transfection	  with	  SRSF1	  smartpool	  
siGENOME	  siRNA;	  a	  mixture	  of	  four	  separate	  siRNAs	  supplied	  in	  a	  single	  tube.	  MDA-­‐MB-­‐453	  cells	  were	  
transfected	  with	  100nM	  of	  either	  a	  non-­‐targeting	  siRNA	  or	  SRSF1-­‐specific	  siRNA	  for	  24	  hours	  before	  RNA	  
extraction,	  reverse	  transcription	  and	  qPCR	  analysis.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  
of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  













































































Figure	  6.38:	  Knockdown	  of	  SRSF1	  mRNA	  in	  MDA-­‐MB-­‐453	  cells	  after	  transfection	  with	  SRSF1	  smartpool	  
siGENOME	  siRNA;	  a	  mixture	  of	  four	  separate	  siRNAs	  supplied	  in	  a	  single	  tube.	  MDA-­‐MB-­‐453	  cells	  were	  
transfected	  with	  100nM	  of	  either	  a	  non-­‐targeting	  siRNA	  or	  SRSF1-­‐specific	  siRNA	  for	  48	  hours	  before	  RNA	  
extraction,	  reverse	  transcription	  and	  qPCR	  analysis.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  
of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  
was	  run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
	  
Figure	  6.39:	  Western	  blot	  of	  SRPK1	  and	  SRSF1	   in	  MDA-­‐MD-­‐453	  cells	  showing,	  0,	  24	  and	  48	  hours	  post	  
transfection.	   MDA-­‐MB-­‐453	   cells	   were	   transfected	   with	   100nM	   siGENOME	   siRNA	   targeting	   SRPK1	   or	  
SRSF1.	  Western	  blot	  was	  performed	  using	  SRPK1	  mouse	  monoclonal	  antibody	  clone	  EE-­‐13:sc100443	  and	  
ASF/SF2	   (SRSF1)	  mouse	  monoclonal	  antibody	  clone	  96:sc33652	  (Santa	  Cruz	  Biotechnology)	  and	  β-­‐actin	  
was	  used	  as	  a	  loading	  control	  Protein	  bands	  indicate	  that	  SRPK1	  and	  SRSF1	  expression	  is	  lowest	  48	  hours	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6.3.3.2. Knockdown	   of	   SRPK1	   and	   SFSF1	   shows	   no	   significant	  
effect	   on	   the	   expression	   of	   HER2	   and	   HER2	   alternative	   splice	  
variants	  in	  MDA-­‐MB-­‐453	  cells	  at	  mRNA	  level	  
In	   MDA-­‐MB-­‐453	   cells,	   slight	   changes	   in	   the	   expression	   of	   HER2	   and	   HER2	   splice	  
variants	   were	   observed	   after	   SRPK1	   and	   SRSF1	   transfection.	   After	   24	   hours	   of	  
transfection	   with	   SRPK1,	   MDA-­‐MB-­‐453	   cells	   showed	   a	   slight	   reduction	   in	   the	  
expression	   of	   wild-­‐type	  HER2	   (fold	   change	   =	   1.23;	   p≥0.05)	   (Figure	   6.40),	  HER2∆ECD	  	  
(fold	  change	  =	  1.28;	  p≥0.05)	  (Figure	  6.41),	  HER2∆16	  (fold	  change	  =	  1.5;	  p≥0.05)	  (Figure	  
6.42),	  and	  HER2∆ATP	  (fold	  change	  =	  1.59;	  p≥0.05)	  (Figure	  6.43);	  and	  a	  slight	  reduction	  
in	   the	   expression	   of	   wild-­‐type	  HER2	   (fold	   change	   =	   1.45;	   p≥0.05)	   (Figure	   6.40)	   and	  
HER2∆ECD	   	   (fold	   change	   =	   1.54;	   p≥0.05)	   (Figure	   6.41)	   after	   24	   hours	   of	   transfection	  
with	   SRSF1.	   These	   changes,	   however,	   are	   not	   statistically	   significant.	   HER2∆16	   and	  
HER2∆ATP	   remain	   unchanged	   after	   siRNA	   transfection	   of	   SRPK1	   and	   SRSF1	   for	   24	  
hours	   (Figure	   6.42	   and	   Figure	   6.43).	   There	   were	   also	   no	   significant	   changes	   in	   the	  
expression	  of	  wild-­‐type	  HER2,	  HER2∆ECD	  ,	  HER2∆16	  and	  HER2∆ATP	  after	  transfection	  
with	  SRPK1	  for	  48	  hours	  [fold	  difference	  =	  (1.4;	  p≥0.05);	  (1.35;	  p≥0.05);	  (1.0;	  p≥0.05);	  
(1.26;	   p≥0.05),	   respectively]	   (Figures	   6.44-­‐6.47),	   nor	   in	   the	   expression	   of	   wild-­‐type	  
HER2,	  HER2∆ECD	  ,	  HER2∆16	  and	  HER2∆ATP	  after	  transfection	  with	  SRSF1	  for	  48	  hours	  
[fold	   difference	   =	   (1.56;	   p≥0.05);	   (1.02;	   p≥0.05);	   (1.17;	   p≥0.05);	   (0.85;	   p≥0.05),	  
respectively]	  (Figures	  6.44-­‐6.47).	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Figure	   6.40:	   Effect	   of	   knockdown	   on	   wild-­‐type	   HER2	   mRNA	   in	   MDA-­‐MB-­‐453	   cells	   24	   hours	   after	  
transfection	  with	  smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  
siRNA	   is	   used	   as	   a	   calibrator	   to	  measure	   the	   fold	   difference	   in	  HER2	  mRNA	   after	   transfection	   for	   24	  
hours.	   Each	   histogram	   bar	   is	   representative	   of	   an	   average	   of	   9	   samples	   consisting	   of	   three	   technical	  
repeats	  of	   three	  biological	   replicates.	  Each	  biological	   replicate	  was	  run	  on	  a	  different	  passage	  of	  cells.	  




Figure	  6.41:	  Effect	  of	  knockdown	  on	  HER2∆ECD	  	  mRNA	  in	  MDA-­‐MB-­‐453	  cells	  24	  hours	  after	  transfection	  
with	  smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  
as	  a	  calibrator	  to	  measure	  the	  fold	  difference	  in	  HER2∆ECD	  	  mRNA	  after	  transfection	  for	  24	  hours.	  Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	  
















































































Figure	  6.42:	  Effect	  of	  knockdown	  on	  HER2∆16	  mRNA	  in	  MDA-­‐MB-­‐453	  cells	  24	  hours	  after	  transfection	  
with	  smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  
as	  a	  calibrator	   to	  measure	  the	   fold	  difference	   in	  HER2∆16	  mRNA	  after	   transfection	   for	  24	  hours.	  Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	  




Figure	  6.43:	  Effect	  of	  knockdown	  on	  HER2∆ATP	  mRNA	  in	  MDA-­‐MB-­‐453	  cells	  24	  hours	  after	  transfection	  
with	  smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  
as	  a	  calibrator	  to	  measure	  the	  fold	  difference	  in	  HER2∆ATP	  mRNA	  after	  transfection	  for	  24	  hours.	  Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	  


















































































Figure	   6.44:	   Effect	   of	   knockdown	   on	   wild-­‐type	   HER2	   mRNA	   in	   MDA-­‐MB-­‐453	   cells	   48	   hours	   after	  
transfection	  with	  smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  
siRNA	  is	  used	  as	  a	  calibrator	  to	  measure	  the	  fold	  difference	  in	  wild-­‐type	  HER2	  mRNA	  after	  transfection	  
for	   48	   hours.	   Each	   histogram	   bar	   is	   representative	   of	   an	   average	   of	   9	   samples	   consisting	   of	   three	  
technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  was	  run	  on	  a	  different	  passage	  




Figure	  6.45:	  Effect	  of	  knockdown	  on	  HER2∆ECD	  	  mRNA	  in	  MDA-­‐MB-­‐453	  cells	  48	  hours	  after	  transfection	  
with	  smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  
as	  a	  calibrator	  to	  measure	  the	  fold	  difference	  in	  HER2∆ECD	  	  mRNA	  after	  transfection	  for	  48	  hours.	  Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	  













































































Figure	  6.46:	  Effect	  of	  knockdown	  on	  HER2∆16	  mRNA	  in	  MDA-­‐MB-­‐453	  cells	  48	  hours	  after	  transfection	  
with	  smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  
as	  a	  calibrator	   to	  measure	  the	   fold	  difference	   in	  HER2∆16	  mRNA	  after	   transfection	   for	  48	  hours.	  Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	  




Figure	  6.47:	  Effect	  of	  knockdown	  on	  HER2∆ATP	  mRNA	  in	  MDA-­‐MB-­‐453	  cells	  48	  hours	  after	  transfection	  
with	  smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  
as	  a	  calibrator	  to	  measure	  the	  fold	  difference	  in	  HER2∆ATP	  mRNA	  after	  transfection	  for	  48	  hours.	  Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	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6.3.3.3. Confirmation	   of	   SRPK1	   and	   SRSF1	   knockdown	   in	  
SKBR3	  cells	  
At	  both	  24	  and	  48	  hours	  post-­‐transfection,	  a	  significant	  knockdown	  was	  observed	  for	  
both	  SRPK1	  and	  SRSF1	   in	  SKBR3	  cells.	  Using	  non-­‐targeting	  siRNA	  as	  a	  calibrator,	  a	  24	  
hour	  transfection	  produced	  a	  reduction	  in	  SRPK1	  mRNA	  of	  4.1	  fold	  (±	  0.08;	  p<0.0001)	  
(Figure	  6.48),	  and	  a	  reduction	  in	  SRSF1	  mRNA	  of	  4.8	  fold	  (±0.34;	  p<0.01)	  (Figure	  6.50),	  
and	  a	  48	  hour	  transfection	  produced	  a	  reduction	  in	  SRPK1	  mRNA	  of	  4.5	  fold	  (p<0.0001)	  
(Figure	  6.49),	  and	  in	  SRSF1	  of	  3.7	  fold	  (±0.56;	  p<0.0001)	  (Figure	  6.51).	  
	  
	  
Figure	   6.48:	   Knockdown	   of	   SRPK1	   mRNA	   in	   SKBR3	   cell	   lines	   after	   transfection	  with	   SRPK1	   smartpool	  
siGENOME	   siRNA;	   a	   mixture	   of	   four	   separate	   siRNAs	   supplied	   in	   a	   single	   tube.	   SKBR3	   cells	   were	  
transfected	  with	   100nM	  of	   either	   a	   non-­‐targeting	   siRNA	   or	   SRPK1-­‐specific	   siRNA	   for	   24	   hours	   before	  
RNA	   extraction,	   reverse	   transcription	   and	   qPCR	   analysis.	   Each	   histogram	   bar	   is	   representative	   of	   an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  









































Figure	   6.49:	   Knockdown	   of	   SRPK1	   mRNA	   in	   SKBR3	   cell	   lines	   after	   transfection	  with	   SRPK1	   smartpool	  
siGENOME	   siRNA;	   a	   mixture	   of	   four	   separate	   siRNAs	   supplied	   in	   a	   single	   tube.	   SKBR3	   cells	   were	  
transfected	  with	   100nM	  of	   either	   a	   non-­‐targeting	   siRNA	   or	   SRPK1-­‐specific	   siRNA	   for	   48	   hours	   before	  
RNA	   extraction,	   reverse	   transcription	   and	   qPCR	   analysis.	   Each	   histogram	   bar	   is	   representative	   of	   an	  
average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  





Figure	   6.50:	   Knockdown	   of	   SRSF1	   mRNA	   in	   SKBR3	   cell	   lines	   after	   transfection	   with	   SRSF1	   smartpool	  
siGENOME	   siRNA;	   a	   mixture	   of	   four	   separate	   siRNAs	   supplied	   in	   a	   single	   tube.	   SKBR3	   cells	   were	  
transfected	  with	  100nM	  of	  either	  a	  non-­‐targeting	  siRNA	  or	  SRSF1-­‐specific	  siRNA	  for	  24	  hours	  before	  RNA	  
extraction,	  reverse	  transcription	  and	  qPCR	  analysis.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  
of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  









































































Figure	   6.51:	   Knockdown	   of	   SRSF1	   mRNA	   in	   SKBR3	   cell	   lines	   after	   transfection	   with	   SRSF1	   smartpool	  
siGENOME	   siRNA;	   a	   mixture	   of	   four	   separate	   siRNAs	   supplied	   in	   a	   single	   tube.	   SKBR3	   cells	   were	  
transfected	  with	  100nM	  of	  either	  a	  non-­‐targeting	  siRNA	  or	  SRSF1-­‐specific	  siRNA	  for	  48	  hours	  before	  RNA	  
extraction,	  reverse	  transcription	  and	  qPCR	  analysis.	  Each	  histogram	  bar	  is	  representative	  of	  an	  average	  
of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  biological	  replicates.	  Each	  biological	  replicate	  
was	  run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
6.3.3.4. Knockdown	  of	  SRPK1	  and	  SFSF1	  affects	  the	  expression	  
of	   HER2	   and	   HER2	   alternative	   splice	   variants	   in	   SKBR3	   cells	   at	  
mRNA	  level	  
Transfection	   of	   SRPK1	   and	   SRSF1	   siRNAs	   in	   SKBR3	   cells	   shows	   a	   reduction	   in	   the	  
expression	   of	   HER2	   and	   HER2	   splice	   variants.	   After	   24	   hours	   of	   transfection	   with	  
SRPK1,	  SKBR3	  cells	  showed	  a	  slight	  reduction	  in	  the	  expression	  of	  wild-­‐type	  HER2	  (fold	  
change	  =	  1.02;	  p≥0.05)	  (Figure	  6.52),	  HER2∆ECD	   	   (fold	  change	  =	  1.16;	  p≥0.05)	  (Figure	  
6.53),	  HER2∆16	  (fold	  change	  =	  1.13;	  p≥0.05)	  (Figure	  6.54),	  and	  HER2∆ATP	  (fold	  change	  
=	  1.75;	  p≥0.05)	  (Figure	  6.55).	  A	  slight	  reduction	  is	  observed	  in	  the	  expression	  of	  wild-­‐
type	  HER2	  (fold	  change	  =	  1.47;	  p≥0.05)	  (Figure	  6.52),	  HER2∆ECD	   	  (fold	  change	  =	  1.26;	  
p≥0.05)	  (Figure	  6.53),	  and	  HER2∆ATP	  (fold	  change	  =	  1.83;	  p≥0.05)	  (Figure	  6.55)	  after	  24	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expression	  of	  HER2∆16	  after	  transfection	  with	  SRSF1	  for	  24	  hours	  (fold	  change	  =	  1.61;	  
p<0.05)	  (Figure	  6.54).	  Transfection	  of	  SRPK1	  and	  SRSF1	  siRNAs	  in	  SKBR3	  cells	  shows	  a	  
significant	  reduction	  in	  the	  expression	  of	  HER2	  and	  HER2	  splice	  variants	  after	  48	  hours.	  
Transfection	  of	  SRPK1	  in	  SKBR3	  cells	  showed	  a	  reduction	  in	  the	  expression	  of	  wild-­‐type	  
HER2	  (fold	  change	  =	  1.81;	  p<0.05)	  (Figure	  6.56),	  HER2∆16	  (fold	  change	  =	  1.44;	  p<0.05)	  
(Figure	  6.58),	   and	  HER2∆ATP	   (fold	   change	  =	   2.67;	   p<0.05)	   (Figure	  6.59).	  At	   48	  hours	  
post-­‐transfection,	   there	   is	   no	   significant	   change	   in	   the	   expression	   of	   HER2∆ECD	  	  
following	  SRPK1	  knockdown	  (fold	  change	  =	  1.42;	  p≥0.05)	  (Figure	  6.57).	  A	  reduction	  is	  
observed	   in	   the	   expression	   of	   wild-­‐type	   HER2	   (fold	   change	   =	   2.02;	   p<0.05)	   (Figure	  
6.56),	  HER2∆16	  (fold	  change	  =	  1.9;	  p<0.05)	  (Figure	  6.58),	  and	  HER2∆ATP	  (fold	  change	  =	  
3.44;	   p<0.05)	   (Figure	   6.59)	   after	   48	   hour	   transfection	   with	   SRSF1.	   A	   less	   significant	  
change	  is	  observed	  in	  the	  reduction	  of	  expression	  of	  HER2∆16	  after	  transfection	  with	  
SRSF1	  and	  in	  the	  expression	  of	  HER2∆ECD	  	  after	  transfection	  for	  48	  hours	  with	  SRPK1	  





Figure	  6.52:	   Effect	   of	   knockdown	  on	  wild-­‐type	  HER2	  mRNA	   in	   SKBR3	   cells	   24	  hours	   after	   transfection	  
with	  smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  
as	  a	  calibrator	  to	  measure	  the	  fold	  difference	  in	  wild-­‐type	  HER2	  mRNA	  after	  transfection	  for	  24	  hours.	  
Each	  histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  
three	  biological	   replicates.	  Each	  biological	   replicate	  was	   run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  
represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  
	  
Figure	  6.53:	  Effect	  of	  knockdown	  on	  HER2∆ECD	   	  mRNA	  in	  SKBR3	  cells	  24	  hours	  after	  transfection	  with	  
smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  as	  a	  
calibrator	   to	   measure	   the	   fold	   difference	   in	  HER2∆ECD	   	   mRNA	   after	   transfection	   for	   24	   hours.	   Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	  









































































Figure	   6.54:	   Effect	   of	   knockdown	   on	  HER2∆16	  mRNA	   in	   SKBR3	   cells	   24	   hours	   after	   transfection	  with	  
smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  as	  a	  
calibrator	   to	   measure	   the	   fold	   difference	   in	   HER2∆16	   mRNA	   after	   transfection	   for	   24	   hours.	   Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	  




Figure	  6.55:	  Effect	  of	   knockdown	  on	  HER2∆ATP	  mRNA	   in	  SKBR3	  cells	  24	  hours	  after	   transfection	  with	  
smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  as	  a	  
calibrator	   to	   measure	   the	   fold	   difference	   in	   HER2∆ATP	   mRNA	   after	   transfection	   for	   24	   hours.	   Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	  












































































Figure	  6.56:	   Effect	   of	   knockdown	  on	  wild-­‐type	  HER2	  mRNA	   in	   SKBR3	   cells	   48	  hours	   after	   transfection	  
with	  smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  
as	  a	  calibrator	  to	  measure	  the	  fold	  difference	  in	  wild-­‐type	  HER2	  mRNA	  after	  transfection	  for	  48	  hours.	  
Each	  histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  
three	  biological	   replicates.	  Each	  biological	   replicate	  was	   run	  on	  a	  different	  passage	  of	  cells.	  Error	  bars	  




Figure	  6.57:	  Effect	  of	  knockdown	  on	  HER2∆ECD	   	  mRNA	  in	  SKBR3	  cells	  48	  hours	  after	  transfection	  with	  
smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  as	  a	  
calibrator	   to	   measure	   the	   fold	   difference	   in	  HER2∆ECD	   	   mRNA	   after	   transfection	   for	   48	   hours.	   Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	  
represent	  the	  standard	  deviations	  of	  the	  CT	  values.	  
	  










































































Figure	   6.58:	   Effect	   of	   knockdown	   on	  HER2∆16	  mRNA	   in	   SKBR3	   cells	   48	   hours	   after	   transfection	  with	  
smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  as	  a	  
calibrator	   to	   measure	   the	   fold	   difference	   in	   HER2∆16	   mRNA	   after	   transfection	   for	   48	   hours.	   Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	  




Figure	  6.59:	  Effect	  of	   knockdown	  on	  HER2∆ATP	  mRNA	   in	  SKBR3	  cells	  48	  hours	  after	   transfection	  with	  
smartpool	  siGENOME	  siRNA	  specific	  to	  SRPK1	  and	  SRSF1	  splice	  factors.	  Non-­‐targeting	  siRNA	  is	  used	  as	  a	  
calibrator	   to	   measure	   the	   fold	   difference	   in	   HER2∆ATP	   mRNA	   after	   transfection	   for	   48	   hours.	   Each	  
histogram	  bar	  is	  representative	  of	  an	  average	  of	  9	  samples	  consisting	  of	  three	  technical	  repeats	  of	  three	  
biological	   replicates.	   Each	   biological	   replicate	   was	   run	   on	   a	   different	   passage	   of	   cells.	   Error	   bars	  
represent	  the	  standard	  deviations	  of	  the	  CT	  values.	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The	  study	  of	  the	  regulation	  of	  splicing	  in	  HER2	  has	  not	  been	  well	  researched	  to	  date.	  
With	  the	  identification	  of	  alternative	  splice	  variants	  of	  HER2,	  and	  the	  identification	  of	  
splice	   factor	   binding	   motifs	   for	   SRSF1	   in	   chapter	   4,	   the	   roles	   of	   certain	   potential	  
regulatory	  factors	  was	  investigated.	  In	  summary:	  
• Inhibition	  of	  SRPK1	   via	  SRPIN340	   increases	   the	   expression	  of	  HER2	   and	  HER2	  
alternative	   splice	   variants	   in	  MDA-­‐MB-­‐453	   cells.	   This	   regulatory	   effect	   is	   not	  
seen	  after	  treatment	  of	  SKBR3	  and	  BT-­‐20	  cells	  with	  SRPIN340.	  
• Inhibition	   of	   CDC2-­‐like	   kinase	   and	   DYRK1A	   via	   TG003	   and	   INDY,	   respectively,	  
does	   not	   show	   any	   significant	   effects	   on	   the	   regulation	   of	   HER2	   and	   HER2	  
alternative	  splice	  variants	  MDA-­‐MB-­‐453,	  SKBR3,	  and	  BT-­‐20	  cells.	  
• Induction	  of	  HIF1-­‐α	  by	  Cobalt	  Chloride	  treatment	  has	  inhibitory	  effects	  on	  the	  
expression	  of	  HER2	  and	  HER2	  alternative	  splice	  variants	  in	  SKBR3	  cells.	  
• Knockdown	   of	   SR	   proteins	   SRPK1	   and	   SRSF1	   in	   MDA-­‐MB-­‐453	   shows	   an	  
inhibitory	   effect	   on	   the	   expression	   of	   HER2	   and	   HER2	   alternative	   splice	  
variants.	  This	   inhibitory	  effect	   is	  not	  seen	  after	  SRPK1	  or	  SRSF1	  knockdown	   in	  
SKBR3	  cells.	  
• The	  MDA-­‐MB-­‐453	  cell	   line	   is	   a	   good	  model	   for	   the	   investigation	  of	  HER2	   and	  
HER2	  alternative	  splice	  variants	  in	  breast	  cancer.	  
• SRSF1	  and	   its	  phosphorylating	  protein	  SRPK1	  are	  potential	   regulators	  of	  HER2	  
and	  HER2	  alternative	  splicing.	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CHAPTER	  7. DISCUSSION	  
Breast	   cancer	   is	   a	   heterogeneous	  disease,	   and	  with	   a	  wide	   range	  of	   histological	   and	  
molecular	   subtypes,	   poses	   a	   challenge	   for	   diagnosis	   and	   prognosis	   in	   the	   clinical	  
settings	  (Jackson	  et	  al.,	  2013).	  
The	  HER2	  gene	  is	  an	  important	  biomarker	  in	  predicting	  the	  prognosis	  and	  outcome	  of	  
patients	   with	   invasive	   breast	   cancer.	  HER2	   overexpression	   or	   gene	   amplification	   as	  
determined	  by	   IHC	  or	  FISH	   is	   indicative	  of	  a	  more	  aggressive	  disease	  phenotype	  and	  
low	  survival	   rates	   in	  patients	  with	  advanced	  breast	  cancer.	   It	   is	  well	  established	   that	  
the	  HER2	   status	   in	   all	   breast	   cancer	  patients	   is	   crucial	   in	   identifying	  high	   risk	   groups	  
and	  for	  the	  administration	  of	  appropriate	  therapies	  (Eroles	  et	  al.,	  2012).	  	  
Trastuzumab,	   a	   recombinant	   monoclonal	   antibody	   targeted	   against	   the	   HER2	  
transmembrane	  receptor	  binds	  with	  high	  affinity	  to	  the	  extracellular	  domain	  of	  HER2,	  
providing	  substantial	  clinical	  benefits	   to	  patients	  with	  HER2-­‐overexpressing	  advanced	  
breast	   cancer,	   and	   improving	   overall	   survival	   when	   administered	   as	   an	   adjuvant	   in	  
early	  breast	  cancer	  (Scaltriti	  et	  al.,	  2007).	  Trastuzumab	  is	  currently	  the	  most	  important	  
therapy	   in	   HER2-­‐positive	   breast	   cancer.	   Several	   clinical	   trials	   have	   shown	   that	  
Trastuzumab	  improves	  relapse-­‐free	  survival	  and	  overall	  survival	  in	  patients	  with	  HER-­‐2	  
overexpressing	   early	   breast	   cancer	   (Castiglioni	   et	   al.,	   2006;	   Dean-­‐Colomb	   &	   Esteva,	  
2008).	  However,	  due	  to	  findings	  that	  many	  patients	  with	  HER2	  positive	  breast	  cancer	  
do	   not	   respond	   well	   to	   Trastuzumab	   therapy,	   recent	   studies	   have	   been	   aimed	   at	  
elucidating	   and	   overcoming	   the	   mechanisms	   of	   Trastuzumab	   resistance.	   The	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mechanisms	   underlying	   Trastuzumab	   resistance	   are	   not	   yet	   well	   understood,	   and	  
elucidating	   the	   resistance	   of	  HER2-­‐positive	   breast	   cancer	   to	   Trastuzumab	   therapy	   is	  
critical	   in	   the	   diagnosis	   and	   treatment	   of	   patients	   whose	   cancers	   express	   this	  
aggressive	  disease	  phenotype.	  	  
Several	  efforts	  have	  been	  made	  to	  overcome	  Trastuzumab	  resistance	  and	  to	  improve	  
overall	  clinical	  outcome	  in	  targeted	  breast	  cancer	  treatment.	  These	  include	  the	  use	  of	  
kinase	   antibodies	   such	   as	   Pertuzumab	   (Kolesta	   et	   al.,	   2008).	   Pertuzumab	   binds	   the	  
HER2	  extracellular	  domain	  in	  an	  area	  other	  than	  Trastuzumab,	  and	  interferes	  with	  the	  
activation	  of	  HER2.	  An	  increasing	  body	  of	  evidence	  indicates	  that	  diverse	  adaptive	  and	  
genetic	   changes	  within	   the	   transformed	   cell	   give	   rise	   to	   resistant	   phenotypes	  of	   the	  
HER2	   protein,	   which	   allow	   them	   to	   survive	   in	   the	   presence	   of	   HER2-­‐targeting	  
antibodies	  (Freudenberg	  et	  al.,	  2009).	  Khoury	  et	  al.,	  (2011)	  established	  that	  mutations	  
in	  the	  juxtamembrane	  domain	  (Trastuzumab	  binding	  site)	  of	  HER2	  is	  a	  rare	  event,	  and	  
would	   therefore	   not	   account	   for	   the	   relatively	   high	   frequency	   of	   Trastuzumab	  
resistance	  encountered	  clinically	  (Khoury	  et	  al.,	  2011).	  	  	  
This	   thesis	   establishes	   an	   overview	   of	  HER2	   expression	   in	  HER2-­‐positive	   breast	   and	  
ovarian	  cancer	  cell	  lines	  by	  immunohistochemistry.	  The	  results	  obtained	  correlate	  well	  
with	   previous	  HER2	   studies	   on	   the	   cell	   lines	   used	   in	   this	   study	   (Wolff	   et	   al.,	   2007).	  
However,	   overall	   protein	   expression	   as	   determined	  by	   IHC	  may	  not	   be	   conclusive	   in	  
determining	   a	   patient’s	   true	  HER2	   status,	   and	  may	   therefore	   not	   be	   adequate	   as	   a	  
single	  method	  of	  testing,	  to	  predict	  patients’	  response	  to	  Trastuzumab	  treatment.	  The	  
antigen-­‐antibody	  interaction	  of	  Trastuzumab	  and	  HER2	  is	  mediated	  by	  a	  portion	  of	  the	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HER2	  subdomain	  IV	  which	  consists	  of	  amino	  acid	  residues	  510	  –	  643.	  The	  Trastuzumab	  
antigen	  has	  affinity	  to	  amino	  acids	  557	  –	  603.	  The	  coding	  regions	  of	  these	  amino	  acid	  
residues	   are	   present	   in	   exons	   17-­‐18.	   	   The	   resistance	   of	   HER2	   breast	   cancer	   to	  
Trastuzumab	  might	  be	  an	  indication	  that	  Trastuzumab	  binds	  differentially	  to	  different	  
HER2	  splice	  isoforms.	  To	  be	  efficacious,	  the	  antibody	  must	  be	  able	  to	  bind	  to	  the	  HER2	  
receptor,	  and	  consequently	  exact	  its	  growth	  inhibitory	  properties.	  This	  binding	  to	  the	  
HER2	   receptor	   is	   entirely	   dependent	   on	   non-­‐covalent	   interactions,	   therefore	   small	  
changes	   in	   the	   antigen	   structure	   such	   as	   the	   loss	   of	   a	   single	   hydrogen	   bond	   can	  
significantly	   reduce	   the	   strength	  of	   the	  antigen	  antibody	   interaction	  by	  over	  a	  1000-­‐
fold	  (Khoury	  et	  al.,	  2011).	  	  
This	  study	  hypothesized	  that	  factors	  other	  than	  the	  total	  copy	  number	  of	  HER2	  may	  be	  
responsible	   for	   disease	   progression	   in	  HER2-­‐overexpressing	   invasive	   breast	   cancers,	  
and	   that	   currently	   unidentified	   alternative	   splice	   variants	   of	  HER2	   may	   give	   rise	   to	  
protein	  isoforms	  with	  potent	  cellular	  functions,	  which	  can	  potentially	  alter	  the	  binding	  
efficiency	  of	  Trastuzumab	  to	  the	  HER2	  receptor.	  	  
Bioinformatic	  analysis	  of	   the	  reference	  HER2	  gene	  revealed	   four	  binding	  sites	  on	   the	  
cell	  surface	  receptor	  of	  the	  HER2	  protein	  which	  consists	  of	  two	  ligand	  binding	  sites,	  a	  
signal	   transduction	   site,	  and	  a	  growth	   factor	   receptor	  domain;	  and	  an	  active	  binding	  
site	   in	   the	   transmembrane	   domain	   which	   is	   responsible	   for	   tyrosine	   kinase	  
phosphorylation,	  acting	  as	  an	  ‘on‘	  or	  ‘off’	  switch	  in	  a	  variety	  of	  cellular	  functions.	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This	   thesis	   demonstrates	   for	   the	   first	   time,	   the	   expression	   of	   two	   novel	   HER2	  
alternative	  splice	  variants,	  HER2∆ATP	  and	  HER2∆ECD,	  which,	  due	  to	  their	  very	  distinct	  
structural	   and	   functional	   differences	   from	   the	  wild-­‐type	  HER2,	   have	   the	  potential	   to	  
alter	  the	  binding	  affinity	  of	  Trastuzumab	  to	  the	  HER2	  receptor,	  thereby	  contributing	  to	  
the	  cellular	  changes	  that	  might	  affect	  patient	  response	  to	  Trastuzumab	  therapy.	  	  
Analysis	   of	   the	   sequences	   obtained	   from	   the	   smaller	   band	   produced	   by	   primer	   pair	  
E15F/E19R	  revealed	  a	  loss	  of	  42	  base	  pairs	  downstream	  of	  the	  HER2	  mRNA	  sequence,	  
indicative	   of	   an	   alternative	   5’	   splice	   site	   in	   exon	   18.	   This	   alternative	   5’	   splice	   site	  
resulted	  in	  the	  novel	  HER2	  isoform	  HER2∆ATP.	  The	  presence	  of	  a	  vertebrate	  splice	  site	  
consensus	   sequence	   at	   the	   new	   splice	   boundaries	   suggest	   that	   this	   is	   not	   a	   splicing	  
event	  mediated	  as	  a	  result	  of	  a	  mutation,	  but	  a	  true	   isoform	  resulting	   in	  an	   in-­‐frame	  
loss	  of	  14	  amino	  acids	  from	  the	  HER2	  protein.	  	  
Analysis	   of	   the	   resulting	   predicted	   protein	   revealed	   the	   deletions	   of	   this	   new	  HER2	  
splice	  variant	  to	  be	  the	  loss	  of	  amino	  acids	  724	  –	  737	  in	  the	  tyrosine	  kinase	  domain	  of	  
the	  HER2	  protein.	  The	  direct	  consequence	  of	  the	  loss	  of	  amino	  acids	  724	  –	  737	  is	  the	  
loss	   of	   the	   entire	   ATP	   binding	   pocket	   of	   the	  HER2	   protein,	   which	   is	   represented	   by	  
amino	  acids	  726	  –	  734.	  	  
In	   the	   HER2∆ATP	   isoform,	   the	   predicted	   HER2	   extracellular	   domain	   remains	  
unchanged.	  Since	  HER2	  dimerization	  occurs	  on	  subdomain	  II	  of	  the	  HER2	  extracellular	  
domain,	  HER2∆ATP	  would	  still	  be	  capable	  of	  dimerization;	  however,	  the	  loss	  of	  amino	  
acids	   in	   the	   tyrosine	   kinase	   region	   may	   inhibit	   phosphorylation	   and	   subsequent	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activation	   of	   downstream	   signalling	   pathways.	   The	   activation	   of	   the	   ligand-­‐binding	  
domain	   of	   the	   HER2	   receptor	   triggers	   conformational	   changes	   within	   the	   HER2	  
cytoplasmic	  domain,	  and	  the	  resulting	  phosphorylation	  of	  ATP	  to	  tyrosine	  residues	  on	  
target	  substrates	  can	  only	  occur	  when	  the	  crucial	  key	  loops	  within	  the	  kinase	  domain	  
are	  appropriately	  positioned	  (Telesco	  &	  Radhakrishnan,	  2009).	  These	  functional	  loops	  
form	   the	   molecular	   regulatory	   mechanisms	   in	   HER2	   phosphorylation;	   amino	   acid	  
residues	  884	  –	  850	  form	  the	  catalytic	   loop	  (C-­‐loop),	  which	  is	  crucial	   in	  the	  transfer	  of	  
phosphoryl	  groups.	  Amino	  acid	  residues	  761-­‐775	  and	  727	  –	  732	  form	  the	  αC	  helix	  and	  
the	  nucleotide	  binding	  loop	  (N-­‐loop),	  respectively,	  and	  these	  two	  loops	  are	  responsible	  
for	  the	  coordination	  of	  the	  ATP	  substrate	  tyrosine.	  Amino	  acid	  residues	  863	  –	  884	  form	  
the	  activation	  loop	  (A	  loop),	  which	  coordinates	  the	  activation	  of	  the	  tyrosine	  kinase	  by	  
regulating	   accessibility	   of	   the	   target	   substrate	   to	   the	   C-­‐loop.	   It	   is	   predicted	   that	   the	  
HER2∆ATP	  splice	  variant	  translates	  a	  protein	  which	  is	  incapable	  of	  phosphorylation,	  as	  
a	  portion	  of	  the	  nucleotide	  binding	  loop	  is	  lost	  in	  translation.	  	  
Analysis	  of	   the	   sequences	  obtained	   from	   the	   smaller	  band	  produced	  by	  primer	  pairs	  
E12F/E15R	  revealed	  a	   loss	  of	  133	  nucleotides	  corresponding	  to	  the	   loss	  of	   the	  entire	  
exon	   13.	   Bioinformatic	   analysis	   of	   this	   novel	   alternative	   splice	   variant	   revealed	   a	  
cassette	   exon	   in	   exon	   13.	   Further	   analysis	   using	   exPASY	   translate	   tool	   revealed	   a	  
truncated	  645	  amino	  acid	  protein	  which	  lacks	  amino	  acids	  1-­‐610	  of	  the	  wild-­‐type	  HER2	  
isoform,	  but	  has	  conserved	  active	  binding	  sites	   in	  the	  transmembrane	  domain	  of	   the	  
HER2	  protein.	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Previous	   studies	   have	   demonstrated	   a	   HER2	   receptor	   termed	   p95HER2	   similar	   in	  
structure	  to	  the	  HER2∆ECD	  alternative	  splice	  variant.	  P95HER2	   is	  an	  amino-­‐terminally	  
truncated	  carboxyl-­‐terminal	  fragment	  (CTF)	  of	  HER2	  with	  kinase	  activity	  that	  lacks	  the	  
Trastuzumab	   binding	   site,	   which	   is	   frequently	   found	   in	  HER2	   overexpressing	   breast	  
cancer	  cell	   lines	  and	  tumours	  (Scaltriti	  et	  al.,	  2007;	  Sperinde	  et	  al.,	  2010;	  Sasso	  et	  al.,	  
2011).	   The	   p95HER2	   isoform	   is	   often	   cited	   as	   a	   contributing	   cause	   of	   Trastuzumab	  
resistance.	   Studies	   have	   demonstrated	   that	   p95HER2-­‐expressing	   tumours	   may	   be	  
sensitive	   to	   the	  effects	  of	  Lapatinib,	  a	   small-­‐molecule	   tyrosine	  kinase	   inhibitor	  which	  
inhibits	  HER2	   phosphorylation	  by	  binding	   to	   the	   intracellular	   kinase	  domain	  of	  HER2	  
(Awada,	   Bozovic-­‐Spasojevic	   &	   Chow,	   2012).	   The	   generation	   of	   p95HER2	   has	   been	  
speculated	   to	   be	   by	   several	   mechanisms;	   the	   proteolytic	   shedding	   of	   the	   HER2	  
extracellular	   domain	   at	   a	   site	   proximal	   to	   the	   transmembrane	   domain;	   alternative	  
initiation	   of	   translation	   at	   the	   mRNA	   encoding	   HER2	   from	   methionine	   611	   located	  
before	  the	  transmembrane	  domain,	  or	  alternative	  initiation	  of	  translation	  at	  the	  mRNA	  
encoding	   HER2	   from	   methionine	   687	   located	   after	   the	   transmembrane	   domain	  
(Scaltriti	   et	   al.,	   2007;	   Sasso	   et	   al.,	   2011).	   Interestingly,	   an	   mRNA	   precursor	   of	   the	  
p95HER2	  has	  not	  been	  discovered	  to	  date.	  	  
This	   thesis	   predicts	   for	   the	   first	   time,	   a	   novel	   alternative	   splice	   variant	   of	  HER2,	   the	  
HER2∆ECD	  splice	  variant,	  potentially	  corresponding	  to	  p95HER2	  protein.	  	  
In	   a	   previous	   study,	   Sperinde	   et	   al.,	   (2010)	   demonstrated	   a	   novel	   antibody	   that	  
measures	  p95HER2	   in	  vitro.	  Due	  to	  the	  HER2∆ECD	  splice	  variant	  not	  being	  previously	  
discovered,	   a	  method	  of	   detecting	  p95HER2	   in	  HER2	  mRNA	  has	  not	  been	  previously	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demonstrated.	   In	   this	   thesis,	   for	   the	   first	   time,	   a	  method	   of	   detecting	  HER2∆ECD	   in	  
genetic	  material	  has	  been	  demonstrated	  using	  RT-­‐PCR	  priming,	  as	  well	  as	  a	  double-­‐dye	  
probe	   (Taqman)	   assay	   to	   detect	   the	   relative	   expression	   of	   HER2∆ECD,	   a	   predicted	  
precursor	  of	  p95HER2.	  	  
Due	  to	  the	  significant	  findings	  leading	  to	  the	  discovery	  of	  novel	  HER2	  splice	  variants	  in	  
this	   study,	   the	   expression	   of	   HER2	   and	   HER2	   alternative	   splice	   variants	   was	  
investigated	   in	   a	   small	   cohort	   of	   human	   samples,	   to	   determine	   whether	   the	   splice	  
variants	   identified	  are	  only	   tumour-­‐specific.	   It	  has	  been	  shown	  here	   that	  despite	   the	  
challenges	  of	  reversal	  of	  cross-­‐linking	  in	  FFPE	  tissue	  samples,	  RNA	  can	  be	  successfully	  
obtained	   from	   FFPE	   samples	   and	   for	   RT-­‐PCR	   amplification	   of	  HER2	   and	  HER2	   splice	  
variants.	  RNA	   from	  FFPE	   sample	   is	   known	   to	  be	  highly	  degraded,	  and	   results	   in	  RNA	  
fragments	   approximately	   200	   nucleotides	   in	   length	   (Abramovitz	   et	   al.,	   2008).	   It	   is	  
reported	  here	  that	  HER2	  fragments	  with	  amplicon	  sizes	  of	  ~400	  nucleotides	  in	  length	  
and	  above	  were	  detected	   in	   the	   FFPE	   samples.	  Of	   the	   fourteen	   samples	   in	   the	   FFPE	  
cohort,	   HER2ΔECD	   was	   detected	   in	   three	   samples,	   HER2ΔATP	   was	   detected	   in	   one	  
sample,	   and	   HER2Δ16	   was	   detected	   in	   six	   samples.	   Although	   the	   expression	   of	  
HER2Δ16	  has	  been	  previously	  identified	  in	  human	  samples	  (Castiglioni	  et	  al.,	  2006),	  it	  is	  
reported	   here	   for	   the	   first	   time	   in	   human	   tissue	   samples	   preserved	   by	   formalin	  
fixation.	  P95HER2,	  which	   is	  predicted	   in	   this	   study	   to	  be	   the	  protein	  encoded	  by	   the	  
novel	  HER2	  splice	  variant	  HER2ΔECD,	  has	  been	  previously	  identified	  in	  human	  samples	  
as	  a	  protein.	  This	  HER2	  isoform	  is	  being	  identified	  in	  human	  tissue	  mRNA.	  In	  addition,	  
the	  HER2ΔATP	  splice	  variant	  which	  corresponds	  with	  the	  loss	  of	  the	  ATP	  binding	  site	  of	  
the	  HER2	  protein	  has	  also	  been	  detected	  here	  in	  FFPE	  samples.	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The	   regulation	   of	   HER2	   and	   HER2	   splice	   variants	   was	   also	   investigated	   in	   cell	   line	  
models.	  The	  role	  of	  splice	  factor	  kinases	  was	  investigated	  by	  the	  use	  of	  protein	  kinase	  
inhibitors	  SRPIN340,	  TG003	  and	   INDY	   in	  HER2	  3+	  SKBR3,	  HER2	  2+	  MDA-­‐MB-­‐453,	  and	  
HER2-­‐	  BT-­‐20	  cell	  lines.	  Of	  all	  three	  cell	  lines,	  only	  MDA-­‐MB-­‐453	  showed	  any	  changes	  in	  
the	  expression	  of	  HER2	  and	  HER2	  alternative	  splice	  variants.	  The	  inhibition	  of	  SRPK1	  by	  
the	  use	  of	  splice	  factor	  kinase	  SRPIN340	  greatly	  increased	  the	  expression	  of	  HER2	  and	  
HER2	   alternative	   splice	   variants.	   Bioinformatic	   analysis	   of	   splice	   factor	   motifs	   in	  
chapter	  4	   revealed	  potential	  binding	  sites	   for	   the	  SR	  kinase	  SRSF1	   (ASF/SF2),	  a	  splice	  
factor	  potent	  regulated	  by	  the	  protein	  kinase	  SRPK1.	  SRPIN340	   is	  a	  selective	  inhibitor	  
of	   SRPK1,	   and	   following	   SRPIN340	   treatment	   of	   MDA-­‐MB-­‐453	   cells,	   levels	   of	   HER2	  
were	  significantly	  elevated	  in	  the	  cells.	  Interestingly,	  direct	  siRNA	  knockdown	  of	  SRPK1	  
and	   SRSF1	   and	   SRSF1	   were	   shown	   to	   have	   inhibitory	   effects	   on	   HER2	   and	   HER2	  
alternative	  splice	  variants	  in	  MDA-­‐MB-­‐453	  cells.	  Little	  is	  known	  about	  the	  regulation	  of	  
HER2	   expression,	   nor	   the	   splice	   factors	   directly	   involved	   in	   HER2	   splicing.	   The	   up	  
regulation	  of	  HER2	   following	  SRPK1	   inhibition	  via	  SRPIN340,	  and	  the	  down	  regulation	  
of	  HER2	  following	  direct	  knockdown	  of	  SRPK1	  and	  SRSF1	  in	  MDA-­‐MB-­‐453	  cells	  present	  
a	  novel	  prediction	  that	  SRPK1	  and	  SRSF1	  may	  be	  potent	  regulators	  of	  HER2	  splicing.	  	  
Hypoxia	  Inducible	  Factor	  (HIF1-­‐α),	  a	  potent	  physiologic	  marker	  for	  hypoxia	  in	  the	  cells,	  
has	   been	   known	   to	   act	   as	   a	   tumour	   suppressor	   in	   certain	   cancers	   (Chiavarina	  et	   al.,	  
2010).	   The	   induction	   of	  HIF1-­‐α	   in	   SKBR3	   cells	   showed	   significantly	   reduced	   levels	   of	  
HER2	   and	  HER2	   splice	   variants	   after	   as	   short	   as	   24	   hours	   following	   treatment	   with	  
hypoxia	  mimetic	  factor	  CoCl2.	  This	  finding	  confirms	  that	  HIF1-­‐α	  may	  play	  also	  a	  crucial	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role	   in	  driving	  down	  cancer	  cells,	  and	  reports	   for	   the	  first	   time	  that	  HIF1-­‐α	  may	  be	  a	  
positive	  factor	  in	  the	  regulation	  of	  HER2	  expression	  and	  splicing.	  
There	   are	   areas	   in	   this	   research	   which	   may	   benefit	   from	   further	   investigation.	   For	  
example,	  there	  is	  not	  much	  information	  available	  on	  the	  exact	  protein	  sequences	  that	  
HER2	   antibodies	   bind	   to.	  With	   findings	   of	   new	   alternative	   splice	   variants	   which	   are	  
potentially	   capable	   of	   altering	   the	   conformation	   of	   the	   HER2	   protein	   with	   serious	  
clinical	   implications,	   targeted	   treatment	   should	   focus	   on	   detecting	   more	   than	   one	  
HER2	   protein,	   as	   a	   combination	   of	   different	  HER2	   isoforms	  may	   contribute	   in	   giving	  
patients	  a	  HER2	  profile,	  thereby	  making	  it	  easier	  to	  determine	  what	  treatment	  will	  be	  
beneficial	   to	   individual	   patients.	   For	   example,	   retrospective	   research	   has	   found	   that	  
p95HER2	   is	   expressed	   in	   a	   large	   number	   of	   HER2	   positive	   breast	   cancers,	   and	   co	  
expression	   of	   p95HER2	   with	   the	   wild-­‐type	   HER2	   has	   been	   found	   to	   give	   rise	   to	  
Trastuzumab	   resistant	  HER2	   tumours.	   These	   studies	   were	   carried	   out	   in	   retrospect,	  
and	  thereforE	  did	  not	  directly	  benefit	  the	  patients	  at	  the	  time	  of	  diagnosis.	  Findings	  of	  
this	   type	  would	   inform	  the	  use	  of	  other	   therapies	   like	  Lapatinib	   in	  combination	  with	  
trasuzumab	   in	   clinical	   trials,	   with	   the	   aim	   of	   potentially	   inhibiting	   HER2	   at	   the	  
extracellular	  level	  at	  the	  same	  time	  as	  the	  intracellular.	  
The	   discovery	   of	   HER2	   splice	   variants	   in	   breast	   tissues	   in	   this	   study	   leads	   to	   the	  
recommendation	   that	  a	   larger	  cohort	  be	   tested,	   to	  give	  more	  significant	   information	  
on	   the	  expression	  of	  HER2	   alternative	   splice	  variants	   in	  women	  who	  suffer	   from	   the	  
disease.	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It	  is	  also	  suggested	  that	  further	  work	  be	  carried	  out	  on	  the	  regulation	  of	  expression	  of	  
HER2	  alternative	  splice	  variants,	  particularly	  the	  expression	  of	  HER2	  splice	  variants	   in	  
non-­‐HER2	  positive	  cell	  line	  models,	  to	  further	  the	  investigations	  into	  the	  role	  of	  these	  
splice	  factors	  in	  breast	  cancer,	  and	  the	  role	  of	  SR	  proteins	  and	  splice	  factor	  kinases	  in	  
the	   regulation	  of	   splicing	   in	  HER2.	   The	  wild-­‐type	  HER2	   is	  often	  coexpressed	  with	   the	  
known	  HER2	   splice	  variants,	   it	  may	  be	  beneficial	   to	   isolate	  the	  wild-­‐type	  HER2	   in	  cell	  
line	  models,	  and	  to	  investigate	  whether	  resistance	  to	  Trastuzumab	  may	  due	  to	  de	  novo	  
resistance	  of	  HER2,	  or	  due	  to	  the	  coexpression	  of	  HER2	  splice	  variants	  which	  may	  have	  
intrinsic	  resistance	  to	  Trastuzumab.	  	  
In	   conclusion	   this	   thesis	   demonstrates	   for	   the	   first	   time	   two	  novel	   alternative	   splice	  
variants	  of	  HER2,	   and	  also	  has	  predicted	  potential	   regulators	  of	   splicing	   in	  HER2	   and	  
HER2	  alternative	  splice	  variants,	  including	  the	  HER2Δ16	  variant.	  The	  detection	  of	  these	  
splice	  variants	   in	  human	  samples	   indicates	  a	  potential	  clinical	   significance,	  which	  can	  
be	   established	   through	   further	   research	   and	   replication	   of	   these	   findings.	   The	  wild-­‐
type	  HER2	  and	  the	  HER2	  alternative	  splice	  variants	  appear	  to	  show	  similar	  changes	  in	  
expression	   levels	   following	   treatments	   that	   have	   been	   administered	   to	   investigate	  
their	  effects	   in	  cell	   line	  models.	   It	  might	  therefore	  be	  beneficial,	   for	  example,	  to	   look	  
into	   the	   expression	   of	   HER2ΔATP	   in	   vivo.	   	   HER2ΔATP,	   being	   a	   potentially	   less	   active	  
HER2	   isoform,	   may	   intrinsically	   inhibit	   phosphorylation	   with	   a	   higher	   potency	   than	  
antibodies	   being	   administered.	   The	   findings	   of	   this	   study	   put	   alternative	   splicing	   of	  
HER2	  at	  a	  focal	  point,	  in	  a	  hypothesis	  that	  the	  effects	  of	  alternative	  splicing	  in	  invasive	  
breast	   cancer	   may	   be	   the	   continuing	   cause	   of	   resistance	   to	   existing	   therapies	   and	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consequently	   disease	   progression	   in	   patients	   with	   HER2	   overexpressing	   or	   gene	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HER2	  sequence	  (Accession	  Number	  NM_004448)	  
	  


















EXON	  5	  (69bp)	  	  
GCCACCCCTGTTCTCCGATGTGTAAGGGCTCCCGCTGCTGGGGAGAGAGTTCTGAGGATTGTC
AGAGCC	  
EXON	  6	  (116bp)	  	  
TGACGCGCACTGTCTGTGCCGGTGGCTGTGCCCGCTGCAAGGGGCCACTGCCCACTGACTGCT
GCCATGAGCAGTGTGCTGCCGGCTGCACGGGCCCCAAGCACTCTGACTGCCTG	  




EXON	  8	  (120bp)	  	  
ACAACTACCTTTCTACGGACGTGGGATCCTGCACCCTCGTCTGCCCCCTGCACAACCAAGAGG
TGACAGCAGAGGATGGAACACAGCGGTGTGAGAAGTGCAGCAAGCCCTGTGCCCGAG	  




EXON	  10	  (74bp)	  	  
GGACCCAGCCTCCAACACTGCCCCGCTCCAGCCAGAGCAGCTCCAAGTGTTTGAGACTCTGGA
AGAGATCACAG	  













EXON	  14	  (91bp)	  	  
GCTCCCCAGGGAGTATGTGAATGCCAGGCACTGTTTGCCGTGCCACCCTGAGTGTCAGCCCCA
GAATGGCTCAGTGACCTGTTTTGGACCG	  




EXON	  16	  (48bp)	  
CTGTGTGGACCTGGATGACAAGGGCTGCCCCGCCGAGCAGAGAGCCAG	  




EXON	  18	  (123bp)	  	  
CTGGTGGAGCCGCTGACACCTAGCGGAGCGATGCCCAACCAGGCGCAGATGCGGATCCTGAA
AGAGACGGAGCTGAGGAAGGTGAAGGTGCTTGGATCTGGCGCTTTTGGCACAGTCTACAAG	  
EXON	  19	  (99bp)	  
GGCATCTGGATCCCTGATGGGGAGAATGTGAAAATTCCAGTGGCCATCAAAGTGTTGAGGGA
AAACACATCCCCCAAAGCCAACAAAGAAATCTTAGAC	  








EXON	  22	  (76bp)	  
GTGCCCATCAAGTGGATGGCGCTGGAGTCCATTCTCCGCCGGCGGTTCACCCACCAGAGTGAT
GTGTGGAGTTATG	  














































Sequences	  of	  HER2	  cDNA	  obtained	  from	  RT-­‐PCR	  assays	  which	  













Figure	  A	  1:	  Sequence	  analysis	  of	  the	  top	  band	  amplified	  using	  primers	  E12F	  +	  E	  15R,	  showing	  exon	  12,	  
exon	   13,	   exon	   14,	   and	   exon	   15.	   In	   Italics	   –	   forward	   and	   reverse	   primers.	   Underlined	   –	   actual	   cDNA	  













Figure	  A	  2:	  Sequence	  analysis	  of	  the	  middle	  band	  amplified	  using	  primers	  E12F	  +	  E	  15R,	  showing	  exon	  
12,	  exon	  13,	  exon	  14,	  and	  exon	  15.	   In	   Italics	  –	   forward	  and	  reverse	  primers.	  Underlined	  –	  actual	  gene	  















Figure	  A	   3:	   Sequence	   showing	   the	   top	   band	   amplified	   using	   primers	   E15F	   +	   E	   19R,	   showing	  exon	   15,	  
exon	  16,	  exon	  17,	  exon	  18,	  and	  exon	  19.	   In	   Italics	  –	   forward	  and	  reverse	  primers.	  Underlined	  –	  actual	  












Figure	  A	  4:	  Sequence	  showing	  the	  lower	  band	  amplified	  using	  primers	  E15F	  +	  E	  19R,	  showing	  exon	  15,	  
exon	  16,	  exon	  17,	  exon	  18,	  and	  exon	  19.	   In	   Italics	  –	   forward	  and	  reverse	  primers.	  Underlined	  –	  actual	  










Figure	  A	  5:	  Sequence	  showing	  the	  top	  band	  amplified	  using	  primers	  NP1+NP2,	  showing	  exon	  15,	  exon	  
16,	  exon	  17,	  and	  exon	  18.	  In	  Italics	  –	  forward	  and	  reverse	  primers.	  Underlined	  –	  actual	  gene	  sequence	  











Figure	  A	  6:	  Sequence	  showing	  the	  top	  band	  amplified	  using	  primers	  NP1+NP2,	  showing	  exon	  15,	  exon	  
16,	  exon	  17,	  and	  exon	  18.	  In	  Italics	  –	  forward	  and	  reverse	  primers.	  Underlined	  –	  actual	  gene	  sequence	  








Figure	  A	  7:	  Sequence	  showing	  the	  top	  band	  amplified	  using	  primers	  NP5+NP6,	  showing	  exon	  15,	  exon	  
16,	  and	  exon	  17.	  In	  Italics	  –	  forward	  and	  reverse	  primers.	  Underlined	  –	  actual	  gene	  sequence	  obtained	  








Figure	  A	  8:	  Sequence	  showing	  the	  top	  band	  amplified	  using	  primers	  NP5+NP6,	  showing	  exon	  15,	  exon	  
16,	  and	  exon	  17.	  In	  Italics	  –	  forward	  and	  reverse	  primers.	  Underlined	  –	  actual	  gene	  sequence	  obtained	  



































5’	  CTTCCCACGGGGCCCTTTAC	  ‘3	   5’	  AGCACGTAGCCCTGCACCTC	  ‘3	  
E3F	  +	  E6R	   EXONS	  3-­‐
6	  
5’	  TCCAGGAGGTGCAGGGCTAC	  ‘3	   5’	  CAGCAGTCAGTGGGCAGTGG	  ‘3	  
E6F	  +	  E9R	   EXONS	  6-­‐
9	  

































5’	  CAGGCACCGCAGCTCATCTA	  ‘3	   5’	  CTCCTCCCTGGGGTGTCAAG	  ‘3	  
E27F	  +	  
E27R1	  
EXON	  27	   5’	  GAGAACCCCGAGTACTTGACAC	  
‘3	  

















Table	  A	  1:	  List	  of	  RT-­‐PCR	  oligonucleotide	  sequences	  	  
230	  	  
RAW	   VALUES	   FOR	   RT-­‐PCR	   SEQUENCES	   (INCLUDING	   SEQUENCES	  
WHICH	   DID	   NOT	   PROCUDE	  MULTIPLE	   BANDS,	   AND	   FOR	  WHICH	  
ALTERNATIVE	  SPLICING	  WAS	  NOT	  OBSERVED)	  





















































































































































































































































































































































































































































































FOLDER	  NAME:	  2010-­‐02-­‐01_ABI55_0266	  
























FOLDER	  NAME:	  2010-­‐02-­‐01_ABI55_0266	  






















FOLDER	  NAME:	  2010-­‐01-­‐29_ABI53_0265	  
























FOLDER	  NAME:	  2010-­‐01-­‐29_ABI53_0265	  



























FOLDER	  NAME:	  2010-­‐01-­‐29_ABI53_0265	  



























FOLDER	  NAME:	  2010-­‐01-­‐29_ABI53_0265	  
























FOLDER	  NAME:	  2010-­‐01-­‐29_ABI53_0265	  
























FOLDER	  NAME:	  2009-­‐12-­‐14_abi54_0258	  























FOLDER	  NAME:	  2009-­‐12-­‐14_abi54_0258	  






















FOLDER	  NAME:	  2009-­‐12-­‐14_abi54_0258	  





















FOLDER	  NAME:	  2009-­‐12-­‐14_abi54_0258	  















































Figure	  A	  9:	  PSIPRED	  output	  showing	  the	  secondary	  structure	  of	  the	  HER2	  protein	  aligned	  with	  the	  amino	  
acid	  sequence.	  α-­‐helices	  are	  represented	  by	  pink	  cylinders,	  β-­‐strands	  are	  represented	  by	  yellow	  arrows,	  
and	  coils	  are	  represented	  by	  black	  lines.	  The	  predicted	  structures	  are	  also	  indicated	  by	  lettering;	  H	  –





pGEM-­‐T	  Easy	  Vector	  Map	  
The	  pGEM-­‐T	  Easy	   is	  a	  high	  copy	  number	  vector	   for	  cloning	  PCR	  products.	   It	   contains	  
both	  T7	  and	  SP6	  RNA	  polymerase	  promoters	  flanking	  a	  multiple	  cloning	  region	  within	  
the	   α-­‐peptide	   coding	   region	   of	   the	   enzyme	   β-­‐galactosidase	   to	   enable	   blue/white	  
screening.	  It	  has	  multiple	  restriction	  enzyme	  sites	  and	  an	  ampicillin	  resistance	  gene	  to	  
facilitate	  bacterial	  selection.	  
	  
	  








CLUSTAL	  OMEGA	  ALIGNMENTS	  OF	  HER2	  mRNA	  TRANSCRIPT	  
VARIANTS	  OBTAINED	  FROM	  THE	  NCBI	  DATABASE:	  
NR_110535    ------------------------------------------------------------ 





	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
NR_110535    ------------------------------------------------------------ 





                                                                               
 
NR_110535    ------------------------------------------------------------ 





                                                                               
 
NR_110535    ------------------------------------------------------------ 





                                                                               
 
NR_110535    -----------------------------------------------------GCTTGCT 





                                                                    ****.   
 
NR_110535    CCCAATCACAGGAGAAGGAGGAGGTGGAGGAGGAGGGCTGCTTGAGGAAGTATAAGAATG 
NM_004448    CCCAATCACAGGAGAAGGAGGAGGTGGAGGAGGAGGGCTGCTTGAGGAAGTATAAGAATG 




                  ** *.***.: *:****.     *: ***** **   .:.*                    
 
NR_110535    AAGTTGTGAAGCTGAGATTCCCCTCCATTGGGACCGGAGAAAC----------------- 





                ******:*.* ...****.**    :. **. **:*.                     
 
254	  	  
NR_110535    ---------CAGGGGAGCCCCCCGGGCAGCCGCGCGCCCCTTCC--CA--CGGGGCCCTT 





                      **..* :.* *** *.***.   .*.* *.*      .*       .* :  
 
NR_110535    TACTGCGCCGCGCGCCCGGCCCCCACCCCTCGCAGCACCCCGCGCCCCGCGCCCTCCCAG 





             **        .. * **.* .*..** *.  *******  .*.*.* *. .****  *** 
 
NR_110535    CCGGGTCCAGCCGGAGCCATGGGGCCGGAGCCGCAGTGAGCACCATGGA-GCTGGCGGCC 





             **.      *** *.**.        **..  *.:*:*** ..**** *   * * **.* 
 
NR_110535    TTGTGCCGCTGGGGGCTCCTCCT--------CGCCCTCTTGCCCCCCGGAGCCGCGAGCA 





                  :** .*...:* *.                                               
 
NR_110535    CCCAAGTGTGCACCGGCACAGACATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACC 





                  ******************************************************* 
 
NR_110535    TGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCA 





             ************************************************************ 
 
NR_110535    CCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTGCAGGTGAGGCCCGTGGGCAACCCAG 





             **************************************                       
 
NR_110535    CCAGGCCCTGCCTCCAGCTGGGCTGAGCCCTCTGTTTACAGGATATCCAGGAGGTGCAGG 





                                                      ******************* 
 
NR_110535    GCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTG 






             ************************************************************ 
 
NR_110535    TGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCCGTGCTAGACAATGGAGACC 





             ************************************************************ 
 
NR_110535    CGCTGAACAATACCACCCCTGTCACAGGGGCCTCCCCAGGAGGCCTGCGGGAGCTGCAGC 





             ************************************************************ 
 
NR_110535    TTCGAAGCCTCACAGAGATCTTGAAAGGAGGGGTCTTGATCCAGCGGAACCCCCAGCTCT 





             ************************************************************ 
 
NR_110535    GCTACCAGGACACGATTTTGTGGAAGGACATCTTCCACAAGAACAACCAGCTGGCTCTCA 





             ************************************************************ 
 
NR_110535    CACTGATAGACACCAACCGCTCTCGGGCCTGCCACCCCTGTTCTCCGATGTGTAAGGGCT 





             ************************************************************ 
 
NR_110535    CCCGCTGCTGGGGAGAGAGTTCTGAGGATTGTCAGAGCCTGACGCGCACTGTCTGTGCCG 





             ************************************************************ 
 
NR_110535    GTGGCTGTGCCCGCTGCAAGGGGCCACTGCCCACTGACTGCTGCCATGAGCAGTGTGCTG 





             ************************************************************ 
 
NR_110535    CCGGCTGCACGGGCCCCAAGCACTCTGACTGCCTGGCCTGCCTCCACTTCAACCACAGTG 





             ************************************************************ 
 
256	  	  
NR_110535    GCATCTGTGAGCTGCACTGCCCAGCCCTGGTCACCTACAACACAGACACGTTTGAGTCCA 





             ************************************************************ 
 
NR_110535    TGCCCAATCCCGAGGGCCGGTATACATTCGGCGCCAGCTGTGTGACTGCCTGTCCCTACA 





             ************************************************************ 
 
NR_110535    ACTACCTTTCTACGGACGTGGGATCCTGCACCCTCGTCTGCCCCCTGCACAACCAAGAGG 





             ************************************************************ 
 
NR_110535    TGACAGCAGAGGATGGAACACAGCGGTGTGAGAAGTGCAGCAAGCCCTGTGCCCGAGTGT 










NR_110535    GCTATGGTCTGGGCATGGAGCACTTGCGAGAGGTGAGGGCAGTTACCAGTGCCAATATCC 





             ************************************************************ 
 
NR_110535    AGGAGTTTGCTGGCTGCAAGAAGATCTTTGGGAGCCTGGCATTTCTGCCGGAGAGCTTTG 





             ************************************************************ 
 
NR_110535    ATGGGGACCCAGCCTCCAACACTGCCCCGCTCCAGCCAGAGCAGCTCCAAGTGTTTGAGA 





             ************************************************************ 
 
NR_110535    CTCTGGAAGAGATCACAGGTTACCTATACATCTCAGCATGGCCGGACAGCCTGCCTGACC 





             ************************************************************ 
 
NR_110535    TCAGCGTCTTCCAGAACCTGCAAGTAATCCGGGGACGAATTCTGCACAATGGCGCCTACT 
257	  	  





             ************************************************************ 
 
NR_110535    CGCTGACCCTGCAAGGGCTGGGCATCAGCTGGCTGGGGCTGCGCTCACTGAGGGAACTGG 





             ************************************************************ 
 
NR_110535    GCAGTGGACTGGCCCTCATCCACCATAACACCCACCTCTGCTTCGTGCACACGGTGCCCT 











NR_110535    GGGACCAGCTCTTTCGGAACCCGCACCAAGCTCTGCTCCACACTGCCAACCGGCCAGAGG 





             ************************************************************ 
 
NR_110535    ACGAGTGTGTGGGCGAGGGCCTGGCCTGCCACCAGCTGTGCGCCCGAGGGCACTGCTGGG 





             ************************************************************ 
 
NR_110535    GTCCAGGGCCCACCCAGTGTGTCAACTGCAGCCAGTTCCTTCGGGGCCAGGAGTGCGTGG 





             ************************************************************ 
 
NR_110535    AGGAATGCCGAGTACTGCAGGGGCTCCCCAGGGAGTATGTGAATGCCAGGCACTGTTTGC 





             ************************************************************ 
 
NR_110535    CGTGCCACCCTGAGTGTCAGCCCCAGAATGGCTCAGTGACCTGTTTTGGACCGGAGGCTG 





             ************************************************************ 
 
NR_110535    ACCAGTGTGTGGCCTGTGCCCACTATAAGGACCCTCCCTTCTGCGTGGCCCGCTGCCCCA 
258	  	  





             ************************************************************ 
 
NR_110535    GCGGTGTGAAACCTGACCTCTCCTACATGCCCATCTGGAAGTTTCCAGATGAGGAGGGCG 





             ************************************************************ 
 
NR_110535    CATGCCAGCCTTGCCCCATCAACTGCACCCACTCCTGTGTGGACCTGGATGACAAGGGCT 





             ********************************** **:**  *.* *           ** 
 
NR_110535    GCCCCGCCGAGCAGAGAGCCAGCCCTCTGACGTCCATCATCTCTGCGGTGGTTGGCATTC 





                * **.**...***..* : *               .* **:* **       *:*** 
 
NR_110535    TGCTGGTCGTGGTCTTGGGGGTGGTCTTTGGGATCCTCATCAAGCGACGGCAGCAGAAGA 





             **  * ** *. *.*:          :::***.:**:..**:. * : * ** .: ::*: 
 
NR_110535    TCCGGA--------AGTACACGATGCGGAGACTGCTGCAGGAAACGGAGCTGGTGGAGCC 





             * * **        * :****.:**  .*.* ** :..*  *    .*.*: *:.      
 
NR_110535    GCTGACACCTAGCGGAGCGATGCCCAACCAGGCGCAGATGCGGATCCTGAAAGAGACGGA 





                   *    . ..*  .******:* **.....*.*:.    :..:.***.*.      
 
NR_110535    GCTGAGGAAGGTGAAGGTGCTTGGATCTGGCGCTTTTGGCACAGTCTACAAGGGCATCTG 





                    **..:.**                                              
 
NR_110535    GATCCCTGATGGGGAGAATGTGAAAATTCCAGTGGCCATCAAAGTGTTGAGGGAAAACAC 






                                                                               
 
NR_110535    ATCCCCCAAAGCCAACAAAGAAATCTTAGACGAAGCATACGTGATGGCTGGTGTGGGCTC 





                                                                               
 
NR_110535    CCCATATGTCTCCCGCCTTCTGGGCATCTGCCTGACATCCACGGTGCAGCTGGTGACACA 





                                                                               
 
NR_110535    GCTTATGCCCTATGGCTGCCTCTTAGACCATGTCCGGGAAAACCGCGGACGCCTGGGCTC 





                                                                               
 
NR_110535    CCAGGACCTGCTGAACTGGTGTATGCAGATTGCCAAGGGGATGAGCTACCTGGAGGATGT 





                                                                               
 
NR_110535    GCGGCTCGTACACAGGGACTTGGCCGCTCGGAACGTGCTGGTCAAGAGTCCCAACCATGT 





                                                                               
 
NR_110535    CAAAATTACAGACTTCGGGCTGGCTCGGCTGCTGGACATTGACGAGACAGAGTACCATGC 





                                                                               
 
NR_110535    AGATGGGGGCAAGGTGCCCATCAAGTGGATGGCGCTGGAGTCCATTCTCCGCCGGCGGTT 





                                                                               
 
NR_110535    CACCCACCAGAGTGATGTGTGGAGTTATGGTGTGACTGTGTGGGAGCTGATGACTTTTGG 





                                                                               
 
NR_110535    GGCCAAACCTTACGATGGGATCCCAGCCCGGGAGATCCCTGACCTGCTGGAAAAGGGGGA 
260	  	  





                                                                               
 
NR_110535    GCGGCTGCCCCAGCCCCCCATCTGCACCATTGATGTCTACATGATCATGGTCAAATGTTG 





                                                                               
 
NR_110535    GATGATTGACTCTGAATGTCGGCCAAGATTCCGGGAGTTGGTGTCTGAATTCTCCCGCAT 





                                                                               
 
NR_110535    GGCCAGGGACCCCCAGCGCTTTGTGGTCATCCAGAATGAGGACTTGGGCCCAGCCAGTCC 





                                                                               
 
NR_110535    CTTGGACAGCACCTTCTACCGCTCACTGCTGGAGGACGATGACATGGGGGACCTGGTGGA 





                                                                               
 
NR_110535    TGCTGAGGAGTATCTGGTACCCCAGCAGGGCTTCTTCTGTCCAGACCCTGCCCCGGGCGC 





                                                                               
 
NR_110535    TGGGGGCATGGTCCACCACAGGCACCGCAGCTCATCTACCAGGAGTGGCGGTGGGGACCT 





                                                                               
 
NR_110535    GACACTAGGGCTGGAGCCCTCTGAAGAGGAGGCCCCCAGGTCTCCACTGGCACCCTCCGA 





                                                                               
 
NR_110535    AGGGGCTGGCTCCGATGTATTTGATGGTGACCTGGGAATGGGGGCAGCCAAGGGGCTGCA 






                                                                               
 
NR_110535    AAGCCTCCCCACACATGACCCCAGCCCTCTACAGCGGTACAGTGAGGACCCCACAGTACC 





                                                                               
 
NR_110535    CCTGCCCTCTGAGACTGATGGCTACGTTGCCCCCCTGACCTGCAGCCCCCAGCCTGAATA 





                                                                               
 
NR_110535    TGTGAACCAGCCAGATGTTCGGCCCCAGCCCCCTTCGCCCCGAGAGGGCCCTCTGCCTGC 





                                                                               
 
NR_110535    TGCCCGACCTGCTGGTGCCACTCTGGAAAGGCCCAAGACTCTCTCCCCAGGGAAGAATGG 





                                                                               
 
NR_110535    GGTCGTCAAAGACGTTTTTGCCTTTGGGGGTGCCGTGGAGAACCCCGAGTACTTGACACC 





                                                                               
 
NR_110535    CCAGGGAGGAGCTGCCCCTCAGCCCCACCCTCCTCCTGCCTTCAGCCCAGCCTTCGACAA 





                                                                               
 
NR_110535    CCTCTATTACTGGGACCAGGACCCACCAGAGCGGGGGGCTCCACCCAGCACCTTCAAAGG 





                                                                               
 
NR_110535    GACACCTACGGCAGAGAACCCAGAGTACCTGGGTCTGGACGTGCCAGTGTGAACCAGAAG 





                                                                               
 
NR_110535    GCCAAGTCCGCAGAAGCCCTGATGTGTCCTCAGGGAGCAGGGAAGGCCTGACTTCTGCTG 
262	  	  





                                                                               
 
NR_110535    GCATCAAGAGGTGGGAGGGCCCTCCGACCACTTCCAGGGGAACCTGCCATGCCAGGAACC 





                                                                               
 
NR_110535    TGTCCTAAGGAACCTTCCTTCCTGCTTGAGTTCCCAGATGGCTGGAAGGGGTCCAGCCTC 





                                                                               
 
NR_110535    GTTGGAAGAGGAACAGCACTGGGGAGTCTTTGTGGATTCTGAGGCCCTGCCCAATGAGAC 





                                                                               
 
NR_110535    TCTAGGGTCCAGTGGATGCCACAGCCCAGCTTGGCCCTTTCCTTCCAGATCCTGGGTACT 





                                                                               
 
NR_110535    GAAAGCCTTAGGGAAGCTGGCCTGAGAGGGGAAGCGGCCCTAAGGGAGTGTCTAAGAACA 





                                                                               
 
NR_110535    AAAGCGACCCATTCAGAGACTGTCCCTGAAACCTAGTACTGCCCCCCATGAGGAAGGAAC 





                                                                               
 
NR_110535    AGCAATGGTGTCAGTATCCAGGCTTTGTACAGAGTGCTTTTCTGTTTAGTTTTTACTTTT 





                                                                               
 
NR_110535    TTTGTTTTGTTTTTTTAAAGATGAAATAAAGACCCAGGGGGAGAATGGGTGTTGTATGGG 






                                                                               
 
NR_110535    GAGGCAAGTGTGGGGGGTCCTTCTCCACACCCACTTTGTCCATTTGCAAATATATTTTGG 





                                                                               
 
NR_110535         AAAACAGCTAAAAAAAAAAAAAAAAAA 
NM_004448         AAAACAGCTAAAAAAAAAAAAAAAAAA 
NM_001289937      AAAACAGCTAAAAAAAAAAAAAAAAAA 
NM_001289936      AAAACAGCTAAAAAAAAAAAAAAAAAA 
NM_001005862      AAAACAGCTAAAAAAAAAAAAAAAAAA 














CLUSTAL	  OMEGA	  ALIGNMENTS	  OF	  HER2	  ISOFORMS	  OBTAINED	  
FROM	  THE	  NCBI	  DATABASE:	  
P04626        MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      ---------------MPRGSWKPQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL 
                                                                           
 
P04626        ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG 
                                                                           
 
P04626        DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA 
                                                                           
 
P04626        LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC 
                                                                           
 
P04626        AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP 
                                                                           
 
P04626        YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN 
                                                                           
 
P04626        IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC 
                                                                           
 
P04626        ------------------------------------------------------------ 
265	  	  
P04626-1      ----------MPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG 
P04626-3      ------------------------------------------------------------ 
P04626-4      PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL 
P04626-3      --------------------------MRRLLQETELVEPLTPSGAMPNQAQMRILKETEL 
P04626-4      ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP 
P04626-3      RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP 
P04626-4      RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR 
P04626-3      YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR 
P04626-4      YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT 
P04626-3      LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT 
P04626-4      LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM 
P04626-3      HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM 
P04626-4      HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA 
P04626-3      IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA 
P04626-4      IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG 
P04626-3      EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG 
P04626-4      EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV 
P04626-3      AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV 
P04626-4      AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ 
P04626-3      NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ 
P04626-4      NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV----- 
P04626-3      GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV----- 
P04626-4      GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPVDLSVF 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
266	  	  
P04626-4      QNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQL 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      FRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECR 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      VLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVK 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      PDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVV 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      VLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKV 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      LGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRL 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      LGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRD 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      LAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDV 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      WSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSEC 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      RPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLV 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      PQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDV 
                                                                           
 
P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      FDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDV 
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P04626        ------------------------------------------------------------ 
P04626-1      ------------------------------------------------------------ 
P04626-3      ------------------------------------------------------------ 
P04626-4      RPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAP 
                                                                           
 
P04626        -------------------------------------------------- 
P04626-1      -------------------------------------------------- 
P04626-3      -------------------------------------------------- 
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1. 	  
EVENT	  TITLE:	  SAN	  ANTONIO	  BREAST	  CANCER	  SYMPOSIUM	  
VENUE:	  HENRY	  B.	  GONZALEZ	  CONVENTION	  CENTER,	  SAN	  ANTONIO,	  TEXAS,	  USA	  
DATE:	  DECEMBER	  6-­‐11,	  2011	  
AWARD	  RECEIVED:	  AACR	  scholar-­‐in-­‐training	  award	  by	  Susan	  G	  Komen	  for	  the	  Cure.	  
ABSTRACT	  	  
Background:	  	  
The	  Human	  Epidermal	  Growth	  Factor	  Receptor	  2	  (HER2)	   is	  an	  oncogene	  expressed	  in	  
25-­‐30%	   of	   invasive	   breast	   cancers.	   HER2	   shares	   extensive	   homology	   with	   other	  
members	  of	  the	  HER	  family	  (HER1,	  HER3	  and	  HER4),	  and	  is	  constitutively	  active	  as	  an	  
homo-­‐and	  heterodimer.	   The	  HER2	   gene	  encodes	   an	  185kDa	   transmembrane	  protein	  
with	   tyrosine	   kinase	   activity.	   Gene	   amplification	   or	   protein	   expression	   of	   HER2	   is	   a	  
predictor	   of	   poor	   clinical	   outcome	   and	   decreased	   survival	   in	   women	   with	   breast	  
cancer,	  and	  also	  indicates	  a	  favourable	  response	  to	  Trastuzumab	  (Herceptin)	  therapy,	  
or	   a	   combinational	   therapy	   comprising	   Herceptin	   plus	   chemotherapy.	   However,	  
resistance	   to	   Trastuzumab	   remains	   the	   case	   in	   approximately	   50%	   of	   HER2	  
amplified/overexpressing	   tumours.	   Understanding	   the	   molecular	   mechanisms	   of	  
Trastuzumab	   resistance	   and	   identifying	   more	   effective	   therapies,	   is	   critical	   in	   the	  
treatment	  of	  patients	  whose	  breast	  cancers	  express	  this	  aggressive	  disease	  phenotype.	  
In	   this	   study,	   it	   is	   postulated	   that	   the	   abnormal	   generation	   of	  mRNA	   splice	   variants	  
may	  be	  responsible	  for	  the	  continued	  tumour	  growth	  and	  progression.	  	  
Aims:	  	  
The	   aim	   of	   this	   study	   is	   to	   increase	   our	   understanding	   of	   the	   role	   of	   HER2	   splice	  
variants	   in	   the	   development	   and	   progression	   of	   breast	   cancer.	   This	   will	   inform	   the	  
development	  of	  more	   sophisticated	  and	  effective	   therapies	   that	   target	   specific	  HER2	  
isoforms,	  rather	  than	  Herceptin,	  which	  targets	  just	  the	  generic	  wild	  type	  HER2	  protein.	  	  
Materials	  and	  Methods:	  	  
The	   coding	   region	   of	   HER2	   cDNA	   was	   PCR-­‐amplified	   using	   12	   sets	   of	   HER2	   specific	  
primers	  in	  HER2	  positive	  cell	  lines	  (SKOV-­‐3,	  SKBR-­‐3,	  MDA-­‐MB-­‐453	  and	  MDA-­‐MB-­‐361).	  
Results:	  	  
RT-­‐PCR	   results	   showed	   multiple	   bands	   in	   various	   regions	   of	   the	   HER2	   mRNA.	  
Sequencing	  of	  these	  bands	  revealed	  novel	  alternative	  splice	  variants	  with	  deletions	  in	  
exons	   13	   and	   18	   of	   the	   HER2	   gene	   expressed	   in	   addition	   to	   the	   wild-­‐type	   HER2.	  
Bioinformatics	  analysis	  of	  the	  deletions	  revealed	  a	  cassette	  exon	  in	  exon	  13,	  and	  a	  loss	  
of	  42	  base	  pairs	   in	  the	  3’	  end	  of	  exon	  18	  compared	  to	  the	  full	   length	  HER2.	  Both	  the	  
full-­‐length	  HER2	  sequence	  and	  the	  sequence	  containing	  the	  deletions	  were	  translated	  
using	  the	  ExPASy	  Translate	  tool.	  This	  revealed	  an	  in-­‐frame	  deletion	  of	  14	  amino	  acids	  
and	  a	  novel	  splice	  isoform	  with	  a	  deletion	  in	  the	  HER2	  protein,	  which	  encompasses	  the	  
entire	  ATP	  binding	  pocket.	  This	  was	  determined	  by	  analysis	  using	  UniProtKB	  to	  identify	  
the	  composition	  of	  amino	  acids	  for	  each	  domain	  of	  HER2.	  
Discussion:	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Our	   studies	   have	   identified	  novel	   splice	   variants	   in	   the	   tyrosine	   kinas	   domain	  of	   the	  
HER2	  gene	  in	  HER2-­‐positive	  cell	  lines.	  The	  loss	  of	  an	  ATP	  binding	  site	  in	  the	  HER2	  gene	  
may	  lead	  to	  a	  less	  active	  HER2	  isoform,	  which	  may	  play	  a	  significant	  role	  in	  prognosis.	  
Current	  work	  is	  being	  carried	  out	  to	  study	  the	  regulation	  of	  these	  splice	  variants	  and	  to	  
study	   the	   role	   of	   splice	   factor	   ASF/SF2	   and	   its	   phosphorylating	   kinase	   SRPK1	   in	   the	  
regulation	   of	   HER2	   splicing,	   and	   to	   elucidate	   any	   significant	   changes	   in	   the	   HER2	  
signalling	   pathways.	   In	   addition,	   the	   expression	   of	   these	   isoforms	   is	   currently	   being	  
investigated	  in	  tissues	  from	  FFPE	  and	  frozen	  breast	  tumours.	  
	  
2. 	  
EVENT	  TITLE:	  POSTGRADUATE	  RESEARCH	  FORUM	  
VENUE:	  UNIVERSITY	  OF	  THE	  WEST	  OF	  ENGLAND	  
DATE:	  APRIL	  12,	  2011	  




The	  Human	  Epidermal	  Growth	  Factor	  Receptor	  2	  (HER2)	   is	  an	  oncogene	  expressed	  in	  
25-­‐30%	   of	   invasive	   breast	   cancers.	   HER2	   shares	   extensive	   homology	   with	   other	  
members	  of	  the	  HER	  family	  (HER1,	  HER3	  and	  HER4),	  and	  is	  constitutively	  active	  as	  an	  
homo-­‐and	  heterodimer.	   The	  HER2	  gene	  encodes	   an	  185kDa	   transmembrane	  protein	  
with	   tyrosine	   kinase	   activity.	   Gene	   amplification	   or	   protein	   expression	   of	   HER2	   is	   a	  
predictor	   of	   poor	   clinical	   outcome	   and	   decreased	   survival	   in	   women	   with	   breast	  
cancer,	  and	  also	  indicates	  a	  favourable	  response	  to	  Trastuzumab	  (Herceptin)	  therapy,	  
or	   a	   combinational	   therapy	   comprising	   Herceptin	   plus	   chemotherapy.	   However,	  
resistance	   to	   Trastuzumab	   remains	   the	   case	   in	   approximately	   50%	   of	   HER2	  amplified/overexpressing	   tumours.	   Understanding	   the	   molecular	   mechanisms	   of	  
Trastuzumab	   resistance	   and	   identifying	   more	   effective	   therapies,	   is	   critical	   in	   the	  
treatment	  of	  patients	  whose	  breast	  cancers	  express	  this	  aggressive	  disease	  phenotype.	  
In	   this	   study,	   it	   is	   postulated	   that	   the	   abnormal	   generation	   of	  mRNA	   splice	   variants	  
may	  be	  responsible	  for	  the	  continued	  tumour	  growth	  and	  progression.	  	  
Aims:	  	  
The	   aim	   of	   this	   study	   is	   to	   increase	   our	   understanding	   of	   the	   role	   of	   HER2	   splice	  
variants	   in	   the	   development	   and	   progression	   of	   breast	   cancer.	   This	   will	   inform	   the	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development	  of	  more	   sophisticated	  and	  effective	   therapies	   that	   target	   specific	  HER2	  
isoforms,	  rather	  than	  Herceptin,	  which	  targets	  just	  the	  generic	  wild	  type	  HER2	  protein.	  	  
Materials	  and	  Methods:	  	  
The	   entire	   coding	   region	   of	   HER2	   cDNA	   was	   PCR	   amplified	   using	   12	   sets	   of	   HER2	  
specific	  primers	   in	  HER2	  positive	  cell	   lines	   (SKOV-­‐3,	  SKBR-­‐3,	  MDA-­‐MB-­‐453	  and	  MDA-­‐MB-­‐361),	  and	  HER2	  negative	  cell	   lines	   (BT-­‐20,	  MDA-­‐MB-­‐361	  MCF-­‐7).	  These	  cell	   lines	  
were	  also	  tested	  for	  protein	  expression	  of	  HER2	  using	  Immunohistochemistry.	  	  
Results:	  	  
RT-­‐PCR	   results	   suggest	   that	   there	  are	  alternatively	  spliced	  variants	  of	  HER2	  between	  
exons	   12-­‐15,	   15-­‐19,	   and	   19-­‐22	   in	   the	   SKOV-­‐3	   and	  MDA-­‐MB-­‐453cell	   lines,	   as	  well	   as	  
potential	  exon	  deletions	  in	  the	  SKBR-­‐3	  cell	  line.	  	  
Conclusion:	  	  
In	  addition	  to	  a	  previously	  described	  exon	  16	  deleted	  HER2	  transcript,	  our	  current	  
findings	  have	  identified	  potential	  novel	  splice	  variants	  in	  the	  transmembrane	  and	  
kinase	  domains	  of	  the	  HER2	  gene	  in	  HER2	  positive	  cell	  lines.	  Functional	  studies	  of	  the	  
proteins	  encoded	  by	  these	  variants	  will	  be	  carried	  in	  order	  to	  elucidate	  any	  significant	  
changes	  in	  the	  HER2	  signalling	  pathways.	  In	  addition,	  the	  expression	  of	  these	  isoforms	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